Title (News Shots)
?Ipsen to Acquire Clementia Pharmaceuticals for $1.31B to Expand its Rare Disease Portfolio
?Ipsen to Acquire Clementia Pharmaceuticals for $1.31B to Expand its Rare Disease Portfolio
JHL Biotech's Trastuzumab Biosimilar (JHL1188) Receives CHMP Positive Scientific Advice to Treat Breast Cancer
Celltrion's Herzuma (Herceptin biosimilar) Receives Marketing Approval in Australia
"Pfizer receives EU approval for Trazimera(Trastuzumab), the First Oncology Biosimilar"
Dr. Reddy Launched Hervycta (biosimilar Trastuzumab) in India
Novartis divests part of Sandoz US Genercis as well as US dermatology business to Aurobindo Pharma for $0.9B
Allergen Announces Acquisition of Bonti for its Two Aesthetic and Therapeutic Products
Mylan Receives EU Marketing Approval for Adalimumab Biosimilar “Hulio”
Amicus Therapeutics Acquires Celenex for its Ten Gene Therapy Programs
Sandoz's Biosimilar Pegfilgrastim Receives CHMP Approval for Febrile Neutropenia
Samsung Bioepis' BLA for SB5 Adalimumab Biosimilar Accepted for Review by the US FDA
"Celltrion and Teva Announces Approval Recommendations for CT-P10's (rituximab, biosimilar) BLA from the US FDA ODAC"
Mundipharma Acquires Cinfa Biotech for Expansion of its Biosimilar Portfolio
Sandoz Signs a Non-Exclusive License Agreement with AbbVie for IPR of its Humira (adalimumab) for Major EU Countries
Merck Terminates Development and Commercialization Deal with Samsung Bioepis for Lusduna Nexvue (insulin glargine)
"Amgen Launches Amgevita (adalimumab, biosimilar) in EU to Treat Inflammatory Diseases post EMA Approval in Feb 2017"
"Samsung Biogen Launches Imraldi (adalimumab, biosimilar) in EU for 14 Autoimmune Conditions"
Novartis to Acquire Endocyte for Expansion of its Investigational Radioligand Therapy (RLT) Platform
Axsome Therapeutics Receives FDA's Orphan Drug Designation for AXS-12 (reboxetine) to Treat Narcolepsy
Allergan Announces Completion of UBR-MD-04 &amp; 3110-105-002 Study for Treatment of Migrane
Eiger Pharmaceuticals Reports Results of Lambda in P-II LIMT (Lambda MonoTx) Study in Hepatitis Delta Virus (HDV) Infection
Janssen Pharmaceuticals (J&amp;J) Receives Health Canada's Approval for Invokana (canagliflozin) in MACE Reduction
Mylan Launches MPA Injectable Suspension for Prevention of Pregnancy in the US
Abbott Receives FDA's Approval for its HeartMate 3 Left Ventricular Assist Device (LVAD) in Patients with Advance Heart Failure
Roche Reports Results of P-III IMpower130 study of Tecentriq (atezolizumab) for 1L Treatment in Advance NSCLC
AstraZeneca &amp; Merck Reports P-III SOLO-1 Trial Results of Lynparza (olaparib) for 1L+ Treatement in Advance BRCAm Ovarian Cancer at ESMO18
Biogen and UCB Reports Results of Dapirolizumab Pegol (DZP) in A P-IIb study for Systemic Lupus Erythematosus (SLE)
Novartis Reports Publication of P-IIIb LIBERTY study's Results of Aimovig (erenumab) in The Lancet
Astrazeneca Expands Existing Deal with Innate Pharma to Strengthen its Oncology Pipeline
Lilly Reports Results of Taltz (ixekizumab) in P-III COAST-V and COAST-W trials for Ankylosing Spondylitis (AS)
Alcon (Novartis Division) Plans to Develop SMART Suite Equipment for Improved Cataract Surgery
Omeros' OMS721 Receives FDA's ODD to Treat Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)
"Takeda Globally Signs Licensing, Co-Development &amp; Co-Promotion Agreement with Enterome for its EB8018 Candidate"
LEO Pharma Signs License and Research Collaboration with Zymeworks to Develop Novel Bispecific Abs
"Amgen Collaborates with Orion for Commercialization of Amgevita (adalimumab, biosimilar) in Finland"
Orion's Darolutamide Achieves 1EP in P-III ARAMIS study in Men with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Pfizer Reports Improved Results of P-III OA (A4091056) Study of Tanezumab in Patients with Osteoarthritis (OA)
"Axovant Reports Dosing of its First Patient in AXO-Lenti-PD study for Parkinson's Disease at NIHR, UCLH"
AstraZeneca Reports Results of Lokelma (sodium zirconium cyclosilicate) in P-III HARMONIZE trial in Patients with Hyperkalaemia
"Seattle Genetics Reports Multiple Results of Adcetris (Brentuximab Vedotin) in P-III ECHELON-1, P-I/II, P-II and P-III AETHERA study in Patients with Hodgkin Lymphoma at ISHL 2018"
Esperion Reports Results of Bempedoic Acid in P-III Study 2 or 1002-047 for Patients with ASCVD or HeFH
Novartis &amp; Pfizer Enter into a Clinical Development Collaboration to Treat Non-Alcoholic Steatohepatitis (NASH)
ProQR Signs Exclusive Worldwide License Agreement with Ionis for IONIS-RHO-2.5 Candidate (now QR-1123)
Jazz Receives FDA Approval for Xyrem's (sodium oxybate) sNDA to Treat Cataplexy or Excessive Daytime Sleepiness in Pediatric Patients with Narcolepsy
AstraZeneca Divests Rights of its Nexium and Vimovo Product to Grunenthal
Astellas' Xtandi (enzalutamide) Receives EU's Approval for Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
"Gilead Reports Results of Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) in P-III Study 1490 for Patients with HIV-1"
Mirati Therapeutics Announces IND Submission of MRTX849 to Treat NSCLC &amp; CRC
Roche Licenses Halozyme's ENHANZE Technology for ~$190M for the Development of Therapeutic Targets
Janssen's (J&amp;J) Invokana (canagliflozin) Receives FDA Approval for MACE events in Adults with T2D
"Biocardia, CellProThera &amp; SlngXpand Collaborates to Develop and Commercialize CD34+ Stem Cells in Singapore for Myocardial Infarction"
"Lupin Recalls its 6,752 Testosterone Bottles from the US market"
Coherus' Udenyca (pegfilgrastim-cbqv) Receives the US FDA Approval for Patients Receiving Myelosuppressive Chemotherapy
"Boehringer Ingelheim (BI) &amp; Eli Lilly Reports RWE Results of Jardiance (empagliflozin) in EMPRISE study, Presented at AHA 2018"
Abeona Signs Exclusive License Agreement with Regenxbio to Develop and Commercialize NAV AAV9 vector
"Merck Signs a Clinical Trial Collaboration with FLX Bio, for a Combination Therapy"
"Regeneron and Sanofi Reports Results of Praluent (alirocumab) in ODYSSEY OUTCOMES study in Patients with MACE events, Presented at AHA 2018"
AstraZeneca Announces Acceptance of Priority Review of Lynparza's (olaparib) sNDA by FDA in Patients with BRAC-Mutated Advance Ovarian Cancer
Merck's Keytruda (pembrolizumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma (HCC)
Roche Reports Acceptance of sBLA from FDA for its Tecentriq (atezolizumab) + Abraxane (nab-paclitaxel) for 1L Metastatic Triple- Negative Breast Cancer (TNBC)
BioTime Acquires Asterias Biotherapeutics with Two of its Clinical Stage Cell Therapy Candidates
BioTime Acquires Asterias Biotherapeutics with Two of its Clinical Stage Cell Therapy Candidates
Merck Reports Initiation of BLA Filling for V920 (rVSV?G-ZEBOV-GP) Under FDA for Ebola Zaire
Ferring Signs an Exclusive License Agreement with Invo for its INVOcell Intravaginal Culture (IVC) System in the US
Wugen Enters into License Agreement with Washington University for its CAR-T Therapy Technologies
Merck Reports Improved Overall Survival Results of Keytruda (pembrolizumab) vs Chemotherapy in KEYNOTE-181 Study
"Grunenthal Acquires Averitas Pharma for its Peripheral Neuropathic Pain Product, Qutenza (capsaicin)"
Lilly Files Lasmiditan to FDA for Acute Treatment of Migrane
Bristol-Myers Squibb Receives CHMP Recommendation for Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) in 1L RCC Based in P-III CheckMate-214 study
"Ipsen's Cabometyx (cabozantinib, as monothx) Receives EU Approval for the Treatment of 2L Advance HCC"
"Pfizer to Raise Prices of its 41 Drugs in the US, in January 2019"
Novartis' Kisqali (ribociclib) (as a Combination Therapy) Receives CHMP's Expanded Label Recommendation for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
Gilead's Vemlidy (Tenofovir Alafenamide) Receives NMPA (CFDA) Approval for Chronic Hepatitis B Virus (HBV) Infection"
AstraZeneca Reports Results of Imfinzi (durvalumab) &amp; Tremelimumab in Global P-III MYSTIC Trial for Stage IV Non-Small Cell Lung Cancer (NSCLC)
Genentech Collaborates with Immunocore to Co-develop IMC-C103C for MAGE-A4 (Melanoma-Associated Antigen A4)
Leidos Collaborates with GeoVax for the Development of Immunotherapies for Cancer
"Sandoz and Pear Therapeutics Launches reSET Medical Mobile APP, for Patients with Substance Use Disorder (SUD)"
Verily (Alphabet's Division) Holds its Smart Lens Project
Boston Scientific Acquires BTG with its Interventional Medicine Portfolio
OrthroXel's Apex Femoral Nailing System Receives CE Mark Clearance in EU
"Mylan Recalls 15 Batches of Valsartan Globally, for the Treatment of Hypertension"
Leo Pharma Collaborates with PellePharm for the Development of Drug Candidate for Gorlin Syndrome and Basal Cell Carcinoma (BCC)
Genentech's Venclexta (venetoclax) Receives FDA's Accelerated Approval for Patients with Newly-Diagnosed Acute Myeloid Leukemia (AML)
Pfizer and Zenith Epigenetics Collaborates to Evaluate ZEN-3694 &amp; Talazoparib for TNBC
Evotec and Immuneering Collaborates to Develop Novel Candidates for Rare Hereditary Metabolic Diseases
Medtronic to Acquire Nutrino Health Along with its AI-Based Continuous Glucose Monitoring (CGM) Technology
Indivior Receives Health Canada Approval for Sublocade (SC) (Buprenorphine Extended-Release) in Patients with Moderate to Severe Opioid Use Disorder(OUD)
"Mundipharma Receives EU Approval for Pelmeg (Pegfilgrastim, Biosimilar)"
Novartis Receives EU Approval for Gene Therapy Luxturna (voretigene neparvovec) in Patients with Rare Inherited Retinal Disease
Bristol-Myers' Opdivo and Yervoy Combination Couldn't Meet OS as Maintenance Therapy in esSCLC Patients Post 1L Chemo
RegenxBio and Rocket Signs Exclusive Worldwide License Agreement for NAV AAV9 Vector
Sandoz's Ziextenzo (pegfilgrastim) Receives EU Approval for Reduction in Duration of Neutropenia
"Genentech's ACTpen Receives FDA's Approval for Actemra (tocilizumab) to Treat Rheumatoid Arthritis (RA), Giant Cell Arteritis (GCA) and Two Forms of Juvenile Arthritis"
Loxo's Vitrakvi (larotrectinib) Receives the US FDA Approval for the Treatment of Solid Tumors in Adults and Pediatric Patients
Novo Nordisk Reports Improved Results of Oral Semaglutide in PIONEER 9 Study in Patients with Type-2 Diabetes (T2D)
Beigene Signs Exclusive License and Development Agreement with Zymeworks (ZW)
Mesa Biotech's Accula RSV Test Receives FDA's 510(K) Clearance and CLIA Waiver for Respiratory Infections
Genentech Acquires Jecure Therapeutics for its Preclinical Stage NLRP3 inhibitors
Merck's Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate) &amp; Pifeltro (doravirine) Receives EU's Approval for the Treatment of HIV-1 Infection
Q BioMed Acquires Rights of Metastron from GE Healthcare
"ElectroCore's gammaCore (nVNS) Receives FDA's 510(k) Approval, a Novel Therapy for Cluster Headache in Adults"
Astellas' Xospata (gilteritinib) Receives FDA ‘s Approval for 1L R/R Acute Myeloid Leukemia (AML) in Adults
Vertex's Kalydeco (ivacaftor) Receives FDA's Expanded Label Approval for Cystic Fibrosis (CF) Aged 12 to &lt; 24 Months
NTU SingaporeTTSH Develops AI based Smart Medical Device for Early Detection of Congestive Heart Failure
Shire's Takhzyro IV (lanadelumab) Receives EU's Approval for Hereditary Angioedema
Bluebird Bio and Celgene Reports Results of bb21217 in P-I (CRB-402) study for 3L+ r/r Multiple Myeloma
Pfizer Reports Results of PF-05280586 (rituximab biosimilar) in REFLECTIONS B328-06 study for CD20-Positive Non-Hodgkin Lymphoma
GSK to Acquire Tesaro for its Zejula (niraparib) for $5.1B (£4.0 billion)
Cilag Acquires Exclusive Worldwide Rights of Argenx's Cusatuzumab (ARGX-110) for $1.6B
"Kite Reports Results of Yescarta (axicabtagene ciloleucel) in ZUMA-1 trial for Refractory Large B-Cell, Lymphoma, Presented at ASH 2018"
Crown Laboratories Acquires Rights for GSK's Five OTC Drugs
Roche Reports Results of Kadcyla (trastuzumab emtansine) in P-III KATHERINE Study for HER2-positive Early Breast Cancer (eBC)
Domain Therapeutics Signs Research and License Agreement with Boehringer Ingelheim (BI) for G-Protein Coupled Receptors (GPCRs)
Roche Collaborates with Icagen for the Development of Drug Candidates for Neurological Disorders
Subtle an AI based Medical Device SubtlePET Receives FDA's 510(K) Clearance
Novartis Reports Results of BYL719 (alpelisib) + fulvestrant in P-III SOLAR-1 trial for HR+/HER2- Advanced Breast Cancer
Biogen Exercises Exclusive Worldwide Option to Develop &amp; Commercialize Ionis's BIIB067 (IONIS-SOD1RX) for Amyotrophic Lateral Sclerosis (ALS)
Novartis Expands its Cell Therapy Collaboration with Intellia Therapeutics for CRISPR/Cas9-Based Therapy
"Gilead's Descovy (Emtricitabine, Tenofovir Alafenamide) Receives NMPA ‘s (CFDA) Approval for HIV-1 Infection"
Innovate and Massachusetts General Hospital Collaborates to Develop Larazotide for Alcoholic Liver Disease
"Celltrion Reports Results of CT-P10 (rituximab, biosimilar) in P-III for Advance Follicular Lymphoma (AFL)"
NeuroPace Reports Positive Results of Next-Gen RNS System for Refractory Epilepsy in the US
"Genentech's Tecentriq Receives FDA Approval a Combination Therapy, for mNon-Sq NSCLC with No EGFR or ALK Genomic Tumor Aberrations"
Daiichi Reports Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in P-I study for HER2 Low Expressing Metastatic Breast Cancer
Merck Licenses Cyclica's In-Silico Artificial Intelligence (AI) based Ligand Express Platform
AstraZeneca Reports Imfinzi (durvalumab) &amp; tremelimumab Results in P-III EAGLE trial for Advanced Head and Neck Cancer
Bristol-Myers (BMS) Collaborates with Vedanta Biosciences to Develop Combination Therapy for Advanced or Metastatic Cancers
Novartis Reports Results of Kisqali (ribociclib) + Endocrine Therapy in P-III MONALEESA trials for (HR+/HER2-) Advanced Breast Cancer
Shionogi Signs a Research Collaboration with UBE Industries for the Development of Anti-RS Virus Drug Candidates
"Sandoz Receives FDA's Clearance for reSET-O, a Medical Mobile App for Opioid Use Disorder (OUD)"
"Astellas to Launch Xospata (gilteritinib) for R/R Acute Myeloid Leukemia (AML) with FLT3 Mutation, in the US"
Circassia Plans to Exercise Option for the US Commercialization Rights for Tudorza (aclidinium) From AstraZeneca
Johnson&amp;Johnson (J&amp;J) Signs a Research Collaboration with Apple for Atrial Fibrillation (AFib)
BioMed X and Boehringer Ingelheim (BI) Collaborates for Neurology Disorders
Ironwood Pharmaceuticals' Linzess (linaclotide) Receives NMPA (CMPA) Approval for Irritable Bowel Syndrome with Constipation (IBS-C)
"FitBit and National Institutes of Health (NIH) Launches a Digital Health Project, Fitbit Bring-Your-Own-Device (BYOD)"
AstraZeneca Signs an Exclusive Promotion Agreement with Luye Pharma for its Xuezhikang in China
"Roche Launches uPath Enterprise Software, a Digital PathologyTechnology"
Abbott Exercises its Option to Acquire Cephea Valve Technologie
Boehringer Ingelheim (BI) and Bioharmony Therapeutics Collaborates to Develop Bacteriophage Lysins
Beigene's Zanubrutinib (BGB-3111) Receives the US FDA's Breakthrough Therapy Designation for Mantle Cell Lymphoma (MCL)
Sanofi Licenses Biomunex Pharmaceuticals' BiXAb Technology to Develop Bi- and Multi-Specific Antibodies
"Abbott's Amplatzer Piccolo Occluder Receives FDA Approval, a Medical Device for Premature and Newborns with Patent Ductus Arteriosus (PDA)"
"Cipla Signs an Exclusive License Agreement with Bio-Thera for its BAT1706 (bevacizumab, biosimilar)"
Array Biopharma Reports Results of Triplet Combination Therapy in P-III BEACON CRC Trial for BRAF-Mutant Metastatic Colorectal Cancer (mCRC)
Exelixis' Cabometyx (cabozantinib) Receives FDA Approval for Previously Treated Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb's (BMS) Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) Receives EU Approval for 1L Intermediate- and Poor-Risk Advanced RCC
Ascletis Signs an Exclusive License Agreement with Alphamab for its KN035
Chiesi Farmaceutici Licenses Tum Bio's NCE401 for $74M
Knight Therapeutics Signs an Exclusive License Agreement with Puma Biotechnology for its Nerlynx (neratinib)
RFPi's iCertainty Receives FDA 510(k) Clearance Approval for Blood Flow in Surgeries
Rafael Pharmaceuticals' Devimistat (CPI-613) Receives EMA's ODD for R/R Acute Myeloid Leukemia (AML) and Metastatic Pancreatic Cancer (mPC)
Yuhan Signs an Exclusive License Agreement with Glenmark for its Ryaltris
Sumitomo Dainippon Reports Results of Lurasidone Hydrochloride (lurasidone) in P-III JEWEL Study in Patients with Schizophrenia
Empatica's Embrace an AI Smartwatch Receives FDA's 510(K) Clearance Approval in Pediatric Patients Aged =6 yrs.
Elevian and Insilico Medicine Collaborates to Develop Therapies Targeting Aging
"Sanofi Reports Results of Cablivi (caplacizumab) in P-III HERCULES Study in Patients with Rare Blood Clotting Disorder, Published in NEJM"
ImmunoGen to Sell Residual Royalty Rights for Kadcyla (ado-trastuzumab emtansine) to OMERS
Janssen (J&amp;J) Reports Filing of Stelara's (ustekinumab) in Group Type II Variation Application to EMA for Moderately to Severely Active Ulcerative Colitis (UC)
Exelixis and Daiichi Sankyo's Minnebro (Esaxerenone) Receives MHLW Marketing Approval In Patients With Hypertension In Japan
Astellas and Amgen Astellas' Evenity (romosozumab) Receives MHLW Approval for Patients with Osteoporosis at High Risk of Fracture in Japan
3SBio Signs a License Agreement with Samsung Bioepis for its Biosimilars
Eli Lilly to Acquire Loxo Oncology for $8B
Novartis's SEG101(crizanlizumab) Receives FDA's Breakthrough Therapy(BT) Designation for Sickle Cell Disease
Merck Exercises its Option to License NGM's NGM313 (MK-3655) for NASH and Type 2 Diabetics
Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) to Collaborate with Boehringer Ingelheim(BI) for Neuropsychiatric Disorders
"Daiichi Signs an Exclusive License Agreement with Esperion, for $1.2B"
"Merck's Keytruda(pembrolizumab) Receives 5 Approvals from PMDA, Japan across 3 Indications"
Bristol-Myers Squibb (BMS) to Acquire Celgene for $74B
Progenics Signs Exclusive License Agreement with Curium for the Development of PyL in EU
"Celgene Licenses Aprinoia's APN-1607 an Imaging Tracer, for Neurodegenerative Diseases"
Bristol-Myers Squibb Receives FDA's Approval for Sprycel (dasatinib) + CT in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Teva's ProAir Digihaler (Albuterol Sulfate 117 mcg) Inhalation Powder Receives FDA Approval for Asthma &amp; COPD Patients Aged 4 Years or Older
Betta Pharma Licenses Inventisbio's D-0316 to Treat Non-Small Cell Lung Cancer (NSCLC)
"FDA Approves Elzonris (tagraxofusp), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy"
Sanofi and Merck Receives FDA Approval for Vaxelis in Pediatric Patients
Horizon Pharma's Ravitchi (Glycerol Phenylbutyrate) Receives FDA Approval for Expansion of Age Range for in Patients with Urea Cycle Disorder (UCD)
Innovent Biologics and Eli Lilly's Tyvyt (Sintilimab injection) Receives NMPA (CFDA) Approval for Classical Hodgkin's Lymphoma (cHL) Patients
JHL Biotech Reports Randomization of Patients in P-III Study of JHL1101 for Diffuse Large B-Cell Lymphoma
Merck and Pfizer Reports Results of Avelumab in P-III JAVELIN Ovarian 100 study for Previously Untreated Advanced Ovarian Cancer
"AbbVie Licenses Lupin's MALT1 Inhibitor Program, for $977M"
Alexion's Ultomiris (Ravulizumab-Cwvz) Receives FDA Approval in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Zydus' Doxycycline Hyclate Delayed-Release Tablets USP and Febuxostat Tablets Receives FDA's Approval
Merck's Keytruda (pembrolizumab) Receives FDA's Approval for LA or Metastatic Merkel cell carcinoma (MCC)
Bristol-Myers (BMS) Divests its UPSA Consumer Health Business to Taisho
AstraZeneca and Merck's Lynparza (olaparib) Receives FDA's Approval for 1L BRCA-Mutated Advanced Ovarian Cancer
Albireo's A4250 Receives EU Orphan Drug Designation (ODD) for Biliary Atresia
Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer
Alcon to Acquire Tear Film Innovations for its iLux Medical Device
Eli Lilly Collaborates with Aduro Biotech for its cGAS-STING Pathway Inhibitor Program to Develop Immunotherapies
Amgen Signs an Immuno-Oncology Agreement with Molecular Partners' for its MP0310
Bristol-Myers' Sprycel (dasatinib) Receives CHMP Recommendation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (ALL)
Ligand Purchases Palvella's Royalty Rights and Milestone Payments of PTX-022 for Pachyonychia Congenita
Merck's Keytruda (pembrolizumab) Receives EU Approval for Resected Stage III Melanoma in Adults
Lilly Acquires Hydra Biosciences with its Pre-Clinical Pain Program for Chronic Pain Syndromes
Merck Acquires Antelliq Group with its Digital Animal Health Technology
Amgen's Nplate (Romiplostim) Receives FDA's Approval for Immune Thrombocytopenia Aged 1 year and Older
Novartis' Xolair (omalizumab) Receives EU's Approval for Severe Allergic Asthma (SAA) and Chronic Spontaneous Urticaria (CSU)
Vertex‘s Orkambi (lumacaftor/ivacaftor) Receives Health Canada Approval for Cystic Fibrosis (CF) Aged 2 to 5 yrs.
Axovant Sciences Licenses Two Gene Therapy Programs from University of Massachusetts for Rare and Fatal Neurodegenerative Genetic Disorders
Eli Lilly's Olumiant (baricitinib) Receives FDA's Fast Track Designation for Systemic Lupus Erythematosus (SLE)
AstraZeneca and AVEO Oncology Enter into an Immuno-Oncology Clinical Collaboration
Lilly Collaborates with AC Immune (AC) to Develop Candidates for Neurodegenerative Diseases
Merck Collaborates with Instituto Butantan to Develop Vaccines for Dengue
Oxford BioTherapeutics Licenses WuXi Biologics' WuXiBody Platform for Five Bispecific Antibodies
CorMedix Reports Results of Neutrolin in P-III LOCK-IT-100 Study for Patients with Hemodialysis
Thyas Signs an Exclusive License Agreement with iPS Academia Japan (iPS-AJ) to Develop Autologous Immunotherapies
"Samsung Bioepis' Biosimilar Transtuzumab Ontruzant (transtuzumab,dttb), Receives US FDA Approval for Oncology Indications"
Vertex Pharmaceuticals' Orkambi (lumacaftor+ivacaftor) Receives EU Approval for Cystic Fibrosis (CF) with Mutation in CFTR gene in Children Aged 2 to 5
Celgene Signs an Exclusive WW License Option with Obsidian for DDs Technology
"Sandoz's Erelzi (etanercept, biosimilar) Receives Health Canada Approval for Psoriatic Arthritis (PsA) in Adults"
Verily‘s Study Watch Receives FDA's 510 (k) Clearance for Cardiovascular Disorders
"Eli Lilly Reports Results of Cyramza (ramucirumab) in P-III REACH 2 study for 2L AFP-High HCC, Published in The Lancet"
ProBioGen and CRISPR Therapeutics Signs a Multi-Year Research Collaboration for In Vivo Delivery Therapies
Eli Lilly Reports Results of Lartruvo (olaratumab) in ANNOUNCE P-III Study for Advanced or Metastatic Soft Tissue Sarcoma (STS)
Amgen's Blincyto (blinatumomab) Receives EU Expanded Indication Approval for Ph- CD19 Positive B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Albireo's A4250 Receives FDA's Orphan Drug Designation (ODD) for Biliary Atresia
Purdue Pharma Signs Exclusive License Agreement with Klaria for its KL-01401
Taiwan Liposome's TLC178 Receives EMA's ODD for Soft Tissue Sarcoma (STS)
Abbott's TactiCath Contact Force Ablation Catheter Receives FDA's Approval for Atrial Fibrillation (AFib)
B-MoGen Biotechnologies and CytoSen Therapeutics Sign an Agreement for the Development of Gene-Modified Therapies
Athersys Reports Results of Multistem Cell Therapy (IV) in Patients with Acute Respiratory Distress Syndrome (ARDS)
Grifols Signs a License and Commercialization Agreement with Rigel Pharmaceuticals for Fostamatinib
23andMe's MAP Report Receives FDA's 510(k) Clearance for Hereditary Colorectal Cancers
"Philogen Collaborates with Johnson&amp;Johnson (J&amp;J), Novartis and Celgene"
"Indian Government to Set Trade Margins of 50 Orphan Drugs, Treatments for Cancer and Rare Diseases"
Mannin Research Signs a Collaboration with Mcmaster University for MAN-01
Vertex Signs an Exclusive License Agreement with Merck KGaA for its Two DNA-PK Inhibitor
Medtronic to Acquire EPIX Therapeutics for its Cardiovascular Technologies
Clovis Oncology's Rubraca (Rucaparib) Receives EU Approval for Maintenance Treatment of Relapsed Ovarian Cancer (OC) in Adults
Dr. Reddy's Tosymra (sumatriptan nasal spray) 10mg Receives the US FDA Approval for Acute Treatment of Migraine
Amgen's Repatha (evolocumab) Receives NMPA (CFDA) Approval for Reduction of Cardiovascular Risks in China
Roche and Basilea Sign a Research Collaboration to Evaluate Derazantinib + Tecentriq (atezolizumab) in Patients with Urothelial Cancer (UC)
"Amgen and Allergan Report Results of ABP 798 (rituximab, biosimilar) in P-I/III (NCT02792699) for Moderate-To-Severe Rheumatoid Arthritis (RA)"
Zimber Biomet's Rosa Knee System Receives the US FDA's 510(k) Clearance for Robotically-Assisted Surgeries
"AbbVie's Imbruvica (ibrutinib) + Gazyva (obinutuzumab) Receives FDA's Approval, First CT Free Treatment for 1L+ CLL/SLL"
Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study in Patients with Atypical Hemolytic Uremic Syndrome (AHUS)
Purdue Pharma Signs an Agreement with Alivio Therapeutics for its ALV-107
"Innovent Biologics Reports Acceptance of BLA for IBI-305 (bevacizumab, biosimilar) from NMPA (CFDA) to Treat NSCLC"
Vertex's Kalydeco (ivacaftor) Receives Health Canada's Approval for Cystic Fibrosis (CF) with CFTR Gene Mutation in Children Aged 12 to
Medtronic Launches Mazor X Stealth Edition for Spine Surgery in the US
"Zai Lab Receives Priority Review for Zejula's (niraparib) NDA from NMPA (CFDA), in China"
Pfizer and Eli Lilly Report Results of Tanezumab in P-III OA study (A4091057) for Moderate-To-Severe Osteoarthritis (OA) Pain
Takeda Reports Results of TAK-003 in P-III TIDES (DEN-301) Trial for Dengue
Sumitomo Dainippon's Latuda (lurasidone HCl) Receives NMPA's (CFDA) Approval for Schizophrenia
"EMA Shifts its Headquarters from London to Amsterdam, The Netherlands"
Neurocrine and Voyager Collaborate to Develop and Commercialize VY-AADC &amp; VY-FXN01 for Parkinson's &amp; Friedreich's Ataxia Disease
Roche Discontinues P-III CREAD-1 and 2 Trials of Crenezumab in Patients with Early Alzheimer's Disease (AD)
AstraZeneca's Lumoxiti Receives FDA approval for the Treatment of R/R 2L+ Hairy Cell Leukemia in patients
Genentech Receives FDA approval for Actemra SC for the Treatment of Active Systemic JIA in patients aged =2 yrs.
Ipsen's Cabometyx Receives Health Canada's Approval for the Treatment of Advanced Renal Cell Carcinoma (RCC) in Adults
Merck's Delstrigo and Pifeltro Receives CHMP Approval for the Treatment of HIV-1 Infection in EU
Coherus Biosciences' Udenyca (Pegfilgrastim Biosimilar) Receives EU Marketing Approval for Febrile Neutropenia
Anaeropharma Science and Astellas Pharma Collaborates to Develop Novel Anti-Tumor Drugs Using i-DPS Technology
I-Mab Biopharma Expands Collaboration with Wuxi Biologics for three more Antibody Programs
Sanofi's Libtayo Receives the US FDA approval for Metastatic Cutaneous Squamous Cell Carcinoma (mCSCC)
Kite and HiFiBio Signs a Research &amp; License Agreement for Neoantigen-Reactive T Cell Receptors (TCRs)
Novo Nordisk's Tresiba Receives Health Canada Approval for Type 1 Diabetes in patients Aged =2 years
Eagle Pharmaceuticals and USAMRICD Signs an Agreement for Ryanodex (dantrolene sodium)
Xbrane Biopharma Reports Results of Xlucane Compared to Lucentis from In-Vivo Study
MeiraGTx Acquires Vector Neurosciences to Strengthen its Neurology Portfolio
Celgene to Present Results of Two P-III Trial SUNBEAM and RADIANCE Part B for Ozanimod to Treat RMS at ECTRIMS 2018
Myriad and Pfizer Signs a Service Agreement for Testing of BRCA-Mutated Triple Negative Breast Cancer
"Therapiva Private Acquires Dr. Reddy's API Manufacturing Unit Jeedimetla, Hyderabad"
Themis Biosciences Signs an Exclusive License Agreement with Max-Planck-Innovation for Oncolytic Virotherapies
AbbVie Announces FDA's Acceptance of sNDA for PR for Imbruvica (ibrutinib) + Gazyva (Obinutuzumab)
"Mylan Launches Hulio (adalimumab, biosimilar) in EU for Autoimmune Diseases"
"Mylan &amp; Biocon Receive CHMP Recommendation to Ogivri (trastuzumab, biosimilar) for HER-2 Breast Cancer"
"At ESMO'18, Pfizer Presents Results of PALOMA-3 Trial Results of Ibrance and Fulvestrant"
Novartis Reports Results of Extended Follow-up P-III COMBI-AD Trial of Tafinlar (dabrafenib) + Mekinist (trametinib) during ESMO18
UCB Reports Improved Results of Extended P-IIb BE ACTIVE study for Bimekizumab in Patients with Psoriatic Arthritis (PsA) Patients
Roche's Xofluza (baloxavir marboxil) Receives FDA Approval for Influenza in Patients Aged =12 yrs.
Medtronic's Valiant Navion(TM) Thoracic Stent Graft System Receives FDA Approval for Aortic Diseases
Regeneron's Eylea (aflibercept) Achieves 1EP &amp; 2EP in P-III PANORAMA trial in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)
Esperion Reports Completion of Bempedoic Acid in Global P-III LDL-C Development Program for Patients with ASCVD or HeFH
Lilly Signs a Global Research and License Collaboration with Dicerna for ~$550M
Henry Ford Health System Signs Development and Commercialization Agreement with G3 Pharma for its Galectin-3 inhibitors
Gilead Signs Global Research Collaboration with Tango to Develop &amp; Commercialize Targeted Immuno-Oncology Therapies
Sandoz's Hymiroz (adalimumab-adaz) Receives the US FDA Approval for Treatment of Chronic Autoimmune Diseases
Roche Reports Results of Venclexta/Venclyxto plus Gazyva/Gazyvaro in P-III CLL-14 study for CLL patients
Roche Receives EU Approval for Venclyxto (venetoclax) plus MabThera (rituximab) to Treat Adults with CLL
Sanofi and Denali Therapeutics Collaborates to Develop &amp; Commercialize Clinical Candidates for Neurology and Inflammatory Disorders
Vertex Receives EU's MAA for Symkevi (tezacaftor/ivacaftor) + Kalydeco (Ivacaftor) to Treat Patients with CF aged =12yrs. with Mutations in CFTR gene
Aileron Therapeutics &amp; Dana-Farber/Boston Children's Cancer and Blood Disorders Center Enters into a Clinical Collaboration to Treat Pediatric Patients with Cancer
"AbbVie Exercises its Option to License Agreement for BioArctic's Alpha-Synuclein Antibody Portfolio, Signed in 2016"
Illumina Acquires Pacific Biosciences for ~$1.2B with its Sequel SMRT Technology
Sage Reports Voting Results from FDA Advisory Committees for Zulresso (brexanolone) to Treat Postpartum Depression (PPD)
Eli Lilly and NextCure Signs a Multi-Year Collaboration to Develop Novel Immuno-Oncology Therapies
"Amgen to Present Long-Term Safety-Efficacy Data of Repatha (evolocumab) in Multiple studies, at AHA 2018"
Amgen Out-Licenses its AMG 714 (PRO-015) Candidate to Provention to Treat Celiac Disease
Eisai Reports Results of Lenvima (Lenvatinib) + Keytruda (pembrolizumab) to Treat Metastatic NSCLC Metastatic Melanoma and Metastatic Urothelial Carcinoma
Amgen Reports Safety &amp; Efficacy Results of Repatha (evolocumab) in OSLER-1 Five-Year Extension Study
Novartis' Gilenya (fingolimod) Receives EU's Approval for Relapsing-Remitting Forms of Multiple Sclerosis (RRMS)
Janssen (J&amp;J) Reports Results of Erleada (apalutamide) in P-III TITAN Study for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) #ASCO2019
Merck's V114 Receives FDA's Breakthrough Therapy Designation to Prevent Invasive Pneumococcal Disease
Columbia's Zuckerman Institute Develops an AI-based Brain-Computer Interface (BCI) for People with Aphasia &amp; Amyotrophic Lateral Sclerosis (ALS)
Eli Lilly's Alimta (pemetrexed) + Keytruda (pembrolizumab) Receives FDA's Expanded Label Approval for 1L Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
Janssen(J&amp;J) Signs an Exclusive Worldwide License Agreement with MeiraGTx for its Gene Therapy Candidates
Bayer Signs an Exclusive License Agreement with Kyoto University for Pulmonary Disorders
Alexion Collaborates with Caelum Biosciences for its CAEL-101 to Treat Light Chain (AL) Amyloidosis
Audentes Reports Next Phase Development of AT132 for X-linked Myotubular Myopathy (XLMTM) with RMAT Designation
ONO Signs a Research Collaboration with Repare Therapeutics for its Pol? Inhibitor Program
?Roche Recalls Lots of Coaguchek Xs Pt Test Strips with FDA's Class I Warning
Evolus' Jeuveau (prabotulinumtoxinA-xvfs) Receives FDA Approval for Moderate-to-Severe Glabellar Lines in Adults
?Novartis' Kymriah Receives NICE Approval for R/R Diffuse Large B-cell lymphoma (DLBCL) in Adults
Merck's KEYTRUDA (pembrolizumab) Receives CHMP Recommendation for 1L Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Argenx Signs a Worldwide License Agreement with Halozyme for its ENHANZE Technology
Eli Lilly Reports Results of Olumiant (baricitinib) in P-III BREEZE-AD1 and BREEZE-AD2 study for Moderate-to-Severe Atopic Dermatitis (AD)
?BioLineRX's BL-8040 Receives FDA's Orphan Drug Designation (ODD) for Pancreatic Cancer
?Eisai and Purdue Report Result of Lemborexant in P-III SUNRISE 2 Study for Insomnia in Adults
AstraZeneca's MEDI8897 Receives FDA's Breakthrough Therapy Designation (BTD) &amp; EMA's PRIME Designation for Lower Respiratory Tract Infection (LRTI) in Infants
Novartis to Acquire AveXis with its Gene Therapy Clinical Candidates
Celgene to Acquire Juno for its Cellular Immunotherapy &amp; Hematology Portfolio
?Sanofi to Acquire Bioverativ to Treat Hemophilia
FDA to Refuse Celgene for Filling Ozanimod's NDA for the Treatment of Relapsing Multiple Sclerosis
"GSK to Acquire 36.5% Stake in Consumer Healthcare Joint Venture, Established with Novartis"
Genentech Signs a Development and Commercialization Agreement with Xencor for its IL-15 &amp; XmAb24306 Programs
?Lilly Reports Negative Results of Solanezumab in P-III EXPEDITION Studies in Patients with Alzheimer Disease
"Novo Nordisk, Genentech and Sanofi to cut off jobs in 2018"
?Kyowa Kirin Signs an Exclusive Commercialization Agreement with Hisamitsu for its HP-3000
?Top Pharma Companies Appointed Their New CEOs in 2018
?Merck Reports Acceptance of NDA from FDA for Its (Imipenem/Cilastatin) + (Relebactam) for Complicated Urinary Tract and Intra-Abdominal Infections in Adults
?GSK to Collaborate with Pfizer to Build a Consumer Healthcare Joint Venture
Sanofi Report Results of Isatuximab in P-III ICARIA-MM Study for Patients with Relapsed/Refractory Multiple Myeloma (MM)
"Pfizer's Retacrit (epoetin alfa-epbx, biosimilar) Receives FDA Approval for Anemia ?"
"Pfizer's Nivestym (filgrastim-aafi, biosmilar) Receives the US FDA Approval for Neutropenia"
Celltrion's Truxima (rituximab-abbs) Receives FDA's Approval for Three on-Hodgkin's Lymphoma Indications
"?Celltrion and Teva's Herzuma (trastuzumab-pkrb, Herceptin biosimilar) Receives FDA's Approval for HER2-Overexpressing Breast Cancer"
"Amgen and Allergan's Mvasi (bevacizumab, biosimilar) + Combination Therapy Receives EU's MAA Approval for Treatment of Certain Types of Cancer"
"Celltrion's Herzuma (Trastuzumab Biosimilar, CT-P6) Receives EMA Approval for Breast Cancer, Metastatic Breast Cancer and Metastatic Gastric Cancer"
"Amgen and Allergan's ABP 980 (biosimilar, Herceptin) Receives CHMP Recommendation for Three Types of Cancer?"
"Sandoz's Zessly (infliximab) Receives EU Approval for Gastroenterological, Rheumatological And Dermatological Diseases"
Sandoz's Hyrimoz (adalimumab) Receives EU Approval for Autoimmune Disorders
"Biocon and Mylan Fulphila (pegfilgrastim, Neulasta biosimilar) Receives CHMP (EMA) Recommendation for Neutropenia"
Mylan and Biocon's Semglee Receives EU Approval for Patients with Diabetes
"GSK Signs a Worldwide Development &amp; Commercialization Collaboration with Merck KGaA, for $4.2B"
?Sanofi's Cablivi (caplacizumab-yhdp) Receives FDA's Approval for Acquired Thrombotic Thrombocytopenic Purpura (aTTP) in Adults
"?Paratek's Reports Results of Nuzyra (Omadacycline) in P-III OPTIC and OASIS-1 Studies for Pneumonia and Skin Infections in Adults, Published in NEJM"
Recordati Licenses Exclusive Commercialization Rights of Juxtapid (lomitapide) from Aegerion Pharmaceuticals ?
AstraZeneca's Fasenra Receives Orphan Drug Designation (ODD) For Hypereosinophilic Syndrome (HES)
P&amp;G to Acquire "This is L." for its Feminine Care Products in the US ?
?Medtronic's Pipeline Flex Embolization Device Receives FDA's Expanded Indication Approval for Intracranial Aneurysms (IAs)
BioMarin Reports Results of Brineura (cerliponase alfa) for Patients with CLN2 Disease Aged 3 to 16 yrs.
?Genagon Signs a Worldwide License Agreement with Ligand for its Omniab Technology
Orthofix Medical's M6-C Artificial Cervical Disc Receives FDA's Approval for Cervical Disc Degeneration
Galapagos Signs a Worldwide Development &amp; Commercialization Agreement with Evotec for Fibrotic Diseases
C-Bridge Capital Signs a Development &amp; Commercialization Agreement with Samsung Bioepis for Biosimilars in China
Regeneron Reports Results of Eylea (aflibercept) in P-III PANORAMA Trial for Diabetic Retinopathy (DR)
?Pfizer Recalls Lots of Ambaro (valsartan and amlodipine besylate salt) for its Carcinogenic Effects in Japan
Finch Therapeutics' CP101 Receives FDA's Breakthrough Therapy Designation (BT) for Recurrent Clostridium Difficile (C. difficile) Infection
?Bristol-Myers Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate-214 study in Patients with Advanced or Metastatic RCC
Astellas Reports Results of Xtandi (enzalutamide) in P-III ARCHES Trial for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Men
?Bayer Signs an Exclusive License Agreement with Moberg Pharma for MOB-015 in EU
Takeda's Adcetris (brentuximab vedotin) + AVD Receives EU Approval for CD30+ Stage IV Hodgkin Lymphoma (HL) in Adults
Genmab's Darzalex (daratumumab) Split Dosing Regimen Receives the US FDA Approval for Multiple Myeloma
?Gilead Reports Results of Selonsertib in P-III STELLAR-4 study for Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)
?AbbVie Signs a Partner and Option to Acquire Agreement with TeneoOne for its TNB-383B
Janssen (J&amp;J) Reports Voting Results from FDA Advisory Committees for Spravato (esketamine) in Adults with Resistant Depression
Almirall Signs an Option to License Agreement with Dermira to Develop and Commercialize Lebrikizumab in EU for Atopic Dermatitis ?
ITROM Pharmaceutical Signs an Exclusive License &amp; Commercialization Agreement with Mithra for 20 years
Novartis' Egaten (triclabendazole) Receives FDA's Approval for Fascioliasis in the US
?Johnson &amp; Johnson to Acquire Auris Health for its Monarch Technology for $5.7B
Clinigen Licenses Commercialization Rights for Proleukin from Novartis in the US
?Amgen Signs a Multi-Target Collaboration with Abilita Bio for Enabled Membrane Proteins (EMPs)
?Roche Signs a Clinical Program Agreement with Vaccibody to Evaluate VB10.16 + Tecentriq (atezolizumab) for Advanced Cervical Cancer
Bayer Reports Results of Darolutamide in P-III ARAMIS trial for Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Nestle Health Science (NHSc) Exercises its Exclusive WorldWide Option to License CDX-6114 from Codexis
Bristol-Myers (BMS) Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-II CheckMate -650 trial for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Signs a Multi-Target Agreement with AbCellera for its Ab-Based Technology
Arvelle Therapeutics Licenses Exclusive Development &amp; Commercialization Rights for Cenobamate from SK Biopharmaceuticals in EU?
Merck Reports Results of Keytruda (pembrolizumab) + Inlyta (axitinib) in P-III KEYNOTE-426 Study in Patients with 1L Advanced Renal Cell Carcinoma (RCC)
Bayer Exercises its Exclusive WW Option to License Vitrakvi &amp; BAY 2731954 with Change-In-Control Clause from Loxo Oncology
Medtronic to Recall its Dual Chamber Implantable Pulse Generators (IPGs) in the US
Medtronic Reports Results of PRODIGY Study in Patients with Opioid-Induced Respiratory Depression (OIRD)?
?Pfizer Reports Results of Bavencio (avelumab) + Inlyta (axitinib) in P-III JAVELIN Renal 101 trial for 1L Advanced Renal Cell Carcinoma (RCC)
Japan Ministry of Health Approves Use of Induced Pluripotent Stem Cells (iPSCs) for Spinal Injuries
Roche's Polatuzumab Vedotin as Combination Therapy &amp; Entrectinib Receives FDA's Priority Review for r/r Diffuse DLBCL &amp; NTRK Fusion-Positive Solid Tumors
Innovent Biosciences Collaborates with ?Chipscreen to Evaluate Chidamide in Combination with Sintilimab &amp; IBI305 in China
?AVEO Oncology Reports Results of Fotivda (tivozanib) in P-III TIVO-3 Study for Refractory Advanced or Metastatic Renal Cell Carcinoma (RCC)
?Merck's Keytruda (pembrolizumab) Receives FDA's Approval for Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node
"Novo Nordisk Receives BLA Approval for Esperoct (turoctocog alfa pegol, N8-GP) for Patients with Haemophilia A"
Alkermes Signs a Research Collaboration with Clovis Oncology to Evaluate ALKS 4230 in Combination with Rucaparib &amp; Lucitanib
?Pfizer and Lilly Report Result of Tanezumab in P-III A4091059 Study for Chronic Low Back Pain (CLBP)
Bausch + Lomb Licenses US Commercial Rights for Eton Pharmaceuticals' EM-100 to Treat Ocular Itching
?Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-240 Study for 1L Advanced Hepatocellular Carcinoma (HCC)
?Mustang Bio Signs an Exclusive Worldwide Collaboration with Nationwide Children's Hospital for Glioblastoma Multiforme
?Novo Nordisk Signs Non -Exclusive Agreement with Abbott for its FreeStyle Libre Mobile App
AbbVie's Humira (adalimumab) Receives Health Canada Approval for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients
Merck to Acquire Immune Design for its Technologies for $300M
AbbVie &amp; Eisai's Humira (adalimumab) Receives Approval for Hidradenitis Suppurativa in Japan
Amgen Reports Initiation of Second P-III METEORIC-HF Study of Omecamtiv Mecarbil for Patients with Heart Failure
Janssen (J&amp;J) Signs an Exclusive WW Research Collaboration with Morphic to Develop Human Integrins Therapies?
Eurofarma Signs an Exclusive Development and Commercialization Agreement with NLS-1 Pharma for its Nalazol Therapy
Mallinckrodt Reports Results of Therakos Photopheresis Therapy in P-III study for Steroid-Refractory Acute Graft-Versus-Host Disease (aGvHD)
?AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THEMIS Trial for Patients with Coronary Artery Disease (CAD) and Type-2 Diabetes (T2D)
? Roche to Acquire Spark Therapeutics for $4.3B
Santhera Reports Results of Raxone (Idebenone) in P-III DELOS trial for Patients with Duchenne Muscular Dystrophy (DMD)?
AbbVie Signs an Exclusive Worldwide Research Collaboration with Voyager Therapeutics for Vectorized Abs
?Danaher to Acquire Biopharma Unit of GE LifeScience for $21.4B
Novartis Exercises its Option to License AKCEA-APO(a)-LRx from Akcea
?Ipsen to Acquire Clementia Pharmaceuticals for $1.31B to Expand its Rare Disease Portfolio
?Amgen Reports In-Favor Uphold of its Two Patents for Repatha from Delaware Jury
?Genmab Reports Results of Darzalex (daratumumab) in P-III COLUMBA Study for Patients with R/R Multiple Myeloma
?AstraZeneca and Merck Report Result of Lynparza (olaparib) in P-III POLO Trial for BRCA-Mutated Metastatic Pancreatic Cancer #ASCO2019
?Roche and Immatics Collaborate to Evaluate IMA101 + Tecentriq (atezolizumab) for Solid Cancers
?Imbrium Signs a License Agreement with TetraGenetics for its TetraExpress Technology
?Medtronic Resolute Drug-Eluting Stent (DES) Platform Receives FDA's Approval for Expanded Indication for Chronic Total Occlusion (CTO)
Sarepta Exercises its Exclusive Option to Acquire Myngonexus Therapeutics for $165M
AstraZeneca's Farxiga and Xigduo XR Receives FDA's Expanded Label Approval for Type 2 Diabetes (T2D) and Moderate Renal Impairment
Janssen's Tremfya (guselkumab) Receives FDA's Approval for Moderate-to-Severe Plaque Psoriasis in Adults
Novartis Signs a Research Agreement with Target PharmaSolutions for Conducting TARGET-DERM Study?
?Novartis and Blackstone Life Sciences Collaborate to Launch Anthos Therapeutics for Cardiovascular Disorders
?Amicus Therapeutics' Galafold (migalastat) Receives FDA Approval for Fabry Disease in Adult Patients
AbCellera and Denali Therapeutics Expand Collaboration to Develop Abs for Neurological Disorders
?Servier's Asparlas (calaspargase pegol-mknl) Receives FDA's Approval for Acute Lymphoblastic Leukemia (ALL)
Shire's Motegrity (prucalopride) Receives FDA Approval for Chronic Idiopathic Constipation (CIC) in Adults
?Catalyst's Firdapse (amifampridine) Receives FDA's Approval for Lambert-Eaton Myasthenic Syndrome
Roche's Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) Receives FDA's Approval for Patients with HER2-Positive Breast Cancers
Biogen's Spinraza (nusinersen) Receives NMPA (CFDA) Approval for Spinal Muscular Atrophy (SMA) Aged 6wks.?
?Pfizer's Daurismo (glasdegib) Receives FDA Approval for Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML)
Sobi's Gamifant (emapalumab) Receives FDA Approval for Primary Haemophagocytic Lymphohistiocytosis (HLH)
Pfizer's Lorbrena (lorlatinib) Receives FDA Approval for Patients with 1L ALK- Positive Metastatic NSCLC
"Alvogen Expands Development and Commercialization Collaboration with Pfenex for PF708 in EU, MENA and ROW"
"Pfizer's Talzenna (talazoparib) Receives FDA Approval for BRCA-Mutated, HER2-Negative LA or MBC"
?Ionis' Tegsedi (inotersen) Receives FDA Approval for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Johnson &amp; Johnson (J&amp;J) Collaborates with AdoRx Therapeutics to Develop Therapies for Lung Cancer
Leadiant Biosciences Revcovi's (elapegademase-lvlr) Receives FDA Approval for Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID) in Pediatric and Adult Patients
Paratek Pharmaceuticals' Nuzyra (omadacycline) Receives FDA Approval for Community-Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Structure Infections (ABSSSI) in Adults
TaiMed Biologics' Trogarzo (ibalizumab-uiyk) Receives Approval for Multidrug Resistant (MDR)-HIV
Paratek's Seysara (sarecycline) Receives FDA's Approval for Treatment of Moderate to Severe Acne
?Verastem Oncology's Copiktra (duvelisib) Receives FDA Approval for r/r 2L+ Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Rigel Pharmaceuticals' Tavalisse (fostamatinib disodium hexahydrate) Receives FDA Approval for Chronic Immune Thrombocytopenia (ITP) in Adults
Merck's Pifeltro (doravirine) Receives FDA Approval for Patients with HIV-1 in Appropriate Patients
Therapeutics MD's Annovera (Segesterone Acetate/Ethinyl Estradiol) Receives FDA Approval for the Prevention of Pregnancy?
?Tetraphase Pharmaceuticals' Xerava (eravacycline) Receives FDA's Approval for Complicated Intra-Abdominal Infections (CIAI)
?Eli Lilly's Olumiant (baricitinib) Receives FDA Approval for Moderately-to-Severely Active Rheumatoid Arthritis (RA) in Adults
GSK's Krintafel (tafenoquine) Receives FDA Approval Preventing the Relapse of P.vivax Malaria?
AstraZeneca's Lokelma Receives FDA's Approval for Patients with Hyperkalaemia in Adults
Amgen's Aimovig (erenumab-aooe) Receives FDA's Approval for Prevention of Migraine in Adults
Agios Pharmaceuticals' Tibsovo (ivosidenib) Receives Approval For R/R Acute Myeloid Leukemia (AML) and IDH1 Mutation?
Janssen's Erleada (apalutamide) Receives FDA Approval for Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)
?Helsinn's (fosnetupitant + palonosetron) Receives FDA Approval for Managing Chemotherapy-Induced Nausea and Vomiting (CINV)
?SIGA Technologies' TPOXX (tecovirimat) Receives FDA Approval for Smallpox
BioMarin's Palynziq (pegvaliase-pqpz) Receives FDA Approval for Phenylketonuria (PKU) in Adults
Achaogen's Zemdri (plazomicin) Receives FDA Approval for Complicated Urinary Tract Infection (cUTI)
GW Pharmaceuticals' Epidiolex (cannabidiol) Receives FDA Approval for Epilepsy for 2yrs. or older
Medicines Development for Global Health's (MDGH) Moxidectin Receives FDA Approval for Onchocerciasis (River Blindness)
?Novavax Reports Results of ResVax in P-III PREPARE Trial for Prevention of RSV Disease in Infants via Maternal Immunization
Biocodex's Diacomit (stiripentol) Receives FDA Approval for Seizures Associated with Dravet Syndrome (DS) in Patients Aged 2 Years or Older
Sanofi's Zynquista (sotagliflozin) and Dupixent (dupilumab) Receives CHMP Recommendation for Type 1 Diabetes and Asthma?
Novartis Reports Results of Cosentyx (secukinumab) in P-III Study in Patients with Moderate to Severe Plaque Psoriasis in China?
?Lupus Therapeutics Signs a Research Agreement with Takeda for its TAK-079
?Biogen to Acquire Nightstar Therapeutics for $800M
?Verastem Oncology Reports Results of Copiktra (Duvelisib) in P-III DUO Study in Patients with R/R CLL/SLL
?Clovis Oncology Launches Rubraca (rucaparib) for Women with Relapsed Ovarian Cancer in Germany
?Ascendis Pharma Reports Results of TransCon Growth Hormone in P-III Height Study for Growth Hormone Deficiency (GHD) in Children
"Bioxcel, Nektar and Merck KGaA in a Triple Collaboration for Pancreatic Cancer"
ProMab Biotechnologies Signs Worldwide License Agreement with NantKwest to Develop Ab for Multiple Myeloma
?Celgene's Fedratinib Receives FDA's Priority Review to NDA Filing for Myelofibrosis
Genentech Announces FDA's Acceptance of sNDA for Xofluza (baloxavir marboxil) in Patients with Influenza
?Pacira to Acquire MyoScience to Expand its Post-Surgical Portfolio
Acceleron's ACE-083 Receives FDA's ODD for Charcot Marie Tooth Disease (CMT)
Pfizer Exercised its Option to License AnTolRx's Immune Tolerance Therapy for Type 1 Diabetes (T1D)
?Allergan Reports Results of Rapastinel in Four P-III RAP-MD Studies for Major Depressive Disorders (MDD)
?BeiGene and Ambrx Enters into a Worldwide Research and Development Collaboration to Develop Novel Biologics
Vertex Reports Positive Results of Triple Combination Therapy in P-III Studies for Cystic Fibrosis?
?Alnylam Reports Positive Result of Givosiran in P-III ENVISION Study for Acute Hepatic Porphyria (AHP)
?Baxter's Eptifibatide Receives the US FDA's Approval for Cardiovascular Diseases
?Shionogi Signs Development &amp; Commercialization Agreement with Akili for its AKL-T01 and AKL-T02 for ADHD &amp; ASD
?Oncternal Therapeutics Reverse Merges with GTx
?Janssen (J&amp;J) Reports Positive Results of Rilpivirine + Cabotegravir in P-III ATLAS and FLAIR Studies for HIV
Zeiss' CIRRUS HD-OCT Receives FDA's 510 (k) Clearance for Epithelial Thickness Mapping (ETM)
?Bayer Submits EU's Marketing Authorization Application to EMA for Darolutamide
Roche's Ventana PD-L1 (SP142) Receives FDA's Approval for Identifying Triple-Negative Breast Cancer (TNBC) as CDx?
?MSD Signs a License Agreement with King's College London &amp; Wellcome's Innovations to Develop Chronic Neuropathic Pain Therapies
Almirall's Ilumetri (tildrakizumab) Receives NICE's Provisional Approval for Moderate-To-Severe Plaque Psoriasis?
?Roche's Tecentriq + Abraxane Receive FDA's Accelerated Approval for mTNBC
?AstraZeneca and Seres Therapeutics Enters into Research Collaboration for 3yrs.
Pfizer's Trazimera (trastuzumab-biosimilar) Receives FDA's Approval for HER-2+ Breast Cancer and m-Gastric/GEJ Cancer?
Allergan Reports Acceptance of NDA from FDA for its Ubrogepant for Migraine
?Fujifilm to Acquire Biogen's Danish Biologics Manufacturing Facility for $890M
?Paige.AI Receives FDA's Breakthrough Designation for its Artificial Intelligence in Pathology
Eli Lilly Reports Positive Results of Cyramza (ramucirumab) in P-III RELAY Study for mNSCLC?
Vertex's Symdeko (tezacaftor/ivacaftor and ivacaftor) Receives TGA's Approval for Cystic Fibrosis with CFTR Gene Mutation in Australia?
?Secura Bio Acquires WW Commercialization Rights to Novartis' Farydak for R/R Multiple Myeloma
?Akebia Therapeutics Reports Positive Results of Vadadustat in P-III J01 &amp; J03 Studies for Anemia Due to Chronic Kidney Disease (CKD) in Japan
?Exactech to Acquire XpandOrtho for its Ligament-Balancing Technology
?Sun Pharma's SPARC Signs a Research Collaboration with HitGen to Develop Therapies
?Retrotope's RT001 Receives EMA's Orphan Drug Designation for Infantile Neuroaxonal Dystrophy (INAD)
?Smith &amp; Nephew to Acquire Osiris Therapeutics for $660M
?Roche's Hemlibra Receives EU's Approval for Severe Haemophilia A without Factor VIII Inhibitors
?Hoth Therapeutics Signs a License Agreement with UMB and Isoprene Pharmaceuticals
?Merck's Keytruda + Chemotherapy Receive EU's Approval for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
?Merck KGaA Collaborates with Iktos for its Artificial Intelligence (AI) Technology
?Bayer Reports Results of Nifurtimox in P-III CHICO Study for Chagas Disease in Pediatric Patients
Roche's MabThera (rituximab) Receives EU's Approval for Rare Autoimmune Disease Pemphigus Vulgaris (PV)
?Abbott's MitraClip Device Receives FDA's Expanded Indication Approval for Secondary Mitral Regurgitation (MR)
AbCellera ?Signs a Research Agreement with Bill &amp; Melinda Gates Foundation to Accelerate Global Health Research
BMS Reports Positive Results of Eliquis (apixaban) in P-IV AUGUSTUS Study for NVAF/ACS/PCI
Alcon to Acquire PowerVision for $285M
?Novartis Reports Results of Entresto (sacubitril/valsartan) in PIONEER-HF 4-Week Extension Study for Systolic Heart Failure
?Cellesce Signs a License Agreement with Hubrecht Organoid Technology (HUB) for the Expansion of Organoids
AstraZeneca Reports Positive Results of Farxiga in P-III DECLARE-TIMI 58 Study for Type-2 Diabetes (T2D)
?Baxter and BioMerieux Collaborates to Develop Biomarkers for Acute Kidney Injury (AKI)
Jazz Pharmaceuticals' Sunosi (solriamfetol) Receives FDA's Approval for the Treatment of Sleep Disorders?
Mylan Voluntary Globally Recalls 2 Lots of Levoleucovorin (250mg/25ml) Injection Used to Prevent Harmful Effects of Methotrexate
Merck Extends its Strategic Collaboration with NGM Biopharmaceuticals
Roche's Tecentriq (atezolizumab) + Chemotherapy (carboplatin and etoposide) Receive FDA's Approval for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
?Biogen and Eisai Terminate P-III ENGAGE and EMERGE Study for Alzheimer's Disease
Théa and OliX Announce Collaboration to Develop RNAi Therapies for the Treatment of AMD
Merck KGaA and Pfizer Terminates P-III JAVELIN Ovarian PARP 100 Study for Advanced Ovarian Cancer
?Celgene Collaborates with Exscientia for its AI Drug Discovery Platform
"?Novartis Announces Spin-Off of Alcon Eye Care Business on April 9, 2019"
AbbVie Reports FDA's Hold on All Clinical Trials Evaluating Venclexta/Venclyxto (venetoclax) for Multiple Myeloma
?Merck KGaA Collaborates with GenScript for the Expansion of Cell and Gene Therapies in China
?Sage Therapeutics' Zulresso (brexanolone) Receives FDA's Approval for Postpartum Depression (PPD)
Evotec and GARDP Collaborates to Develop Novel Antibiotics for Antimicrobial Resistance (AMR)?
AstraZeneca Signs Development and Commercialization Agreement with Kyowa Hakko Kirin for its Fasenra (beralizumab)?
?Thermo Fischer to Acquire Brammer Bio for $1.7B
?Almirall Signs a Research Collaboration with HitGen for its DNA-Encoded Technology
?Lupin and YL Biologics' Etanercept Biosimilar (YLB113) Receive PMDA's Approval for Moderate-to-Severe Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA) in Japan
"AbbVie's Skyrizi (risankizumab) Receives Japanese Ministry of Health, Labour and Welfare (MHLW) Approval to Treat Plaque Psoriasis, Generalized Pustular Psoriasis, Erythrodermic Psoriasis and Psoriatic Arthritis in Adults"
?Celgene Files NDA for Ozanimod to the US FDA for Relapsing Forms of Multiple Sclerosis (RMS)
Novartis' Mayzent (siponimod) Receives FDA's Approval for Patients with Secondary Progressive Multiple Sclerosis (SPMS)?
?Eli Lilly Signs an Exclusive Worldwide License Agreement with ImmuNext to Develop Therapies for Autoimmune Disorders
?AstraZeneca's Forxiga (dapagliflozin) Receives MHLW's Approval for Type-1 Diabetes (T1D) in Japan
"?Gilead's Biktarvy (Bictegravir, Emtricitabine and Tenofovir Alafenamide) Receives MHLW's Approval for HIV-1 Infection in Japan"
?Jazz Pharmaceuticals Reports Results of JZP-258 in P-III Study for Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness
Takeda Collaborates with LegoChem Biosciences (LCB) to Develop Antibody-Drug Conjugates in Immuno-Oncology
?Eisai Signs a Research Agreement with Cerveau Technologies for its Novel Tau Imaging Agent
AstraZeneca's Forxiga (dapagliflozin) Receives EU's Approval for Type-1 Diabetes (T1D) in Adults
?BioLineRx Reports Engraftment Data of BL-8040 in P-III GENESIS Trial for Patients with Multiple Myeloma
?Chugai's Risdiplam Receives MHLW's Orphan Drug Designation for Spinal Muscular Atrophy (SMA)
?Ono Pharmaceutical Signs a Multi-Year Collaboration with LifeArc and Cancer Research UK to Develop Immuno-Therapies for Cancer
?Apple Launches its Watch Series 4 Enabled with ECG App and Irregular Rhythm Notification in Europe and Hong Kong
?Johnson &amp; Johnson (J&amp;J) Vision Launches Acuvue Oasys with Transitions Light Intelligent Technology in the US
?Bayer Signs a Non-Exclusive Licensing Agreement with ProteoNic Biotechnology for its 2G UNic Technology
?Gilead and Galapagos' Report Results of Filgotinib in P-III FINCH 3 Trial for Moderate-To-Severe Active Rheumatoid Arthritis (RA)
?AstraZeneca Signs a Worldwide Development and Commercialization Agreement with Daiichi Sankyo for $6.9B
?Mitsubishi Tanabe Pharma (MTPA) Collaborates with Massachusetts General Hospital (MGH) for ALS Biomarker Study
Takeda Signs a Multi-Target Agreement with StrideBio to Develop Gene Therapies for Neurological Disorders
?Bluebird Bio's Zynteglo Receives CHMP's Positive Opinion for Conditional Marketing for Patients with Transfusion-Dependent ß-Thalassemia (TDT) without ß0/ß0 Genotype
?Novartis to Acquire IFM Tre for its Clinical and Preclinical Portfolio of NLRP3 Inhibitors for $1.5B
?Boehringer Ingelheim (BI) to Acquire ICD Therapeutics for its MacroDel Delivery Technology
?Roche Reports Result of Ipatasertib + Tecentriq (atezolizumab) in P-Ib Study for 1L Patients with Advanced Triple-Negative Breast Cancer (TNBC)
?VistaGen Therapeutics Reports Positive Results of PH94B in P-III study for Social Anxiety Disorder (SAD)
AveXis to Purchase Biologics Manufacturing Facility in Colorado
?Merck's Keytruda (pembrolizumab) + Chemotherapy Receive NMPA's (CFDA) Approval for 1L Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Novartis' Cosentyx (secukinumab) Receives NMPA's (CFDA) Approval for Patients with Plaque Psoriasis in Adults
Sangamo Therapeutics Signs an Option Agreement with Brammer Bio for its AAV Manufacturing Facility
Allergan and Molecular Partners Report Result of Abicipar pegol in P-III MAPLE Study for Neovascular Macular Degeneration (nAMD)?
?Astellas Signs a Research and License Agreement with Xencor for Bispecific Antibody Program in Oncology
?Encore Dermatology to Acquire US Commercialization Rights for Dr. Reddy's Three Dermatology Products
?Dermelix Collaborates with EspeRare to Co-develop and Commercialize DMX-101 for XLHED
?Channel Medsystems' Cerene Cryotherapy Device Receives FDA's Approval for Heavy Menstrual Bleeding
?Liquidia Reports Results of LIQ861 in P-III INSPIRE Trial in Patients with Pulmonary Arterial Hypertension (PAH)
"?Fresenius Kabi's Idacio (adalimumab, biosimilar) Receives EU's Marketing Approval in Rheumatology, Gastroenterology and Dermatology"
?Editas Medicine Signs a Research and Cross-Licensing Agreement with BlueRock Therapeutics for their Technologies
?Genmab and Janssen Biotech Report Initiation of P-III MMY3021 Study for Darzalex (daratumumab) in Multiple Myeloma
AstraZeneca and the US NIAID Report Results of Fasenra (benralizumab) in P-II Study for Hypereosinophilic Syndromes (HES)
?Oncology Venture Signs an Exclusive Option Agreement to In-License Commercialization Rights for R-Pharm's Ixempra (ixabepilone) in EU
?Myriad Expands its Companion Diagnostic Collaboration with AstraZeneca and Merck
?Abbott Signs a Non-Exclusive License Agreement with Banyan Biomarkers for its Traumatic Brain Injury (TBI) Blood Biomarkers
?Roivant Launches Cytovant Sciences to Collaborates with Medigene for the Development of Cellular Therapies in Asia
?Amazon Launches Alexa's Health Services for Managing Health and Handling Patients Data
?Novartis' Kisqali + Aromatase Inhibitor Receive FDA's Breakthrough Therapy Designation for HR+/HER2- Advanced Breast Cancer
?Roche's Hemlibra Receives FDA's Breakthrough Therapy Designation for Hemophilia A without Factor VIII Inhibitors
Roche's Tecentriq + Avastin Receive FDA's Breakthrough Designation as 1L Treatment for Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Proteostasis' PTI-428 Receives FDA's Breakthrough Therapy Designation for Cystic Fibrosis (CF)
Novartis' Promacta Receives FDA's Breakthrough Therapy Designation for Severe Aplastic Anemia (SAA)
Seattle Genetics' Adcetris (brentuximab vedotin) Receives FDA's Breakthrough Designation for Frontline Peripheral T-Cell Lymphomas?
?Compass Pathways' Psilocybin Therapy Receives FDA's Breakthrough Therapy Designation for Treatment-Resistant Depression
Sage Therapeutics' SAGE-217 Receives FDA's Breakthrough Designation for CNS Disorders
?Avita Medical Reports Results of RECELL System in Investigational Device Exemption (IDE) Compassionate Use and Continued Access Studies for Third-Degree Burns in Pediatric Patients
?Celgene and Acceleron Pharma Submit Biologics License Application (BLA) to the US FDA for Luspatercept
?Sanofi and Alnylam Exercise Research and Option Phase Collaboration for its 2014 Deal
Xoma Purchases Royalty Rights for Aronora's Five Preclinical and Clinical Hematology Candidates
"?Regeneron Collaborates with Alnylam to Discover, Develop and Commercialize RNAi Therapeutics for Ophthalmic and CNS Disorders"
ViiV Healthcare's Dovato (dolutegravir/lamivudine) Receives FDA's Approval to Treat HIV-1 Infection in Adults?
?uniQure's AMT-130 Receives FDA's Fast Track Designation for Huntington's Disease
?Audentes Signs an Exclusive License Agreement with Nationwide Children's Hospital (NCH) for the Expansion of its AAV Technology and Pipeline
?BeiGene Signs a Worldwide Co-Development and Commercialization Agreement with BioAtla for BA3071 and Tislelizumab
Amgen's Evenity (romosozumab-aqqg) Receives FDA's Approval for Osteoporosis in Postmenopausal Women at High Risk for Fracture
?Xinhua Healthcare Signs an Exclusive License Agreement with ArcDia for its mariPOC Technology in China
?AstraZeneca and Merck's Lynparza (olaparib) Receive EU's Approval as a Monotherapy to Treat Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer
?­Alkermes' Reports Results of Aristada (aripiprazole lauroxil) and Invega Sustenna (paliperidone palmitate) in P-IIIb ALPINE Study to Treat Schizophrenia
Shanghai Fosun Signs an Exclusive License Agreement with ReNeuron for its CTX and hRPC Cell Therapy in China
?Astellas Collaborates with Concerto HealthAI on Real-World Evidence (RWE) Initiative for Acute Myeloid Leukemia (AML)
?Shanghai Miracogen Signs a Non-Exclusive License Agreement with Synaffix for its ADC Technologies
Sandoz Signs a Commercialization Agreement with Shionogi for Rizmoic (naldemedine) in Europe
Cognoa Signs an Exclusive License Agreement with Stanford for its Google Glass-based Technology for Children with Autism Spectrum Disorder (ASD)
?BioDelivery Sciences (BDSI) Signs a License Agreement with Shionogi to Commercialize Symproic (naldemedine) in the US
Merck's Keytruda (pembrolizumab) Receives FDA's Expanded Monotherapy Label Approval for Patients with 1L Stage III Non-Small Cell Lung Cancer (NSCLC)
Evotec Signs a Research Agreement with Indivumed to Develop Precision Therapies for Colorectal Cancer (CRC)
Moleculin Signs a Clinical Research Agreement with Emory University for Brain Tumor in Pediatric Patients
Gilead and Novo Nordisk Collaborate to Conduct a Combination Therapy Trial in NASH
Omron Healthcare Receives FDA's Approval for Complete a Blood Pressure Monitoring Device with ECG Facility
?Alnylam Reports Results of Givosiran in P-III ENVISION Study to Treat Acute Hepatic Porphyria
?Tracon Terminates its P-III TAPPAS Trial of TRC105 (carotuximab) + Votrient (pazopanib) for Advanced or Metastatic Angiosarcoma
?Dr. Reddy's to Acquire a Portfolio of 42 Abbreviated New Drug Applications (ANDA) in the US
Santhera to Present Result of DELOS &amp; SYROS Study at the 2019 MDA Clinical and Scientific Conference ?
?Generium and Selexis Launch Eculizumab Biosimilar for Paroxysmal Nocturnal Hemoglobinuria (PNH) and Hemolytic Uremic Syndrome (aHUS) in Russia
Novartis Reports FDA's Acceptance of BLA for Brolucizumab (RTH258) to Treat Wet AMD
?Castle Creek Collaborates with Fibrocell to Develop and Commercialize FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Eagle Restructured its Licensing Agreement with Teva for Bendeka (bendamustine hydrochloride)
Janssen Expands Clinical Development for Tremfya(R) (guselkumab) in Familial Adenomatous Polyposis (FAP)?
Alnylam Initiates P-III ILLUMINATE-B Study of Lumasiran for Primary Hyperoxaluria Type 1 (PH1) in Pediatric Patients
Tessa Collaborates with Merck to Evaluate a Combination Therapy for Metastatic or Recurrent Cervical Cancer?
?Novartis Reports Results of Zolgensma (onasemnogene abeparvovec-xioi) in P-III STR1VE Study for Spinal Muscular Atrophy (SMA) Type 1
?FDA Orders Immediate Stop on Commercialization of Surgical Mesh for Women with Pelvic Collapse in the US
Thermo Fisher Collaborates with NX Prenatal to Develop Proteomics Assays for Adverse Pregnancy Outcomes
?Gilead Collaborates with Insitro to Discover and Develop Novel Therapies in Nonalcoholic Steatohepatitis (NASH) for 3yrs.
?Boehringer Ingelheim Collaborates with PureTech to Develop Immuno-Oncology Candidates for Immune Modulation
?CASI Pharmaceutical Signs an Exclusive Worldwide License Agreement with Black Belt for its TSK011010 Program
Medtronic Reports Results of VenaSeal Closure System in VeClose Extension Study for Chronic Venous Diseases
?OncoSec Signs Research Agreement with Duke University School of Medicine to Evaluate the Combination of TAVOPLUS with a HER2-Plasmid Vaccine
World Health Organization (WHO) Reports 10 Guidelines on Digital Health Interventions
Pfizer &amp; Eli Lilly Report Results of Tanezumab in Long-Term P-III Study for Osteoarthritis
?AbbVie's Skyrizi (risankizumab) Receives Health Canada's Approval for Moderate to Severe Plaque Psoriasis
?Mylan and TB Alliance Collaborate to Commercialize Pretomanid in Two Combination Regimens for Tuberculosis
?NICE Publishes Final Recommendation for Almirall's Ilumetri (tildrakizumab) to Treat Moderate-To-Severe Plaque Psoriasis in Adults
?Almac Diagnostic Collaborates with Queen's University to Bring Personalized Chemotherapy for Esophageal Cancer
?Alvogen Voluntary Recalls Nationwide Two Lots of Fentanyl Transdermal System Due to Product Mislabeling
?TELA Bio's Restella Reconstructive BioScaffolds Receives FDA's 510(k) Clearance for Reconstructive Surgery
?Lilly Signs a Global Research and Licensing Agreement with Avidity Biosciences to Develop Therapies in Immunology
Merck's Keytruda (pembrolizumab) + Inlyta (axitinib) Receive FDA's Approval as 1L Treatment for Advanced Renal Cell Carcinoma
?Lilly Reports Results of Taltz (ixekizumab) in P-III COAST-X Study for Non-Radiographic Axial Spondyloarthritis
?Roche Launches Ventana HER2 Dual ISH CDx for the Identification of Breast and Gastric Cancer
?Eli Lilly to Sell Rights for its Two Antibiotics and a Manufacturing Facility to Eddingpharm in China for $375M
?Alder BioPharmaceuticals Reports FDA's Acceptance of BLA for Eptinezumab to Prevent Migraine
NuVasive Reports Results of Cohere Porous PEEK Implants for Degenerative Cervical Disc
BAROnova's TransPyloric Shuttle Device Receives FDA's Approval for the Treatment of Obesity in Adults
Teva Discontinues its P-III ENFORCE Study of Fremanezumab for Episodic Cluster Headache
?OncoSec Initiates a Triple Combination Immunotherapy Trial for Squamous Cell Head and Neck Cancer
AbbVie's Skyrizi (risankizumab-rzaa) Receives FDA's Approval for Moderate to Severe Plaque Psoriasis
Fulcrum Therapeutics ?Signs an Exclusive Worldwide License Agreement with GSK to Develop and Commercialize Losmapimod for Facioscapulohumeral Muscular Dystrophy
?Takeda Signs a Licensing Option Agreement with Emendo Biotherapeutics for its OMNI Nuclease Program
Perelman School of Medicine Signs a Research and Development Agreement with Sensus Healthcare for its Sculptura Intraoperative Radiation Therapy System
ADC Therapeutics Signs a License Agreement with Adagene for its SAFEbody Technology
Eli Lilly Facilitates the Withdrawal of Lartruvo (olaratumab) from the Global Market for Advanced Soft Tissue Sarcoma
?B. Braun Launches its Heparin Sodium Prefilled Syringe in the US
Salix (Bausch Health) Signs an Exclusive License Agreement with Mitsubishi Tanabe for its MT-1303 (amiselimod)
Merck Reports Updated Results of Keytruda (pembrolizumab) in P-III KEYNOTE-062 Study as a Monotherapy for 1L Treatment of Advanced Gastric Cancer
Takeda Files NDA for Cabometyx (cabozantinib) to MHLW for Advanced Renal Cell Carcinoma in Japan
?Gilead Reports Results of Selonsertib in P-III STELLAR 3 Study for Bridging Fibrosis (F3) due to NASH
Novo Nordisk Files MAA for Semaglutide to the EMA for Type 2 Diabetes?
?AstraZeneca and Merck's Lynparza (olaparib) Receive CHMP's Positive Opinion for 1L Maintenance Treatment of BRCA-Mutated Advanced Ovarian Cancer
Sanofi and Lexicon's Zynquista (sotagliflozin) Receive EU's MAA to Treat Type-1 Diabetes in Adults
Acutus Medical's AcQMap Contact Mapping Software Receives CE Mark Approval
"?Novo Nordisk's Esperoct (turoctocog alfa pegol, N8-GP) Receives CHMP's Positive Opinion to Treat Hemophilia A in Adolescents and Adults"
Sandoz Signs an Agreement with EirGenix to Commercialize Proposed Trastuzumab Biosimilar for HER2+ Cancer Tumors
ViiV Healthcare Files NDA for Cabotegravir + Edurant (rilpivirine) to the US FDA to Treat HIV-1 Infection in Adults?
?Janssen Collaborates with Iktos for its Artificial Intelligence (AI) Technology
?AstraZeneca Collaborates with BenevolentAI to Develop Therapies for Chronic Kidney Disease and Idiopathic Pulmonary Fibrosis
Abbott Reports Results of High Sensitive Troponin-I Blood Test for Risk Assessment of Heart Diseases
Vertex's Kalydeco (ivacaftor) Receives FDA's Approval for Cystic Fibrosis in Eligible Infants Aged 6 to Less than 12 Months
?AbbVie's Mavyret (glecaprevir and pibrentasvir) Receives FDA's Approval for All Genotypes of Hepatitis C in Pediatric Patients
?Roche Spin-Off Nimble Therapeutics to Commercialize its Drug Development Technology
?AbbVie's Skyrizi (risankizumab) Receives European Commission's Approval for Moderate to Severe Plaque Psoriasis
?Medtronic Launches Solitaire X Revascularization Device for Acute Ischemic Stroke in the US
?Exelixis Initiates P-III COSMIC-313 Study of Triple Combination Therapy for Advanced Renal Cell Carcinoma
Medtronic's Attain Stability Quad MRI SureScan Left Heart Lead Receives FDA's Approval for Heart Failure?
?Eisai Terminates its Worldwide Development &amp; Commercialization Agreement with Purdue Pharma for Lemborexant
?Tmunity Signs an Exclusive Research Agreement with the University of California to Advance TCR Therapies for Pediatric Cancers
Sanofi's Dengvaxia Receives FDA's Approval to Prevent Dengue in Endemic Region in the US
?AstraZeneca Signs an Exclusive Option and Research Agreement with Transgene for Oncolytic Immunotherapies
?GSK Reports Results of Trelegy Ellipta in P-III CAPTAIN Study for Asthma
?Boehringer Ingelheim Signs a Clinical Research Agreement with Amal for the Evaluation of Combination Therapy to Treat Stage IV colorectal cancer
?Celgene Collaborates with Presage to Evaluate Therapies with its CIVO Technology for Multiple Cancers
"?AstraZeneca's Qternmet XR (dapagliflozin, saxagliptin, metformin hydrochloride) Receives FDA's Approval for Type-2 Diabetes in the US"
?Roche's Kadcyla (trastuzumab emtansine) Receives FDA's Expanded Approval as an Adjuvant Treatment for HER2+ Early Breast Cancer in the US
?Lundbeck to Acquire Abide Therapeutics for $400M
?Astellas Reports Results of Mirabegron in P-IV PLUS Study to Reduce Overactive Bladder Symptoms in Men
?Pfizer's Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) Receive FDA's Approval for Transthyretin Amyloid Cardiomyopathy
?Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Two P-III Studies to Treat Low- and High-Frequency Episodic Migraine
?Roche Reports Results of Risdiplam in FIREFISH and SUNFISH Studies for Spinal Muscular Atrophy
?BioMarin's Palynziq (pegvaliase injection) Receives European Commission's MAA Approval for Phenylketonuria
Takeda Collaborates with Skyhawk Therapeutics to Develop RNA Splicing Modifiers for Neurodegenerative Diseases
?Novartis Reports Results of MS Progression Discussion Tool in a Validation Study for Patients with Multiple Sclerosis
?AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic Leukaemia
?Roche Reports Results of Ocrevus (ocrelizumab) in Three P-III Studies for Relapsing and Primary Progressive Multiple Sclerosis
?Sanofi's Dupixent (dupilumab) Receives European Commission Approval for Severe Asthma with Type 2 Inflammation
?AstraZeneca and Daiichi Report Results of Trastuzumab Deruxtecan (DS-8201) in P-II DESTINY-Breast01 Study for Refractory HER2+ Metastatic Breast Cancer
?FDA Issues an Alert on Medtronic's Pacemaker or Cardiac Resynchronization Therapy Pacemaker for its Premature Battery Depletion
Pfizer to Acquire Therachon for the Expansion of its Rare Disease Portfolio
?Novartis Acquires Worldwide Rights of Takeda's Xiidra (lifitegrast ophthalmic solution) for $5.3B
?Medtronic Reports Results of MiniMed 640G System in the SMILE Study for Reducing Hypoglycemia in Patients with Type 1 Diabetes
?Janssen (J&amp;J) Expands its PTG-200 Collaboration with Protagonist for Second Generation Oral IL-23 Receptor Antagonists
Gilead Collaborates with Goldfinch Bio to Develop and Commercialize Therapies for Kidney Disorders
Takeda Signs a Licensing Agreement with Curadev for Stimulator of Interferon Genes (STING) Agonist
?Ethicon Acquires Rights of Takeda's TachoSil Fibrin Sealant Patch for ~$400M
?BMS Report Results of Opdivo + Radiation in P-III CheckMate -498 Study in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme
?Medtronic To Acquire Titan Spine for its Portfolio of Implants and nanoLock Surface Technology
?Takeda Reports FDA's Acceptance of BLA for Entyvio (Vedolizumab SC) as a Maintenance Therapy in Moderate to Severe Active Ulcerative Colitis
?Boston Scientific to Acquire Vertiflex for its Superion Indirect Decompression System
AstraZeneca Reports Results of Roxadustat in Global Phase III Programme for Cardiovascular Safety in Patients with Chronic Kidney Disease
?Eli Lilly's Cyramza (ramucirumab) Receives FDA's Approval as a Second-line Treatment in Patients with High AFP Hepatocellular Carcinoma
"?Novartis Voluntary Nationwide Recalls Three Lots of Promacta (eltrombopag, 12.5 mg) Oral Suspension Due to Peanut Contamination"
?Boston Scientific Reports Results of Emblem S-ICD System in UNTOUCHED Study to Prevent Sudden Cardiac Death
The US FDA Issues Final Guidance on Interchangeable Biosimilars
?Roche Launches Cobas MTB-RIF/INH Test for the Detection of Antimicrobial Resistance in Tuberculosis
?Regeneron's Eylea (aflibercept) Injection Receives FDA's Approval for Diabetic Retinopathy
?Exelixis and Daiichi Report Launch of Minnebro (Esaxerenone) Tablets for Hypertension in Japan
?AliveCor's KardiaMobile 6L Receives FDA's Clearance as Six-Lead Personal ECG Device
?HanX Biopharmaceuticals Signs a License Agreement with Onconova to Develop and Commercialize Rigosertib in Greater China
?Myovant Sciences Reports Results of Relugolix Combination Therapy in P-III LIBERTY 1 Study for Uterine Fibroids in Women
?Merck KGaA and Pfizer's Bavencio (avelumab) + Inlyta (axitinib) Receive FDA's Approval as 1L Treatment for Advanced Renal Cell Carcinoma
?Abbott Collaborates with NIH on Brain Initiative for Advancing Research on Neurological Disorders
?Progenics Signs an Exclusive Agreement with ROTOP Pharmaka to Develop and Commercialize Imaging Agent 1404 for Prostate Cancer in Europe
?REGENXBIO Launches a Manufacturing Facility for Developing Gene Therapies Based on NAV-Technology
?Roche and AbbVie's Venclexta (venetoclax) + Gazyva (obinutuzumab) Receive FDA's Approval for Untreated Chronic Lymphocytic Leukemia
Vertex Signs a 4 Years Agreement with Kymera to Discover and Develop Protein Degradation Therapies
?Takeda and Frazier Healthcare Collaborate to Launch a Facility Phathom Pharmaceutical for Gastrointestinal Disorders
"?NeuClone to Initiate P-I Clinical Study of Stelara (ustekinumab, biosimilar) in Australia"
?GSK Expands its License Agreement with Zymework to Develop and Commercialize Bi-Specific Antibodies
?Sanofi and Regeneron Report Updated Results of Libtayo (cemiplimab-rwlc) in P-II EMPOWER-CSCC-1 Study for Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma
?Thermo Fisher to Acquire Manufacturing Facility from GSK for ~$100M
?Pfizer's Fragmin (dalteparin sodium) Receives FDA's Approval for Symptomatic Venous Thromboembolism in Pediatric Patients
?Exelixis Signs an Exclusive Option and License Agreement with Iconic Therapeutics for Advancing ADC Program
Roche Signs a Worldwide License Agreement with Parvus Therapeutics to Develop and Commercialize Navacim Platform for Autoimmune Diseases
?AbbVie Reports Results of Depatux-M (depatuxizumab mafodotin) in P-III INTELLANCE-1 Study for Glioblastoma
?Takeda Reports Results of Entyvio (vedolizumab) in P-III VARSITY Study for Ulcerative Colitis
?Ethicon (J&amp;J) Recalls Endo-Surgery Intraluminal Staplers Due to Complete Staple Line Failure
Takeda's Gattex (teduglutide) Receives the US FDA's Approval for Short Bowel Syndrome in Children
?UCB's Nayzilam (midazolam) Receives FDA's Approval for the Treatment of Seizure Cluster in Epilepsy in the US
?Santhera Signs a Pre-Clinical Research Agreement with Biozentrum to Advance Gene Therapy for Congenital Muscular Dystrophy
?Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-119 Study for Metastatic Triple-Negative Breast Cancer
AstraZeneca Reports Results of Symbicort Turbuhaler (budesonide/formoterol) in Novel START Study for Mild Asthma
?Clovis Oncology Reports Results of Rubraca (rucaparib) in P-III ARIEL3 Study for Advanced Ovarian Cancer
?Merck to Acquire Peloton Therapeutics for $2.2B
Verily Collaborates with Global Pharma Companies to Develop Clinical Research Program
?Array BioPharma Reports Results of Combination Therapy in P-III BEACON CRC Study for BRAF(V600E)- Mutant Metastatic Colorectal Cancer
?Abbott Reports Results of Minimally Invasive Device in TRILUMINATE Study for Tricuspid Heart Valve Leaks
Medtronic Reports Results of Symplicity Renal Denervation System in Two Studies for Hypertensive Heart Diseases
"Biocon and Mylan's Ogivri (trastuzumab, biosimilar) Receives Health Canada's Approval for HER2-Positive Breast and Gastric Cancers"
?Takeda's Entyvio (vedolizumab) Receives MHLW's Approval for Moderate to Severely Active Crohn's Disease in Japan
Santhera Signs an Exclusive License Agreement with Chiesi to Develop and Commercialize Raxone for Leber's Hereditary Optic Neuropathy
?OncoSec Reports Result of Keytruda + TAVO in P-II KEYNOTE-890 Study for Refractory Metastatic Triple Negative Breast Cancer
?Synlogic Collaborates with Roche to Evaluate the Combination of SYNB1891 and Tecentriq (atezolizumab) for Advanced Solid Tumors
?Boston Scientific Initiates OPTION Study of Watchman FLX Device for Stroke Risk Reduction Post-AF Ablation
?GSK's Shingrix Receives NMPA's Approval for the Prevention of Shingles in China
"?Celltrion's Herzuma (trastuzumab, biosimilar) Receives ANVISA's Approval for Breast and Gastric Cancer in Brazil"
?Hologic &amp; Cepheid's Diagnostic Tests Receive 510(k) Clearance for Extragenital Testing in Chlamydia and Gonorrhea
?Roche's Cobas TV/MG Test Receives FDA's 510 (k) Clearance for the Detection of Sexually Transmitted Diseases
?BrightInsight Launches a CE-Marked Dosing Calculator for Emicizumab to Treat Patients with Hemophilia A
?Novartis' Piqray (alpelisib) + Fulvestrant Receive FDA's Approval for Patients with a PIK3CA Mutation in HR+/HER2- Advanced/Metastatic Breast Cancer
?Pfizer Reports Results of Lyrica (pregabalin) in P-III Study for Primary Generalized Tonic-Clonic Seizures
?Novartis' Zolgensma (onasemnogene abeparvovec-xioi) Receives FDA's Approval for Spinal Muscular Atrophy in Pediatric Patients
?Calecim Collaborates with Menarini Asia-Pacific to Expand the Worldwide Sales of its Product
?Santhera Reports Submission of Marketing Authorization Application to the EMA for Puldysa (Idebenone) in Duchenne Muscular Dystrophy
?Matas to Acquire Kosmolet for its Make-up Brand Nilens Jord
?Nanobiotix Launches Curadigm Facility with Nanoprimer Technology in France and the US
BioMarin Reports Results of Valoctocogene Roxaparvovec in P-III GENEr8-1 Study for Hemophilia A
Eli ?Lilly Signs an Exclusive Worldwide License Agreement with Centrexion Therapeutics for its CNTX-0290
?Celgene's Revlimid (Lenalidomide) + Rituximab Receive FDA's Approval for Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma in Adults
"Prestige BioPharma Reports EMA's Acceptance of Marketing Authorization Application for its Tuznue (trastuzumab, biosimilar)?"
?Bayer Signs a License Agreement with Sensible Medical for its ReDS Technology in Europe
?Arvinas' ARV-110 Receives the US FDA's Fast Track Designation for Metastatic Castration-Resistant Prostate Cancer in Men
?Ziopharm Signs an Exclusive License Agreement with NIH to Develop and Commercialize TCRs Targeting Neoantigen for Cancer
Bayer Signs a Worldwide Agreement with Roche's Foundation Medicine to Develop and Commercialize CDx for Cancer
?Novartis Reports Results of QMF149 (indacaterol acetate and mometasone furoate) in P-III QUARTZ Study for Inadequately Controlled Asthma
?Roche's Tecentriq (atezolizumab) Combination Therapy Receives Health Canada's Approval for Metastatic Non-Squamous Non-Small Cell Lung Cancer in Adults
?Philips Reports Results of Stellarex .035 Low-Dose Drug-Coated Balloon in Two Clinical Studies for Peripheral Arterial Disease
?Medtronic's SelectSite C304-HIS Deflectable Catheter System Receives FDA's Clearance for HIS Bundle Pacing
?Janssen Reports Results of Darzalex (daratumumab) in P-III MAIA Study for Patients with Multiple Myeloma Ineligible for ASCT
?Sumitomo Dainippon Pharma Signs a Co-Promotion &amp; Commercialization Agreement with Novartis for Diabetes in Japan
?Roche and GE Healthcare Launch NAVIFY Tumor Board 2.0 for Personalized Treatment Decision in Cancer Care
"?Pfenex and Alvogen Report EMA's Acceptance of MAA for PF708 (biosimilar, teriparatide)"
?Merck Reports Result of Keytruda (pembrolizumab) in P-III KEYNOTE-048 Study as a 1L Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Genmab's Darzalex (daratumumab) + Bortezomib + Thalidomide and Dexamethasone (VTd) Receive FDA's Priority Review to sBLA Filing for Frontline Multiple Myeloma?
Novartis Reports Results of Xolair (omalizumab) in Two P-III Studies for Chronic Rhinosinusitis with Nasal Polyps in Adults
?Sanofi Reports Results of Isatuximab Combination Therapy in P-III ICARIA-MM Study for Relapsed/Refractory Multiple Myeloma #ASCO2019
?Novartis Reports Result of Kisqali (ribociclib) + Endocrine Therapy in P-III MONALEESA-7 Study for HR+/HER2- Advanced Breast Cancer #ASCO2019
Novartis Reports Results of Capmatinib in P-II GEOMETRY mono-1 Study for Non-Small Cell Lung Cancer with MET exon-14 Skipping Mutation #ASCO2019
?AstraZeneca and Merck Report Results of Lynparza (olaparib) in P-III SOLO3 Study for Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer #ASCO2019
Merck's Zerbaxa (ceftolozane and tazobactam) Receives FDA's Approval for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia in Adults
"Fresenius Kabi Launches its Idacio (adalimumab, biosimilar) in Germany"
British Columbia Expands Use of Biosimilars to Explore Treatment Options
The US FDA Releases Drafts Guidance Recommending on Comparative Analytical Assessment for Biosimilars
UnitedHealthcare to Use Brand-Name for Pegfilgrastim from July'19
AbbVie Resolves Humira (adalimumab) Litigation with Boehringer Ingelheim
Roche Reports Results of Xofluza (baloxavir marboxil) in P-III BLOCKSTONE Study for the Prevention of Influenza
Takeda Reports Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks
Celgene and Acceleron Report FDA's Acceptance of BLA for Luspatercept to Treat Myelodysplastic Syndromes and Beta-Thalassemia
Astellas and Seattle Genetics Report Results of Enfortumab Vedotin in P-II EV-201 Study for Patients with Locally Advanced or Metastatic Urothelial Cancer #ASCO2019
?Eli Lilly's Emgality (galcanezumab-gnlm) Receives FDA's Approval for Episodic Cluster Headache in Adults
Roche Reports Results of Venclexta/Venclyxto (venetoclax) in P-III CLL14 Study for Chronic Lymphocytic Leukemia #ASCO2019
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
?BioMarin's Vimizim (elosulfase alfa) Receives NMPA's (CFDA) Approval for Treatment of Morquio A Syndrome
?Bayer Signs a Research and Development Collaboration with Arvinas for its PROTAC Technology
IBM Watson Health Reports Real-World Progress of AI in Oncology in #ASCO2019
?Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-AL1 Study in Patients with Relapsed or Refractory Systemic Light-Chain Amyloidosis
Enzyvant Reports FDA's Acceptance of BLA for RVT-802 to Treat Pediatric Congenital Athymia
Oncolytics Biotech Signs a Clinical Trial Collaboration with Merck KGaA and Pfizer
Celgene Reports FDA and EMA's Acceptance of NDA for Ozanimod to Treat Relapsing Forms of Multiple Sclerosis
AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ELEVATE-TN Trial for Patients with Previously Untreated Chronic Lymphocytic Leukemia
GSK's Nucala (mepolizumab) Receives FDA's Approval for its Two New Self-Administered Methods for Patients with SEA and EGPA
Novartis Reports Histology Data of CFZ533 (iscalimab) in Kidney Transplantation for Extended Survival of Transplanted Organs
Novartis' LysaKare (arginine hydrochloride/lysine hydrochloride) Solution Receives CHMP's Positive Opinion for Reduction of Kidney Exposure to Radiation During PPRT with Lutathera
Vertex to Expand its Collaboration with CRISPR Therapeutics to Develop Therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1
STADA to Acquire GSK's OTC Portfolio for the Expansion of its Consumer Health Business in Europe
Eli Lilly Reports Results of Ultra Rapid Lispro (URLi) in Two P-III Studies for Type 1 And Type 2 Diabetes
?Theramex Signs an Exclusive License Agreement with Therapeutics MD to Commercialize Bijuva and Imvexxy Outside the US
?Merck To Acquire Tilos Therapeutics for ~ $773M
?Medtronic and Tidepool Collaborates to Develop Interoperable Automated Insulin Pump System for Diabetes Management
Innovate Biopharmaceuticals Initiates P-III Clinical Study for Celiac Disease?
?Roche's Polivy (polatuzumab vedotin-piiq) Combination Therapy Receives FDA's Accelerated Approval for Relapsed/Refractory Lymphoma
Eli Lilly Reports Results of Taltz (ixekizumab) in 5 Years P-III Study for Plaque Psoriasis #WCD2019?
?Innovative Health Solution's IB-Stim Receives FDA's Clearance for the Treatment of Functional Abdominal Pain in Irritable Bowel Syndrome
?Abbvie Reports Two Years Data of Skyrizi (risankizumab) in P-III IMMhance Study for Moderate to Severe Plaque Psoriasis #WCD2019
Eli Lilly and Boehringer Ingelheim Report Cardiovascular Outcomes of Tradjenta (linagliptin) in CAROLINA Study for Type 2 Diabetes
?Merck's Keytruda (pembrolizumab) Receives FDA's Approval for 1L Treatment of Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma
Janssen Reports Cardiovascular Outcomes of Invokana (canagliflozin) in P-III CREDENCE Study for Type 2 Diabetes and Chronic Kidney Disease
Janssen Signs an Exclusive Worldwide License and Option Agreement with Genmab for its HexaBody-CD38
?Biogen To Report New Data of its Biosimilar Anti-TNF Portfolio at European Congress of Rheumatology (EULAR) 2019
?Genentech Reports Acceptance of sBLA for Rituxan (rituximab) to Treat Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in Children with 2 Years and Older
?Novo Nordisk Reports Cardiovascular Outcomes of Oral Semaglutide in PIONEER 6 Study for Type 2 Diabetes
?AbbVie Reports Results of Upadacitinib in Two P-III Studies for Rheumatoid Arthritis #EULAR2019
?Genentech Reports Positive Results of Rituxan (rituximab) in P-III PEMPHIX Study to Treat Patients with Moderate to Severe Pemphigus Vulgaris
?Pfizer Reports Results of Xeljanz XR (tofacitinib) in the P-IIIB/IV ORAL Shift Study for Moderate to Severe Rheumatoid Arthritis #EULAR2019
"?Celltrion Reports Results of CT-P13 SC (biosimilar, infliximab) in a Clinical Study for Rheumatoid Arthritis #EULAR2019"
?Sobi Acquires Novimmune's Emapalumab with its All Related Assets to Strengthen its Focus in Hematology and Immunology
"?Amgen and Allergan's Kanjinti (biosimilar, trastuzumab) Receive the US FDA's Approval for All Approved Indications of Herceptin"
?BMS Reports Results of Orencia (abatacept) in P-IV Early AMPLE Study for Moderate-to-Severe Rheumatoid Arthritis #EULAR2019
?BeiGene Reports Updated Results of Tislelizumab in P-II Study in Chinese Patients with R/R Classical Hodgkin Lymphoma #EHA2019
?Eli Lilly to Report Positive Results of Taltz (ixekizumab) in P-IIIb/IV SPIRIT-H2H Study for Active Psoriatic Arthritis #EULAR2019
?Upsher-Smith Signs an Agreement with Dr. Reddy's Laboratories to Acquire its Two Neurology Products
?AstraZeneca Reports Results of Lokelma (sodium zirconium cyclosilicate) in P-IIIb DIALIZE Study to Treat Hyperkalaemia in Patients with End-Stage Renal Disease
?Janssen Reports Results of Tremfya (guselkumab) in Two P-III DISCOVER Studies for Psoriatic Arthritis
?Immunophotonics Signs a Research Agreement with Clinical Laserthermia Clinical Laserthermia Systems for Cancer Patients with Solid Tumors
?Pfizer to Acquire Array Biopharma for ~$11.4B
?AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic Leukemia #EHA2019
?Novo Nordisk's Victoza (liraglutide) Receives FDA's Approval for Type 2 Diabetes in Children and Adolescents
BeiGene Terminates its Worldwide Development and Commercialization Agreement with Celgene for Tislelizumab
?Roche's Rozlytrek (entrectinib) Receives MHLW's Approval for NTRK Fusion-Positive Advanced Recurrent Solid Tumors in Adult and Pediatric Patients in Japan
?AstraZeneca and MSD's Lynparza (olaparib) Receive European Commission's Approval as 1L Maintenance Treatment for BRCA-Mutated Advanced Ovarian Cancer
?Abbott Launches Afinion HbA1c Dx (Rapid Point-Of-Care Test) to Aid the Diagnosis of Diabetes
?Merck's Keytruda (pembrolizumab) Receives FDA's Accelerated Approval as a Monotherapy for Metastatic Small Cell Lung Cancer
?Ironwood and Allergan Report Positive Results of Inzess (linaclotide) in P-IIIb Trial for Patients with Irritable Bowel Syndrome with Constipation
?AstraZeneca's Breztri Aerosphere (PT010) and Bevespi Aerosphere Receive MHLW's Approval for Chronic Obstructive Pulmonary Disease in Japan
Roche's Hemlibra (emicizumab injection) Receives Health Canada Approval for Patients with Hemophilia A Without Factor VIII Inhibitors ?
"?Bristol-Myers Squibb to Sell its Manufacturing Facility to Catalent in Anagni, Italy"
?Sanofi Signs an Agreement with Google to Develop Virtual Innovation Lab for Transforming Healthcare Services
Gilead Signs an Agreement with Nurix to Develop and Commercialize Protein Degradation Therapies for Cancer and Other Disease
?Amgen Signs a Research Agreement with the University of Washington's IPD for the Development of Protein-Based Therapies
Alexa to Detect Cardiac Arrest with AI-Enabled Tool for Smart Speakers and Smartphones
?Resolution Bioscience Collaborates with Janssen to Develop Cell-Free DNA CDx for Niraparib to Treat Prostate Cancer
?Alexion's Ultomiris (ravulizumab) Receives MHLW's Marketing Authorization to Treat Paroxysmal Nocturnal Hemoglobinuria in Adults
"?Novo Nordisk's Esperoct (turoctocog alfa pegol, N8-GP) Receives European Commission Approval for the Treatment of Hemophilia A"
IBRI Signs a License Agreement with Eli Lilly to Access its Fab Phage Display Library
?Valneva Terminates its Agreement with GSK for Regaining Control of Research and Development Assets
?Bayer Initiates P-III Study of Aflibercept for the Prevention of Blindness in Premature Infants with Retinopathy of Prematurity
Sanofi and Regeneron Report Results of REGN3500 in P-II Study for Asthma
Allergan's BOTOX (onabotulinumtoxinA) Receives FDA's Approval for Upper Limb Spasticity in Pediatric Patients
Pfizer's Talzenna (talazoparib) Receives European Commission Approval for Germline BRCA-Mutated Locally Advanced or Metastatic Breast Cancer?
"Henlius Reports EMA's Acceptance of Marketing Authorization Application for HLX02 (biosimilar, trastuzumab)"
?Bristol-Myers Squibb Reports Results of Opdivo (nivolumab) in P-III CheckMate-459 Study as 1L Treatment for Patients with Unresectable Hepatocellular Carcinoma
"?Allergan's CoolTone Device Receives FDA's Clearance to Strengthen, Tone and Firm Abdominal Muscles"
?Gilead Signs an Agreement with Carna Biosciences to Develop and Commercialize Immuno-Oncology Therapies
"Novartis to Collaborate with Glenmark to Promote, Commercialize and Distribute Three Respiratory Therapies for COPD in Brazil?"
?AbbVie to Acquire Allergan for $63B
Bristol-Myers Squibb to Divest Celgene's Otezla (apremilast) to Gain the US FTC's Approval on Celgene Acquisition?
C4X Discovery Signs a Neurodegeneration Drug Discovery Agreement with PhoreMost for Parkinson's Disease
?Almirall Exercises its Option to License Dermira's Lebrikizumab for Atopic Dermatitis in Europe
?Tilt Biotherapeutics Signs an Agreement with Merck KGaA and Pfizer to Investigate the Dual Combination for Solid Tumors
?Eisai Reports Results of Fycompa (perampanel) in P-III FREEDOM Study for Patients with Newly Diagnosed or Untreated Partial Onset Seizures
?Lilly Reports Results of Trulicity (dulaglutide) in P-III AWARD-11 Study for Type 2 Diabetes
?Boehringer Ingelheim and Eli Lilly's Empagliflozin Receive FDA's Fast Track Designation for Chronic Heart Failure
?Daiichi Sankyo to Return Exclusive Development and Commercialization Rights for Four Diagnostic Imaging Agents to GE Healthcare in Japan
Louisiana Department of Health Launches Innovative Payment Model with Asegua Therapeutics to Eliminate Hepatitis C in Louisiana
Regeneron and Sanofi's Dupixent (dupilumab) Receives FDA's Approval for Chronic Rhinosinusitis with Nasal Polyposis?
AstraZeneca Reports Results of Imfinzi (durvalumab) in P-III CASPIAN Study for 1L Extensive-Stage Small Cell Lung Cancer?
?Sanofi Reports FDA's Acceptance of BLA for MenQuadfi to Prevent Meningococcal Meningitis
GSK Amends its Development and Commercialization Agreement with Liquidia for Inhaled Therapies
?Janssen's Darzalex (daratumumab) in Combination with Lenalidomide + Dexamethasone Receive FDA's Approval for Transplant Ineligible Patients with Multiple Myeloma
?Alexion's Soliris (eculizumab) Receives FDA's Approval for Anti-Aquaporin-4 Antibody Positive Patients with Neuromyelitis Optica Spectrum Disorder
?Apple Disrupting the Healthcare with the Availability of One Drop Blood Glucose Monitor at its Retails Outlets in the US
Sanofi and Regeneron's Dupixent (dupilumab) Receive CHMP's Positive Opinion for Moderate-To-Severe Atopic Dermatitis in Adolescents?
"?Innovent and Eli Lilly Report NMPA's Acceptance of NDA for IBI301 (rituximab, biosimilar) for Non-Hodgkin's lymphoma"
"?Pfizer's Zirabev (biosimilar, bevacizumab) Receives the US FDA's Approval for Five Types of Cancer"
?Pfizer Reports Results of Revatio (sildenafil citrate) in P-III Study for Persistent Pulmonary Hypertension in the Newborns
?AstraZeneca's Forxiga and Fasenra (Prefilled Syringe and Pen) Receive EU CHMP's Positive Opinion for CV Outcomes in T2D and Asthma
?Janssen's Imbruvica (ibrutinib) Receives CHMP Positive Recommendation for its Expanded Use in Chronic Lymphocytic Leukaemia and Waldenstrom's Macroglobulinemia in Europe
Roche's Tecentriq (atezolizumab) + Abraxane Receives CHMP's Recommendation for its Approval in Europe
?Biogen Reports Results of Spinraza (nusinersen) in P-II NURTURE Study as a Foundation of Care in Spinal Muscular Atrophy
Regeneron and Sanofi's Libtayo (cemiplimab) Receives European Commission's Approval for Advanced Cutaneous Squamous Cell Carcinoma
?Teva Reports Results of Fremanezumab in P-IIIb FOCUS Study for Migraine in Adults
"?Egis Pharmaceuticals Signs an Exclusive Distribution Agreement with Mundipharma for Pelmeg (biosimilar, pegfilgrastim) in Central and Eastern Europe"
"?Amgen to Withdraw the ABP 710 (biosimilar, infliximab) MAA with European Medical Agency"
?Boehringer Ingelheim Signs a License Agreement with Yuhan Corporation to Develop Dual Agonist for Nonalcoholic Steatohepatitis
Foundation Medicine's FoundationOne CDx Receives FDA's Approval as a CDx for Lynparza (olaparib)
?Varian to Acquire Boston Scientific's Oncology Assets for $90M
?Genentech Reports Results of Xofluza (baloxavir marboxil) in P-III MINISTONE-2 Study for Influenza in Children
?Sandoz Launches Generic Gefitinib for Locally Advanced or Metastatic Non-Small Cell Lung Cancer in 13 European Countries
?ViiV Healthcare's Dovato (dolutegravir/lamivudine) Receives European Commission Marketing Authorization for HIV-1 Infection in Adults and Adolescents
GSK to Initiate P-III ContRAst Studies of Otilimab to Treat Moderate to Severe Rheumatoid Arthritis
Asieris Signs a Worldwide Development and Commercialization Agreement with Photocure for Cevira
?Samsung Bioepis and Genentech Settles Patent Dispute of Trastuzumab Biosimilar-Ontruzant
Alexion's Ultomiris (Ravulizumab) Receives European Commission's Marketing Authorization for Paroxysmal Nocturnal Hemoglobinuria in Adults
?Karyopharm's Xpovio (selinexor) Receives FDA's Accelerated Approval for Relapsed/Refractory Multiple Myeloma
"Samsung Bioepis Reports EU Label Update with Extended Storage Conditions for Imraldi (biosimilar, adalimumab)"
?Nosopharm Signs an Agreement with Evotec to Accelerate the Development of Antibiotics
?Janssen Returns its Exclusive Rights to Develop and Commercialize Hanmi's Antidiabetic Obesity Therapy
?SIFI Acquires Laboratoire Gifrer Barbezat's Dacudoses and Novoptine for $6.7M in France
Grifols' Xembify (20% SC Immunoglobulin) Receives FDA's Approval for the Treatment of Primary Immunodeficiencies?
?Fraunhofer MEVIS' Experts Develops Intelligent Catheter Navigation System in Germany
?SDSC and Moores Cancer Center Collaboratively Work with CureMatch to Develop Machine Learning Model for the Diagnosis of Bladder Cancer
?Fresenius Kabi Voluntary Recalls Two Lots of Fluorouracil Injection Due to Potential for Glass Particulate
?BeiGene's Tislelizumab Receives NMPA's Priority Review to sNDA for Urothelial Carcinoma in China
?Isansys Lifecare Develops Patient Status Engine Wearable Body Patch for the Detection of Sepsis
?Novo Nordisk Reports Results of Refixia (nonacog beta pegol) in Two P-III Studies for Hemophilia B in Children
?Takeda Reports Updated Results of Adynovate in P-IIIb/IV PROPEL Study for Personalized Prophylaxis in Patients with Severe Hemophilia A
ViiV Healthcare Initiates CUSTOMIZE Study of Dual-Drug Injectable Regimen for the Treatment of HIV
?Bayer Reports Results of Xarelto (rivaroxaban) in P-III EINSTEIN-Jr. Study for Venous Thromboembolism
Roche Reports Updated Results of Hemlibra (emicizumab) in P-III HAVEN and P-IIIb STASEY Studies for Hemophilia A
?The US Department of Defense Awarded Contract to SIGA for Expanded Indication of TPOXX (tecovirimat) for $19.5M
?Merck Reports FDA's Acceptance of sBLA of Keytruda (pembrolizumab) with Six-Week Dosing Schedule for Multiple Indications
?Boehringer Ingelheim Reports Results of Pradaxa (dabigatran etexilate mesylate) for the Management of Venous Thromboembolism in Children
?Sanofi Reports FDA's Acceptance of BLA to Review Isatuximab for Relapsed/Refractory Multiple Myeloma
?ViiV Healthcare Reports Results of Dual-Drug Regimen in P-III TANGO Study for HIV-1 Infection
?Mirati Signs a Non-Exclusive Clinical Collaboration with Novartis to Evaluate the Combination of MRTX849 and TNO155 for Solid Tumors
?Janssen Signs an Agreement with Celsius Therapeutics to Identify Response Biomarkers for Ulcerative Colitis
?Jazz Pharmaceuticals Acquires Redx Pharma's Pre-clinical Pan-RAF Inhibitor Program for RAF and RAS Mutant Tumors
?Sandoz Launches Pre-Filled Epinephrine Injection for Type 1 Allergic Reactions in the US
?Celgene's Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada's Approval for Multiple Myeloma
?Torrent Signs a Non-Exclusive License Agreement with Glenmark to Co-Commercialize Remogliflozin Etabonate for Type 2 Diabetes in India
?Takeda's Vyvanse (lisexamfetamine dimesylate) Chewable Tablet Receives Health Canada's Approval for the Treatment of Patients with Attention-Deficit/Hyperactivity Disorder Aged= 6yrs.
?Amazon's AI-Powered Alexa to Deliver NHS Health Advice in the UK
?Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in P-III Study for Episodic Cluster Headache
?I-Mab Signs an Exclusive License Agreement with MacroGenics to Develop and Commercialize Enoblituzumab in Greater China
"?Novartis, Amgen and Banner Alzheimer's Institute Terminate Two P-II/III Studies of CNP520 (umibecestat) for the Prevention of Alzheimer's Disease"
Abbott's Alinity S System Receives FDA's Approval for Blood and Plasma Screening in the US?
?Ono Pharmaceutical Signs an Exclusive License Agreement with Forty Seven to Develop and Commercialize 5F9 in Selected Asian Countries
Valeo Launches Onstryv (safinamide tablet) for the Treatment of Parkinson's Disease in Canada?
Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Three P-III Studies for Chronic and Episodic Migraine
?GSK Reports Results of Zejula (niraparib) in P-III PRIMA Study as 1L Maintenance Therapy for Ovarian Cancer
?Gilead to Raise Stake in Galapagos with ~$5.1B Deal
?Janssen Reports Submission of BLA to the US FDA for Darzalex (daratumumab) Subcutaneous Formulation for Multiple Myeloma
?AbbVie Acquires Mavupharma for its STING (STimulator of INterferon Genes) Modulators to Treat Cancer
?Boehringer Ingelheim Acquires AMAL Therapeutics for its KISIMA Immunization Platform
?Abbott's MitraClip G4 Receives the US FDA's Approval for the Treatment of Mitral Regurgitation
?Bayer's Gadavist (gadobutrol) Injection Receives the US FDA's Approval for use in CMRI in Patients with Coronary Artery Disease
?T-CiRA Research Collaboration Initiates Clinical Study of iCART Therapies for the Treatment of Cancer
?Novartis Reports FDA's Acceptance of BLA for Crizanlizumab (SEG101) to Treat Sickle Cell Disease
Genentech Signs an Exclusive Option and License Agreement with Skyhawk to Discover and Develop RNA Splicing Modifiers for Oncology and Neurodegenerative Diseases?
Genentech Enters into an Exclusive Worldwide Collaboration and Option to Acquire Agreement with Convelo to Discover Remyelinating Therapies
?Knight Therapeutics' Nerlynx (neratinib) Receives Health Canada Approval as Extended Adjuvant Therapy for HR+ and HER2+ Breast Cancer
?Merck's Recarbrio (imipenem/cilastatin/relebactam) Receives the US FDA's Approval for Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections
?Allergan Reports FDA's Acceptance of NDA for Bimatoprost Sustained-Release to Treat Glaucoma or Ocular Hypertension
Genentech Signs a Research and License Agreement with Sosei Heptares to Develop GPCR Modulating Therapies
?MacroGenics Plans to Advance the Development of Flotetuzumab for Acute Myeloid Leukemia
?Novartis' Kisqali (ribociclib) + Fulvestrant Receive NICE Approval for Advanced or Metastatic Breast Cancer
?Paragon Biosciences Launches a Facility for the Advancement of QuantX Medical Imaging AI System Diagnosing Breast Cancer
?Bayer Signs a Clinical Collaboration Agreement with BMS and Ono to Evaluate Dual Regimen for Metastatic Colorectal Cancer
Astellas Signs a License Agreement with Frequency Therapeutics to Develop and Commercialize FX-322 for Hearing Loss
Takeda and Chembio Diagnostics Collaborate to Develop Point-of-Care Diagnostic Test
Interpace Diagnostics Signs an AI-Driven Agreement with Predictive Oncology for Diagnosing Thyroid Cancer
Boehringer Ingelheim Signs a Worldwide License Agreement with Bridge Biotherapeutics for its BBT-877 for $1.28B
Boehringer Ingelheim Reports Results of Ofev (nintedanib) in INMARK Study for Patients with Idiopathic Pulmonary Fibrosis (IPF)
Mallinckrodt Signs an Agreement with Silence Therapeutics to Develop and Commercialize RNAi Therapeutics for Complement-Mediated Diseases
Amgen and Allergan Report Availability of Mvasi (biosimilar bevacizumab) and Kanjinti (biosimilar trastuzumab) in the US
Gilead Signs an Exclusive Worldwide License Agreement with Novartis for its Three Preclinical Antiviral Programs
Sandoz Reports Patient Enrollment in P-I/III ROSALIA Study of Proposed Biosimilar Denosumab for Postmenopausal Osteoporosis
Celgene's Otezla (apremilast) Receives FDA's Approval for Oral Ulcers Associated with Behçet's Disease
Takeda Reports Results of Entyvio (vedolizumab SC) in P-III VISIBLE 2 Study for Moderately to Severely Active Crohn's Disease
Medtronic Collaborates with Viz.ai to Facilitate Adoption of AI Software for Stroke Centers in the US
Gilead Signs an Exclusive Worldwide License Agreement with Durect for its HIV and Hepatitis B Products
Baxter's Myxredlin Ready-To-Use Insulin for IV Infusion Receives FDA's Approval for Diabetes Mellitus?
Sanofi Signs an Exclusive Agreement with Roche for OTC Rights of Tamiflu (oseltamivir phosphate) in the US
ViiV Healthcare Reports Results of Fostemsavir in P-III BRIGHTE Study for HIV-1 infection
AstraZeneca Reports Inclusion of Overall Survival Data in Labelling of Imfinzi (durvalumab) in the US
Merck and Eisai's Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive FDA's Third Breakthrough Therapy Designation as 1L Therapy for Hepatocellular Carcinoma
Chiasma Reports Results of Mycapssa (octreotide) in P-III CHIASMA OPTIMAL Study as a Maintenance Therapy for Acromegaly
"Pfizer's Ruxience (biosimilar, rituximab) Receives FDA's Approval for Cancer and Autoimmune Diseases"
"Samsung Bioepis' Hadlima (biosimilar, adalimumab) Receives FDA's Approval for Autoimmune Diseases"
Ligand to Acquire Ab Initio Biotherapeutics for its Antigen Technology
Medtronic Solicits the US FDA for Non-Adjunctive Labeling Approval of MiniMed 670G Insulin Pump Sensor
Gilead Reports Updated Results of Descovy in P-III DISCOVER Study for Pre-Exposure Prophylaxis of H
Celgene Partners with Multiple Sclerosis Association of America Bringing MS MindShift Brain Bulb Hot Air Balloon to Raise Awareness of Multiple Sclerosis and Brain Health
Synapse Signs an Agreement with Pfizer in Oncology Precision Medicine
Eli Lilly's Baqsimi (glucagon 3mg) Nasal Powder Receives FDA's Approval for the Treatment of Severe Hypoglycemia
BMS Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -227 Part 1a Study for 1L Non-Small Cell Lung Cancer
Celgene Reports Update on its Collaboration with Jounce Therapeutics
Allergan Voluntary Recalls Worldwide BIOCELL Textured Breast Implants and Tissue Expanders?
Regenxbio Signs an Exclusive Development and Commercialization Agreement with Neurimmune for AAV Gene Therapies Targeting Neurodegenerative Diseases
Sanofi Enter into an Exclusive License Agreement with Verastem Oncology to Develop and Commercialize Copiktra (duvelisib) for all Oncology Indications
Boehringer Ingelheim's Ofev (nintedanib) Receives FDA's Advisory Committee Recommendation for Systemic Sclerosis Associated ILD
Janssen Reports Results of Ponesimod in P-III OPTIMUM Study for Relapsing Multiple Sclerosis
BMS' Triple Regimen Receives Positive CHMP Recommendation for its Approval to Treat R/R Multiple Myeloma in Europe
Roche's Tecentriq Receives EU's CHMP Recommendation for its Approval as 1L Therapy for Extensive-Stage Small Cell Lung Cancer
Epizyme Reports FDA's Acceptance of NDA for Tazemetostat to Treat Epithelioid Sarcoma
ViiV Healthcare Reports Submission of MAA to EMA for the Combination of Cabotegravir + Rilpivirine to Treat HIV-1 Infection
Pfizer in Talks with Mylan to Merge its Off-Patent Drug Business ?
Pfizer's Upjohn Off-Patent Drug Business to Merge with Mylan to Form a New Pharmaceutical Company
Sanofi Reports Results of Zynquista (sotagliflozin) in P-III InSynchrony Program for Type2 Diabetes and Terminates Its Collaboration with Lexicon
Baxter Launches PrisMax Acute Care System for Acute Kidney Injury in the US
Merck Reports Results of Keytruda (pembrolizumab) + Chemotherapy in P-III KEYNOTE-522 Study for Triple-Negative Breast Cancer
Exact Sciences to Merge with Genomic Health Forming a New Cancer Diagnostics Company
Eli Lilly Reports Results of Verzenio (abemaciclib) in P-III MONARCH 2 for HR+ and HER2- Advanced Breast Cancer
Merck Receives EU's CHMP Positive Opinion for its Zerbaxa (ceftolozane and tazobactam) and Keytruda (pembrolizumab) + Inlyta (axitinib) Regimen
Novartis' Lucentis Receive EU's CHMP Positive Opinion for Retinopathy of Prematurity in Preterm Infan
Bayer's Nubeqa (darolutamide) Receives the US FDA's Approval for Non-Metastatic Castration-Resistant Prostate Cancer in Men
Biogen and Alkermes Report Results of Diroximel Fumarate in P-III EVOLVE-MS-2 Study for Multiple Sclerosis
Gates Foundation Grants $13M to Lyndra Therapeutics for the Development of Once-Monthly Oral Contraceptive
Bayer's Vitrakvi (larotrectinib) Receives Health Canada Approval for Advanced Solid Tumors Harboring NTRK Gene Fusion
Merck's Keytruda (pembrolizumab) Receives FDA's Approval as a Monotherapy for 1L+ Recurrent Locally Advanced or Metastatic Esophageal Cancer Expressing PD-L1 (CPS =10)
Pfizer Signs a License Agreement with Regenxbio for its NAV AAV9 Vector to Treat Friedreich's Ataxia
Novartis Reports Results of Kisqali in Second Phase P-III MONALEESA-3 Study for HR+/HER2- Advanced Breast Cancer in Women
Chimerix Signs an Exclusive Worldwide License Agreement with Cantex for CX-01 to Treat Acute Myeloid Leukemia
Exelixis Signs a Research Collaboration and Option to License Agreement with Aurigene to Discover and Develop Therapies for Cancer
LEO Pharma's Enstilar Foam and Taclonex Topical Suspension Receive the US FDA's Expanded Approval for Plaque Psoriasis
Sun Pharma Reports Submission of Manufacturing and Marketing Authorization Application of Tildrakizumab in Japan
GSK's Nucala (mepolizumab) Receives European Commission Approval for Self-Administration in Severe Eosinophilic Asthma
Nektar and BMS Receive the US FDA's Breakthrough Designation for Bempegaldesleukin (NKTR-214) + Opdivo (nivolumab) to Treat Advanced Melanoma
Arcellx Signs a Development Evaluation and License Agreement with Pfenex for Advancing SparX Proteins
"Mylan and Biocon Launch Ogivri (biosimilar, trastuzumab) in Australia"
Voluntis' Oleena Digital Application Receives FDA's Marketing Approval to Self-Manage Cancer Symptoms
Thermo Fisher Enters into a Collaboration with Genome Canada and OICR to Develop NGS Assays for Cancer
AbbVie's Maviret (glecaprevir/pibrentasvir) Receives European Commission Approval for Treatment-Naive Patients with Chronic Hepatitis C and Compensated Cirrhosis
Daiichi Sankyo's Turalio (pexidartinib) Receives the US FDA's Approval for the Symptomatic Tenosynovial Giant Cell Tumor
Roche Reports Results of Tecentriq in P-III IMvigor130 Study for Previously Untreated Advanced Bladder Cancer
Takeda Signs an Exclusive Multi-Target Research Agreement with Sosei Heptares to Develop and Commercialize Therapies Modulating GPCR
AstraZeneca Reports Label Update with Positive Cardiovascular Outcomes and Renal Data for Forxiga (dapagliflozin) in EU
Pfizer Reports Results of Rivipansel in P-III RESET Study for Sickle Cell Disease with Vaso-Occlusive Crisis
NUST MISIS Laboratory Develops an Ultrasound Tomography System for the Diagnosis of Cancer
"Cipla Gulf Signs an Exclusive Commercialization Agreement with Alvotech for AVT02 (biosimilar, adalimumab)"
Coherus Biosciences Reports Winning of Pegfilgrastim Patent Dispute Against Amgen
"Celltrion to Initiate P-I trial for CT-P39 (biosimilar, omalizumab)"
Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in P-III CONQUER Study for Chronic and Episodic Migraine
Chong Kun Dang and Dong-A ST Plan to Launch Nesp biosimilar in Japan
"Mundipharma and Prestige Enters into an Exclusive License and Supply Agreement for Tuznue (biosimilar, trastuzumab, HD201)"
Sanofi and Regeneron's Dupixent Receives European Commission Approval for Moderate-To-Severe Atopic Dermatitis in Adolescents
LifeOmic Launches AI-Based LIFE Extend App to Expand Healthcare and Enable People to Adopt Five Health Pillars?
MannKind Enter into an Agreement with One Drop to Combine Bluetooth-Connected Inhaler with Dose Detection into the One Drop Platform
Innovent and Shenogen Enter into a Collaboration to Evaluate the Combination of Tyvyt (sintilimab injection) + SNG1005 for Advanced Cancer
GSK and Sabin Signs an Exclusive Agreement to Advance the Development of Ebola and Marburg Vaccines
Astellas Initiates P-III BRIGHT SKY Clinical Program for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms
Allergan Reports the Acceptance of EMA's MAA for Abicipar to Treat Neovascular Age-Related Macular Degeneration
Spring Bank Signs a Research Agreement with the University of Texas Southwestern Medical School to Evaluate STING Antagonist Compounds
AstraZeneca and MSD's Report Results of Lynparza in P-III PROfound Study for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Mutation
ADC Therapeutics and Sophia Genetics Collaborate to Identify Biomarkers in Clinical Study
NIH Launches LUCA Biologics to Develop Live Biotherapeutics for Women's Health
Newsoara Biopharma Signs a Licensing Agreement with Zenith Epigenetics for its ZEN-3694
Aevi Genomic Medicine Signs an Option and License Agreement with AstraZeneca for its MEDI2338
Stoke Therapeutics' STK-001 Receives FDA's Orphan Drug Designation for Dravet Syndrome
Myriad to File sPMA to the US FDA of BRACAnalysis CDx as a Companion Diagnostic for Lynparza (olaparib) to Treat Metastatic Castrate-Resistant Prostate Cancer in Men
Akcea Therapeutics and Ionis Pharmaceutical Launch Waylivra (volanesorsen) for Familial Chylomicronemia Syndrome in EU
Gilead Sciences Receives the US FDA Advisory Committee's Recommendation on Approval of Descovy for PrEP
Mitsubishi Tanabe's Edaravone Receives NMPA's Approval for Amyotrophic Lateral Sclerosis (ALS)
Bayer to Acquire BlueRock Therapeutics for its Cell Therapies
Eli Lilly with Evidation Health and Apple Report Results of Digital Alzheimer's Study
Takeda Reports Submission of NDA to MHLW for Vedolizumab SC to Treat Moderately to Severely Active Ulcerative Colitis in Japan
AstraZeneca Reports Updated Positive Results of Tagrisso (osimertinib) in P-III FLAURA Study for 1L EGFR-Mutated Non-Small Cell Lung Cancer
Ziopharm Oncology's Controlled IL-12 Platform Receives EMA's COMP Positive Recommendation for Orphan Drug Designation to Treat Glioma
"Gilead's Biktarvy (Bictegravir, Emtricitabine and Tenofovir Alafenamide) Receives NMPA's Approval for Treatment of HIV-1 Infection"
SMS-Oncology Signs a Clinical Trial Collaboration with Cytovation to Treat Solid Tumors
Atricure to Acquire SentreHEART for Expansion of Therapies to Treat Atrial Fibrillation
Oncologie and Merck Collaborate to Evaluate Bavituximab + Keytruda for Treatment of Advanced Gastric or Gastroesophageal Cancer
?Zai Lab and Novocure's Optune Receive NMPA's Innovative Medical Device Designation for its Tumor Treating Field Delivery System
Boehringer Ingelheim Signs a Multi-Year Agreement with University of Texas for the Advancement of Cancer Therapies
Baxter's PrisMax System Receives Health Canada's Approval for Maximizing Treatment in the Intensive Care Unit
Pharming Signs an Exclusive Development and Commercialization Agreement with Novartis for its CDZ173 to Treat Activated Phosphoinositide 3-kinase Delta Syndrome
Jazz Pharmaceutical to Acquire Cavion for the Expansion of its Sleep and Neurology Portfolio
Eli Lilly Reports Superiority Results of Taltz (ixekizumab) in P-IV IXORA-R Study for Patients with Moderate to Severe Plaque Psoriasis
Roche's Tecentriq (atezolizumab) Receives Health Canada's Approval for 1L Extensive-Stage Small Cell Lung Cancer in Adults
Innovate Initiates its Dosing For P-III CeD LA 3001 Trial for Celiac Disease
Janssen's Imbruvica (ibrutinib) Receives European Commission Approval for Chronic Lymphocytic Leukaemia and Waldenstrom's Macroglobulinemia in Adults
AstraZeneca's Calquence (acalabrutinib) Receives the US FDA's Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia
Leo Pharma Enters into a Sub-Licensing Agreement with Bausch Health to Develop and Commercialize Brodalumab for Moderate-to-Severe Psoriasis Outside Europe
AstraZeneca and MSD Report Results of Lynparza in P-III PAOLA-1 Study as 1L Maintenance Therapy for Advanced Ovarian Cancer
Regeneron's Eylea (aflibercept) Receives the US FDA's Approval as a Prefilled Syringe
Regeneron Reports Positive Results of Evinacumab in P-III Study for Homozygous Familial Hypercholesterolemia
Roche's Rozlytrek (entrectinib) Receives the US FDA Approval for ROS1-Positive Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors
Ultragenyx Enters into a Partnership and Option to Acquire Agreement with GeneTx to Develop its GTX-102 for Angelman Syndrome
Gilead and Galapagos Reports the Validation of EMA's MAA for Filgotinib to Treat Rheumatoid Arthritis
Baxter Collaborates with Cosmed to Commercialize Q-NRG+ Indirect Calorimetry Device to Support Global Clinical Nutrition ?
Mallinckrodt Reports Positive Results of Terlipressin in P-III CONFIRM Study for Hepatorenal Syndrome Type 1
Profound Medical's TULSA-PRO Receives the US FDA's 510(k) Clearance for Ablation of Prostate Tissue
AbbVie's Rinvoq (upadacitinib) Receives the US FDA's Approval for Moderate to Severe Rheumatoid Arthritis
Celgene's Inrebic (fedratinib) Receives the US FDA's Approval for Myelofibrosis
Alcon to Launch PRECISION1 Daily Disposable Contact Lenses in the US
CVRx's Barostim Neo Device Receives the US FDA's Approval as World's First Heart Failure Neuromodulation Device
Glenmark's Combination Therapy of Remogliflozin Etabonate + Metformin Hydrochloride Receive Approval for Type 2 Diabetes in India
"Dr. Reddy's Laboratories Launches Versavo (biosimilar, bevacizumab) for Multiple Cancer Indications in India"
AstraZeneca Reports Results of Farxiga (dapagliflozin) in P-III DAPA-HF Study to Treat Patients with Heart Failure
Boston Scientific's ImageReady MRI For Vercise Gevia Deep Brain Stimulation System Receives FDA's Approval for Parkinson's Disease
Nabriva's Xenleta (lefamulin) Receives FDA's Approval for the Treatment of Community-Acquired Bacterial Pneumonia in Adults
Elanco To Acquire Bayer's Animal Health Business for $7.6B
"Gedeon Richter Launches Terrosa (biosimilar, teriparatide) in Europe"
Biotheus Enters into an Agreement with Alligator Bioscience to Develop Bispecific Molecules in Greater China
AstraZeneca Reports Results of Imfinzi (durvalumab) + Tremelimumab in P-III NEPTUNE Study for Stage IV Non-Small Cell Lung Cancer?
GSK Reports Submission of NDA to MHLW for Daprodustat to Treat Patients with Renal Anaemia due to Chronic Kidney Disease in Japan
BioInvent to Initiate P-I/IIa Study with BI-1206 in Combination with Merck's Keytruda (pembrolizumab) for Solid Tumors
Orexo Enters into an Agreement with GAIA to Develop and Commercialize Digital Therapy for Opioid Use Disorder?
Vivus Reports Results of Qsymia in Pilot Clinical Study for Patients with Laparoscopic Sleeve Gastrectomy Surgery
Pfizer to Invest $500M in State-of-the-Art Gene Therapy Facility in North Carolina
"Biocon Receives EU's GMP Certification for its Semglee (biosimilar, Insulin Glargine) Manufacturing Facility in Malaysia"
Clarus Therapeutics' Jatenzo (Testosterone Undecanoate Capsules for Oral Use) (CIII) Receives FDA'S Approval for Testosterone Replacement Therapy in Certain Adult Men
EMD Serono's Mavenclad (Cladribine) Receives FDA's Approval for RRMS and SPMS in Adults
Johnson &amp; Johnson's Balversa (erdafitinib) Receives FDA's Approval for Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alteration
Amgen's Corlanor (ivabradine) Receives FDA's Approval to Reduce Risk of Hospitalization for Worsening Heart Failure in Patients with Chronic Heart Failure
Bausch's Duobrii (Halobetasol Propionate and Tazarotene) Receives FDA's Approval for Topical Treatment of Plaque Psoriasis in Adults
Janssen's Darzalex (daratumumab) Receives MHLW's Approval for Transplant Ineligible Patients with Multiple Myeloma in Japan
"Samsung Bioepis Eticovo's (etanercept-ykro, biosmilar) Receives FDA's Approval for All Eligible Indication"
Jacobus Pharmaceutical's Ruzurgi (amifampridine) Receives the US FDA's Approval for Lambert-Eaton myasthenic syndrome
AstraZeneca Signs an Agreement with Sobi to Buy its Priority Review Voucher for $95M
Exeltis' Slynd Receives the US FDA's Approval for the Prevention of Pregnancy
Innovent Signs a License Agreement with Eli Lilly to Develop and Commercialize OXM3 in China
AstraZeneca and FibroGen's Roxadustat Receive NMPA's Approval for the Treatment of Anemia in Non-Dialysis-Dependent Patients with Chronic Kidney Disease in China
"Palatin Technologies' Vyleesi (bremelanotide injection) Receives FDA's Approval for Premenopausal Women with Acquired, Generalized Hypoactive Sexual Desire Disorder"
MSD Signs an Exclusive License and Research Agreement with Themis Bioscience to Develop Vaccine Therapies
"Amgen and Allergan Report Results of ABP 798 (biosimilar, rituximab) in JASMINE Study for Non-Hodgkin's Lymphoma"
Roche's Tecentriq (atezolizumab) Receives MHLW's Approval as the First Immunotherapy for Extensive-Stage Small Cell Lung Cancer in Japan
Cantargia Extends Licensing Agreement with BioWa for its POTELLIGENT Technology
Novartis Signs an Option Agreement with Iconic Therapeutics for its Ophthalmology Program
OxThera's Oxabact Receives EMA's Positive Decision on Pediatric Investigational Plan to Treat Primary Hyperoxaluria
Amgen to Acquire Celgene's Otezla (apremilast) for $13.4B
Miracor's PiCSO Impulse System Receives FDA's Breakthrough Device Designation for Treatment of Patients with STEMI
Zogenix to Acquire Modis Therapeutics for its MT1621
Eli Lilly and Incyte Report Results of Olumiant (baricitinib) + Topical Corticosteroids in P-III BREEZE-AD7 Study for Moderate to Severe Atopic Dermatitis
Laminate Reports Results of VasQ External Support Device in a Clinical Study for Arteriovenous Fistulas in Hemodialysis Patients
Freenome Signs an Agreement with ADC Therapeutics to Develop Biomarker for its ADCT-402 (loncastuximab tesirine)
Eli Lilly's Taltz (ixekizumab) Receives Third US FDA's Approval for Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)?
Alcon's AcrySof IQ PanOptix Receives the US FDA's Approval as the First Trifocal Lens for Patients Undergoing Cataract Surgery in the US?
Abbott Reports Positive Data of its Blood Test Technology Detecting Traumatic Brain Injury in Patients with Negative CT Scan
AstraZeneca's Farxiga Receives the US FDA's Fast Track Designation for Chronic Kidney Disease?
GSK Exercises Its Option to License Ionis' Antisense Therapy for Chronic Hepatitis B Virus Infection
Everyday Health Group to Acquire Johnson and Johnson's BabyCenter a Global Digital Pregnancy and Parenting Resource
BMS Signs a Research Collaboration with Presage to Evaluate Novel Cancer Therapies In Phase 0 Studies Utilizing CIVO Technology
Alexion's Soliris (eculizumab) Receives European Commission's Approval for Neuromyelitis Optica Spectrum Disorder?
AstraZeneca Reports Results of Breztri Aerosphere in P-III ETHOS Study for Chronic Obstructive Pulmonary Disease
BMS's Triple Regimen Receives European Commission Approval for Relapse/Refractory Multiple Myeloma?
AstraZeneca Receives the US FDA's Orphan Drug Designation for its First Respiratory Biologic Fasenra (benralizumab) to Treat Eosinophilic Esophagitis
Kyowa Kirin's Nourianz (istradefylline) Receives FDA's Approval as an Adjunctive Therapy in Patients with Parkinson's Disease
Janssen Collaborates with Arrowhead for the Initiation of REEF-1 P-IIB Study in Patients with Chronic Hepatitis B Infection
Celgene Signs an Option to License Agreement with Immatics to Develop Novel Adoptive Cell Therapies Targeting Multiple Cancers
Mitsubishi Tanabe Reports Initiation of P-III BouNDLess Trial in Patients with Fluctuating Parkinson's Disease
Roche's Tecentriq (atezolizumab) + Abraxane Receive European Commission's Approval for Patients with PD-L1-Positive Metastatic Triple-Negative Breast Cancer
AstraZeneca Reports Results of Anifrolumab in P-III TULIP 2 Study for Patients with Systemic Lupus Erythematosus
Roche Reports Launch of First CDx VENTANA PD-L1 (SP142) Assay Identifying TNBC Patients Eligible for Treatment with Tecentriq (atezolizumab)
AbbVie to Discontinue its P-III MERU Trial of Rovalpituzumab Tesirine (Rova-T) as 1L Maintenance Therapy for Patients with Advanced Small-Cell Lung Cancer
Novartis Reports Results of Ofatumumab (OMB157) in P-III ASCLEPIOS I and II Studies for Multiple Sclerosis
Sandoz Recalls Losartan Potassium and Ezetimibe Prescription Drug Bottles due to Packaging Issues?
Janssen Extends its Research and Licensing Agreement with SVI to Develop Therapies for Alzheimer's Disease
"Innovent Biologics Reports Results of IBI303 (biosimilar, adalimumab) in P-III Studies for Ankylosing Spondylitis?"
Celltrion and Teva Report Results Updated Results of CT-P6 in P-III Study for Patients Receiving Neoadjuvant Treatment for HER2-Positive Early Breast Cancer
United Healthcare to Prefer Amgen's Two Anticancer Biosimilars in October 2019
Philips Collaborates with LindaCare for the Remote Monitoring of Patients with Cardiac Implantable Electronic Devices
Paratek Reports Results of Nuzyra (omadacycline) in P-III OASIS-2 Study for Skin Infections
Roche Reports Positive Results of Xofluza (baloxavir marboxil) in Two P-III MINISTONE-2 and BLOCKSTONE Studies for Influenza Infection
Novartis Reports Results of Entresto (sacubitril/valsartan) in Three P-III PARAGON-HF and P-IV PROVE-HF with EVALUATE-HF Studies for Patients with HFpEF and HFrEF
UniSA Evaluates Computer Vision Technology to Monitor Premature Babies in Neonatal Units
AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THEMIS Study for Coronary Artery Disease and Type-2 Diabetes
Chugai Files an Application to MHLW for an Additional Indication of Kadcyla (trastuzumab emtansine) as an Adjuvant Therapy for HER2-Positive Early Breast Cancer in Japan
AstraZeneca Reports Detailed Results of Farxiga (dapagliflozin) in P-III DAPA-HF Study to Treat Patients with Heart Failure?
Helsinn Enters into an Exclusive Distribution and License Agreement with Blanver and Varifarma for Pracinostat in South America
"Federal Circuit to Dismiss Halt Sales of Amgen's Mvasi (biosimilar, bevacizumab-awws) in the US"
Polpharma Signs an Exclusive Worldwide Commercialization Agreement with Sandoz for Proposed Biosimilar Natalizumab to Treat Relapsing-Remitting Multiple Sclerosis
The European Society of Cardiology Recommends Bayer's Xarelto (rivaroxaban) in Combination with Aspirin for the Management of Diabetes and Chronic Coronary Syndromes
Boehringer Ingelheim and Zealand Pharma to Initiate P-II Study of BI 456906 for Obesity and Diabetes
Alytas Therapeutics Signs an Agreement with Velabs Therapeutics to Develop Novel Immune-Based Therapy for Obesity
Vertex to Acquire Semma Therapeutics for Developing Curative Cell-Based Therapies to Treat Type 1 Diabetes
"Celltrion Enters into a Contract to Manufacture Agreement for its Remsima (biosimilar, infliximab) with Lonza?"
"STADA to Launch its Movymia (biosimilar, teriparatide) to Treat Osteoporosis in 24 Countries"
AstraZeneca's Tagrisso (osimertinib) Receives NMPA's Approval as a 1L Therapy for EGFR-Mutated Non-Small Cell Lung Cancer in China?
Boehringer Ingelheim Enters into a Licensing Agreement with Lupin to Expand its KRAS Cancer Program
Karolinska Institutet Evaluates AsthmaTuner Self-monitoring Mobile App for Managing Uncontrolled Asthma?
Merck's Keytruda (pembrolizumab) in Combination with Inlyta (axitinib) Receives European Commission's Approval as a 1L Therapy for Advanced Renal Cell Carcinoma
Janssen's Investigational Prophylactic Vaccine Receives the US FDA's Breakthrough Therapy Designation to Prevent Respiratory Syncytial Virus
BMS Signs an Agreement with BioMotiv to Develop Therapies for Patients with Serious Disorder
Regenxbio Signs an Exclusive Worldwide Option and License Agreement with Clearside Biomedical to Evaluate its Delivery Platform for RGX-314
Mylan to Make Amendments in its 2018 License Agreement with Revance for Biosimilar of BOTOX
"Samsung Bioepis Initiates Recruitment of Patients in P-III Study for SB12 (biosimilar, eculizumab) to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH) in India"
Conglomerate of Rheumatology and Spondylitis Organizations Released New Updated Guidelines Against Mandatory Switching to Biosimilars
AstraZeneca Collaborates with Schrödinger to Utilize its Molecule-Modeling Platform for Drug Discovery
Google Collaborates with Cochlear and GN Hearing to Support Direct Phone Streaming to Hearing Aids for Patients with Hearing Loss
BioNTech Signs an Agreement with Gates Foundation to Develop Therapies for HIV and Tuberculosis
Janssen's Stelara (ustekinumab) Receives EC's Approval for its Expanded Use to Treat Moderately to Severely Active Ulcerative Colitis
AbbVie Signs a Research Agreement with Idera Pharmaceuticals to Evaluate Combination Therapy
Novartis Signs an Exclusive Research and Option to Acquire Agreement with IFM Due to Develop Therapies Targeting cGAS/STING Pathway
Takeda Recalls Natpara (parathyroid hormone) Injection Formulation in the US
AstraZeneca Signs a License Agreement with Theragnostics for its PARP Inhibitor
SpeeDx's ResistancePlus MG FleXible Receives CE-IVD Clearance for Detection of Sexually Transmitted Infection (STI)
BMS Reports Results of Opdivo (nivolumab) in P-III CheckMate-548 Study for Patients Newly Diagnosed with MGMT-Methylated Glioblastoma Multiforme
Roche's Tecentriq Based Combination Therapy Receives EC's Approval as 1L Treatment for Non-Squamous Non-Small Cell Lung Cancer
OncoCyte to Acquire Razor Genomics for the Expansion of its Capabilities in Early-Stage Lung Cancer
Roche's Tecentriq + Chemotherapy Receives EC's Approval as 1L Treatment for Extensive Stage Small Cell Lung Cancer
Sumitomo Dainippon and Roivant Signs a Memorandum of Understanding to Form $3B Alliance
Eli Lilly Signs an Agreement with Thermo Fisher to Develop CDx for its Selpercatinib (LOXO-292)
AstraZeneca Reports Results of Imfinzi (durvalumab) in P-III CASPIAN Study for 1L Extensive-Stage Small Cell Lung Cancer
Abbott to Initiate World's First Study to Evaluate its TriClip Transcatheter Tricuspid Valve Repair System in the US?
Allergan and Molecular Partners Report Acceptance of FDA's BLA and Validation of EMA's MAA for Abicipar Pegol
Genmab Signs an Agreement with Tempus to Develop Novel Targets and Biomarkers for Cancer Indications
Alexion Enters into an Exclusive License Agreement with Eidos to Develop and Commercialize AG10 in Japan
Medtronic's MiniMed 670G Insulin Pump System Receives Reimbursement for Patients with T1D in Germany
BMS Reports Pooled Five Year Results of Opdivo (nivolumab) in Two P-III Studies for Advanced Non-Small Cell Lung Cancer
Mallinckrodt to Divest its Subsidiary BioVectra for $250M?
Baxter to Acquire Cheetah Medical for ~$230M
Sanofi Terminates its Four Years Alliance with Lexicon for Zynquista (sotagliflozin)?
Xeris' GVOKE (glucagon) Receives FDA's Approval as The First Ready-To-Use Stable Liquid Glucagon for Severe Hypoglycemia
Google Collaborates with Mayo Clinic for Healthcare Innovation Utilizing AI and Cloud Computing?
"Samsung Bioepis Reports the Availability of Brenzys (biosimilar, etanercept) in Brazil"
Merck KGaA's Tepotinib Receives FDA's Breakthrough Therapy Designation for Metastatic NSCLC with METex14 Skipping Alterations
Apple to Launch a Research App for Three Medical Studies Monitoring Health Issues
GSK to Acquire Sitari Pharmaceuticals for its Celiac Diseases Program
"Teva Canada's Herzuma (biosimilar, trastuzumab) Receives Health Canada Approval for Multiple Cancer Indications?"
Roche Reports Results of Satralizumab in Second P-III Study for Neuromyelitis Optica Spectrum Disorder
Zentiva to Acquire Sanofi's Ankleshwar Manufacturing Facility in India
Janssen Reports Results of Ponesimod in P-III OPTIMUM Study for Relapsing Multiple Sclerosis in Adults
Hansoh Enters into a Collaboration with Atomwise for AI-Based Drug Discovery
Vertex Signs an Access Agreement with Scottish Government for Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor)
Aytu BioScience to Acquire Innovus Pharmaceuticals for ~$24M
Roche Reports Results of Perjeta (pertuzumab) Fixed Dose SC Combination Therapy in P-III FeDeriCa Study for HER2+ve Breast Cancer
GSK's Nucala (mepolizumab) Receives the US FDA's Approval as First Biologic for Severe Eosinophilic Asthma in Children Aged 6-11yrs.
Celgene Reports Results of CC-486 in P-III QUAZAR AML-001 Study as Maintenance Therapy for Acute Myeloid Leukemia
GE Healthcare's Critical Care Suite AI-Powered X-ray Device Receives FDA's 510(k) Clearance to Identify Pneumothorax
Eisai And Biogen to Terminate Two P-III Clinical Studies of Elenbecestat (E2609) for Early Alzheimer's Disease?
Lundbeck to Acquire Alder BioPharmaceuticals for $1.95B
Sanofi and Abbott Collaborate to Assimilate Glucose Sensing and Insulin Delivery Technologies to Manage Diabetes
Medtronic and Novo Nordisk Collaborate to Deliver Integrated Digital Solutions Easing the Hassles of Diabetes Management
AstraZeneca's Farxiga (dapagliflozin) Receives FDA's Fast Track Designation to Treat Patients with Heart Failure
Boehringer Ingelheim Signs an Exclusive Worldwide License Agreement with Oncoheroes Biosciences for Volasertib
Janssen Reports Submission of sBLA to the US FDA for Tremfya (guselkumab) to Treat Active Psoriatic Arthritis
Seattle Genetics and Astellas Report Acceptance of BLA for Enfortumab Vedotin to Treat Locally Advanced or Metastatic Urothelial Cancer?
Medtronic's Envision Pro Continuous Glucose Monitoring System Receives CE Mark in Europe
Acceleron to Discontinue its P-II Study of ACE-083 for Facioscapulohumeral Muscular Dystrophy?
Glenmark's GBR 1342 Receives the US FDA's Orphan Drug Designation for Multiple Myeloma
Merck Reports Acceptance of BLA to the US FDA for V920 Ebola Virus Vaccine
Bayer Signs a License Agreement with Informed Data Systems to Utilize its One Drop Digital Therapeutics Platform
Mylan Launches Generic Faslodex Injection for the Expansion of its Oncology Portfolio in the US
Generium Launches First Biosimilar of Dornase Alfa Utilizing Selexis' SUREtechnology Platform?
AstraZeneca Amends its Development and Commercialization Agreement with Ironwood for Linzess (linaclotide) Signed in 2012 ?
Roche's Gazyva (obinutuzumab) Receives FDA's Breakthrough Therapy Designation for Lupus Nephritis
Regeneron and Sanofi Launch Educational Campaign Focusing on Patients Living with Moderate-To-Severe Atopic Dermatitis
The US FDA Initiates its First Step Towards Project Orbis for Concurrent Review of Cancer Therapies
Merck's Keytruda (pembrolizumab) + Eisai's Lenvima (lenvatinib) Receives FDA's Approval for Certain Types of Endometrial Carcinoma?
Novigenix Collaborates with BioLizard to Develop AI-Based Diagnostic Algorithm for Detecting Colon Cancer
Roche Renews its Support to the Phelophepa Healthcare Trains in South Africa Marking the 25th Anniversary
Novartis Reports Results of Galvus (vildagliptin) Combination Therapy in P-IV VERIFY Study for Type 2 Diabetes Mellitus?
Biogen to Initiate P-II/III DEVOTE Study Evaluating the Higher Doses of Spinraza (nusinersen) for Spinal Muscular Atrophy
TB Alliance's Pretomanid Combination Therapy Receives the US FDA's Approval for Highly Drug-Resistant Forms of Tuberculosis
Harmony Biosciences' Wakix (pitolisant) Receives the US FDA's Approval for Treatment of Excessive Daytime Sleepiness in Adult Patients with Narcolepsy
Novo Nordisk Reports Results of Tresiba (insulin degludec) in CONCLUDE Study for Type 2 Diabetes
Novartis Reports the Reimbursement of Kisqali as 1L Treatment for Metastatic Breast Cancer in Quebec
Merck KGaA Signs a License Agreement with Y-Trap to Develop Antibody-Ligand Traps for Immuno-Oncology
Roche's cobas Babesia Blood Test Receives the US FDA's Approval for Donor Screening
Takeda and Lundbeck's Trintellix (vortioxetine) Receives MHLW's Approval for Major Depressive Disorder in Japan?
Eli Lilly's Trulicity (dulaglutide) Receives CHMP Recommendation for Label Update to Include Results from REWIND Study
Astellas and FibroGen's Evrenzo (roxadustat) Receives MHLW's Approval for Anemia Associated with Chronic Kidney Disease in Dialysis Patients
Boehringer Ingelheim Enters into an Agreement with Inflammasome Therapeutics to Co-Develop Therapies for Retinal Diseases
"PharmaShots Weekly Snapshot (September 16– 20, 2019)"
AstraZeneca's Qtrilmet Receives CHMP's Recommendation for its Approval to Treat Patients with Type-2 Diabetes in Europe
Novo Nordisk's Rybelsus (semaglutide) Receives FDA's Approval as the First Oral GLP-1 analog for Type 2 Diabetes
Clovis Oncology Signs a License Agreement with 3B Pharmaceuticals for FAP-Targeted Radiopharmaceutical Program
Biogen's Plegridy (peginterferon beta-1a) and Avonex (interferon beta-1a) Receive CHMP's Positive Opinion to Use During Pregnancy and Breastfeeding?
Mallinckrodt Reports Results of StrataGraft Regenerative Tissue in P-III STRATA2016 Study for Deep Partial-thickness Thermal Burns?
"Celltrion's CT-P13 (biosimilar, infliximab) Receives CHMP's Positive Opinion for its SC Formulation to Treat Rheumatoid Arthritis?"
MSD Collaborates with I-Mab to Evaluate Keytruda + TJC4 for Multiple Cancer Indications
Bayer's Vitrakvi (larotrectinib) Receives EMA's Approval as the First Tumor Agonist in Europe?
Sandoz Voluntary Recalls Ranitidine Hydrochloride Capsules Due to Elevated Amount of N-Nitrosodimethylamine in the US
Bayer Collaborate with Women's Hospital and Massachusetts General Hospital to Launch Joint Lab Targeting Chronic Lung Diseases
Takeda Collaborates with Evotec to Discover Clinical Candidates for Multiple Therapeutic Areas
BMS' Opdivo (nivolumab) Receives CHMP Recommendation for Approval of its Four-Week Dosing Schedule?
Aldeyra's ADX-2191 Receives FDA's Fast Track Designation to Prevent Proliferative Vitreoretinopathy
Biocon Biologics Acquires Pfizer's Research Facility to Expand its Research and Development Footprint
Pfizer Expands its Collaboration with Flatiron Health to Integrate the Use of Real-World Evidence in Oncology
Amgen Reports Results of Blincyto (blinatumomab) in Two P-III Studies for Relapsed Acute Lymphoblastic Leukemia in Pediatric Patients?
Bavarian Nordic's Jynneos Vaccine Receives FDA's Approval to Prevent Smallpox and Monkeypox Disease in Adults
Achillion's Danicopan (ACH-4471) Receives FDA's Breakthrough Therapy Designation for Paroxysmal Nocturnal Hemoglobinuria
Ethicon Launches Echelon Circular as the First Powered Circular Stapler for Colorectal Gastric and Thoracic Surgery?
Takeda Reports Results of Vedolizumab in its First Head-to-Head Biologic Study for Ulcerative Colitis
Abbott's ARCHITECT STAT High Sensitivity Troponin-I Blood Test Receives FDA Clearance to Detect Heart Attacks Faster and Accurately
Thermo Fisher to Expand its Clinical Trials Capabilities and Collaborates with Frontier to Develop Therapy for HIV
Jazz Reports Results of JZP-258 in a P-III Study to Treat Cataplexy and Excessive Daytime Sleepiness in Patients with Narcolepsy
AstraZeneca and Innate Pharma to Advance Monalizumab in a P-III Study for Head and Neck Cancer
Medtronic to Initiate Clinical Study Evaluating Infuse Bone Graft in TLIF Spine Procedures
AbbVie's Mavyret (glecaprevir/pibrentasvir) Receives FDA's Approval for its Expanded Indication in Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes
Janssen's Darzalex (daratumumab) Combination Therapy Receives FDA's Approval for Frontline Multiple Myeloma?
Medtronic Reports Results of Resolute Onyx DES in Onyx ONE Global Study for High-Bleeding Risk Patients with One-Month DAPT ?
Ieso Launches Eight Billion Minds Digital Initiative Addressing Unmet Mental Health Needs
Simcere Signs an Exclusive License Agreement with JW Pharmaceutical for an Anti-Gout Drug Candidate URC-102 in China?
Pfizer Reports Results of Abrocitinib in P-III JADE MONO-2 Study for Moderate to Severe Atopic Dermatitis
Incyte Reports Updated Results of Pemigatinib in P-II FIGHT-202 Trial for Patients with Previously Treated Advanced Cholangiocarcinoma
Sobi to Acquire Dova Pharmaceuticals for $915M?
Roche's Rituxan (rituximab) Receives the US FDA's Approval for Two Rare Blood Vessel Disorders in Pediatric Patients Aged 2yrs. and Above?
GSK Reports Results of Nucala (mepolizumab) in REALITI-A Study for Severe Eosinophilic Asthma?
Merck Reports Results of Recarbrio (imipenem/cilastatin/relebactam) in P-III RESTORE-IMI 2 Study for Patients with HABP/VABP
Celltrion Signs an Exclusive Co-Marketing Agreement with Juno in Australia
Fresenius Kabi to Establish R&amp;D Center for Biosimilars in Switzerland
Vertex Collaborates with Ribometrix to Discover and Develop up to Three RNA Targeted Candidates
Mochida Receives Marketing Authorization for Teriparatide Biosimilar in Japan
SymBio Signs Worldwide Exclusive License Agreement with Chimerix to Develop and Commercialize Brincidofovir
"Dr. Reddy Plans the Onset of P-III trial for DRL_RI (biosimilar, rituximab) in the Korea"
AstraZeneca to Divest Worldwide Commercialization Rights of Losec (omeprazole) to Cheplapharm
Janssen's Invokana (canagliflozin) Receives the US FDA's Approval for Patients with Type 2 Diabetes and Diabetic Kidney Disease ?
Roche Reports Result of Tecentriq (atezolizumab) + Platinum-Based CT in P-III IMvigor130 Study for Advanced Bladder Cancer
"Pfizer to Launch its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019"
Taisho Signs an Exclusive License Agreement with Moberg Pharma to Develop and Commercialize MOB-015 in Japan?
Eisai Signs a Research and Option Agreement with Numab to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancer?
Novartis Signs a Multiyear Agreement with Microsoft to Transform Medicine with the Launch of AI Innovation Lab
"Biocon and Mylan Launch Semglee (biosimilar, Insulin Glargine) in Australia"
Philips Collaborates with Air Ambulance Kent Surrey Sussex to Provide Emergency Services in the UK
Eli Lilly Reports Results of Taltz (ixekizumab) in Head-to-Head P-IV IXORA-R Study for Moderate to Severe Plaque Psoriasis
Merck's Keytruda Receives NMPA's Approval as Monotherapy for 1L Treatment of Advanced Non-Small Cell Lung Cancer with PD-L1 Tumor Expression in China?
Eli Lilly Reports the Availability of Emgality (galcanezumab) to Prevent Migraine in Canada
Novo Nordisk Collaborates with Noom to Provide Digital Health Solutions Targeting Weight Management in Patients with Obesity
Takeda Signs a License Agreement with Goldfinch Bio for its GFB-024 to Treat Rare and Metabolic Kidney Diseases
Gilead's Descovy Receives the US FDA's Approval for HIV Pre-Exposure Prophylaxis ?
AstraZeneca's Fasenra Pen (Pre-Filled Auto-Injector) Receives the US FDA's Approval for Severe Eosinophilic Asthma?
Silver Cloud Health Partners with Microsoft to Deploy AI for Enhancing its Digital Mental Healthcare
Arbutus to Discontinue its P-Ia/Ib Clinical Study of AB-506 to Treat Patients with Chronic Hepatitis B
Janssen's Niraparib Receives the US FDA's Breakthrough Therapy Designation for Metastatic Castration-Resistant Prostate Cancer
AveXis Reports Results of AVXS-101 (Intrathecal) in P-I/II STRONG Study for Patients with SMA Type 2
Takeda Signs Multi-Target Strategic Collaboration with Prometheus to Develop Targeted Therapies for Inflammatory Bowel Disease
Eli Lilly Report Results of Cyramza (ramucirumab) in P-III RELAY Study for 1L Treatment of EGFR-Mutated Non-Small Cell Lung Cancer
"Alvogen and Pfenex's PF708 (biosimilar, teriparatide) Receives FDA's Approval for the Treatment of Osteoporosis?"
Pfizer Signs an Exclusive Worldwide License Agreement with Akcea for its AKCEA-ANGPTL3-L(Rx)
Biofourmis' Biovitals Analytics Engine Receives FDA's 510(k) Clearance for Ambulatory Physiologic Monitoring?
Innovate Merging with RDD Pharma to Form New Gastroenterology Company Focusing on Specialty Rare and Orphan Diseases
Allergan to Launch Three REFRESH RELIEVA Lubricant Eye Drops Expanding its REFRESH Portfolio
MSD Signs a Research and Option to License Agreement with 4D Pharma to Develop Live Biotherapeutics for Vaccines
Medtronic Initiates Worldwide Pivotal Study to Evaluate its Extravascular Implantable Cardioverter Defibrillator System
Novartis' Beovu (brolucizumab) Receives FDA's Approval for the Treatment of Wet Age-Related Macular Degeneration
Gilead Reports Submission of NDA to MHLW for Filgotinib to Treat Rheumatoid Arthritis in Japan
GSK Signs a Five Years Collaboration with Lyell to Develop Technologies Improving Cell Therapies for Cancer
AstraZeneca Canada's Calquence (acalabrutinib) Receives Health Canada Approval for Patients Previously Treated with Mantle Cell Lymphoma (MCL)
Prevail Signs an Agreement with Lonza to Develop and Manufacture AAV9 Gene Therapy Programs for Patients with Neurodegenerative Diseases
Amgen Canada's EVENITY (romosozumab) Receives Health Canada Approval to Treat Osteoporosis in Postmenopausal Women at High Risk for Fracture
GE Healthcare Signs a Worldwide Development and Commercialization Agreement with Theragnostics for Late Stage PSMA Diagnostic for Prostate Cancer
"Samsung Bioepis Reports Real-World Data of Benepali (biosimilar, etanercept) in Patients with Psoriasis at EADV 2019"
Bluebird Bio Signs a Three-Year Research Collaboration with Novo Nordisk to Develop In-Vivo Genome Editing Therapies for Hemophilia A
Mitsubishi Tanabe Signs a License Agreement with Viela Bio for its Inebilizumab
Evotec Signs an Agreement with Celmatix to Develop Pre-Clinical Candidates for Women Health
Boehringer Ingelheim Reports Results of OFEV (nintedanib) in P-III INBUILD Trial for Patients with Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (1)
Bayer Launches a LifeHub UK for the Development of AI-Enabled Imaging Solutions Enhancing Data-Driven Drug Discovery and Disease Diagnosis
Sun Pharma Reports Four Years Result of Ilumya (tildrakizumab-asmn) in P-III reSURFACE 1 and 2 Trials in Patients with Moderate-to-Severe Plaque Psoriasis
UCB to Acquire Ra Pharma to Improve Therapies for Patients with Myasthenia Gravis and Other Rare Diseases
Reata Regains Exclusive Worldwide Rights of its Nrf2 Activator Product Platform from AbbVie
Aclaris to Divest its Rhofade (oxymetazoline hydrochloride) with all IPR Rights to EPI Health
Bayer's G4A Digital Health Partnerships Program Signs an Agreement with Eleven Digital Health Startups Transforming Digital Health Solutions
Boehringer Ingelheim's Ofev (nintedanib) Receives the US FDA's Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
Biocon Biologics Signs an In-License Agreement with Just - Evotec Biologics
Alexion Signs an Option to Co-Develop and Commercialize Agreement with Stealth for Elamipretide
OraSure Technologies' Rapid Diagnostic OraQuick Ebola Rapid Antigen Test Receives the US FDA Marketing Approval for Detection of Ebola Virus Antigens
?Alnylam Reports Submission of MAA to Brazilian Health Regulatory Agency for Onpattro (patisiran) to Treat Hereditary ATTR Amyloidosis with Polyneuropathy
?ImaginAb Collaborates with Three Global Pharmaceutical Companies Focusing on the Development of its CD8 ImmunoPET Technology
Roche Reports Results of MabThera/Rituxan (rituximab) in P-III PEMPHIX Study for Pemphigus Vulgaris?
?Lilly's Reyvow (lasmiditan) Receives FDA's Approval as the First Therapy in a New Class of Acute Treatment for Migraine
?Exact Sciences and Mayo Clinic Initiate Voyage Study Evaluating the Real-World Impact of Cologuard
?Aytu BioScience to Acquire Cerecor's Prescription Product Portfolio for $17M
?Sanofi Launches its First Digital Manufacturing Facility for Delivering Next-Generation Biologics in Massachusetts
?Takeda to Divest its Portfolio of Select OTC and Non-Core Assets to Acino for ~$200M in NEMEA Countries
?Abbott Collaborates with Omada Health to Provide Integrated Digital Health and Coaching Experience for Patients with Type 2 Diabetes
?Bayer and Janssen's Xarelto (rivaroxaban) Receive FDA's Approval to Prevent Venous Thromboembolism in Acutely Ill Patients
?Kyowa Kirin Reports the Availability of Nourianz (Istradefylline) to Treat Parkinson's Disease “Off” Episodes in the US
CRISPR Therapeutics and KSQ Therapeutics Cross Licenses their IP Rights to Facilitate Cell Therapy Programs in Oncology?
?Reata Reports Results of Omaveloxolone in P-II MOXIe Registrational Study for Patients with Friedreich's Ataxia
?Abbott and Tandem Collaborate to Explore Integrated Diabetes Solutions Improving Diabetes Management
?Sanofi and Kaken to Terminate their Co-Marketing Agreement for Clexane by the Year End 2019
?Daiichi Sankyo Acquires Rights for Astellas' Three Therapies to Boost its Presence in Asia
?ProQR's Sepofarsen Receives FDA's Rare Pediatric Disease Designation to Treat Leber's Congenital Amaurosis 10
Alexion to Acquire Achillion for ~$930M?
Lilly Reports Results Pegilodecakin + Folfox in P-III SEQUOIA Study for Metastatic Pancreatic Cancer?
?Sandoz Terminates its Prescription Digital Therapies Agreement with Pear Therapeutics
?AstraZeneca Collaborates with PetaGene to Deploy PetaSuite in its Core Genomics Initiative
?AstraZeneca and Daiichi Report the US FDA's Acceptance of BLA for Trastuzumab deruxtecan (DS-8201) and Granted Priority Review
Sun Pharma Launches Drizalma Sprinkle (duloxetine delayed-release capsules) for Neuro-Psychiatric and Pain Disorders in the US?
Ipsen Signs Exclusive Worldwide License Agreement with Blueprint to Develop &amp; Commercialize BLU-782 for Fibrodysplasia Ossificans Progressiva?
UCB Reports Results of Bimekizumab in P-III BE VIVID Study to Treat Moderate to Severe Chronic Plaque Psoriasis?
Fitbit Collaborates with BMS-Pfizer Alliance Focusing on Improving Atrial Fibrillation Detection?
?Roche's Xofluza (baloxavir marboxil) Receives the US FDA's Approval for People at High Risk of Developing Influenza-Related Complications
Amgen and UCB's Evenity (Romosozumab) Receive CHMP Positive Opinion to Treat Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture?
Cipla to Acquire Venus Remedies' Elores to Strengthen its Critical Care Footprints in India
Merck's V920 Ebola Zaire Vaccine Receives CHMP Positive Opinion to Protect Against Ebola Virus Disease
AbbVie's Rinvoq (Upadacitinib) Receives CHMP Positive Opinion to Treat Moderate to Severe Active Rheumatoid Arthritis?
Johnson &amp; Johnson Initiates Voluntarily Recall of a Single Lot of its Baby Powder in the US
Roche Reports Result of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 Study for Unresectable Hepatocellular Carcinoma
GSK to Divest its Rabipur and Encepur Vaccines to Bavarian Nordic for ~1B
?AstraZeneca's Farxiga (dapagliflozin) Receives the US FDA's Approval for Reducing the Risk of Hospitalization for Heart Failure in Patients with Type-2 Diabetes
?Sartorius to Acquire Danaher's Life Science Portfolio for $750M
?Janssen's Stelara (ustekinumab) Receives the US FDA's Approval for Moderately to Severely Active Ulcerative Colitis
?Humana and Microsoft Collaborate to Reimagine Health Leveraging Azure Cloud and AI with Voice Technologies
?Bayer to Terminate its JV Agreement with CRISPR Therapeutics
?Takeda Acquires Exclusive Worldwide License Rights for COUR's CNP-101 to Treat Celiac Disease
?Pfizer and OPKO Reports Results of Somatrogon in P-III Study for Children with Growth Hormone Deficiency
?Vertex's Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Receives the US FDA's Approval to Treat the Underlying Cause of Cystic Fibrosis
?BMS Reports Result of Opdivo (nivolumab) + Yervoy (ipilimumab) + CT in P-III CheckMate-9LA Study as 1L Therapy for Lung Cancer
"?Alvogen Signs an Exclusive Commercialization Agreement with Three Pharma Companies for PF708 (biosimilar, teriparatide)"
?Novo Nordisk's Fiasp (insulin aspart injection) Receives the FDA's Approval for use in Insulin Infusion Pumps to Treat Type 1 or Type 2 Diabetes
?Biogen and Eisai Plan to File BLA to the US FDA for Aducanumab to Treat Alzheimer's Disease
?BerGenBio's Bemcentinib Receives the US FDA's Fast Track Designation for Relapsed Acute Myeloid Leukemia
?Brii Biosciences Collaborates with Qpex to Develop and Commercialize Antibiotics for Drug-Resistant Infections in China
?Biomica Signs an Agreement with Weizmann Institute of Science to Develop a Selective Treatment Against Antibiotic-Resistant Bacteria
Novartis Collaborates with Pliant Therapeutics to Develop Therapies for NASH and Fibrotic Diseases
?GSK's Zejula (niraparib) Receives FDA's Approval for Late-line Treatment in Women with Recurrent Ovarian Cancer
Bausch Health In-Licenses Clearside's Xipere (triamcinolone acetonide suprachoroidal injectable suspension) For Macular Edema Associated with Uveitis?
?NovoCodex Collaborates with Ambrx to Develop and Commercialize its ARX305 in China
?WHO Signs MoU with IGBA for Promoting the Access to Biosimilars and Generics
?AbbVie Collaborate with Cystic Fibrosis Foundation to Advance CFTR Potentiator
?Allergan's BOTOX (onabotulinumtoxinA) Receives the US FDA's Approval for Pediatric Patients with Lower Limb Spasticity Excluding Spasticity Caused by Cerebral Palsy
?Astellas' Xospata (gilteritinib) Receives EC's Approval as Monotherapy for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
?Zentiva to Acquire Alvogen's Generics and OTC Business in Central and Eastern Europe
?NHS England Signs an Agreement with Vertex to Access All Licensed Cystic Fibrosis Therapies
?Urology San Antonio Collaborates with Anixa Biosciences on Ccheck Prostate Cancer Study
?Gilead Collaborates with Glympse Bio to Utilize Biomarker Technology in NASH Clinical Program
?AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV Non-Small Cell Lung Cancer
?Pfizer's Bavencio (avelumab) + Axitinib Dual Regimen Receive EC's Approval as 1L Treatment for Advanced Renal Cell Carcinoma
GSK Reports Results of M72/AS01E in P-IIb Study for the Prevention of Pulmonary Tuberculosis Disease
MorphoSys and Galapagos in Collaboration with Novartis Terminate Clinical Development of MOR106 in Atopic Dermatitis
?Astellas' ASP1128 Receives the US FDA's Fast Track Designation for Patients at High Risk of Acute Kidney Injury
Boehringer Ingelheim Collaborates with The Defeat-NCD Partnership to Tackle the Impacts of Non-Communicable Diseases
"GSK's Benlysta (belimumab, IV) Receives EC's Approvals as the First Biologic to Treat Lupus in Children"
AstraZeneca Divests Rights of Seroquel and Seroquel XR to Cheplapharm in Europe and Russia
Roche Reports EMA and FDA's Acceptance of Marketing Application for Satralizumab to Treat Neuromyelitis Optica Spectrum Disorder
Novartis Reports FDA's Hold on P-I/II Intrathecal Study Evaluating Zolgensma/AVXS-101 (onasemnogene abeparvovec-xioi) for Spinal Muscular Atrophy Type 2
LEO Pharma Signs an Option Agreement with Ubiquigent to Access its Two Novel Therapies
Biogen and Alkermes' Vumerity (diroximel fumarate) Receive FDA's Approval for Multiple Sclerosis
Pear Therapeutics Signs an Agreement with Ironwood to Assess Prescription Digital Therapeutics for GI Indications
Astellas Signs an Exclusive License Agreement with Pandion to Deliver Immunomodulators for Autoimmune Diseases of the Pancreas
Johnson &amp; Johnson Vision Launches TECNIS Eyhance Monofocal Intraocular Lens for Post Cataract Surgery Patients in India
AliveCor and Huami Collaborate to Bring the Next Generation ECG Wearables Devices
Roche Signs a Development and Commercialization Agreement with Dicerna for its DCR-HBVS to Treat Chronic Hepatitis B Virus Infection
Janssen's Darzalex (daratumumab) Combination Regimen Receives Health Canada Approval for Transplant Ineligible Patients with Multiple Myeloma
Amgen Acquires Stake in BeiGene to Expand its Oncology Portfolio in China
Pfizer Reports Launch Date for its Two Anticancer Biosimilars
"Formycon Reports Initiation of P-I Trial for FYB202 (biosimilar, ustekinumab)"
"Pfenex Reports Results of Human Factors Study for its PF708 Candidate (biosimilar, teriparatide)"
"NeuClone Reports Dosing of NeuLara (proposed biosimilar, ustekinumab) in P-I Trial"
Novartis Reports Results of Cosentyx (secukinumab) in Head to Head P-III EXCEED Study for Psoriatic Arthritis
AbbVie Reports Results of Rinvoq (upadacitinib) in P-III SELECT-PsA 2 Study for Psoriatic Arthritis
Vertex Reports Results of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Two P-III Studies for Cystic Fibrosis
"Mundipharma's Pegfilgrastim Mundipharma (biosimilar, pegfilgrastim) Receives CHMP Positive Opinion for MAA in EU"
Beam Therapeutics Signs Exclusive License Agreement with Prime Medicine for Prime Editing Technology
Medtronic Reports MHLW's Shonin Approval and Launches Valiant Navion Thoracic Stent Graft System in Japan
Google to Acquire Fitbit for ~$2.1B
Sanofi Reports Results of Toujeo (insulin glargine 300 Units/mL) in P-III EDITION JUNIOR Study in Children and Adolescents with Type 1 Diabetes
Janssen Collaborates with Vifor Pharma to Co-commercialize Invokana (canagliflozin) for the Treatment of Diabetic Kidney Disease in the US
Yas Holding to Acquire Stake in Alvotech and Signs an Exclusive Agreement for its Three Biosimilar Candidates
Halozyme to Discontinue its P-III HALO-301 Study of PEGPH20 for the Treatment of Metastatic Pancreatic Cancer
Boehringer Ingelheim and Lilly Restructure their Alliance to Emphasis Full Expertise and Investment on Jardiance
"Sandoz's Ziextenzo (biosimilar, pegfilgrastim) Receives the US FDA's Approval to Decrease the Incidence of Febrile Neutropenia"
Takeda to Divest its Portfolio of Select OTC and Non-Core Assets to STADA for ~$660M
Sanofi's Fluzone High-Dose Quadrivalent (Influenza Vaccine) Receives the FDA's Approval for Adults Aged= 65yrs.
Henlius and Ascentage Pharma Collaborate to Evaluate the Combination Therapy for Chronic Lymphocytic Leukemia in China
Stryker to Acquire Wright Medical for $5.4B
BeiGene Signs an Exclusive Worldwide License Agreement with Seattle Genetics to Advance Preclinical Candidates Treating Cancer
Takeda Signs an Exclusive License and Research Agreement with MD Anderson for CAR NK Cell Therapies
BioLineRx Reports Results of BL-8040 in Combination with Keytruda (pembrolizumab) in P-IIb Trial for Patients with Metastatic Pancreatic Cancer
Vela Diagnostics' Sentosa SQ HIV-1 Genotyping Assay Receives the US FDA's DE Novo Authorization for Detection of HIV-1 Genomic Drug Resistance Mutations (DRMs)
Evotec Collaborates with Vifor Pharma to Launch a Joint Venture to Discover and Develop Therapies for Nephrology
Eisai to Transfer Royalty Rights for Tazemetostat to Royalty Pharma Outside Japan
Regeneron Signs a Research and Option to License Agreement with Vyriad for Oncolytic Virus-Based Therapies
Biogen Signs an Exclusive Commercialization Agreement with Samsung Bioepis to Expand its Biosimilars Portfolio
Coherus Signs an Exclusive License Agreement with Bioeq for Biosimilar of Lucentis (ranibizumab) in the US
Promega Signs a Worldwide Agreement with Merck to Develop MSI Technology as CDx for Keytruda
Novo Nordisk Signs an Exclusive Worldwide License Agreement with UBE Industries for its UD-014
STADA Signs an Exclusive Commercialization Agreement with Alvotech for Seven Biosimilars in Europe
AstraZeneca to Invest $1B for the Transformation of Healthcare in China
"Bio Thera's QLETLI (biosimilar, adalimumab) Receives NMPA's Approval for Auto-Immune Diseases in China"
"Teva and Celltrion Reports the Availability of Truxima (biosimilar, Rituxan) in the US"
AstraZeneca Reports Results of Roxadustat in P-III OLYMPUS and ROCKIES Studies for Chronic Kidney Disease Patients with Anaemia
Sierra Oncology Amends its Asset Purchase Agreement with Gilead for Momelotinib Signed in 2018
Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM4 Study as 1L Treatment for Multiple Myeloma Patients Not Treated with Stem Cell Transplantation
Yuhan Pharmaceutical Collaborates with Cyclica to Enhance Drug Development Utilizing AI-Integrated Drug Discovery Platform
Triumvira's TAC01-CD19 Receives FDA's Fast Track Designation for R/R Diffuse Large B-Cell Lymphoma
Janssen Reports Submission of MAA to EMA for its Investigational Ebola Vaccine Regimen to Prevent Ebola Virus Disease
Sandoz to Acquire Aspen's Japanese Operations and Associated Assets for ~$440M
AstraZeneca Reports Pooled Cardiovascular Safety and Efficacy Analyses of Roxadustat in P-III Program for CKD Patients with Anaemia
Roche Reports Results of Risdiplam in Pivotal SUNFISH Study for Patients with Type 2 or 3 Spinal Muscular Atrophy
Celgene's Reblozyl (luspatercept–aamt) Receives FDA's Approval as the First Therapy to Treat Patients with Rare Blood Disorder
Roche Reports Results of Gazyva (obinutuzumab) in P-II NOBILITY Study for Lupus Nephritis
Medtronic Reports Results of World's Smallest Pacemaker in MARVEL 2 Study for Patients with Atrioventricular Block
Merck's Ervebo [Ebola Zaire Vaccine (rVSV?G-ZEBOV-GP) live] Receives EC's Conditional Approval to Prevent Ebola Virus Disease
Lupin to Divest its Stake in Kyowa to Unison for ~$525M
BMS Reports Acceptance of sBLA for Opdivo (nivolumab) + Yervoy (ipilimumab) for Patients with Previously Treated Advanced Hepatocellular Carcinoma
Janssen Reports Results of Tremfya (guselkumab) in P-III DISCOVER Studies for Active Psoriatic Arthritis
Bluebird Bio Collaborates with Forty Seven to Evaluate Antibody Conditioning Regimen in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy
Mylan and Pfizer Names Viatris as the New Company for Mylan-Upjohn's Combination
Celgene Amends its Existing Collaboration with Editas to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for Cancer and Autoimmune Diseases
Celgene Signs an Exclusive Worldwide License Agreement with Skyhawk to Develop Therapies Modulating RNA Splicing
AbbVie Reports Results of Rinvoq (upadacitinib) in P-II/III SELECT-AXIS 1 Study for Patients with Ankylosing Spondylitis
Boehringer Ingelheim and Lilly Commence P-III EMPULSE Study to Evaluate Jardiance in People Hospitalized for Acute Heart Failure Who Have Been Stabilized
GSK Reports Results of Nucala (mepolizumab) in P-III Study for Hypereosinophilic Syndrome
Merck Acquires Calporta Therapeutics for ~$576M
Pfizer Collaborates with Centogene to Access its Rare Disease Data
Shreis Scalene's Cytotron Receives the US FDA's Breakthrough Device Designation for the Treatment of Multiple Cancer Indications
Boehringer Ingelheim and Lilly Report FDA's EMDAC Outcomes for Empagliflozin (2.5mg) as Adjunct to Insulin for T1D Patients
Takeda Expands its Collaboration with Finch Therapeutics to Develop Microbiome Therapies Utilizing Human-First Discovery Platform
Zambon Signs a License Agreement with Aquestive to Develop and Commercialize Riluzole Oral Film for Amyotrophic Lateral Sclerosis in EU
Clinuvel's Scenesse Receives the US FDA's Approval for Erythropoietic Protoporphyria (EPP)
Bayer Collaborates with Dewpoint to Develop New Therapies Targeting Cardiovascular and Gynecological Diseases
Galderma's Aklief (trifarotene) Receives the US FDA's Approval for the Treatment of Acne in 20 Years
Ardelyx's Ibsrela (tenapanor) Receives the US FDA's Approval for Irritable Bowel Syndrome with Constipation (ISB-C) for Adults
Foamix's Amzeeq (topical minocycline) Receives the US FDA's Approval for Moderate to Severe Acne
Allergan Signs an Exclusive Option and License Agreement with Exicure to Discover and Develop SNA-based Therapies for Hair Loss Disorders
Metacel Pharmaceuticals' Ozobax (baclofen) Receives the US FDA's Approval for Spasticity Due to Multiple Sclerosis
AstraZeneca and MSD Report FDA's Acceptance of NDA for Selumetinib in Patients with Neurofibromatosis Type 1
BeiGene's Brukinsa (zanubrutinib) Receives the US FDA's Accelerated Approval for Patients with Mantle Cell Lymphoma Who Received At least One Prior Therapy
Shionogi's Fetroja (cefiderocol) Receives the US FDA's Approval for the Treatment of Complicated Urinary Tract Infections
Sarepta Signs a License Agreement with Stride Bio to Develop In vivo AAV-Based Gene Therapies
Stanford Medicine Reports Results of Apple Heart Study for Detecting Atrial Fibrillation
Roche's Kadcyla (trastuzumab emtansine) Receives CHMP's Recommendation for Approval as an Adjuvant Treatment for Patients with HER2+ eBC with Residual Invasive Disease After Neoadjuvant Treatment
Roche to Acquire Promedior for $1.39B
"Pfizer's Abrilada (biosimilar, adalimumab) Receives the US FDA's Approval for Rheumatoid Arthritis"
Novartis' Adakveo (crizanlizumab) Receives the US FDA's Approval for Reducing the Frequency of VOCs in Sickle Cell Disease
Novo Nordisk Collaborates with Dicerna to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases
Aerie Pharmaceuticals to Acquire Avizorex Pharma to Expand its Footprint in Ophthalmology
Merck and Bayer Report Results of Vericiguat in P-III VICTORIA Study for Patients with Worsening Chronic Heart Failure
Novartis Collaborates with Biofourmis To Offer Digital Therapeutics for Managing Heart Failures
Alkermes to Acquire Rodin Therapeutics for $950M
Santhera Reports Results of Idebenone in SYROS Study for Duchenne Muscular Dystrophy
Janssen Redefines Clinical Trial Design by Leveraging Wearable Technology
Vertex Collaborates with Molecular Templates to Discover and Develop Conditioning Regimens Enhancing Hematopoietic Stem Cell Transplants
"Samsung Bioepis Reports FDA's Acceptance of BLA for SB8 (biosimilar, bevacizumab)"
Merck KGaA Collaborates with Personalis to Develop Novel Biomarkers for Cancer Therapies
CRISPR Therapeutics and Vertex Report Results of CTX001 from First Two Patients with Severe Hemoglobinopathies
Myovant Sciences Reports Results of Relugolix in P-III HERO Study for Men with Advanced Prostate Cancer
Janssen's Darzalex (daratumumab) Combination Regimen Receives EC's Approval for Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma
BioVentrix's Revivent TC Transcatheter Ventricular Enhancement System Receives FDA's Breakthrough Device Designation for Heart Failure
Merck's Keytruda (pembrolizumab) Receives EC's Approval as 1L Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma
BMS Reports Update of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -915 Study for Patients with Resected High-Risk Melanoma and PD-L1
AbbVie Collaborates with Dragonfly Therapeutics to Develop Therapies for Autoimmune and Oncology Indications
Alnylam's Givlaari (givosiran) Receives the US FDA's Approval as the First Therapy for Acute Hepatic Porphyria
Novartis Collaborates with Mila to Transform Therapies with Artificial Intelligence in Canada
Sanofi Collaborates with Aetion to Leverage its Evidence Platform for Advancing Regulatory Submissions
Astellas Signs a License Agreement with Welldoc to Develop and Commercialize Digital Therapies
"Aerie's Rhokiinsa (netarsudil ophthalmic solution, 0.02%) Receives EC's Approval for Patients with Open-Angle Glaucoma or Ocular Hypertension"
AbbVie Enters into an Exclusive Option and License Agreement for HPN217 and Expands its Existing Collaboration with Harpoon Therapeutics
Knight Therapeutics Signs an Exclusive License Agreement with Onconova for Rigosertib in Canada
AstraZeneca's Calquence (acalabrutinib) Receives the US FDA's Approval for Chronic Lymphocytic Leukemia Under the Project Orbis
GSK and ViiV Healthcare Sign an Exclusive License Agreement with NIH for its Investigational bNAb to Treat and Prevent HIV
Medtronic's IN.PACT AV Drug-Coated Balloon Receives the US FDA's Approval for the Treatment of Arteriovenous Fistula Lesions
BioMarin Reports Submission of MAA to EMA for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Lupin Launches Smart Device for Metered-Dose Inhalers to Support Treatment of Respiratory Diseases in India
Novartis to Acquire The Medicines Company for $9.7B
Roche Reports the US FDA's Acceptance of NDA for Risdiplam and Granted Priority Review to Treat Spinal Muscular Atrophy
Takeda's Takhzyro (lanadelumab injection) Receives CADTH's CDEC Positive Opinion for the Routine Prevention of Hereditary Angioedema Attacks
Roche Reports Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 for Unresectable Hepatocellular Carcinoma at ESMO Congress 2019
Takeda Reports Results of Alunbrig (brigatinib) in P-III ALTA-1L Study for Advanced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer
Ferring and Blackstone Collaborate to Establish Joint Venture Focusing on the Development of Gene Therapy for Bladder Cancer
Zogenix Reports the US FDA Acceptance of NDA and Granted Priority Review for Fintepla (fenfluramine) to Treat Dravet Syndrome
Bayer Reports Submission of MAA to EMA for Rivaroxaban to Treat Venous Thromboembolism in Children
Kyowa Kirin Signs Two Agreement with Ardelyx to Expand its Existing Partnership
Yas Holding Collaborates with Alvogen to Commercialize its Generic Portfolio in MENA Region
Merck's Keytruda (pembrolizumab) + CT Receives NMPA's approval as 1L Treatment for Metastatic Squamous Non-Small Cell Lung Cancer
Novoheart Collaborates with AstraZeneca to Develop World's First Heart-in-a-Jar Model of Heart Failure
"Biocon Report the US FDA's Approval of sBLA for Fulphila (biosimilar, pegfilgrastim) Manufactured at its New Facility in Bengaluru"
"Celltrion's Remsima SC (biosimilar, infliximab) Receives EC's Approval for Rheumatoid Arthritis"
Elsevier Acquires 3D4Medical for ~$50M
Amazon's Alexa Launches Medication Management Feature for Giant Eagle's Clients
Astellas' Xtandi (enzalutamide) Receives NMPA's Approval for Metastatic Castration-Resistant Prostate Cancer in Men
Incyte Reports Acceptance and Priority Review of NDA for Pemigatinib to Treat Patients with Cholangiocarcinoma
AbbVie UK Collaborates with NorthWest EHealth to Generate Real World Evidence for Exploring Autoimmune Conditions
Mochida Launches Teriparatide Biosimilar for the Treatment of Osteoporosis in Japan
Boehringer Ingelheim's Ofev (nintedanib) Receives Health Canada's Approval as the First Therapy to Treat SSc-ILD in Canada
Chugai Launches Tecentriq Intravenous Infusion 840mg as an Optimal Formulation to Treat PD-L1+ Triple-Negative Breast Cancer in Japan
JW Pharma Acquires C&amp;C Research Laboratories a Joint Venture with Chugai
Simcere Signs an Exclusive Regional Licensing Agreement with GI Innovation for its GI-101 Candidate
Octavus Consulting Collaborates with IBCI for Delivering of Professional Educational Programs in India from 2020
Avion Signs an Exclusive License Agreement with ImmuPharma to Develop and Commercialize Lupuzor
Roche's Kadcyla (trastuzumab emtansine) Receives Health Canada's Approval for The Treatment of HER2-Positive Early Breast Cancer After Surgery
WuXi ATU and GeneMedicine Collaborate to Develop and Manufacture Oncolytic Virus Products
AstraZeneca Reports the US FDA Acceptance of sBLA and Granted Priority Review for Imfinzi (durvalumab) to Treat Patients with Extensive-Stage Small Cell Lung Cancer
AstraZeneca Collaborates with JVP to Invest in Digital Health Program in Israel
ONO Reports Submission of MAA to MHLW for Tirabrutinib Hydrochloride to Treat Waldenstrom Macroglobulinemia and Lymphoplasmacytic Lymphoma
Roche Reports Results of Satralizumab in P-III SAkuraSky Study to Treat Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Y-mAbs Reports Initiation of Rolling Review of BLA for Naxitamab to the US FDA to Treat Neuroblastoma
Fosun Pharma's FN-1501 Receives the US FDA's Orphan Drug Designation for Leukemia
Chipscreen Bioscience's Epidaza (chidamide) Receives NMPA Approval for Breast Cancer Indication
Merck's Keytruda (pembrolizumab) Receives FDA's Priority Review for sBLA to Treat High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)
"Mylan and Biocon Launch Ogivri (biosimilar, trastuzumab) in the US"
Neurocrine Signs a License Agreement with Xenon to Develop Therapies for Epilepsy
Baxter to Acquire Seprafilm Adhesion Barriers from Sanofi for $350M
Astellas to Acquire Audentes Therapeutics for $3B
STADA to Acquire Biopharma's Pharmaceutical Prescription and Consumer Health Business to Expand Its Footprint in Ukraine
AstraZeneca Divests Commercial Rights of Seroquel and Seroquel XR to Cheplapharm in the US and Canada
Gene Techno Science Signs an Agreement with Kishi Kasei to Co-Develop Biosimilar of Aflibercept
Seattle Genetics and Astellas Collaborate with Merck to Evaluate Enfortumab Vedotin + Keytruda (pembrolizumab) for Metastatic Urothelial Cancer
GE Healthcare Signs an Agreement with Affidea to Deploy Digital Imaging Technologies
Kamada Collaborates with Alvotech to Commercialize its Six Biosimilar Products in Israel
StemoniX Collaborates with Atomwise to Form a Joint Venture Targeting Rett Syndrome
Ethicon Launches VISTASEAL Fibrin Sealant (Human) for Sealing Off Bleeds During Surgery
Lupin Plans to Launch Two of its Biosimilars in the US
"Qilu Reports Initiation of P-III Trial for QL1206 (biosimilar, denosumab) in China"
Merck KGaA and Ping An Good Doctor Collaborate to Support Health Management in China
Roche's Tecentriq + CT (abraxane and carboplatin) Receive the US FDA's Approval for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
Johnson &amp; Johnson Vision Launches TECNIS Toric II 1-Piece IOL as a New Monofocal Option for Cataract Patients with Astigmatism in the US
Veracyte Signs an Exclusive License Agreement with NanoString for its nCounter FLEX System
Eris Lifesciences Acquires Novartis' Zomelis (vildagliptin) in India for $13M
BMS' Orencia (abatacept) Receive the FDA's Breakthrough Therapy Designation to Prevent Acute Graft-Versus-Host Disease After Stem Cell Transplant
LEO Pharma Collaborates with Portal Instruments to Develop Needle-Free Drug Delivery Device
Lannett Reports Results of Biosimilar Insulin Glargine in Human Clinical Study to Treat Patients with Type 2 Diabetes
Novartis Collaborates with Amazon to Leverage Cloud Services for its Business Operations
Novartis Highlights its Blockbuster Portfolio at R&amp;D Day 2019
Takeda Collaborates with Enzyre to Develop Diagnostic Device to Regulate Coagulation Status in Patients with Hemophilia at Home
AstraZeneca and MSD's Lynparza (olaparib) Receive NMPA's Approval as 1L Maintenance Therapy for BRCA-Mutated Advanced Ovarian Cancer
Philips Collaborates with Humana to Deliver Remote Monitoring Capabilities to Select Medicare Advantage Members
Bayer Collaborates with Children's Hospital of Philadelphia to Develop Oral Non-Replacement Therapy for the Treatment of Hemophilia
AstraZeneca Signs an Agreement with Gatehouse Bio to Identify New Therapies Targeting Respiratory and Cardiovascular Diseases
Cerecor to Acquire Aevi Genomic Medicine for ~$22.6M
FDA and NIH Launch CURE ID Crowdsourcing App for Patients with Infectious Diseases
The US FDA Draft New Guidelines for Proposed Biosimilars and Interchangeable Insulins
Novartis Reports Results of QMF149 in P-III PALLADIUM Study for Patients with Uncontrolled Asthma
Y-mAbs Reports EMA's Acceptance of Pediatric Investigation Plan for Omburtamab
Bayer And Simulations Plus Collaborate to Advance ADMET Predictor for Improving Data Integrity in Drug Discovery
Bio-Thera Reports NMPA's Acceptance of IND for BAT2206 Proposed Biosimilar of Stelara (ustekinumab)
Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders
Sanofi to Acquire Synthorx for $2.5B
Janssen to Acquire XBiotech's Bermekimab for $750M
Sobi's Dova Pharmaceutical Reports Results of an Online Survey Highlighting Disease Burden and Impact for Patients with Immune Thrombocytopenia
Boehringer Ingelheim Collaborates with Healx to Identify New Treatments for Rare Neurological Diseases
"Amgen's Avsola (biosimilar, infliximab) Receives the US FDA's Approval for the Same Indications as Remicade (infliximab)"
AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ELEVATE TN Study for Previously Untreated Chronic Lymphocytic Leukemia
Merck to Acquire ArQule for $2.7B
AstraZeneca Collaborates with DeepMatter for Optimization of Compound Synthesis Leveraging AI and Machine Learning
Roche's Accu-Chek SugarView App Receives CE Mark Approval for Non-Insulin-Dependent Patients with Type 2 Diabetes or Pre-Diabetes
AbbVie Signs an Exclusive Agreement with Scripps Research to Develop New Therapies Targeting Multiple Therapeutic Areas
Merck Collaborates with Seven and Eight BioPharmaceuticals to Evaluate the BDB001 + Keytruda (pembrolizumab) for Advanced Solid Tumors
AbbVie to Deploy Adaptive's clonoSEQ Assay to Assess MRD Status Across Multiple Myeloma Studies
Engitix and Morphic Collaborate to Detect ECM-Related Targets in Fibrostenotic Inflammatory Bowel Disease
Sanofi Divulges its Strategic Framework to Drive Innovation and Growth
Sanofi and Regeneron to Restructure its Collaboration for Kevzara (sarilumab) and Praluent (alirocumab)
Roche and Novartis Report the US FDA's Acceptance of sBLA for Xolair (omalizumab) to Treat Nasal Polyps
"AffaMed Therapeutics' AMT901 (biosimilar, trastuzumab) Receives NMPA's Approval to Initiate P-III Clinical Study in China"
Vertex's Kalydeco (ivacaftor) Receives EC's Approval for Infants with Cystic Fibrosis with CFTR Gene Mutation Aged 6 to
Amgen Reports Results of KYPROLIS (carfilzomib) and DARZALEX (daratumumab) in P-III CANDOR study for Patients with Relapsed or Refractory Multiple Myeloma
Dermira‘s Lebrikizumab Receives the US FDA's Fast Track Designation to Treat Atopic Dermatitis
Kite and Kiniksa Collaborate to Evaluate the Combination of Yescarta (axicabtagene ciloleucel) and Mavrilimumab for R/R Large B-Cell Lymphoma
Kite Reports Submission of BLA to the US FDA for its Second CAR T Cell Therapy
Novartis Signs Worldwide License Agreement with Forendo Pharma to Discover Therapies Targeting Chronic Liver Diseases
Almirall to Accelerate Drug Discovery Process Utilizing Iktos' AI Technology
Roche Reports Results of Fixed-Dose SC Combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) in P-III FeDeriCa Study for HER2-Positive Breast Cancer
Amgen and UCB's Evenity (romosozumab) Receive EC's Approval to Treat Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture
AstraZeneca and Daiichi Sankyo Report Result of Trastuzumab Deruxtecan in P-II DESTINY-Breast01 Study for HER2 Positive Metastatic Breast Cancer
AstraZeneca's Imfinzi (durvalumab) Receives NMPA's Approval for Unresectable Stage III Non-Small Cell Lung Cancer
Alvogen to Acquire Assertio's Gralise (gabapentin) for $127.5M
iTeos Therapeutics Collaborates with Merck to Evaluate EOS100850 + Keytruda (pembrolizumab) for Solid Tumors
PerkinElmer's Screening Kit Receives the FDA's Approval as the First Test to Aid in Newborn Screening for Duchenne Muscular Dystrophy
Roche Reports Results of Triple Combination Regimen in P-III IMspire150 Study for Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma
Equillium Expands its Exclusive Licensing Agreement with Biocon for Itolizumab
Pfizer's Xeljanz XR (tofacitinib) Receives the US FDA's Approval for Ulcerative Colitis
SK Life Sciences' XCOPRI (cenobamate tablets) Receives the US FDA's Approval for Partial-Onset Seizures in Adults
Global Blood's Oxbryta (Voxelotor) Receives the US FDA's Accelerated Approval for Treatment of Sickle Cell Disease
RedHill Biopharma's Talicia Received the US FDA's Approval for H. pylori in Adults
ViiV Healthcare Reports Regulatory Submission to the US FDA and EMA for Dispersible Formulation of Tivicay (dolutegravir)
Sun Pharmaceuticals' Absorica Received the US FDA's Approval for Severe Recalcitrant Nodular Acne
Aquestive Therapeutics' Exservan (riluzole) Receives the US FDA Approval to Treat Amyotrophic Lateral Sclerosis (ALS)
Cumberland Pharmaceuticals' RediTrex (methotrexate) Injection Receives the US FDA's Approval for Rheumatoid Arthritis and Psoriasis
Janssen's Darzalex (daratumumab) Combination Regimen Receives CHMP's Positive Opinion for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
"Pfizer's Amsparity (biosimilar, adalimumab) Receives CHMP's Positive Opinion for Inflammatory and Autoimmune Disorders"
Roche Launches cobas Zika Blood Screening Test to Detect Zika Virus RNA
Tandem's Predictive Insulin Pump Software Receives the US FDA's Approval to Deliver Accurate Doses of Insulin in Patients Utilizing t:slim X2 Insulin Pump
Novartis Terminates Clinical Development of Fevipiprant (AW039) in P-III LUSTER Studies for Patients with Uncontrolled GINA 4/5 Asthma
Boehringer Ingelheim and Lilly Report Results of Jardiance (empagliflozin) in P-III EMPERIAL Studies for Chronic Heart Failure
SanBio and Sumitomo Dainippon Pharma Terminate Joint Development and License Agreement for SB623 in North America
Lilly Collaborates with DexCom to Utilize Dexcom CGM in its Personalized Diabetes Management System
Charles River to Acquire HemaCare Corporation for $380M
Medtronic and ChristianaCare Collaborate to Deploy Value-Based Healthcare Initiatives in Delaware
Alexion Exercises its Option to License Dicerna's Two Additional GalXC RNAi Programs
Eagle Pharmaceuticals' Ryanodex (dantrolene sodium) Receives the US FDA's ODD for the Treatment of Organophosphate Exposure
BeiGene Report Results of Brukinsa (zanubrutinib) in P-III ASPEN Study for Waldenström's Macroglobulinemia
Janssen's Erleada (apalutamide) Receives Health Canada's Approval for Metastatic Castration-Sensitive Prostate Cancer
Xiangxue Signs an Exclusive License Agreement with Athenex to Expand their Existing Partnership
Sangamo Highlights its Genomic Medicine Pipeline at R&amp;D Day 2019
Medtronic Acquires Klue to Bolster its Personalized Closed Loop Technology for Diabetes Management
Merck Receives the US FDA Advisory Committee's Recommendation on Approval of Keytruda (pembrolizumab) for Patients with High-Risk Non-Muscle Invasive Bladder Cancer
Takeda Collaborates with Cerevance to Develop New Therapies for Gastrointestinal Disorders
BioInvent Collaborates with MSD to Evaluate BI-1206 in Combination with Keytruda (pembrolizumab) for Advanced Solid Tumors
AstraZeneca and Merck &amp; Co Receive the US FDA Advisory Committee's Recommendation on Approval of Lynparza (olaparib) as 1L Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Eisai Signs a Research Collaboration with BioArctic to Characterize BAN2401's Mechanism of Action
Chondrial Therapeutics Signs a Reverse Merger Agreement with Zafgen
Genentech Signs a Clinical Trial Collaboration with Arcus for Colorectal and Pancreatic Cancers
"GSK Reports Results of Benlysta (belimumab, IV) in P-III BLISS-LN Study for Patients with Active Lupus Nephritis"
Specialised Therapeutics Signs an Exclusive License Agreement with Onconova Therapeutics for Rigosertib
AbbVie's RINVOQ (upadacitinib) Receives the EC's Approval for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis
Novartis Terminates its Agreement with Akcea for AKCEA-APOCIII-LRx
Biogen Signs an Exclusive License Agreement with Ionis for IONIS-MAPTRx
Exelixis Signs a Clinical Trial Collaboration with Roche for Patients with Solid Tumors
Genmab and CureVac Collaborate to Develop mRNA-based Antibody Therapeutics
"Amgen and Allergan Report Submission of BLA to the US FDA for its ABP 798 (biosimilar, rituximab)"
Smith Medical Recalls Medfusion 4000 Syringe Pump Due to its Software Failure
Merck's Ervebo Vaccine Receives the US FDA's Approval for Prevention of Ebola Virus
Gilead Reports Submission of Filgotinib's NDA Under Priority Review to the US FDA for Rheumatoid Arthritis Treatment
Novo Nordisk Signs a Five-Year Agreement with UVA Center for Diabetes Technology for Type 2 Diabetes
AstraZeneca to Sell Commercialization Rights of its Two Oncology Candidates to Juvise Pharmaceuticals
Roche Signs an Exclusive Worldwide Option and License Agreement with Rheos Medicines to Develop and Commercialize Therapies for Immunometabolism
Roche Signs a License Agreement with Sarepta for its Gene Therapy Candidate SRP-9001
BMS' Revlimid + Rituximab Receives EC's Approval to Treat Adults Previously Treated Follicular Lymphoma (Grade 1-3a)
Johnson &amp; Johnson to Acquire TARIS Biomedical for its Drug Delivery Technology to Treat Bladder Cancer
"Gilead's Vosevi (sofosbuvir, velpatasvir and voxilaprevir) Receives NMPA's Approval for Chronic Hepatitis C Infection Who Require Re-Treatment"
Pfizer Signs a Worldwide License Agreement with Theravance BioPharma for its Pan-JAK Inhibitor Program
Gilead Signs a Co-Promotion Agreement with Eisai for Filgotinib in Japan
Allergan's Ubrelvy (ubrogepant) Receives the US FDA's Approval for Acute Treatment of Migraine with or without Aura in Adults
AstraZeneca's Triple Combination Regimen Receives NMPA's Approval as the Maintenance Treatment for COPD in China
Pfizer Extends its Research and License Agreement with BioInvent to Develop Ab Targeting Tumor-Associated Myeloid Cells
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) Receive the FDA's Accelerated Approval for HER-2 Positive Unresectable/ Metastatic Breast Cancer
OBI Pharma's OBI-999 Receives the US FDA's Orphan Drug Designation for Pancreatic Cancer
Astellas Acquires Xyphos Biosciences for ~$665M
Kadmon and Meiji Collaborate to Form JV for the Development and Commercialization of KD025 in Japan
ONO and BMS Report Submission of sBLA for Opdivo (nivolumab) + Yervoy (ipilimumab) in Japan
Chugai Receives MHLW's Approval for the Expanded Use of FoundationOne CDx as a Companion Diagnostic of Rozlytrek (entrectinib)
Immunomedics Reports the US FDA's Acceptance of BLA for Sacituzumab Govitecan to Treat Metastatic Triple-Negative Breast Cancer
Luye Pharma Reports Submission of NDA to the US FDA for LY03005
Pharming to Reacquire Exclusive Commercialization Rights for its Ruconest from Sobi
Eisai Reports Results of DAYVIGO (lemborexant) in P-III SUNRISE 1 Study in Patients with Insomnia Disorder
Zai Lab's Zejula (niraparib) Receives NMPA's Approval as Maintenance Therapy for Patients with Recurrent Ovarian Cancer in China
AstraZeneca and Merck &amp; Co's Lynparza Receive the US FDA's Approval as a 1L Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer
Eli Lilly Opens its P-III LIBRETTO-531 Clinical Trial for LOXO-292 (selpercatinib) to Treat RET-Mutant Medullary Thyroid Cancer (MTC) Patients
BeiGene's Tislelizumab Receives NMPA's Approval for the Treatment of 2L Classical Hodgkin's Lymphoma (cHL)
Acceleron Signs a License Agreement with Fulcrum for the Identification of Therapies to Treat Pulmonary Diseases
GenScript Signs an Agreement with Selecxine to Develop Therapies for Immuno-Oncology
"Clover Reports First Patient Dosing in P-III Trial with SCB-808 (biosimilar, etanercept) in China"
MorphoSys Reports Submission of Tafasitamab's BLA to the US FDA to Treat Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)
Axsome Therapeutics Reports Results of AXS-07 in MOMENTUM P-III Migraine Trial in Patients with History of Inadequate Response
MappBio Collaborates with Aridis Pharmaceuticals to Develop Therapies Utilizing APEX Technology
Roche Signs an AI-Based Research Agreement with Sensyne Health
Sol-Gel Reports Results of Twyneo in Two P-III Trials for Acne Vulgaris
Amgen Signs an Agreement with BeiGene for the Expansion of its Oncology Footprints in China
Johnson &amp; Johnson Signs a License Agreement with Pulmatrix to Develop Therapies for Lung Cancer
Arena Signs a Multi-Year Agreement with Beacon Discovery to Develop Therapies for Immune and Inflammatory Diseases
Incyte Reports Results of Itacitinib in GRAVITAS-301 P-III Study for Patients with Treatment-Naive Acute Graft-Versus-Host Disease
Innate's Lumoxiti (moxetumomab pasudotox-tdfk) Receives EMA's MAA to Treat Patients with Relapsed or Refractory Hairy Cell Leukemia
RedHill Terminates its 2014 Deal with Salix Pharmaceuticals for RHB-106
BeiGene Signs an Exclusive Option and License Agreement with Leap Therapeutics for DKN-01
AstraZeneca's Farxiga (dapagliflozin) Receives the US FDA's Priority Review Voucher for the Reduction of CV Risks and Death in Patients with Type-2 Diabetes
Kyowa Kirin's Istradefylline (KW-6002) Receives EMA's MAA as an Adjunctive Treatment to Levodopa-Based Regimens in Adult with Parkinson's disease Experiencing “Off” Time
AstraZeneca's Lokelma (sodium zirconium cyclosilicate) Receives NMPA's Approval for Patients with Hyperkalaemia
I-Mab Reports Dosing of TJ202/MOR202 in P-II Trial for Patients with Relapsed or Refractory Multiple Myeloma
Merck &amp; Co. Signs an Exclusive Worldwide License Agreement with Taiho and Astex to Develop Targeted Therapies
InxMed Signs a Clinical Trial Collaboration with Merck &amp; Co for Patients with Pancreatic Cancer
Sorrento's Partner Mabpharm Files NDA to the NMPA for Infliximab Biosimilar in China
Merck &amp; Co Reports Results of Keytruda in P-III KEYNOTE-604 Trial in 1L Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Mundipharma Signs an Exclusive Commercialization and Distribution Agreement with Biosolution in South Korea
Merck KGaA and Pfizer Report Results of Bavencio (avelumab) in P-III JAVELIN Bladder 100 Study for Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Mithra Signs a License Agreement with Alvogen for its Estelle in Hong Kong and Taiwan
Evotec Expands its 2016 Agreement with Bristol-Myers Squibb
Bicycle Therapeutics Signs Clinical Development Partnership with Cancer Research UK for BT7401
MiNA Therapeutics Signs a Research Collaboration with AstraZeneca to Evaluate Therapies for Metabolic Diseases
Eagle Signs a Co-Promotion Agreement with Tyme for SM-88 to Treat Cancer
Innovent Signs a Clinical Trial Agreement with Sirnaomics to Treat Cancer and Fibrotic Diseases in the US
Abbott's HeartMate 3 Heart Pump Receives the US FDA's Approval for Patients to Avoid Open Heart Surgery
PhoreMost Signs a Multi-Project Drug Discovery Agreement with Boehringer Ingelheim
Gilead Signs a License Agreement with Xencor for its GS-9722 to Treat HIV
Veracyte Signs a Multi-Year Agreement with AstraZeneca
Merck &amp; Co's Keytruda (pembrolizumab) Receives the US FDA's Approval for Patients with BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer
Almirall Signs an In-License Agreement with 23andMe for Multiple Inflammatory Diseases
Mylan Voluntarily Recalls Nationwide Three Lots of Nizatidine Capsules USP Due to Trace Amounts of NDMA (N-Nitrosodimethylamine)
Evotec Signs a Five-Year Collaboration with Bayer to Develop Therapies for Polycystic Ovary Syndrome
BioMed Collaborates with Merck &amp; Co for Autoimmune Diseases
Gilead Signs an Exclusive License Agreement with Rockefeller University for its Portfolio of HIV Abs
Kaleido Signs a Collaboration with Janssen for Microbiome Metabolic Therapies (MMT)
Pfizer Signs an Exclusive Worldwide License Agreement with eFFECTOR to Develop Therapies for Cancer Indications
Immunic Exercises its Worldwide Exclusive Option to License for IMU-856 with Daiichi Sankyo
Bayer Signs a Three Year Multi Target AI-based Agreement with Exscientia to Treat Cardiovascular and Oncology Diseases
Eli Lilly to Acquire Dermira for $1.1B
Nektar Therapeutics Signs a Clinical Trial Collaboration with Bristol-Myers Squibb
Iovance Signs a License Agreement with Novartis to Develop and Commercialize IOV-3001
AstraZeneca's Lynparza (olaparib) + Bevacizumab Receive the US FDA's Priority Review for 1L Treatment of Advanced Ovarian Cancers
Incyte Signs a Worldwide License Agreement with MorphoSys for Tafasitamab
Roche Signs a Technology License Agreement with Amunix Pharmaceutical to Develop Non-Oncology Therapies
Mundipharma Collaborates with Samsung Bioepis to Commercialize Multiple Biosimilar Candidates in Hong Kong and Taiwan
Biogen to Acquire Pfizer's PF-05251749 to Bolster its Neurological Pipeline
BeiGene Collaborates with EUSA Pharma to Develop and Commercialize Sylvant (siltuximab) and Qarziba (dinutuximab beta) in Greater China
Coherus Signs a License Agreement with Innovent Biologics to Commercialize Biosimilar of Avastin (bevacizumab) in the US and Canada
MSD Signs a Multiyear Agreement with Just – Evotec Biologics for Gaining Access to J.POD Facility
Roche Collaborates with Illumina to Expand the Adoption of NGS Based Testing in Oncology
Astellas and Adaptimmune Signs Co-Exclusive Agreement for Universal Donor Cell Platform and Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
Amgen Collaborates with Guardant Health and Qiagen to Expand Molecular Testing for Patients with Non-Small Cell Lung Cancer
Axsome In-Licenses Pfizer's Reboxetine and Esreboxetine in the US
Bayer Signs an Exclusive Option to License Agreement with Dare Biosciences to Commercialize Ovaprene in the US
Takeda Collaborates with Charles River to Identify and Develop Preclinical Candidates
Genome &amp; Company Signs a Clinical Trial Agreement with Merck KGaA and Pfizer to Evaluate the Combination Therapy
Astellas' Xospata (gilteritinib) Receives Health Canada Approval for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
ViiV Healthcare's Dovato (dolutegravir/lamivudine) Receives MHLW's Approval to Treat HIV 1 Infection
Insilico Collaborates with Pfizer to Explore Novel Data and AI System for Target Discovery
JAMP Signs an Agreement with Alvotech to Commercialize Five Biosimilars in Canada
Alexion to Initiate P-III CHAMPION-ALS Study Evaluating Ultomiris (ravulizumab) in Amyotrophic Lateral Sclerosis
Kymera Signs a DNA-Encoded Library Based Drug Discovery Research Agreement with HitGen
BioLineRx's Motixafortide (BL-8040) Receives EC's ODD to Treat Pancreatic Cancer in Europe
Galapagos Signs an Exclusive Option to License Agreement with Fibrocor to Expand their Existing 2019 Partnership for Fibrosis
JT Signs an Exclusive License Agreement with Dermavant to Develop and Commercialize Tapinarof in Japan
Livongo to Integrate Dexcom's G6 CGM System into its Applied Health Signals Platform
Wuxi Biologic to Acquire Bayer's Production Facility in Germany
UCB's Cimzia (certolizumab pegol) Receives Health Canada Approval for Non-Radiographic Axial Spondyloarthritis
BMS Reports the US FDA Acceptance of sBLA for Opdivo (nivolumab) + Yervoy (ipilimumab) as 1L Treatment for Non-Small Cell Lung Cancer
Sun Pharma Signs a License Agreement with Rockwell Medical for Triferic in India
"Meiji and Dong-A Socio Initiate P-I Trial for DMB-3115 (biosimilar, ustekinumab)"
Boehringer Ingelheim Report Results of BI 695501 in P-III Trial for Patients with Crohn's Disease
BioNTech To Acquire Neon to Bolster its Immunotherapy Pipeline
"Celltrion Reports Results of Truxima (biosimilar, rituximab) in P-III Study for Advanced Follicular Lymphoma in the US"
"Clover Reports Dosing of SCB-808 (biosimilar, etanercept) in P-III Trial in China"
"Neuclone Reports Dosing of NeuLara (biosimilar, ustekinumab) in P-I Trial"
Samsung Bioepis Initiates P-III Trial for Ontruzant in China
Novo Nordisk's Ozempic (semaglutide) Receives the US FDA's Approval for Reduction in MACE in Patients with Type 2 Diabetes
Just – Evotec Signs a Development and Manufacturing Agreement with OncoResponse for OR2805
Healthy.io Launches Digital Wound Management Solution to Treat Chronic Wounds
Charles River Collaborates with Fios Genomics for Bioinformatics-Driven Drug Discovery and Safety Assessment
Arena's APD418 Receives FDA's Fast Track Designation to Treat Patients with Decompensated Heart Failure
AstraZeneca's Lynparza (olaparib) Receives the US FDA's Priority Review for HRR-Mutated Metastatic Castration-Resistant Prostate Cancer
AstraZeneca's Imfinzi (durvalumab) + Tremelimumab Receive the US FDA's Orphan Drug Designation for Liver Cancer
Cyclica and AUM Biosciences Collaborate to Develop Novel Cancer Therapies Under Project Nexus
CMS Signs a License Agreement with Zydus for Desidustat in Greater China
Astellas to Establish a New Manufacturing Facility for API of Prograf in Toyama Technology Center
TB Alliance Collaborates with Hongqi Pharma to Commercialize New Therapy for Highly Drug-Resistant Forms of TB in China
Novartis' Mayzent (siponimod) Receives EC's Approval to Treat Patients with Secondary Progressive Multiple Sclerosis with Active Disease
Roche's Polivy (polatuzumab vedotin) Based Combination Regimen Receives EC's Approval for Patients with R/R Diffuse Large B-Cell Lymphoma
Pharming Receive EMA's Approval to Establish New Facility for Manufacturing Ruconest (conestat alfa)
Jazz Pharmaceuticals' Sunosi (solriamfetol) Receives EMA's MAA for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
Inotrem Signs a Worldwide License agreement with Roche Diagnostic for CDx Test in Septic Shock
PhoreMost Signs Multi-Project Drug Discovery Collaboration with Otsuka Pharmaceutical to Identify Novel Targets
Janssen's Darzalex (daratumumab) Combination Regimen Receives EC's Approval for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
OBI Pharma's OBI-999 Receives the US FDA's Orphan Drug Designation to Treat Gastric Cancer
MD Anderson to Acquire Bellicum's Manufacturing Facility for $15M
Fresenius Kabi Forms a Joint Venture in Collaboration with Bio-Techne and Wilson Wolf to Advance Cell and Gene Therapies
Horizon Therapeutics' Tepezza (teprotumumab-trbw) Receives the US FDA's Approval as the First Therapy for Thyroid Eye Disease
Medtronic's Micra AV Receives the US FDA's Approval as the World's Smallest Pacemaker to Treat AV Block
Theramex to Acquire Commercial Rights of MSD's Zoely to Expand its Footprints
GSK's Belantamab Mafodotin Receives FDA's Priority Review for Relapsed or Refractory Multiple Myeloma
Genialis Collaborates with Oncologie on Precision Medicine Initiative in Gastric Cancer
Roche Reports Results of Risdiplam in FIREFISH Study for Infants with Type 1 Spinal Muscular Atrophy
Bayer's Nubeqa (darolutamide) Receives MHLW's Approval for Men with Non-Metastatic Castration-Resistant Prostate Cancer
Bayer Reports Submission of MAA to the EMA for Pre-Filled Syringe to Administer Eylea (aflibercept solution for intravitreal injection)
Evotec and Indivumed Collaborate to Develop Therapies for Patients with Non-Small Cell Lung Cancer
Merck &amp; Co's Keytruda (pembrolizumab) Receives Health Canada's Approval as 1L Treatment for Advanced Renal Cell Carcinoma
Janssen Receives EC's Approval for the Expanded Use of Stelara (Ustekinumab) to Treat Pediatric Patients with Moderate to Severe Plaque Psoriasis
Roche Reports Results of Tecentriq (atezolizumab) in P-III IMvigor010 Study for Patients with Muscle-Invasive Urothelial Cancer
Pfizer to Launch Two Oncology Biosimilars at Lowest Wholesale Acquisition Cost in the US
Evarsana Signs an Agreement with Evoke Pharma to Commercialize Gimoti in the US
Epizyme's Tazverik (tazemetostat) Receives the US FDA's Accelerated Approval as the First Therapy for Epithelioid Sarcoma
AbbVie to Divest Allergan's Brazikumab and Zenpep (pancrelipase) to Gain the US FTC and EC's Approval on Pending Allergan Acquisition
AstraZeneca to Divest its Hypertension Therapies to Atnahs Pharma
Roche Reports Submission of sBLA to the US FDA for Tecentriq (atezolizumab) + Avastin (bevacizumab) to Treat Unresectable Hepatocellular Carcinoma
AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THALES Study for Patients with Minor Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
Merck &amp; Co's Dificid (fidaxomicin) Receives FDA's Approval to Treat Clostridioides difficile in Children Aged Six Months and Older
Sanofi and Regeneron Receive the US FDA's Priority Review Acceptance for Dupixent's sBLA to Treat Moderate-to-Severe Atopic Dermatitis in Children Aged 6 to 11 Years
GSK Out Licenses its Tuberculosis Vaccine (M72/AS01E ) to Bill &amp; Melinda Gates Medical Research Institute
Eli Lilly and Boehringer Ingelheim's Triple Regimen Receive the US FDA's Approval for Type 2 Diabetes
Bausch + Lomb Collaborates with TerraCycle to Launch First Contact Lens Recycling Program in Canada
Ningbo NewBay Medical Technology Signs an Exclusive License Agreement with Genentech to Develop and Commercialize GDC-0570
Alkermes Reports the US FDA Acceptance of NDA for ALKS 3831 to Treat Schizophrenia and Bipolar I Disorder
Timber Pharmaceuticals Signs a Reverse Merger Agreement with BioPharmX
Takeda Report Submission of NDA to MHLW for Cabometyx (cabozantinib) to Treat Advanced Hepatocellular Carcinoma in Japan
Kite Reports the Validation of EMA's MAA for KTE-X19 to Treat Relapsed or Refractory Mantle Cell Lymphoma
Eli Lilly's Selpercatinib (LOXO-292) Receives Priority Review Status for the Treatment of RET-Driven Cancer Indications
Verastem Reports Dosing of Copiktra (duvelisib) in CPSC's Chinese Study for Relapsed or Refractory Follicular Lymphoma
Akcea and Ionis Report Results of AKCEA-ANGPTL3-LRx in P-II Study for Patients with Cardiovascular and Metabolic Diseases
Johnson &amp; Johnson Initiates the Development of Vaccines Against Coronavirus
Sanofi Reports Results of Olipudase alfa in Two Studies for Acid Sphingomyelinase Deficiency in Adults and Pediatric Patients
Astellas Reports Submission of sNDA to MHLW for Evrenzo (roxadustat) to Treat Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan
Sorrento Collaborates with Celularity to Initiate the Development of Emergency Allogeneic Natural Killer Cell Therapy for Coronavirus Infection
Janssen Receives EC's Approval for Expanded Use of Erleada (apalutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer
Bayer Report Result of Nubeqa (darolutamide) + ADT in P-III ARAMIS Study for Non-Metastatic Castration-Resistant Prostate Cancer
Spring Bank Discontinues the Development of Inarigivir to Treat Patients with Chronic Hepatitis B Virus
Inovio Collaborates with Beijing Advaccine to Advance the Development of INO-4800 Vaccine Targeting Coronavirus in China
Abbott's Tendyne Receives CE Mark as the World's First Transcatheter Mitral Valve Implantation System in Europe
Microsoft Launches $40M AI Program to Accelerate Health Initiatives Globally
Accenture Collaborates with Google Cloud to Support Life Sciences Companies Advancing Research and Development of Innovative Therapies
ProQR's QR-421a Receives FDA's Rare Pediatric Disease Designation for Retinitis Pigmentosa
Alnylam's Givlaari (givosiran) Receives CHMP's Positive Opinion to Treat Acute Hepatic Porphyria in Adults and Adolescents
Eli Lilly's Fast-Acting Insulin Lispro Receives CHMP's Positive Opinion in Patients with Diabetes
GSK Collaborates with CEPI to Develop Vaccine Against Corona Virus
Eli Lilly Launches Reyvow (lasmiditan) C-V for the Treatment of Migraine in the US
Teva Reports Results of Ajovy (fremanezumab) in Two P-II/III Clinical Studies for the Treatment of Migraine in Japan
"Pfizer's Ruxience (biosimilar, rituximab) Receives CHMP's Positive Opinion for Cancer and Autoimmune Diseases"
"Amgen Launches Amgevita (biosimilar, adalimumab) for the Treatment of Inflammatory Diseases in Brazil"
Danaher Receives S.Korean FTC's Conditional Approval for its $21.4B GE Biopharma Acquisition
IMIDomics Collaborates with Gossamer Bio to Develop Therapies for Treating Immune-Mediated Inflammatory Diseases
"Bio-Thera Reports Results of BAT1706 (biosimilar, bevacizumab) in P-III Trial for Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC)"
Kyowa Kirin Terminates its Agreement with Zeria Pharmaceuticals for ASACOL (mesalazine)
CELLINK Expands its Multi-Target Collaboration with AstraZeneca for Drug Discovery
Boehringer Ingelheim Reports Real-World Data for Spiriva Respimat (tiotropium bromide) Inhalation Spray 1.25mcg in Patients with Asthma
GSK Reports EMA's Acceptance of MAA for Belantamab Mafodotin to Treat Relapsed or Refractory Multiple Myeloma
Regeneron Expands its Existing Collaboration with HHS'BARDA to Develop Antibody Therapies for Coronavirus
BioMotiv and BMS to Launch Anteros Pharmaceuticals
AbbVie's Rinvoq (upadacitinib) Receives ANVISA's Approval for Rheumatoid Arthritis
The US FDA Grants Emergency Use Authorization for Coronavirus Diagnostic Test
Merck &amp; Co. to Spin-Off its Non-Core Business into a New Company to Focus on its Core Therapy Areas
Seqirus' Audenz Receives the US FDA's Approval as the First Adjuvanted Cell-Based Pandemic Influenza A (H5N1) Vaccine
Navrogen and Levena Collaborate to Develop ADCs for Humoral Immuno-Suppressed Cancers
Alector's AL101 Receives FDA's Fast Track Designation to Treat Frontotemporal Dementia
Merck &amp; Co. Collaborates with Atreca to Identify Novel Antibody Targets in Oncology
Sanofi Reports Results of SAR442168 in P-IIb Study for Relapsing Multiple Sclerosis
Fresenius Kabi Reports the Availability of Glucagon Emergency Medicine Kit to Treat Hypoglycemia in the US
Roche Reports Results of Risdiplam in SUNFISH Part 2 Study for Patients with Type 2 Or 3 Spinal Muscular Atrophy
Nestle Health Science Signs a Worldwide Exclusive Agreement with VALBIOTIS to Develop and Commercialize TOTUM-63 for Reducing the Risk of T2D
Bridge Biotherapeutics Signs a License Agreement with Konkuk University for its Back-Eye Disease Therapy
Almirall Collaborates with Plug and Play to Offer Digital Solutions in Dermatology
Roche Reports Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 Study in Chinese Patients with Hepatocellular Carcinoma
Merck &amp; Co. to Initiate P-II Study of MK-5890 for Non-Small Cell Lung Cancer
Collegium to Acquire US Rights of Assertio's Nucynta Franchise for $375M
Novo Nordisk to Invest ~$117.4M in Expansion of its Production Facilities in Denmark
Curis Amends its Existing Collaboration with Aurigene for the Development and Commercialization of CA-170
­WHO to Accelerate Global Research and Innovation Against Corona Virus
Eli Lilly Reports Results of Solanezumab in P-II/III DIAN-TU Study for Dominantly Inherited Alzheimer's Disease
Regeneron Reports Results of Eylea (aflibercept) in P-III PANORAMA Study for Patients with Diabetic Retinopathy
Zealand Pharma to Acquire Valeritas' Business and Retain its Employees
Bayer Plans Two P-III Studies to Evaluate Aflibercept 8mg Formulation
Roche Reports Results of Gantenerumab in P-II/III DIAN-TU-001 Study for Autosomal Dominant Alzheimer's Disease
BioIntelliSense's BioSticker Receives FDA's 510 (k) Clearance for Month-Long Vitals Monitoring
Sapphire Biotech Collaborates with Arizona State University to Develop Metastatic Cancer Inhibitor
Kite's KTE-X19 Receives the US FDA's Priority Review for Relapsed or Refractory Mantle Cell Lymphoma
Bayer and Nuvisan Collaborate to Establish a New Research Entity in Berlin
Eagle's Pemfexy (pemetrexed for injection) Receives Final FDA's Approval to Treat Nonsquamous Non-Small Cell Lung Cancer
Novartis' Capmatinib (INC280) Receives FDA's Priority Review for METex14 Mutated Advanced Non-Small Cell Lung Cancer
Janssen Reports Submission of sBLA to the US FDA for Darzalex (daratumumab) based Combination Regimen for Relapsed/Refractory Multiple Myeloma
Caption Health's Caption Guidance Receives FDA's Marketing Authorization as the First AI-Guided Image Acquisition System
Janssen Collaborates with BARDA to Facilitate the Development of Corona Virus Vaccine
Pfizer Terminates its License Agreement with GlycoMimetics Signed in 2011
"Novo Nordisk Launches Esperoct [antihemophilic factor (recombinant), glycopegylated-exei] to Treat Hemophilia A in the US"
Eli Lilly's Taltz (ixekizumab) Receives Health Canada's Approval for Active Ankylosing Spondylitis
Cognoa Collaborates with Autism Learning Partners for Screening App to Accelerate Early Diagnosis of Autism
Astellas and Pfizer Report Results of Xtandi (enzalutamide) in P-III PROSPER Study for Non-Metastatic Castration-Resistant Prostate Cancer
Merck &amp; Co. Reports Results of Keytruda (pembrolizumab) + CT in P-III KEYNOTE-355 Study as 1L Treatment for Metastatic Triple-Negative Breast Cancer
Dr. Reddy's to Acquire Wockhardt's Select Business Divisions for ~$259M in India
Deciphera Reports the US FDA's Acceptance of NDA and Priority Review for Ripretinib to Treat Patients with Advanced Gastrointestinal Stromal Tumors
Vizient Submits Response to the US FDA for Draft Guidance on Biosimilars Development
Alvotech Signs an Exclusive Commercialization Agreement with JAMP Pharma for Biosimilars in Canada
Medtronic Recalls its MiniMed 600 Series Insulin Pumps Due to Incorrect Insulin Dosing
BenevolentAI Collaborates with UC San Diego to Develop Non-Invasive Therapies for Cerebral Cavernous Malformations
Medtronic to Acquire Digital Surgery to Bolster its Robotic-Assisted Surgery Platform and AI Capabilities
Amgen Receives Health Canada's Marketing Authorization Transfer of Otezla for Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis
BMS Receives FDA's Priority Review Acceptance of Lisocabtagene Maraleucel's BLA for Patients with Relapsed or Refractory Large B-Cell Lymphoma
Thermo Fisher Collaborates with NanoPin to Facilitate Infectious Diseases Diagnosis
Roche's Tecentriq (atezolizumab) + CT Receive NMPA's Approval as 1L Treatment for Extensive-Stage Small Cell Lung Cancer
Orthofix's STIM onTrack 2.1 Mobile App Receives the US FDA's Approval for Bone Growth Stimulators
Codagenix Collaborates with Serum Institute of India to Co-Develop a Live-Attenuated Vaccine Against Coronavirus (COVID-19)
Soligenix's RiVax Receives the US FDA's Fast Track Designation for the Prevention of Ricin Poisoning
Epizyme Reports the US FDA Acceptance of NDA for Tazverik (tazemetostat) to Treat Follicular Lymphoma
Teva Collaborates with Global HOPE and Direct Relief for Providing Access to Medications in Africa
"Merck &amp; Co's Ervebo (Ebola Zaire Vaccine, Live) Receives Approval in Four African Countries"
PharmaMar and Jazz Receive the US FDA's Priority Review Acceptance of Lurbinectedin's NDA for Patients with Relapsed Small Cell Lung Cancer
"Celltrion Reports Results of Remsima SC (biosimilar, infliximab) in a Clinical Study for Active Crohn's Disease and Ulcerative Colitis #ECCO2020"
Novartis' Beovu (brolucizumab) Receives EC's Approval for Wet Age-Related Macular Degeneration
Zydus Cadila Launches a Research Program to Develop Vaccine Against Coronavirus
Chugai and Sanofi to Terminate their Licensing Agreement for Tofogliflozin Hydrate in Japan
GSK's Voltaren Arthritis Pain Receives the US FDA's Approval as an OTC Medication
Noxopharm Collaborates with GenesisCare to Bring Combination Regimen of Veyonda (idronoxil) and Lu-PSMA in Australia
MVC Collaborates with the US NIH to Develop Vaccine Against Corona Virus
­WAT Medical Reports Results of HeadaTerm TENS Therapy in a Clinical Study to Treat Acute Migraine
"Pfizer's Vyndaqel (tafamidis, 61mg) Receives EC's Approval as the First Therapy to Treat Transthyretin Amyloid Cardiomyopathy in the EU"
Chugai's RG6042 Receives MHLW's Orphan Drug Designation for Huntington's Disease in Japan
Sanofi Collaborates with BARDA to Facilitate the Development of Coronavirus Vaccine
Roche Reports the US FDA Acceptance of sBLA and Granted Priority Review for Tecentriq (atezolizumab) as 1L Monotherapy for Advanced Non-Small Cell Lung Cancer
Hyperfine Research Receives the US FDA's 510(k) Clearance for its World's First Bedside MRI system
Abbott's Gallant ICD and CRT-D Device Receives CE Mark in the EU
Janssen Expands its Collaboration with BARDA to Expedite the Discovery of COVID-19 Therapies
Sarepta Receives the US FDA's Approval for VYONDYS 53 (golodirsen) Injection to Treat Duchenne Muscular Dystrophy (DMD) in Patients with Amenable to Skipping Exon 53
Abbott Collaborates with Insulet to Integrate Glucose Sensing Technology with Automated Insulin Delivery System for Seamless Diabetes Care
Astellas and Seattle Genetics' PADCEV (enfortumab vedotin-ejfv) Receives the US FDA's Approval for Locally Advanced or Metastatic Urothelial Cancer in Adults
WuXi Vaccines Signs Twenty Years Manufacturing Agreement with Global Vaccine Leaders for $3B
Merck KGaA to Divest its Allergopharma to Dermapharm
Astellas and Seattle Genetics' Padcev (enfortumab vedotin-ejfv) + Keytruda Receive FDA's Breakthrough Therapy Designation as 1L Treatment for Advanced Bladder Cancer
Intra-Cellular's CAPLYTA (lumateperone) Receives the US FDA's Approval for the Treatment of Schizophrenia in Adults
Blueprint Medicines' Ayvakit (avapritinib) Receives FDA's Approval to Treat Patients with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
Vifor Pharma and Fresenius Kabi Collaborate to Establish Joint Venture in China
Eisai's Dayvigo (lemborexant) Receives the US FDA's Approval to Treat Insomnia in Adults
Abbott to Recall Coronary Dilatation Catheters Due to Failure of Balloon Deflation
Genentech Signs an Agreement with Nimble to Discover and Develop Novel Peptide-Based Therapies
Roche Introduces RocheDiabetes InsulinStart to Facilitate the Access to Insulin Therapy for T2D Patients
GSK Signs an Agreement with Immatics to Develop Adoptive Cell Therapies for Multiple Cancer Indications
BioMarin Receives the US FDA's Priority Review Acceptance of Valoctocogene Roxaparvovec's BLA for Patients with Hemophilia A
VBL Therapeutics to Initiate P-II Study Evaluating VB-111 (ofranergene obadenovec) + Nivolumab in Patients with Metastatic Colorectal Cancer
Teva Reports Results of Austedo (deutetrabenazine) in Two Clinical Studies for Tourette Syndrome
Chugai's Rozlytrek Receives MHLW's Approval for ROS1 Fusion-Positive Non-Small Cell Lung Cancer
Esperion's NEXLETOL (bempedoic acid) Tablet Receives the US FDA's Approval for Lowering Cholesterol Level
Novartis Reports Acceptance of Ofatumumab's (OMB157) sBLA from the US FDA and EMA to Treat Relapsing Forms of Multiple Sclerosis (RMS)
Eli Lilly's Trulicity (dulaglutide) Receives the US FDA's Approval to Reduce MACE in T2D Adults
Lundbeck's Vyepti (eptinezumab-jjmr) Receives the US FDA's Approval to Prevent Migraine in Adults
Asuragen's AmplideX Fragile X Dx and Carrier Screen Kit Receives the US FDA's Approval for Detecting Fragile X Syndrome (FXS)
Paratek Signs an Exclusive License Agreement with Almirall for SEYSARA (sarecycline)
GSK Signs a Research Collaboration with Clover for the Evaluation of Coronavirus (COVID-19) Vaccine
Sanofi to Establish New Company to Provide Active Pharmaceutical Ingredients in the EU
Roche Reports Acceptance of BLA for Fixed-Dose SC Combination of Perjeta and Herceptin to Treat HER2-Positive Breast Cancer
AstraZeneca to Divest Global Rights of Movantik (naloxegol) to RedHill Biopharma
STADA Acquires GSK's Consumer Healthcare Portfolio to Expand its OTC Business
Takeda's Alunbrig (brigatinib) Receives the US FDA's Priority Review to Treat ALK + Metastatic Non-Small Cell Lung Cancer
FMCNA's Novalung ECMO System Receives the US FDA's Approval for Acute Respiratory and Cardiopulmonary Failure
Genentech Collaborates with Bicycle Therapeutics to Develop and Commercialize Bicycle-Based Immuno-Oncology Therapies
Novartis Collaborates with DNDi to Develop LXE408 for Visceral Leishmaniasis
WuXi Biologics and Vir Biotechnology Collaborate for the Global Development of Antibodies Against COVID-19
Takeda Exercises its Exclusive Option to Acquire PvP Biologics for ~$330M
Johnson &amp; Johnson in Collaboration with Apple Launch Heartline Study App in the US
The US FDA Upgrades the Purple Book to Assist the Transparency in Biosimilars
Eisai Signs a License Agreement with FUJI YAKUHIN for Dotinurad to Treat Hyperuricemia and Gout in China
Gilead Reports the Initiation of Two P-III Studies of Remdesivir to Treat COVID-19
Gemini Therapeutics Signs a Research Agreement with SERI to Identify New Therapies for Age-related Macular Degeneration
Hikma Signs an Exclusive License Agreement with Glenmark to Commercialize Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) in the US
Esperion Receives the US FDA's Approval for Nexlizet (Non-Statin LDL-Cholesterol Lowering Therapy)
GSK Reports the Acceptance of EMA's MAA for Zejula (niraparib) as 1L Maintenance Treatment for Platinum-Responsive Advanced Ovarian Cancer
Co-Diagnostics Receives CE Mark for its Logix Smart Coronavirus PCR Test
"Celltrion's Remsima SC (biosimilar, infliximab) Receives KFDA's Approval for Rheumatoid Arthritis"
Biogen Signs an Exclusive Worldwide License Agreement with Sangamo to Develop Gene Therapies for Multiple Neurological Diseases
Boehringer Ingelheim Collaborates with Trutino Biosciences to Develop New Therapies Utilizing On-Demand-Cytokine Platform
Fujifilm's CAD EYE Receives CE Mark to Support the Detection of Colonic Polyp Utilizing AI in the EU
Gates Foundation Forms an Alliance with Global Pharma Companies to Develop PAN-TB Drug Regimen for Tuberculosis
Takeda's Vedolizumab SC Receives CHMP's Positive Opinion as a Maintenance Therapy for Moderately to Severely Active UC or CD
Companion Medical's InPen Diabetes Management System Receives the US FDA's Approval for Fixed Dosing and Meal Estimation
Merck KGaA's ERBITUX (cetuximab) Receives NMPA's Approval as a 1L treatment for Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck
Boehringer Ingelheim's Nintedanib Receives CHMP's Positive Opinion to Treat Systemic Sclerosis-Associated Interstitial Lung Disease
Medexus Acquires Aptevo BioTherapeutics for its Hematology Asset IXINITY
Gilead to Acquire Forty Seven for $4.9B
Takeda to Divest a Portfolio of Select OTC and Non-Core Assets to Hypera Pharma in Latin America for $825M
Pfizer and Eli Lilly Report the US FDA Acceptance of BLA for Tanezumab to Treat Chronic Pain Due to Moderate-to-Severe Osteoarthritis
uniQure Signs an Exclusive Research and License Agreement with Gen-X to Develop Novel Synthetic Promoters
Sanofi's Sarclisa (isatuximab-irfc) Receives the US FDA's Approval for Relapsed Refractory Multiple Myeloma
Thermo Fisher Scientific to Acquire QIAGEN for ~$11.5B
Insulet to Halt Study of Omnipod Horizon Due to Software Anomaly
Genentech's Esbriet (pirfenidone) Receives FDA's Breakthrough Therapy Designation for Unclassifiable Interstitial Lung Disease
Lucid Diagnostics Collaborates with the University of Pennsylvania to Evaluate EsoCheck in Patients with Eosinophilic Esophagitis
Novartis' Mayzent Receives Health Canada's Approval for Secondary Progressive Multiple Sclerosis with Active Disease
BMS Collaborates with Voluntis to Co-Develop Digital Therapies to Treat Cancer Indications
Roche's Elecsys GALAD scores Receive the US FDA's Breakthrough Device Designation for Earlier Diagnosis of Hepatocellular Carcinoma
Takeda to Initiate the Development of Plasma-Derived Therapy to Treat Corona Virus (COVID-19)
Alnylam's Givlaari (givosiran) Receives EC's Approval for Acute Hepatic Porphyria in Adults and Adolescents
Iktos and SRI Collaborate to Accelerate Discovery and Development of Novel Anti-Viral Therapies
Janssen Reports Submission of Ponesimod's MAA to EMA for the Treatment of Relapsing Multiple Sclerosis
Vir and Alnylam Expand their 2017 License Agreement to Target COVID-19
Allergan and Editas Report First Patient Dosing in P-I/II BRILLIANCE Study with AGN-151587 (EDIT-101) to Treat LCA10
The US FDA and FTC Sign Agreement to Support the Development of Biosimilars
The US FDA Released Draft Guidelines for Proposed Biosimilar or Proposed Interchangeable Biosimilars
Alopexx Signs an Exclusive License Agreement with Shenogen Pharma to Develop and Commercialize DI-LEU16-IL2 for B-Cell Lymphomas in China/Asia
Roche's Actemra (tocilizumab) Receives Approval to Combat Coronavirus Complications in China
Insud's mAbxience Inaugurates New Biosimilar Plant Facility in Argentina
Zuellig Pharma Acquires Alliance Pharma (Cambodge) to Bolster its Presence in Indochina
The US FDA Informs About Cybersecurity Vulnerabilities in Medical Devices with Bluetooth Low Energy
Heat Biologics Signs a Research Collaboration with University of Miami to Develop Vaccine Against COVID-19
Baysient to Release iDose Software Technology Platform 1.0 to Reduce the Biosimilar Cost in Market
Novartis Enters into a Four-Year Collaboration with Orionis Biosciences to Tackle Intractable Disease Targets
Zydus' Saroglitazar Receives DCGI's Approval as the World's First Therapy for Non-Cirrhotic NASH in India
Allergan's Durysta (bimatoprost implant) Receives the US FDA's Approval as the First Intracameral Biodegradable Sustained-Release Implant for Patients with OAG and OHT
AstraZeneca Reports Results of Imfinzi and Tremelimumab in P-III DANUBE Study for Unresectable Stage IV Bladder Cancer
Mount Sinai Signs a Multi-Year Collaboration with Harbour BioMed to Develop Novel Biotherapies for Multiple Cancer Indications and COVID-19
Tetra Therapeutics and Shionogi Expand their Existing 2018 Collaboration to Develop and Commercialize BPN14770
Novartis' Isturisa (osilodrostat) Receives the US FDA's Approval for Cushing's Disease
AbbVie's Maviret (glecaprevir/pibrentasvir) Receives EC's Marketing Authorization as Eight-Week Regimen for Treatment-Naïve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis
Zydus Signs a License Agreement with XOMA to Advance IL-2- Based Immuno-Oncology Therapy
BMS Reports Results of Triple Regimen in P-III ELOQUENT-1 Study for Patients with Newly Diagnosed Untreated Multiple Myeloma
Biocon and Mylan Report the US FDA Acceptance of BLA for Proposed Biosimilar of Avastin (bevacizumab)
AbbVie Collaborates with Global Health Authorities to Investigate its Kaletra/Aluvia (lopinavir/ritonavir) Against COVID-19
"Celltrion Reports Submission of MAA to EMA for CT-P17 (biosimilar, adalimumab)"
ViiV Healthcare Renews its 2015 Collaboration with UNC-Chapel Hill to Discover a Cure for HIV
Boehringer Ingelheim's Ofev (nintedanib) as the First Treatment for Chronic Fibrosing ILDs with Progressive Phenotype
Novo Nordisk's Fiasp (insulin aspart injection) Receives Health Canada's Approval for Children with Diabetes
­Bora Pharmaceuticals to Acquire GSK's Facility in Canada
CEPI Expands its Investment in the Development of Vaccine Against COVID-19
Roche's CINtec PLUS Cytology Receives the US FDA's Approval as the First Biomarker-Based Triage Test to Improve the Prevention of Cervical Cancer
Bridge Biotherapeutics Signs an AI-Based Research Agreement with Atomwise to Expand its Pellino Inhibitor Portfolio
Janssen's JNJ-6372 Receives the US FDA's Breakthrough Therapy Designation for Non-Small Cell Lung Cancer
Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM2 Study for Transplant Ineligible Patients with Multiple Myeloma
BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive the US FDA's Approval for Patients with Hepatocellular Carcinoma Prior Treated with Sorafenib
Vir Biotechnology Collaborates with NIH Vaccine Research Center to Advance the Development of mAbs Against Coronavirus
"Henlius Reports the NMPA's Acceptance of IND for HLX14 (biosimilar, denosumab)"
Teva's Ajovy (fremanezumab) Receives NICE Positive Recommendation for Prevention of Migraine in Adults
AstraZeneca's Calquence (acalabrutinib) Receives the US FDA's Breakthrough Therapy Designation to Treat Chronic Lymphocytic Leukaemia (CLL) in Adults
Novavax and Serum Institute of India Collaborate to Develop and Commercialize Vaccines for Malaria
AstraZeneca's Selumetinib Receives the US FDA's Breakthrough Therapy Designation for Neurofibromatosis Type 1
F2G's Olorofim Receives the US FDA's Breakthrough Therapy Designation to Treat Invasive Mold Infections in Patients with Limited or No Treatment Options
AbbVie's Dual Regimen Receives EC's Approval for Patients with Previously Untreated Chronic Lymphocytic Leukemia
Thermo Fisher Scientific Collaborates with Janssen to Co-Develop CDx for Multiple Cancer Indications
Bayer's Aliqopa (copanlisib) Receives the US FDA's Breakthrough Therapy Designation to Treat Marginal Zone Lymphoma in Adults
Merck and Eisai's Dual Regimen Receives the US FDA's Breakthrough Therapy Designation as 1L Treatment for Advanced Unresectable Hepatocellular Carcinoma
Novartis's Capmatinib (INC280) Receives the US FDA's Breakthrough Therapy Designation for MET-Mutated Advanced Non-Small Cell Lung Cancer
Chugai's Nemolizumab Receives the US FDA's Breakthrough Therapy Designation to Treat Pruritus Associated with Prurigo Nodularis
Agios' Tibsovo (ivosidenib) Receives the US FDA's Breakthrough Therapy Designation for Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation
AbCellera and Eli Lilly Collaborate to Co-develop Antibody Therapies Targeting COVID-19
Roche's cobas SARS-CoV-2 Test Receives the US FDA's Emergency Use Authorization to Identify Corona Virus
Usona Institute's Psilocybin Receives the US FDA Breakthrough Therapy Designation for Major Depressive Disorder
AstraZeneca and MSD Report Results of Cediranib + Lynparza in P-III GY004 Study for Patients with Platinum-Sensitive Relapsed Ovarian Cancer
Boehringer Ingelheim and Eli Lilly's Jardiance (empagliflozin) Receives the US FDA's Fast Track Designation for Chronic Kidney Disease
EMD Serono and Pfizer to Terminate P-III JAVELIN Head and Neck 100 Study Evaluating Bavencio + CRT for Squamous Cell Carcinoma of the Head and Neck
I-Mab to Initiate the Development of TJM2 for Treating Cytokine Release Syndrome Associated with COVID-19
Johnson &amp; Johnson Collaborates with the Beth Israel Deaconess Medical Center to Accelerate the Development of Vaccine Against COVID-19
Fosun Pharma Signs an Agreement with BioNTech to Develop and Commercialize BNT162 for COVID-19
Eli Lilly and Incyte's Olumiant (baricitinib) Receives the US FDA's Breakthrough Therapy Designation for Alopecia Areata
Biogen Collaborates with Vir Biotechnology to Develop Antibodies Against COVID-19
Sanofi and Regeneron to Initiate the Clinical Program Evaluating Kevzara (sarilumab) in Patients with Severe COVID-19
"Teva and Celltrion Launch Herzuma (biosimilar, trastuzumab) in the US"
Pfizer and BioNTech Collaborate to Co-Develop BNT162 Against COVID-19
Novo Nordisk Halts Clinical Studies Evaluating Concizumab (anti-TFPI mAb) for Hemophilia A and B With or Without Inhibitors
AcelRx to Acquire Tetraphase Pharmaceuticals to Expand its Product Portfolio
AstraZeneca Reports Results of Imfinzi + Tremelimumab in P-III CASPIAN Study as 1L Treatment for Extensive-Stage Small Cell Lung Cancer
Alphabet's Verily Launched its COVID-19 Screening Site in Collaboration with California's Government
GSK's Nucala Receives Health Canada's Approval for Severe Eosinophilic Asthma in Children and Adolescents
NIH Initiates its P-I Trial for COVID-19 at KPWHRI in Seattle
Moleculin Collaborates with UTMB to Evaluate WP1122 for Multiple Viruses Including Coronavirus
Merck &amp; Co. Reports Results of Gefapixant (MK-7264) in Two P-III Studies for Refractory or Unexplained Chronic Cough
NuProbe Collaborates with QIAGEN to Develop Diagnostics Tests for Cancer Indications
Regeneron to Initiate COVID-19 Antibody Program in Early Summer
IDEAYA and Pfizer Collaborate to Evaluate IDE196 + Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations
Samsung Biologics Collaborates with APRINOIA Therapeutics to Expand its Presence in Greater China
Juno Therapeutics Signs License and Clinical Supply Agreement with Oxford Biomedica for LentiVector Platform
Roche to Initiate P-III COVACTA Study of Actemra/RoActemra in Hospitalized Patients with Severe Covid-19 Pneumonia in Collaboration with BARDA
Novartis' Zolgensma (onasemnogene abeparvovec) Receives MHLW's Approval for Spinal Muscular Atrophy
Eli Lilly and ISDH Collaborate to Accelerate the Testing for COVID-19
AstraZeneca's Lynparza (olaparib) Receives MHLW's Orphan Drug Designation for BRCA-Mutated Metastatic Pancreatic Cancer
FDA Divulges Guidance for Conducting Clinical Studies During COVID-19 Pandemic
Janssen Reports Submission of Ponesimod's NDA to the US FDA for the Treatment of Relapsing Multiple Sclerosis
CEPI Collaborates with University of Hong Kong to Develop Vaccine for COVID-19
Gilead's Epclusa (Sofosbuvir/Velpatasvir) Receives the US FDA's Approval for Children with Chronic Hepatitis C Infection
Abbott Launches its Molecular Test to Detect COVID-19 and Receives the US FDA's Emergency Use Authorization
FDA Recommends Avoiding the Use of NSAIDs for COVID-19 Symptoms
BGI Reports the Availability of RT-PCR SARS-CoV-2 Test for Clinical Use in the US
Insights+ Exclusive: COVID-19 Healthcare News Updates
Merck Collaborates with Dragonfly to Develop and Commercialize Novel Therapies Utilizing TriNKET Platform
Takeda's Entyvio (vedolizumab) Receives NMPA's Approval to Treat Moderate to Severe Active Ulcerative Colitis and Crohn's Disease
Bayer Signs a Research and License Agreement with Curadev to Develop Novel STING Antagonists Across Multiple Indications
Microsoft and Adaptive Biotechnologies Expand Their Collaboration for Mapping the Immune Response to COVID-19
Sorrento Develops STI-4398 (COVIDTRAP Protein) to Prevent and Treat COVID-19
Celltrion to Launch Rapid Self-Testing Kit and Accelerates the Development of Treatment Against COVID-19
Takeda Collaborates with Codexis to Advance Novel Gene Therapies for Rare Genetic Disorders
Amgen and its Foundation Grant $12.5M to Support COVID-19 Relief Efforts Globally
Roche Highlights its Response to COVID-19 Pandemic
Sorrento and SmartPharm To Develop Novel Gene-Encoded Antibody Vaccine for COVID-19
Genentech Receives the US FDA's Approval for P-III Clinical Study Evaluating Actemra to Treat Hospitalized Patients with Severe COVID-19 Pneumonia
QIAGEN Releases QIAstat-Dx Test Kit as the First Syndromic Test to Detect COVID-19 Under New FDA Policy
Astellas Collaborates with CytomX Therapeutics to Develop Probody T-Cell Engaging Bispecific Therapies for Cancer Indications
Sorrento Signs an Exclusive License Agreement with Mabpharm for ACE-MAB to Treat COVID-19
Elevar Therapeutics Acquires Worldwide Development and Commercialization Rights for Oasmia's Apealea
"Alvotech Signs an Exclusive License Agreement with DKSH for AVT02 (biosimilar, adalimumab) in Asia"
Horizon's Procysbi (Cysteamine Bitartrate) Receives the US FDA's Approval for Delayed Release Oral Tablets
"Samsung Bioepis Receives the US FDA's Approval for Multi-Dose Vial of Ontruzant (biosimilar, trastuzumab)"
Merck KGaA's Tepmetko (tepotinib) Receives the Japanese MHLW's Approval for Advanced NSCLC with METex14 Skipping Alterations
AstraZeneca Collaborates with Silence Therapeutics to Develop siRNA Therapeutics Targeting Multiple Diseases
Agile Therapeutics Receives the US FDA's Approval for Twirla (levonorgestrel and ethinyl estradiol) Transdermal System
Biohaven's Nurtec Receives the US FDA's Approval for Treatment of Migraine in Adults
Sorrento to Initiate the Novel Decoy Cellular Vaccine Program for COVID-19
Baudax Bio's Anjeso Receives the US FDA's Approval to Manage Moderate to Severe Pain
Esperion's Nexlizet (bempedoic acid and ezetimibe) Tablet Receives the US FDA's Approval as LDL-Cholesterol Lowering Medicine
GSK's Advil Dual Action in Combination with Acetaminophen Receives the US FDA's Approval for Pain Relief
Vir Biotechnology Signs a License Agreement with Xencor to Utilize Xtend Fc Technology in Antibodies Targeting COVID-19
Acacia's Barhemsys (amisulpride) Receives the US FDA's Approval for the Prevention of Postoperative Nausea and Vomiting
AstraZeneca's Lokelma (sodium zirconium cyclosilicate) Receives MHLW's Approval for the Treatment of Hyperkalemia in Japan
Gates Foundation Collaborates with the Consortium of Life Sciences Companies to Address Challenges Against the Pandemic COVID-19
PRA Health Sciences Launches COVID-19 Monitoring App to Track Symptoms
Boehringer Ingelheim Signs a Second Research Collaboration with Saniona to Develop Therapies Targeting Schizophrenia
BMS' Zeposia (ozanimod) Receives the US FDA's Approval as New Oral Treatment for Relapsing Forms of Multiple Sclerosis
Sanofi's Sarclisa (isatuximab) Receives CHMP's Positive Opinion for Relapsed and Refractory Multiple Myeloma
Quidel's Lyra SARS-CoV-2 Assay Receives the US FDA's Expanded Emergency Use Authorization for Molecular Detection of COVID-19
Medopad Provides its Remote Patient Monitoring Platform to Support Global COVID-19 Pandemic
Mylan Delays its Merger with Upjohn Due to COVID-19 Pandemic
Sanofi Collaborates with Translate Bio to Develop Novel mRNA Vaccine Against COVID-19
Sanofi and Regeneron Expand Clinical Program of Kevzara (sarilumab) for the Treatment of COVID-19 Outside the US
"Mylan and Lupin Receive CHMP's Positive Opinion for Nepexton (biosimilar, etanercept)"
AstraZeneca's Imfinzi (durvalumab) Receives the US FDA's Approval for Extensive-Stage Small Cell Lung Cancer
Eli Lilly's Taltz (ixekizumab) Receives the US FDA's Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
BMS's Zeposia (ozanimod) Receives the CHMP's Positive Opinion to Treat Adults with Relapsing-Remitting Multiple Sclerosis with Active Disease
Johnson &amp; Johnson and BARDA to Fund ~$1B in Research and Development of Novel COVID-19 Vaccines
Abbott Receives FDA's Emergency Use Authorization for its Point-Of-Care Test to Detect Novel COVID-19 in Five Minutes
Bayer's Nubeqa (darolutamide) Receives the EC's Approval for Men with Non-Metastatic Castration-Resistant Prostate Cancer
The US FDA Authorizes the Emergency Use of Antimalarial Drugs to Combat COVID-19
AstraZeneca's Lokelma Receives CHMP's Recommendation for Approval for Patients with Hyperkalemia on Stable Hemodialysis
Lilly Signs a Worldwide License and Research Agreement with Sitryx to Develop New Immunometabolic Therapies
Sorrento and the University of Texas Medical Branch Collaborate for the Preclinical Testing of COVID-19 Therapeutic Candidates
Amgen Provides Update on its Clinical Activities and Medicine Supply Amid COVID-19 Pandemic
VIVUS Expedites the Launch of Telemedicine and Remote Monitoring Modules for Effective Patient Care During COVID-19
Amgen Repurchases Astellas' Stakes in Amgen Astellas JV to Strengthen its Footprints in Japan
Daiichi Sankyo Signs a Non-Exclusive License Agreement with Ultragenyx for Gene Therapy Manufacturing Technology
QIAGEN's QIAstat-Dx Test Kit Receives the US FDA's EUA as the First Syndromic Test to Detect COVID-19
BD and BioMedomics Launch Rapid Serology Test to Detect Exposure to COVID-19 in 15 Minutes
Three Global Pharmaceutical Companies Launch Worker Volunteer Programs to Combat COVID-19
Y-mAbs Reports the Submission of Naxitamab's BLA to the US FDA for Relapsed/Refractory High-Risk Neuroblastoma
FDA Launches Emergency Program to Expedite the Development of COVID-19 Treatments
Gilead Initiates Two P-III Studies Evaluating Remdesivir (GS-5734) for COVID-19 in the UK
Merck &amp; Co. Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 Study for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer
Vir and Alnylam Expand Their Existing Collaboration to Develop RNAi Therapeutics Targeting Host Factors for COVID-19
"Pfizer's Ruxience (biosimilar, rituximab) Receives EC's Approval for Cancer Indications and Autoimmune Diseases"
Celularity's New Cell Therapy Receives the US FDA's IND Approval for COVID-19
Amgen and Adaptive Biotechnologies Collaborate to Develop Therapies Targeting COVID-19
Novartis and Incyte Intend to Initiate the P-III RUXCOVID Study of Jakavi (ruxolitinib) as a Treatment for Patients with COVID-19 Associated Cytokine Storm
Celltrion Enters the Next Phase of Development for its Antiviral Therapy to Combat COVID-19 Pandemic
Sorrento Initiates the Next Phase of its Collaboration with Celularity
GSK Collaborates with Innovax to Evaluate a Vaccine Against COVID-19 Pandemic
EMA's CHMP Recommends Compassionate Use of Gilead's Remdesivir for COVID-19
Janssen Signs a Worldwide Collaboration with Fate Therapeutics for Novel iPSC-Derived Cell-Based Cancer Immunotherapies
Gilead Sciences and Second Genome Signs a Four-Year Collaboration to Identify Biomarkers and Therapies Targeting Inflammatory Bowel Disease
Takeda Signs a Multi-Year Research Collaboration with Evotec to Expedite Research Program Across its Core Therapeutic Areas
Sanofi and Regeneron Finalizes the Restructuring of Their Collaboration on Praluent (alirocumab)
Alnylam and Dicerna Collaborate to Develop and Commercialize RNAi Therapeutics for Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
GSK Collaborates with Vir to Develop Treatment for COVID-19
Takeda's Alunbrig (brigatinib) Receives EC's Approval as a 1L Treatment for ALK+ Advanced Non-Small Cell Lung Cancer
CytoDyn Collaborates with UK's Department of Health to Provide Emergency Access to Leronlimab (PRO 140) for Patients with COVID-19
Merck Receives the US FDA's Priority Review for Keytruda's (pembrolizumab) sBLA Based on Biomarker Regardless of Tumor Type
The US FDA Delays its Decision on Roche's Risdiplam for the Treatment of Spinal Muscular Atrophy
Oxford Biomedica Joins Consortium to Develop ChAdOx1 nCov-19 for COVID-19
BMS Expands its Existing Patient Support Programs to Aid Uninsured Patients in the US Amid COVID-19
Bayer Launches Eylea (aflibercept) Pre-Filled Syringe in Europe
Zai Lab Signs a Development and Commercialization Agreement with Regeneron for REGN1979 in Oncology
The US FDA will Approve a New Pathway for Biosimilars
Biocad with its Partner ICM Received the Registration Certificate for two of its Biosimilar in EU
Roche Signs a License Agreement with Arrakis Therapeutics for the Discovery of RNA-Targeted Small Molecule Therapies
AstraZeneca Focuses on the Discovery of Monoclonal Antibodies Neutralizing SARS-CoV-2 Virus
Revance and Mylan Provide Updates on Development BOTOX (onabotulinumtoxinA) Biosimilar
Chugai Initiates P-III Clinical Study of Actemra for COVID-19 Pneumonia in Japan
Novavax Accelerates the Initiation of Clinical Study for NVX-CoV2373 to Mid-May 2020
The US FDA to Waive Interchangeability Standard for Insulin Biosimilars
EMD Serono and Pfizer's Bavencio (avelumab) Receive the US FDA's Breakthrough Therapy Designation as 1L Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Global Pharmaceuticals and the University of Cambridge Collaborate to Launch a Laboratory for COVID-19 Testing
Pfizer and BioNTech Provide Updates on its Collaboration for Global COVID-19 Vaccine
Astellas Reports NMPA's Acceptance of NDA for XOSPATA (gilteritinib) to Treat R/R AML with a FLT3 Mutation in Adults
BMS Signs a Clinical Trial Collaboration with NeoImmune to Evaluate Opdivo (nivolumab) in Combination with NT-I7 (Hyleukin-7)
Cipla Receives FDA's ANDA Approval for its HFA Inhalation Aerosol to Treat Acute Episodes of Bronchospasm or to Prevent Asthmatic Symptoms
Abbott's TriClip Transcatheter Tricuspid Valve Repair System Receives the CE Mark for Minimally Invasive Tricuspid Valve Repair
Samsung Biologics Signs an Agreement with Vir Biotechnology to Develop Abs for COVID-19
Amgen Signs a Partnership with Adaptive Biotechnologies to Develop Abs for COVID-19
Revance and Mylan Provide Updates on Development BOTOX (onabotulinumtoxinA) Biosimilar
Apple and Google Collaborate on Contact Tracing Technology to Combat COVID-19
Eli Lilly Signs a Clinical Trial Collaboration with NIH to Evaluate Baricitinib Against COVID-19
Terumo BCT and Marker Therapeutics Receive the US FDA's Emergency Use Authorization for their Purification Device to Treat COVID-19
AstraZeneca and MSD's Koselugo (selumetinib) Receives the US FDA's Approval as the First Therapy for Pediatric Patients with Neurofibromatosis Type 1 Plexiform Neurofibromas
"Bausch Health to Initiate Clinical Study Evaluating Virazole (Ribavirin for Inhalation Solution, USP) in Patients with COVID-19 in Canada"
Blackstone and Alnylam Enter into a Collaboration to Accelerate the Advancement of RNAi Therapeutics
"Biocon and Mylan Launch Fulphila (biosimilar, Pegfilgrastim) in Australia"
Celltrion Anticipates the Initiation of its First-in-Human Clinical Studies Targeting COVID-19 in July
BD Receives Second FDA's Emergency Use Authorization for its New Molecular Diagnostic Test to Detect COVID-19
Sanofi and GSK Collaborate to Develop Adjuvanted COVID-19 Vaccine
B. Braun Receives the US FDA's EUA for the Use of Infusion Pumps with Nebulizers to Treat COVID-19
Alnylam's Vutrisiran Receives the US FDA's Fast Track Designation to Treat Polyneuropathy of hATTR Amyloidosis
AstraZeneca Initiates CALAVI Study Evaluating Calquence (acalabrutinib) Against COVID-19
Boehringer Ingelheim Collaborates with Insilico on AI-Based Drug Discovery
Sosei Heptares to Utilize its Structure-Based Drug Design Expertise in New COVID-19 R&amp;D Program
"Merck Launches Ontruzant (biosimilar, trastuzumab) in the US"
Ortho Clinical Diagnostics' Total Antibody Test Receives the US FDA's Emergency Use Authorization for COVID-19
Abbott Launches its Third Test to Detect COVID-19
GE Healthcare and Microsoft Exploit Remote Patient Data Monitoring Technology to Support Clinicians for the Treatment of COVID-19
Vanda Signs a Collaboration with UW Medicine to Initiate CALYPSO Program for Evaluating the Role of Genetic Variation in COVID-19
QIAGEN Launches Therascreen BRAF Test as CDx to a BraftovI Regimen for Metastatic Colorectal Cancer
Novavax Signs a Clinical Trial Agreement with Nucleus Network to Initiate the Clinical Study Evaluating NVX-CoV2373 Against COVID-19
Dynavax Signs an Agreement with Sinovac to Develop a Vaccine for COVID-19
Regeneron Reports the US FDA's Acceptance of Priority Review for REGN-EB3's BLA to Treat Ebola
Sanofi and Luminostics Collaborate to Develop Smartphone-Based Self-Testing Solution for COVID-19
Roche Develops Elecsys Anti-SARS-CoV-2 Serology Test to Detect Ab Against COVID-19
BARDA Grants ~ $483M to Moderna for Accelerating the Development of mRNA-1273 Against COVID-19
Chi-Med's Surufatinib Receives the US FDA's Fast Track Designations for Pancreatic and Non-Pancreatic Neuroendocrine Tumors
1Health.io Launches Self-Collection Kits to Detect COVID-19
Sinovac Initiates the P-I Clinical Study for Vaccine Candidate Against COVID-19
Novartis Signs an Agreement with the US FDA to Evaluate Hydroxychloroquine in Patients with COVID-19
Roche Reports the FDA and EMA's Acceptance of sBLA for Ocrevus Shorter 2-Hour Infusion Time
Incyte Initiates P-III RUXCOVID Study Evaluating Jakafi (ruxolitinib) to Treat Patients with COVID-19 Associated Cytokine Storm
Fosun Pharma Receives the US FDA's EUA for its COVID-19 RT-PCR Detection Kit
Otsuka Signs a Development and Commercialization Agreement with Esperion for Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) in Japan
Alexion to Initiate P-III Study of Ultomiris (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19
"RedHill Biopharma Collaborates with NIAID to Investigate RHB-107 (upamostat, WX-671) Against COVID-19"
Cue Biopharma Signs Clinical Trial Collaboration with Merck to Evaluate CUE-101 + Keytruda (pembrolizumab) as 1L Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer
Roche's cobas HPV Test Receives the US FDA's Approval for cobas 6800/8800 System to Identify Women at Risk for Cervical Cancer
Noxopharm Anticipates the US FDA's Approval for Evaluating Veyonda in a Clinical Study for COVID-19
Sangamo Signs an Exclusive License Agreement with Mogrify for iPSC and ESC-Derived Regulatory T-Cells
Novartis Reports Results of Mayzent (siponimod) in P-III EXPAND Study for Secondary Progressive Multiple Sclerosis
Bayer Collaborates with the Population Health Research Institute to Identify Treatment for COVID-19
Gilead and Kite Sign a Three Years Agreement with oNKo-innate to Discover Cancer Immunotherapies
Novartis' Kymriah (tisagenlecleucel) Receives the US FDA's Regenerative Medicine Advanced Therapy Designation for Follicular Lymphoma
Hope Biosciences Reports its Third US FDA's Approval for Clinical Trial in COVID-19
Pfizer and BioNTech to Commence Clinical Study for COVID-19 in Germany
Sobi's Affiliate Florio GmbH Launches a Digital Platform to Improve the Lives of Patients with Hemophilia
Valneva and Dynavax Collaborate to Advance the Development of Vaccine Against COVID-19
The European Commission Approves the Merger of Mylan and Upjohn with Conditions
AstraZeneca and Saint Luke's Mid America Heart Institute to Initiate P-III DARE-19 Evaluating Farxiga Against COVID-19
LabCorp Receives the US FDA's Emergency Use Authorization for its COVID-19 At-Home Test Kit
Mobidiag Receives Emergency Use Authorization for its Automated COVID-19 Test in Finland
Theravance Reports First Patient Dosing in P-I Study with TD-0903 to Treat Patients with Acute Lung Injury Associated with COVID-19
Janssen Collaborates with Emergent BioSolutions to Accelerate the Manufacturing of its Vaccine Against COVID-19
Merck &amp; Co. Reports the Resubmission of sBLA to the US FDA for Keytruda (pembrolizumab) Six-Week Dosing Schedule
AstraZeneca and MSD Report Results of Lynparza in P-III PROfound Study for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Takeda to Divest Select OTC and Non-Core Assets in Europe to Orifarm for $670M
Sanofi Receives the US FDA's Approval for its MenQuadfi Meningococcal (MenACWY) Conjugate Vaccine
Santhera Signs a Clinical Trial Agreement with Cold Spring Harbor Laboratory to Evaluate Lonodelestat (POL6014) Against Acute Respiratory Distress Syndrome Associated with COVID-19
Janssen Reports Submission of Two sBLA to the US FDA for SIMPONI ARIA (golimumab) to Treat Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
Chugai Reports Results of P-III SAkuraStar Study of Satralizumab for Neuromyelitis Optica Spectrum Disorder
Regeneron and Sanofi Provide Update of P-II/III Adaptive-Designed Trial of Kevzara in Hospitalized Patients with COVID-19 in the US
Capital Health Launches Antibody Testing Initiative for COVID-19
Merck Collaborates with ISB to Evaluate the Mechanism of COVID-19 and to Identify Potential Prognostic Biomarkers
Roche and PTC Therapeutics Report Results of Risdiplam in FIREFISH Part 2 Study for Infants with Type 1 Spinal Muscular Atrophy
CEPI Collaborates with Clover to Support the Development of Vaccine Against COVID-19 in Australia 
Takeda's Mobocertinib (TAK-788) Receives the US FDA's Breakthrough Therapy Designation for NSCLC Patients with EGFR Exon 20 Insertion Mutations
Abbott's Freestyle Libre System Receives Health Canada Authorization Under Interim Order for Hospitalized Patients During COVID-19
Moderna to Initiate P-II Study of mRNA-1273 Against Novel COVID-19
"Biocon and Mylan Launch Fulphila (biosimilar, pegfilgrastim) in Canada"
Sarepta Signs a Research Agreement with the US Department of Defense to Identify Antisense Oligonucleotides Against COVID-19
Novartis' Cosentyx (secukinumab) Receives EC's Approval for Axial Spondyloarthritis Spectrum Marking its Fourth Indication in EU
BioNTech and Pfizer Complete Dosing of BNT162 in First Cohort of P-I/II Study in Germany
Astellas Signs a Three-Year Research Alliance with Harvard University Across Multiple Therapeutic Areas
Novartis Plans to Commence P-III Clinical Study Evaluating Canakinumab for Patients with COVID-19 Pneumonia
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Indications
Johnson &amp; Johnson Signs a Manufacturing Agreement with the Catalent to Bolster the Capacity of COVID-19 Vaccine in the US
Gilead Reports Results of Remdesivir in P-III SIMPLE Studies for Patients with Severe COVID-19
AstraZeneca Signs a Worldwide Development and Distribution Agreement with Oxford University for Vaccine Against COVID-19
GSK's Zejula (niraparib) Receives the US FDA's Approval as 1L Monotherapy Maintenance Treatment for Women with Advanced Ovarian Cancer Regardless of Biomarker Status
Curium's Pulmotech MAA Receives the US FDA's Approval for Lung Imaging
Bergenbio's Bemcentinib Selected to be Fast-Tracked Under UK's ACCORD Program Targeting COVID-19
Rockwell's Triferic AVNU Receives the US FDA's Approval to Replace Iron and Maintain Hemoglobin Hemodialysis Patients
MSD Signs a Two-Year Research Agreement with Almac to Discover DUB Therapeutic Targets for Neurodegenerative Diseases
Pfizer Signs a Development and Commercialization Agreement with Valneva for Lyme Disease Vaccine
Moderna Signs a Ten-Year Worldwide Agreement with Lonza to Manufacture mRNA-1273 Against COVID-19
"Novartis' Enerzair Breezhaler (QVM149, IND/GLY/MF) Receives CHMP's Recommendation for Approval as a Treatment for Uncontrolled Asthma"
WuXi Biologics and Aravive Collaborate to Develop Novel High-Affinity Bispecific Antibodies for Cancer and Fibrosis
Gilead's Remdesivir Receives the US FDA's Emergency Use Authorization for the Treatment of COVID-19
"Revance and Mylan to Extend Biosimilar to BOTOX Program Decision Beyond April 30, 2020"
MHLW Expedites the Reviews of Gilead's Remdesivir to Treat Patients with COVID-19 in Japan
Roche Receives FDA's Emergency Use Authorization for its Elecsys to Detect COVID-19
"Teva and Celltrion Launch Truxima (biosimilar, rituximab) to Treat Wegener's Granulomatosis and Microscopic Polyangiitis in the US"
Lilly and Junshi Collaborate to Co-Develop Antibody Therapies for the Treatment of COVID-19
Vir and Alnylam Anticipate the Initiation of Clinical Study Assessing VIR-2703 By the Year End
Alexion to Acquire Portola for ~$1.41B
Bio-Rad Receives the US FDA's Emergency Use Authorization for its Droplet Digital PCR Test Kit to Detect COVID-19
Pfizer and BioNTech Report First Patient Dosing with BNT162 in P-I/II Study for COVID-19 in the US
NeoGenomics Collaborates with Bayer to Provide NTRK Testing for Patients with Colorectal and Thyroid Cancer
Regeneron Anticipates the Initiation of Clinical Study for its COVID-19 Antibody Cocktail in June
Bavarian Nordic Collaborates with AdaptVac to Advance COVID-19 Vaccine Program
Sanofi and Regeneron Report Results of Libtayo (cemiplimab) in a P-II Study as 2L Treatment for Advanced Basal Cell Carcinoma
iBio Supports AzarGen's Development of a Biosimilar to Rituximab
PTC Therapeutics to Acquire Censa Pharmaceuticals to Bolster its Rare Disease Portfolio
"Novartis and Incyte's Tabrecta (capmatinib, INC280) Receives the US FDA's Approval for Metastatic Non-Small Cell Lung Cancer with METex14"
"Bausch + Lomb Signs an Exclusive License Agreement with STADA and Xbrane for Xlucane (biosimilar, ranibizumab) in the US and Canada"
Amgen Reports Results of Otezla (apremilast) in P-III ADVANCE Study for Mild-To-Moderate Plaque Psoriasis
Laurent Receives Health Canada's Approval to Initiate P-II RESOLUTION Study Evaluating LAU-7b for COVID-19
Gedeon Richter Signs an Asset Purchase Agreement with Mycenax for Biosimilar Tocilizumab to Treat Rheumatoid Arthritis
Henlius HLX02 (Trastuzumab for Injection) Receives EU GMP Certificates
"Henlius Receives NMPA's IND Approval for its HLX13 (biosimilar, ipilimumab)"
"Xbrane Biopharma Reports Update on the Ongoing P-III Xplore Study of Xlucane (biosimilar, ranibizumab)"
Gilead's Veklury (remdesivir) Receives MHLW's Approval for Patients with Severe COVID-19 in Japan
Sanofi's Insulin Aspart Biosimilar Receives CHMP's Positive Recommendation for Approval in the EU
Moderna Anticipates the Initiation of P-III Study of mRNA-1273 for COVID-19 by Early Summer
CoVIg-19 Plasma Alliance to Initiate Clinical Study Evaluating Hyperimmune Therapy for COVID-19 by Summer 2020
GSK to Evaluate Otilimab for Treating Pulmonary Disease Associated with COVID-19
"Celltrion Launches Remsima SC (biosimilar, infliximab) for the Treatment of Autoimmune Diseases in the Netherlands"
Fitbit Launches Heart Study to Validate its Wearable Technology for Identifying Atrial Fibrillation
AstraZeneca Terminates Their License Agreement with Allergan for Brazikumab Signed in 2016
Sorrento Collaborates with Mount Sinai Health System to Develop COVI-SHIELD Antibody Cocktail Targeting COVID-19
Regeneron's RGC Signs a Research Collaboration with Colorado Center to Advance the Drug Discovery for Personalized Medicine
Eli Lilly's Retevmo (selpercatinib) Receives the US FDA's Approval as the First Therapy to Treat Advanced RET-Driven Lung and Thyroid Cancers
Sanofi Reports Results of Sarclisa (isatuximab) in P-III IKEMA trial in Patients with Relapsed Multiple Myeloma
Neurocrine Biosciences Exercises its Option with Idorsia for ACT-709478
PharmaMar Signs an Exclusive License Agreement with MegaPharm for Lurbinectedin
Novartis Signs an Agreement with Dyno to Develop Novel AVV Therapies Utilizing AI Technology for Ocular Diseases
Abbott Receives FDA's Emergency Use Authorization for its Fourth Ab Blood Test to Detect COVID-19
GRYT Health and BMS Sign an Agreement to Launch Virtual Platform COVID Advocacy Exchange
Gilead Collaborates with Generics Makers to Supply Remdesivir in 127 Countries
Moderna's mRNA-1273 Receives the US FDA's Fast Track Designation to Treat COVID-19
Alvotech Reports Results of AVT02 (a proposed biosimilar to adalimumab) in Two Clinical Studies for Autoimmune Diseases
Skyhawk Therapeutics Expands its Agreement with Merck to Develop Novel Small Molecules Modulating RNA Splicing
LifeScan Collaborates with Noom to Launch Digital Diabetes and Weight Loss Management Program
"BMS and bluebird bio to Resubmit the BLA for Idecabtagene Vicleucel (ide-cel, bb2121) to Treat Patients with Multiple Myeloma"
Sanofi's Sutimlimab Receives the US FDA's Priority Review to Treat Hemolysis Patients with Cold Agglutinin Disease
Novocure and ZaiLab's Optune Receive NMPA's Approval for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
Roche to Present Results of Tiragolumab in P-II CITYSCAPE Study for Non-Small Cell Lung Cancer at ASCO20
Innovent and Eli Lilly Report Results of TYVYT (sintilimab) in P-II ORIENT-2 Study as 2L Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Boehringer Ingelheim Acquires Northern Biologics' Preclinical Cancer Antibody Pipeline to Bolster its Immuno-oncology Portfolio
Seattle's TUKYSA (tucatinib) Receives the US FDA's Approval for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer
Immunomedics' Trodelvy Receives the US FDA's Accelerated Approval for 2L Patients with Metastatic Triple-Negative Breast Cancer (TNBC)
UroGen's Jelmyto Receives the US FDA's Expedited Approval as a Novel Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer
"Incyte's Pemazyre (pemigatinib) Receives the US FDA's Approval as the Novel Treatment for Adults with Previously Treated, Unresectable LA or Metastatic Cholangiocarcinoma"
Sanofi's COVID-19 Vaccine to be Available Globally
Roche Launches v-TAC Blood Gas Digital Solution for Improving Patient Care
Recursion Signs a Worldwide License Agreement with Takeda to Develop TAK-733 for Hereditary Cancer Syndrome
"Samsung Bioepis Reports Results of Ontruzant (biosimilar, trastuzumab) in P-III Follow-up Study (SB3-G31-BC-E) for Early or Locally Advanced HER2-Positive Breast Cancer"
Janssen to Present Updated Results of JNJ-4528 in P-Ib/II CARTITUDE-1 Study for Multiple Myeloma at ASCO 2020
Daiichi Sankyo and AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki) Receive the US FDA's Breakthrough Therapy Designation for HER2 Mutant Metastatic Non-Small Cell Lung Cancer
AstraZeneca's Bevespi Aerosphere (glycopyrronium/formoterol fumarate) Receives NMPA's Approval for Patients with COPD
EMA to Grant Initial Authorization to Gilead's Remdesivir for COVID-19 is Imminent
Moderna Reports Positive Interim P-I Data of mRNA-1273 Against COVID-19
Roche's Tecentriq Receives the US FDA's Approval as 1L Monotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
Teva's Austedo (deutetrabenazine) Receives the NMPA's Approval to Treat Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults
Samsung Bioepis Reports Results of SB11 (proposed biosimilar ranibizumab) in P-III Study for Neovascular Age-Related Macular Degeneration
Roche Signs an Exclusive Worldwide Option and License Agreement with Vividion Focusing on Novel E3 Ligases
Innovent Biologics and MD Anderson Collaborate to Co-develop TYVYT (sintilimab) in Rare Cancer Indications in the US
AveXis Receives EC's Conditional Approval and Activates “Day One” Access Program for Zolgensma (onasemnogene abeparvovec) to Treat Spinal Muscular Atrophy
Biocon Receives EMA's GMP Certification for Multiple Biosimilars Manufacturing Facilities in Bengaluru
Roche Launches Elecsys Anti-SARS-CoV-2 Antibody Blood Test in the US
Eiger BioPharmaceuticals Reports the US FDA's Acceptance of NDA for Zokinvy (lonafarnib) to Treat Progeria and Progeroid Laminopathies
Aldeyra Therapeutics to Advance ADX-1612 to Clinical Testing and Provides Update on ADX-629 for COVID-19
Astellas and FibroGen Report EMA's Acceptance of MAA for Roxadustat to Treat Patients with Chronic Kidney Disease
Apple and Google Launch COVID-19 Exposure Notification System to Support Health Agencies
AstraZeneca Receives First Supply Agreement for University of Oxford's ChAdOx1 nCoV-19 Vaccine Against COVID-19
Synlogic Terminates its Agreement with AbbVie for Synthetic Biotic Medicines to Treat Inflammatory Bowel Disease
Gilead and Galapagos Report Results of Filgotinib in P-IIb/III SELECTION Study for Moderately to Severely Active Ulcerative Colitis
Roche Acquires Stratos Genomics to Advance the Development of Nanopore Sequencer
GSK Collaborates with Samsung Biologics for Large Scale Biopharmaceutical Manufacturing
Daiichi Sankyo and AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki) Receive the US FDA's Orphan Drug Designation for Gastric Cancer
Top 20 Medical Device Companies Based on 2019 Revenue
Bayer Reports Submission of MAA to the MHLW for Larotrectinib to Treat Solid Tumors with NTRK Gene Fusion
Gilead Plans to Submit MAA to CDSCO for its Remdesivir to Treat COVID-19 in India
"BMS Reports EMA's Validation of MAA for Idecabtagene Vicleucel (Ide-cel, bb2121) and CC-486"
"Fresenius Kabi Reports EMA's Acceptance of MAA for its MSB11455 (biosimilar, pegfilgrastim)"
AbCellera Signs an Exclusive Multi-Year Agreement with Eli Lilly to Develop Abs for up to Nine Targets
BARDA to Fund $1B to AstraZeneca for Research and Development of Novel COVID-19 Vaccines
"Evofem Biosciences' Phexxi (lactic acid, citric acid, and potassium bitartrate) Vaginal Gel Receives the US FDA's Approval for the Prevention of Pregnancy"
Sanofi and Regeneron Report Positive Results of Dupixent (dupilumab) in P-IIIa Dupixent Eosinophilic Esophagitis Study for EoE
Novavax Initiates P-I/II Study of NVX-CoV2373 Vaccine Against COVID-19
AstraZeneca Signs an Agreement with ArcherDX for Utilizing Personalized Cancer Assays to Detect MRD in Patients with Early-Stage Non-Small Cell Lung Cancer
Chi-Med and BeiGene Collaborate to Evaluate the Combinations of Surufatinib and Fruquintinib with Tislelizumab for Solid Tumors
NeoGenomics Collaborates with Inivata to Commercialize InVisionFirst-Lung Liquid Biopsy Test in the US
Merck Reports Three Major Initiatives Focusing on Developing Vaccine Against COVID-19
Algernon Reports Submission of IND to the US FDA for Ifenprodil to Treat COVID-19
Boehringer Ingelheim and Lilly Collaborate with DCRI for Evaluating Jardiance (empagliflozin) in a Pragmatic EMPACT-MI Study
Shionogi to Acquire Tetra Therapeutics for ~$500M
Glenmark to Initiate P-III Clinical Study Evaluating the Combination Therapy for Hospitalized Patients with COVID-19 in India
Roche Reports Results of Port Delivery System with Ranibizumab in P-III Archway Study for Neovascular Age-Related Macular Degeneration
Sanofi's Dupixent (dupilumab) Receives the US FDA's Approval as First Biologic for Children Aged 6-11 Years with Moderate-to-Severe Atopic Dermatitis
BMS Signs an Exclusive Worldwide Agreement with Repare Therapeutics to Identify Multiple Precision Oncology Therapies
Eli Lilly and Junshi to Initiate Clinical Trials of COVID-19 Antibody in Q2'2020
Gilead Signs a Ten Years Agreement with Arcus to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies
Roche Initiates P-III REMDACTA Study Evaluating Actemra (tocilizumab) + Remdesivir for Hospitalized Patients with Severe COVID-19 Pneumonia
Roche's Ocrevus (ocrelizumab) Shorter 2-Hour Infusion Time Receives EMA's Approval for Relapsing or Primary Progressive Multiple Sclerosis
AcelRx Amends its Agreement to Acquire Tetraphase Pharmaceuticals
"Fresenius Kabi Reports the US FDA's Acceptance of BLA for its MSB11455 (biosimilar, pegfilgrastim)"
Atriva to Initiate P-II Clinical Study Evaluating ATR-002 for Treatment of Patients with COVID-19
AstraZeneca Signs an Agreement with Serum Institute to Supply 1B Doses of Oxford University's COVID-19 Vaccine
"Fresenius Kabi Signs an Agreement with Medec to Commercialize IDACIO (adalimumab, biosimilar) in Germany"
Eli Lilly's Tauvid (flortaucipir F 18) Receives the US FDA's Approval as the First Drug to Image Tau Pathology in Patients Being Evaluated for Alzheimer's Disease
Roche Reports Updated Data of Alecensa in P-III ALEX Study for Patients with ALK-Positive Non-Small Cell Lung Cancer
"JHL Biotech Reports Dosing of its First Patient with JHL1266 (biosimilar, denosumab) in P-I Study in Australia"
European Commission Waives the Takeda's Commitment to Obtain Clearance on Shire's Acquisition
"Celltrion Launches its Third Biosimilar Truxima (biosimilar, rituximab) in Brazil"
Genmab Reports Results of Daratumumab Based Combination Therapy in P-III ANDROMEDA Study for Light-chain Amyloidosis
Amgen Reports Clinical Data of AMG 510 in CodeBreaK 100 Study for Multiple Solid Tumors #ASCO20
Celltrion and MSD Report Results of First-Line Triplet Regimen P-I/II PANTHERA trial in Patients with HER2-Positive Advanced Gastric Cancer
AbbVie Signs a Worldwide License Agreement with Jacobio to Advance SHP2 Inhibitors
Merck KGaA and Pfizer's Bavencio (avelumab) Demonstrates the Potential in Gestational Trophoblastic Tumors #ASCO20
Seattle Genetics Report Updated Results of Tukysa (tucatinib) in HER2CLIMB Study for Patients with HER2-Positive Breast Cancer with Stable or Active Brain Metastases #ASCO20
Mycenax Signs an Agreement with Gedeon Richter for LusiNEX
"Daewon Pharmaceutical Launches its Terrosa (biosimilar, teriparatide) to Treat Osteoporosis"
Merck's Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 for Patients with MSI-H Colorectal Cancer #ASCO20
Takeda to Present Results of Iclusig (ponatinib) in P-II OPTIC Study for Chronic Myeloid Leukemia in the Chronic Phase at ASCO and EHA #ASCO20
AstraZeneca Reports Results of Tagrisso (osimertinib) in P-III ADAURA study for EGFR-Mutated Lung Cancer #ASCO20
AstraZeneca and Daiichi Sankyo Provide Updates of Enhertu (fam-trastuzumab deruxtecan-nxki) in HER2-Positive Metastatic Colorectal Cancer and HER2-Mutant Non-Small Cell Lung Cancer #ASCO20
Eli Lilly Initiates the World's First Clinical Study to Evaluate the Potential of COVID-19 Antibody Treatment in Humans
"Mylan and Lupin Receive EC's MAA for Nepexto (biosimilar, etanercept)"
Inovio to Initiate P-I/II Study of INO-4800 Against COVID-19 in South Korea
AstraZeneca Signs Exclusive Worldwide License Agreement with Accent for RMP-Targeting Therapies
Roche's Elecsys IL-6 Test Receives the US FDA's EUA to Identify Patients at High Risk of Severe Inflammatory Response with COVID-19
Formycon To Update on its Biosimilar Programs
Celltrion Anticipates the Launch of Insulin Pen Biosimilar by 2025
Lilly Reveals New Data for Olumiant (baricitinib) to Treat Rheumatoid Arthritis and Systemic Lupus Erythematosus #EULAR
Eli Lilly to Present Data of Taltz (ixekizumab) for Patients with Psoriatic Arthritis at EULAR 2020 #EULAR
Personalis Collaborates with Sarepta Therapeutics on Immune Response to Precision Genetic Therapeutics
The US FDA Extends Review of sBLA of Ofatumumab (OMB157) for Patients with Relapsing Multiple Sclerosis
Intravacc and EpiVax Collaborate to Develop an Emerging Vaccine for COVID-19
Y-mAbs Reports the US FDA's Acceptance of Priority Review for Danyelza's (naxitamab) BLA to Treat Neuroblastoma
Regeneron and Intellia Expand Their 2016 Collaboration to Develop CRISPR/CAS9 Based Therapies
Sanofi's Sarclisa (isatuximab) Receives EC's Approval for adults with Relapsed and Refractory Multiple Myeloma
Roche's Tecentriq + Avastin Receives the US FDA's Approval for Unresectable or Metastatic Hepatocellular Carcinoma
Revance and Mylan to Advance Development Program for a Proposed Biosimilar to BOTOX
"Henlius and Accord Receive CHMP's Positive Opinion for its HLX02 (biosimilar, trastuzumab)"
Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals
Novartis Reports Results of Enerzair Breezhaler (QVM149) in P-IIIb ARGON Study to Treat Uncontrolled Asthma
AstraZeneca in Talks with Gilead for a Megamerger
AbbVie Enters into a Collaboration to Develop Monoclonal Antibody Therapy for Preventing COVID-19
Oxford Biomedica Signs a Five-Year Agreement with the Vaccines Manufacturing and Innovation Centre (VMIC) for (VMIC)
AstraZeneca Reports Results of Calquence (acalabrutinib) in CALAVI Study for Hospitalized COVID-19 Patients
Eli Lilly to Initiate P-I Study of its Second Antibody Treatment Against COVID-19
Alphamab Oncology Signs an Agreement with Sanofi for KN026
Roche Signs an Agreement with Innovent to Develop Therapies for Hematological and Solid Cancers
Astellas Reports Results of Roxadustat in P-III DOLOMITES Study to Treat Anemia in Non-Dialysis Dependent Adult Patients with Chronic Kidney Disease
Mallinckrodt Reports Completion of BLA Submission to the US FDA for StrataGraft to Treat Deep Partial-Thickness Thermal Burns in Adults
Eli Lilly Reports Dosing of its First Patient with Tirzepatide in P-III SURPASS-CVOT Study for Cardiovascular Outcomes
Eli Lilly Signs Five-Years License Agreement with Evox Therapeutics for its DeliverEX Platform
Denali and Sanofi Provide Update on its RIPK1 Program
"Sandoz Receives Health Canada's Approval to Launch Ziextenzo (biosimilar, pegfilgrastim) and Riximyo (biosimilar, rituximab) in Canada"
AstraZeneca Plans to Advance the Combination of Neutralizing Antibody for COVID-19 into Clinical in Next Two Months
AbbVie Collaborates with Genmab to Develop and Commercialize Therapies for Cancer Worth Over $3B
BMS Signs a Clinical Trial Collaboration with UbiVac to Evaluate the Triplet Therapy for Advanced Triple Negative Breast Cancer
Takeda Signs an Exclusive License and Research Agreement with Debiopharm to Develop Novel Microbiome Therapeutics for the Gastrointestinal Disorders
Dexcom's Glucose Monitoring Wearable System Receives CE Mark in the Europe
Johnson &Johnson to Initiate P-I/IIa Clinical Study of its COVID-19 Vaccine in July
RedHill Biopharma Reports the Submission of CTA for P-II/III Study Evaluating Opaganib Against COVID-19 in Russia
Cipla to Acquire 21.85% Stake in GoApptiv for ~$1.2M
BMS' Opdivo (nivolumab) Receives the US FDA's Approval for Advanced Esophageal Squamous Cell Carcinoma
Sorrento Submits EUA to the US FDA for its COVI-TRACK Test to Detect COVID-19
"Pfizer Receives the US FDA's Approval for its Nyvepria (biosimilar, pegfilgrastim)"
"Celltrion to Evaluate Remsima (biosimilar, infliximab) Against COVID-19 in the UK"
Novo Nordisk to Acquire AstraZeneca's Spin-off Corvidia for ~$2.1B
"Mylan and Biocon Receive the US FDA's Approval for Semglee (biosimilar, insulin glargine)"
Moderna to Initiate P-III Study of its mRNA-1273 Against COVID-19 in July 2020
Lannett to Submit Biosimilar Application to the US FDA for its Insulin Glargine by the End of 2022
Regeneron Initiates its First Clinical Study of Antibody Cocktail for the Treatment and Prevention of COVID-19
Takeda to Divest OTC and Select Non-core Assets to Celltrion for ~ $278M
Medtronic Receives CE Mark for MiniMed 780G Insulin Pump to Treat Type 1 Diabetes
AstraZeneca To Supply 400M Doses of Vaccines to IVA by the End of 2020
Gilead Signs a License Agreement with Zydus and Dr. Reddy's for Remdesivir to Treat COVID-19
Eli Lilly Initiates P-III Study Evaluating Baricitinib in Hospitalized Patients with COVID-19
Merck's Gardasil 9 Receives the US FDA's Approval to Prevent HPV-Related Head and Neck Cancers
Foundation Medicine Acquires Lexent to Expand its Liquid Biopsy Platforms
AstraZeneca Signs an Agreement with Catalent to Manufacture AZD1222 for COVID-19
Akili's EndeavorRx Receives the US FDA's Approval as the First Game-Based Digital Therapeutic to Improve Attention Function in Children with ADHD
Celltrion Anticipates the Launch of its POCT Kit for COVID-19 in July 2020
Bayer and MassBio to Launch Joint Mentoring Program to Foster Startups in Asia
"Celltrion Report Results of Truxima (biosimilar, rituximab) Based Regimen in P-II Study for R/R Aggressive B-cell Lymphoma #EHA25"
Sun Pharma Signs a License Agreement with Hikma for Ilumya (tildrakizumab) in MENA Regions
Takeda and Neurocrine Collaborate for Seven Neuro Programs Worth Up to $2B
Merck and Pfizer Report Results of Steglatro (ertugliflozin) in P-III VERTIS CV Study for Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
GSK Signs a Synthetic Lethality Cancer Agreement with Ideaya for ~$170M
Novartis' Cosentyx (secukinumab) Receives the US FDA's Approval for Active Non-Radiographic Axial Spondyloarthritis
Sanofi Report Results of Avalglucosidase alfa in P-III COMET Study for Late Onset Pompe Disease
Deciphera Pharmaceuticals' Qinlock (ripretinib) Receives the US FDA's Approval to Treat 4L Gastrointestinal Stromal Tumor
Zionexa And Petnet Solutions' Cerianna (Fluoroestradiol F 18) Receive the US FDA's Approval for Advancing Treatments in Metastatic Breast Cancer Patients
Amivas's Artesunate Receives the US FDA's Approval for Treatment of Severe Malaria
Tolmar's Fensolvi Received the US FDA's Approval to Treat Pediatric Patients Two Years of Age and Older withntral Prec Ceocious Puberty (CPP)
AstraZeneca Signs an Agreement with Cobra Biologics for Vaccines Against COVID-19
Gilead to Initiate P-II/III Study Evaluating Remdesivir in Pediatric Patients Hospitalized With COVID-19
Roche Reports Results of Tecentriq + CT in P-III IMpassion031 Study for Patients with Early Triple-Negative Breast Cancer
Samsung Launches a Blood Pressure Monitoring App in South Korea
AstraZeneca Collaborates with Gendius to Provide Diabetes Management Support for Patients in the GCC
Genmab and Janssen's Darzalex Faspro (daratumumab and hyaluronidase-fihj) Receive the US FDA's Approval to Treat Multiple Myeloma in Adults
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as Monotherapy for Patients with Unresectable or Metastatic Tumor Mutational Burden-High Solid Tumors
Dr. Reddy's Elyxyb (celecoxib oral solution) Receives the US FDA's Approval for Acute Treatment of Migraine with or Without Aura in Adults
Sunovion Pharmaceutical's Kynmobi (apomorphine hydrochloride) Receives the US FDA's Approval to Treat Parkinson's Disease Off Episodes
PRA Collaborates with Microsoft to Foster COVID-19 Monitoring
Astellas' VESIcare LS (solifenacin succinate) Receives the US FDA's Approval to Treat Neurogenic Detrusor Overactivity (Ndo) In Pediatric Patients Aged 2 Years and Older
AbbVie and Neurocrine's Oriahnn Receive the US FDA's Approval as the First Oral Therapy for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women
AbbVie Signs an Exclusive Worldwide Option and License Agreement with Alpine to Develop and Commercialize ALPN-101
Roche and Cipla Expand Their 2018 Agreement to Improve Access of Oncology Therapies in India
RedHill Expands its P-II/III Study Evaluating Yeliva (opaganib) Against COVID-19 in Italy and UK
"Innovent Receives the NMPA's Approval for Byvasda (biosimilar, bevacizumab) to Treat Non-Small Cell Lung Cancer and Metastatic Colorectal Cancer in China"
Pfizer and Sangamo's Giroctocogene Fitelparvovec (SB-525) Demonstrate Positive Effect in P-I/II Alta Study for Hemophilia A
Ultragenyx and Kyowa Kirin's Crysvita (burosumab) Receive the US FDA's Approval for the Treatment of Tumor-Induced Osteomalacia
Glenmark Launches FabiFlu (favipiravir) as the First Oral Medication to Treat Mild to Moderate COVID-19 in India
Merck KGaA and Pfizer Report EMA's Validation for Bavencio (avelumab) as a 1L Treatment for Locally Advanced or Metastatic Urothelial Carcinoma
Novartis Halts Clinical Trial Evaluating Hydroxychloroquine Against COVID-19 Due to Slow Enrollment
Cipla Launches Cipremi (remdesivir lyophilized powder for injection 100 mg) to Treat Patients with Severe COVID-19
Merck's Keytruda Receives the NMPA's Approval as a 2L Treatment for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Gilead to Initiate P-I Study Evaluating Inhaled Version of Remedesivir Against COVID-19 in August 2020
Sanofi Expands its 2018 Collaboration with Translate Bio to Develop mRNA Vaccines Against Infectious Diseases
AbbVie Reports the US FDA's Acceptance of BOTOX's sBLA for Pediatric Patients with Neurogenic Detrusor Overactivity
ATAI Launches IntroSpect Digital Therapeutics to Foster Mental Health Care
BioInvent Reports the Enrollment of First Patient in P-I/IIa Study of BI-1206 + Keytruda for Solid Tumors
Schrodinger Expands its Drug Discovery Efforts Against COVID-19 Deploying Parallel Computing on Google Cloud
Sanofi Anticipates the Approval of its COVID-19 Vaccine by First Half of 2021
Gilead Holds an Exclusive Option to Acquire Pionyr Immunotherapeutics for ~$1.75B
Sarepta Signs a Two-Year Research and Option Agreement with Codiak for Up to Five Neuromuscular Targets
AstraZeneca Signs an Agreement with Symbiosis for Sterile Manufacturing of its AZD1222 Against COVID-19
The US FDA Launches Project Patient Voice to Share Patient-Reported Outcomes from Cancer Trials
FibroGen Report Enrollment of First Patient in P-II Study Evaluating Pamrevlumab in Patients Hospitalized with Acute COVID-19
CSL Behring to Acquire uniQure' Hemophilia B Candidate (AMT-061) for ~$2B
Merck Collaborates with Yumanity to Accelerate the Development of Two Therapies Targeting Neurodegenerative Diseases
AstraZeneca Reports Results of Breztri Aerosphere in P-III ETHOS Study to Treat COPD
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma
Fulcrum Initiates P-III LOSVID Study Evaluating Losmapimod for Patients Hospitalized with COVID-19
Theravance Reports First Patient Dosing in a P-II Study of TD-0903 for Hospitalized Patients with Acute Lung Injury Associated with COVID-19
AbbVie Signs an Exclusive Research and Option to License Agreement with Sosei Heptares Targeting Inflammatory and Autoimmune Diseases
Zogenix's Fintepla (fenfluramine) Receives the US FDA's Approval for the Treatment of Seizures Associated with Dravet Syndrome
EMA Anticipates the EC's Conditional Marketing Authorization for Gilead's Remdesivir in Coming Week
Roche Launches uPath PD-L1 (SP263) Automated Digital Pathology Algorithm to Speed Up NSCLC Diagnosis
Sandoz Launches the Biosimilars Generation Campaign in Canada
Medtronic Receives the US FDA's Approval for its Percept PC Neurostimulator with BrainSense Technology
EMA's CHMP Recommends the Approval of Two Biosimilar Referencing Lilly's Forsteo (teriparatide) for the Treatment of Osteoporosis
Daiichi Sankyo in Talks with AstraZeneca for the Supply of AZD1222 to Combat COVID-19 in Japan
MHLW Approves Novartis' Five New Therapies Expanding its Footprints in Japan
Alexion's Ultomiris (ravulizumab) Receives EC's Approval for Atypical Hemolytic Uremic Syndrome
Roche's Enspryng (satralizumab) Receives MHLW's Approval for Neuromyelitis Optica Spectrum Disorder in Japan
"Samsung Bioepis' Aybintio (biosimilar, bevacizumab) Receives CHMP's Positive Opinion to Treat Multiple Cancer Indications"
Gilead Unveils the Price of Remdesivir as $390 per Vial in Developed Countries
Abbott Integrates its CGM Technology with Tandem's Insulin Delivery System for Improving Diabetes Management
Bharat Biotech to Initiate Clinical Trials Evaluating Covaxin (India's First COVID-19 Vaccine) in July 2020
AstraZeneca and MSD's Selumetinib Receive MHLW's Orphan Drug Designation for Neurofibromatosis Type 1 in Japan
Roche's Phesgo (fixed-dose combination of Perjeta and Herceptin) Receives the US FDA's Approval for Early and Metastatic HER2-Positive Breast Cancer
"Celltrion's Remsima SC (biosimilar, infliximab) Receives CHMP's Positive Opinion for an Additional Five Indications Including Inflammatory Bowel Disease and Ankylosing Spondylitis"
Takeda Collaborates with Carmine for Non-Viral Gene Therapies Worth Up to $900M
G1 Therapeutics and Boehringer Ingelheim Collaborate to Co-Promote Trilaciclib for Small Cell Lung Cancer in the US and Puerto Rico
Samsung Bioepis Reports the Initiation of P-III Study for SB15 Proposed Biosimilar to Eylea (aflibercept)
Merck KGaA and Pfizer's Bavencio (avelumab) Receive the US FDA's Approval as a 1L Treatment for Locally Advanced or Metastatic Urothelial Carcinoma
Boston Scientific Receives the US FDA's 510(k) Clearance for its LUX-Dx Insertable Cardiac Monitor System
QurAlis Signs a License Agreement with Eli Lilly for its ALS Therapeutic Candidates
Pfizer and BioNTech Report Results of BNT162b1 mRNA-Based Vaccine in P-I/II Study Against COVID-19
Dr. Reddy's and GRA Collaborate with Fujifilm for Avigan (favipiravir) to Treat COVID-19 Outside Japan
Sorrento Selects T-VIVA-19 as a Targeted Protein Vaccine Candidate Against COVID-19
Janssen Receives EC's Approval for its Ebola Vaccine Dual Regimen
"Henlius Reports Positive Results of HLX04 (biosimilar, bevacizumab) in P-III Trial for Metastatic Colorectal Cancer"
Yuhan Collaborates with GI Innovation for its Allergy Treatment Worth up to $1.2B
"Kyowa Kirin's FKB327 (biosimilar, adalimumab) Receives the MMA Approval in Japan"
Biogen Signs a License Agreement with Massachusetts Eye and Ear to Develop Treatment for Inherited Retinal Disorder
Helsinn and MEI Terminate its P-III Study of Pracinostat for Patients with AML
Sarepta Signs an Exclusive Worldwide License with Hansa to Develop Imlifidase for Duchenne Muscular Dystrophy and Limb-Girdle Muscular Dystrophy
Sanofi and Regeneron's Kevzara (sarilumab) Fails in P-III Trial for Patients with COVID-19 in the US
Zydus to Initiate Clinical Trials Evaluating ZyCoV-D Vaccine Against COVID-19 in July 2020
ViiV Healthcare's Rukobia (fostemsavir) Receives the US FDA's Approval for HIV in Patients with Limited Treatment Options
Medivir's MIV-818 Receives EC's Orphan Medicinal Product Designation to Treat Hepatocellular Carcinoma
CytoDyn Signs an Agreement with American Regent for Leronlimab to Treat COVID-19 Patients in the US
MSD Signs a Clinical Trial Collaboration with Ascentage Pharma for Solid Tumors
Mylan's Remdesivir Lyophilized Powder for Injection Receives the DCGI Accelerated Approval for Restricted Emergency Use in COVID-19 Patients in India
Regeneron with its Partner NIAID Report the Initiation of P-III Trial to Evaluate REGN-COV2 for Treatment and Prevention of COVID-19
EspeRare's ER-004 Receives the US FDA's Breakthrough Therapy Designation for Prenatal Treatment of XLHED
Emergent Signs a Five-Year Manufacturing Services Agreement with Janssen for Ad26.COV2-S to Treat COVID-19
Becton Dickinson Receives the US FDA's EUA for its Third Point-Of-Care SARS-CoV-2 Diagnostic Test to Detect COVID-19
BMS Signs an Exclusive Option to License Agreement with Dragonfly Therapeutics to Develop Novel Therapies for Multiple Sclerosis and Neuro-inflammation Targets
Abbott's Gallant ICD and CRT-D Devices Receives the US FDA's Approval for Heart Rhythm Disorder with Bluetooth Connectivity
Novartis' Enerzair Breezhaler Receives the EC's Approval as a Maintenance Treatment of Asthma in Adult Patients Uncontrolled with LABA/ICS
Daiichi Reports EMA's Validation of MAA and Accelerated Assessment for Trastuzumab Deruxtecan to Treat HER2 Positive Metastatic Breast Cancer
Regeneron Signs an Agreement with BARDA and the US Department of Defense for REGN-COV2 Worth $450M
GSK and Medicago to Initiate P-I Trial of Plant-Based COVID-19 Vaccine in July 2020
Angion Commences P-II Study of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia in Brazil
Zai Lab Signs an Exclusive License Agreement with Turning Point Therapeutics for Repotrectinib in Greater China
AstraZeneca and MSD's Lynparza (olaparib) Receives EC's Approval for BRCA-Mutated Metastatic Pancreatic Cancer
Merck Collaborates with Foghorn to Develop Oncology Therapies Against Transcription Factor Target
Biogen and Eisai Complete the Submission of BLA to the US FDA for Aducanumab to Treat Alzheimer's Disease
Roche and Reverie Labs Collaborate to Advance Kinase Drug Discovery Programs
AstraZeneca's Brilinta (ticagrelor) Receives the US FDA's Priority Review for Reducing Stroke in Patients with Acute Ischemic Stroke or Transient Ischemic Attack
The European Commission Signs an Agreement with Roche and Merck to Supply their COVID-19 Therapies in EU
"Mylan and Fujifilm Kyowa Kirin Receive the US FDA's Approval for its Hulio (biosimilar, adalimumab)"
Cipla Launches Cipremi at $53.34 per Vial in India
Sanofi Signs an Agreement with Kymera to Advance Novel Protein Degrader Therapies Worth Up to $2.1B
Bayer Reports Results of Finerenone P-III FIDELIO-DKD Renal Outcomes Study in Patients with Chronic Kidney Disease and Type 2 Diabetes
AstraZeneca Collaborates with ProteinQure to Design Novel Peptide Therapeutics
Philips Collaborates with BioIntelliSense to Enhance Remote Patient Monitoring
LEO Reports the US FDA's Acceptance of BLA for Tralokinumab to Treat Adults with Moderate to Severe Atopic Dermatitis
Biocon's ALZUMAb (itolizumab) Receives the DCGI's Approval for Emergency Use to Treat Patients with Moderate to Severe COVID-19
Roche Reports Results of Tecentriq in P-III IMagyn050 Study for Women with 1L Newly Diagnosed Advanced Stage Ovarian Cancer
Samsung Biologics Expands its Development Partnership with STCube for STM418
Pfizer with its Partner BioNTech Receives the US FDA's Fast Track Designation for Two mRNA Based Therapies to Treat COVID-19
Gilead's Veklury (remdesivir) Receives the TGA's Approval to Treat Adults and Adolescents with Severe COVID-19 Symptoms
Paige Secures Funding from Goldman Sachs to Continue Innovation in Digital Pathology
Roche Signs a ~$1B Agreement with Blueprint Medicines for its Precision Therapy to Treat Patients with RET-Altered Cancer Indications
Roche's Mosunetuzumab Receives the US FDA's Breakthrough Therapy Designation to Treat Relapsed or Refractory Follicular Lymphoma
Roche Expands its Collaboration with Immunomedics to Evaluate Tecentriq Based Combination Therapy in Urothelial and Non-Small Cell Lung Cancers
Merck Signs an Exclusive Agreement with Dewpoint Therapeutics to Develop Curative Treatment for HIV
Sanofi and MD Anderson Sign a Five-Year Pact to Expedite Oncology Research and Development
"Moderna to Commence Late-stage COVID-19 Vaccine Trial on 27 July, 2020"
Samsung Biologics Signs Multi-Product Development and Manufacturing Agreement with ImmuneOncia
3M Collaborates with MIT to Develop Paper-Based Diagnostic Test for COVID-19
GSK's Belantamab Mafodotin Receives the US FDA Advisory Committee's Recommendation to Treat Relapsed/Refractory Multiple Myeloma
AstraZeneca and the University of Oxford to Share Positive News on its COVID-19 Vaccine Imminently
Medtronic to Acquire Medicrea for Boosting its Spine Offerings
Novartis Launches Zero Profit Portfolio for Symptomatic Treatment of COVID-19
AstraZeneca Report Results of Brilinta (ticagrelor) in P-III THALES Study for Patients with Acute Ischemic Stroke or Transient Ischemic Attack
Zydus Initiates Adaptive P-I/II Clinical Study Evaluating its ZyCoV-D Against COVID-19 in India
NCCN Collaborates with Pfizer to Explore Adoption of Biosimilars in Oncology
MSD Collaborates with Novocure to Evaluate Tumor Treating Fields Together with Keytruda (pembrolizumab) in Non-Small Cell Lung Cancer
Merck and Bayer Receive the US FDA's Priority Review for Vericiguat to Reduce the Risk of CV Death in Patients with Symptomatic Chronic Heart Failure with HFrEF
Kronos Bio to Acquire Gilead's SYK Inhibitor Portfolio
Merck KGaA Takes an Early Option in its Existing Immuno-Oncology Collaboration with F-star
Kiniksa's Rilonacept Receives the US FDA's Orphan Drug Designation to Treat Pericarditis
Thermo Fisher Scientific Amends its Agreement to Acquire QIAGEN
Eli Lilly Reports Results of Mirikizumab in P-III OASIS-2 Study to Treat Moderate to Severe Plaque Psoriasis
Oncorus Initiates P-I Study of ONCR-177 in Patients with Advanced/ Refractory Cutaneous Subcutaneous or Metastatic Nodal Solid Tumors
Celltrion Initiates P-I Study of its COVID-19 Antibody Treatment in South Korea
GSK to Acquire 10% stake in CureVac for $163M
Roche Signs RWD Collaboration with PicnicHealth to Create Personalized Treatment for Patients with Multiple Sclerosis
Quest Diagnostic Receives the US FDA's First EUA for Sample Pooling in COVID-19
Royalty Pharma Acquires PTC's Royalty Interest in Risdiplam for $650M
AstraZeneca and Oxford University's AZD1222 Delivers Dual Immune Response in its P-II/III COV001 Study Against COVID-19
Pfizer and BioNTech Elicits Strong T-cell Response in P-I/II Study Against COVID-19
Mylan Launches Remdesivir Under the Brand Name Desrem for COVID-19 in India
Roche Collaborates with Jnana Therapeutics to Discover Novel Therapies to Treat Immune-Mediated and Neurological Diseases
The UK Government to Launch AbC-19 Lateral Flow Free Finger-Prick Test for COVID-19
Paige Receives the US FDA's 510(k) Clearance for its FullFocus Viewer to Use in Digital Pathology
Biocon Collaborates with Voluntis on Digital Therapeutics for Insulins
Gilead to Acquire Tizona's Stakes for $300M
Boston Scientific Receives the US FDA's Approval for Next-Generation WATCHMAN FLX Left Atrial Appendage Closure Device
Evotec Collaborates with Quantro Therapeutics to Discover and Develop Novel Therapies for Cancer and Other Diseases
AbbVie Reports Results of Rinvoq (upadacitinib) as Monotherapy in a P-III Measure Up 2 Study for Atopic Dermatitis
Viela Bio's Uplizna (inebilizumab-cdon) Receives the US FDA's Approval to Treat Neuromyelitis Optica Spectrum Disorder (NMOSD)
Pharma Mar's Zepzelca (lurbinectedin) Receives the US FDA's Accelerated Approval for Adult Patients with Metastatic Small Cell Lung Cancer (SCLC)
Ultragenyx's Dojolvi (UX007/triheptanoin) Receives the US FDA's Approval to Treat Long-Chain Fatty Acid Oxidation Disorders
ViiV Healthcare's Tivicay PD (dolutegravir) Receives the US FDA's Approval for Children Living with HIV
Daiichi Sankyo Signs a Research Agreement Gustave Roussy for DS-1062 and Patritumab Deruxtecan to Treat Lung and Breast Cancer
Glenmark Report Results of FabiFlu (favipiravir) in P-III Clinical Study for Patients with Mild to Moderate COVID-19
Genentech Reports Results of Port Delivery System with Ranibizumab in P-III Archway Study for Neovascular Age-Related Macular Degeneration
Ovid Therapeutics and University of Connecticut Collaborate to Accelerate the Development of OV101 (gaboxadol) for Angelman Syndrome
BioMarin Reports the Submission of MAA to EMA for Vosoritide to Treat Children with Achondroplasia
Zydus to Initiate Clinical Study of Desidustat in Patients with Chemotherapy-Induced Anemia (CIA)
Synaffix Expands its Existing Collaboration with ADC Therapeutics to Explore Two Additional Programs
PharmaShots Celebrates Successful Accomplishment of Two Years
Pfizer and BioNTech Initiate P-II/III Global Study of its Lead mRNA Vaccine Candidate Against COVID-19
Eli Lilly Amends its 2013 Agreement with Chi-Med to Commercialize Elunate (fruquintinib) in China
Eli Lilly's P-tau217 Blood Test Demonstrate High Accuracy in Diagnosis of Alzheimer's Disease
Roche's Actemra/RoActemra (tocilizumab) Fails to Meet the Primary Endpoint in P-III COVACTA Study for Patients with COVID-19 Associated Pneumonia
AbbVie Report Results of Rinvoq (upadacitinib) in a P-III AD Up Study for Patients with Atopic Dermatitis
Baxter and Ayogo Expand their Partnership to Advance Digital Health Solution for Home Dialysis
BARDA Signs a Multi-Year Agreement with Regeneron for its REGN-EB3 for National Preparedness
UCB Canada's Brivlera (brivaracetam) Receives Health Canada Approval to Treat Partial-Onset Seizures in Pediatric Epilepsy Patients
"Henlius and Accord's Zercepac (trastuzumab, biosimilar) Receive the EMA Approval for HER2-Positive Breast Cancer and Gastric Cancer"
AstraZeneca's Tagrisso (osimertinib) Receives the US FDA's BT Designation for the Adjuvant Treatment of Patients with Stage IB-IIIA EGFR-Mutated Lung Cancer
Eli Lilly Reports Results of Jardiance (empagliflozin) in P-III EMPEROR Trial for Heart Failure Patients with Reduced Ejection Fraction with and without Diabetes
Sangamo Signs a Worldwide License Agreement with Novartis to Develop Genomic Therapies for Three Neurodevelopmental Targets
Johnson & Johnson Initiates P-I/IIa Study of its Ad26.COV2.S Against COVID-19 in the US and Belgium
Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant to Manufacture and Supply AXO-Lenti-PD for Parkinson's Disease
MorphoSys' Monjuvi (tafasitamab-cxix) + Lenalidomide Receives the US FDA's Approval as 2L Treatment for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Immunic Reports Results of IMU-838 in P-II EMPhASIS Study in Patients with Relapsing-Remitting Multiple Sclerosis
Regeneron Collaborates with BioNTech to Advance the Combination of FixVac and Libtayo (cemiplimab) in Melanoma
Roche's Rozlytrek Receives EC's Conditional Marketing Authorization for NTRK Fusion-Positive Solid Tumors and ROS1-Positive Advanced NSCLC
RedHill Replaces its Co-Commercialization Agreement with Daiichi Sankyo for Movantik (naloxegol)
Novartis Reports Results of Kymriah (tisagenlecleucel) in P-II ELARA Study for Follicular Lymphoma
AstraZeneca Signs a License Agreement with Redx Pharma for RXC006 to Treat Idiopathic Pulmonary Fibrosis
LEO Pharma Receives the US FDA's Fast Track Designation for Delgocitinib Cream to Treat Moderate-to-Severe Chronic Hand Eczema
AbbVie Terminates Tau and ASN Agreement with Voyager Signed in 2018 and 2019
Roche's cobas Epstein-Barr Virus Test Receives the US FDA's Authorization for Transplant Patients
BioNTech and Fosun Pharma Initiate Clinical Trial of BNT162b1 Against COVID-19 in China
"Celltrion's Remsima SC (infliximab, CT-P13) Receives the EC's MAA for Additional Five Indications"
"Bio-Thera Signs a License Agreement with Pharmapark for BAT2506 (golimumab, biosimilar)"
Lundbeck Halts P-II Study of Lu AF11167 in Patients with Negative Symptoms of Schizophrenia
UCB's Cimzia (certolizumab pegol) Receives the EMA's Approval for a Reduced Maintenance Dose in Patients with Axial Spondyloarthritis Spectrum
Moderna Prices its COVID-19 Vaccine at $32-$37 per Dose for Smaller Volume Agreements
Evotec Signs an Agreement with Sanofi for Novel Drug Development
Emergent BioSolutions Announces Completion of Acquisition of PaxVax for ~$270M
Mitsubishi Tanabe Pharma (MTP-CA) Receives Health Canada Approval of Radicava for Amyotrophic Lateral Sclerosis (ALS)
Konan Medical Receives FDA 510(k) Approval for its objectiveFIELD Device
Palette Life Sciences Signs a Worldwide Commercialization and Development Agreement with Nestle Skin Health
J&amp;J to Acquire Ci:z Holdings for Expansion of its Dermatology Portfolio
Novartis Receives EU Approval for Cosentyx's (secukinumab) Label Update in Patients with Psoriatic Arthritis (PsA)
AstraZeneca Divests US Rights of Synagis &amp; MEDI8897 to Sobi for Prevention of Serious Lower Respiratory Tract infection (LRTI)
GSK's Trelegy Ellipta (Fluticasone Furoate/Umeclidinium/Vilanterol ‘FF/UMEC/VI') Receives Expanded Level Approval from EU for COPD
"Dragonfly and Celgene Extended their Collaboration from 2017, for the Treatment of Solid and Hematological Cancers"
Arena Pharmaceutical Licenses Exclusive Worldwide Rights of Ralinepag (APD811) to United Therapeutics for $1.2B
Vela Diagnostics' ViroKey SARS-CoV-2 RT-PCR Test Receives the US FDA's Emergency Use Authorization
Eli Lilly's Lyumjev (insulin lispro-aabc injection) Receives the US FDA's Approval for Type 1 and Type 2 Diabetes
Evoke's Gimoti (metoclopramide) Receives the US FDA's Approval to Relief Symptoms in Adults with Acute and Recurrent Diabetic Gastroparesis
Chugai and Biofourmis Collaborate to Develop Solutions for Digitally Measuring Endometriosis Pain
Abbott's IOS-Compatible App Receives the US FDA's Approval for Patients with Neurological Disorder
AstraZeneca's Breztri Aerosphere Receives the US FDA's Approval for the Maintenance Treatment of COPD
Gilead and Galapagos' Jyseleca (filgotinib) Receive the CHMP's Positive Opinion for Moderate to Severe Rheumatoid Arthritis
Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies Targeting COVID-19 and Cancer
AstraZeneca Signs an Agreement with Daiichi Sankyo to Develop and Commercialize DS-1062 Worth Up to $6B
"Centus Biotherapeutics' Equidacent (bevacizumab, biosimilar) Receives CHMP's Positive Opinion for the Treatment of Multiple Cancer Indications"
Kite's Tecartus (brexucabtagene autoleucel) Receives the US FDA's Approval as the First Cell-Based Gene Therapy for Relapsed or Refractory MCL
"Cadila to Launch its Bevaro (bevasizumab, biosimilar) in India"
Three Pharma Companies Launch Favipiravir to Treat COVID-19 in India
AstraZeneca Signs an Agreement with Emergent BioSolutions to Expand Manufacturing of AZD1222 for COVID-19
AstraZeneca Report Results of Farxiga in P-III DAPA-CKD Study for Patients with Chronic Kidney Disease
Zebra Medical Receives the US FDA's Approval for its HealthMammo Mammography Tool
Roche and UCB Collaborate to Develop UCB0107 for Alzheimer's Disease
Sanofi and GSK Sign an Agreement with the UK Government to Supply ~60M Doses of COVID-19 Vaccine
Merck's MK-6482 Receives the US FDA's Breakthrough Therapy Designation to Treat Patients With Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma
"Cadila to Launch its Ritucad (rituximab, biosimilar) in India"
Roche's Tecentriq + Cotellic and Zelboraf Receives the US FDA's Approval for Patients with Advanced Melanoma
Takeda's Pevonedistat Receives the US FDA's Breakthrough Therapy Designation to Treat Patients with Higher-Risk Myelodysplastic Syndrome
Roche Receives the US FDA's Approval for VENTANA HER2 Dual ISH Test as CDx to Identify Breast Cancer
Sanofi and GSK Receive $2.1B from the US Government to Supply 100M Doses of COVID-19 Vaccine
Eli Lilly in Collaboration with NIAID Initiate P-III Study of LY-CoV555 to Prevent COVID-19
Siemens Healthineers to Acquire Varian for $16.4B
Merck and Hanmi Collaborate to Develop Efinopegdutide for NASH
"Janssen's Darzalex (daratumumab, SC) Receives Health Canada Approval for the Treatment of Patients with Multiple Myeloma"
Lupin and SunPharma Launch Generic Favipiravir to Treat Mild to Moderate COVID-19 in India
Teva and Alvotech Collaborate to Commercialize Five Biosimilar Candidates in the US
Johnson &amp; Johnson Signs an Agreement with the US Government to Supply 100M Doses of COVID-19 Vaccine Worth ~$1B
AstraZeneca Collaborates with Eko to Advance the Digital Health Tools for the Diagnosis of CV Diseases
Novartis Reports Results of Ofatumumab (OMB157) in P-III ASCLEPIOS Trials for Relapsing Multiple Sclerosis
Biogen Signs an Agreement with Denali on LRRK2 Program for Parkinson's Disease Worth ~$2.125B
Roche's Tecentriq (atezolizumab) + Paclitaxel Fail to Meet the Primary Endpoint in P-III IMpassion131 Study for Patients with Metastatic Triple-Negative Breast Cancer
AstraZeneca Collaborates with Daiichi Sankyo to Evaluate the Combination of Patritumab Deruxtecan (U3-1402) + Tagrisso for EGFR-Mutated Non-Small Cell Lung Cancer
Bausch Health to Spin off its Eye Health Business
Elanco Receives EC's Approval for its Pending Acquisition of Bayer Animal Health
Merck Animal Health to Acquire Rights to Sentinel Brand of Combination Parasiticides for Companion Animals in the US for $400M
Elanco Receives the US FTC's Approval for Acquisition of Bayer Animal Health
Merck Animal Health Receives the US FDA's Approval for Bravecto (fluralaner) Monthly Chews to Protect Dogs and Puppies Against Fleas and Ticks
Boehringer Ingelheim Receives Approval for its Classical Swine Fever Live Vaccine in China
?Elanco To Acquire Bayer's Animal Health Business for $7.6B
Cadila Pharma Launches NuPTH Biosimilar to Forteo for the Treatment of Osteoporosis in India
Roche's Evrysdi (risdiplam) Receives the US FDA's Approval for SMA in Adults and Children
Boehringer Ingelheim Acquires GST to Boost its Stem Cell Capabilities in Animal Health
The US FDA Approves Guardant360 CDx as the First Liquid Biopsy NGS Assay to Identify EGFR Mutations in Non-Small Cell Lung Cancer
Roche Report Mixed Results of Etrolizumab in P-III Studies for Patients with Moderately to Severely Active Ulcerative Colitis
"Samsung Bioepis Launches Ontruzant (trastuzumab, biosimilar) for Early and Metastatic HER2-Overexpressing Breast Cancer in Brazil"
Gilead Reports NDA Submission to the US FDA for Veklury (Remdesivir) to Treat COVID-19
Olympus to Acquire Arc Medical Design for Expanding its Product Portfolio
Bayer to Acquire KaNDy Therapeutics for Augmenting its Women's Healthcare Portfolio
Ligand to Acquire Pfenex for $516M
Medtronic to Acquire Companion Medical for Adding Smart Insulin Pen to its Diabetes Unit
BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) + CT Receive Health Canada Approval for Metastatic Non-Small Cell Lung Cancer
Sarepta Therapeutics Collaborates with University of Florida to Accelerate the Development of Therapies for Rare Genetic Diseases
Innovent and Eli Lilly Report sNDA Acceptance of Tyvyt (sintilimab) Combination Regimen as 1L Therapy in Squamous Non-Small Cell Lung Cancer in China
Roche Collaborates with Celleron Therapeutics for Emactuzumab to Treat Patients with Tenosynovial Giant Cell Tumor
Regeneron Reports the US FDA's Acceptance of Evinacumab's BLA for Priority Review as a Treatment for Patients with HoFH
Roche Reports the US FDA's Acceptance of sBLA for Xolair (omalizumab) Prefilled Syringe for Self-Administration Across All Indications
Alphabet's Verily Establishes CLIA-Certified Lab Focusing on COVID-19 Testing
Zydus Launches Cheapest Version of Remdesivir at $37.41 per Vial in India
Novo Nordisk Resumes P-III Study of Concizumab for Patients with Hemophilia A and B
Strata Oncology Collaborates with Mirati Therapeutics to Broaden Enrollment in Clinical Trial of MRTX849 for Patients with Advanced Solid Tumors
AstraZeneca to Initiate Production of its COVID-19 Vaccine Early in 2021
EC Concludes Exploratory Talks with J&amp;J to Supply 200M Doses of COVID-19 Vaccine
SK bioscience Collaborate with Novavax to Supply Antigen for COVID-19 Vaccine
Novavax Collaborates with UK Government to Supply 60M Doses of NVX-CoV2373 to Combat COVID-19
Solasia Signs a License Agreement with Isofol to Develop and Commercialize Arfolitixorin for mCRC in Japan
Sanofi to Acquire Principia Biopharma for ~$3.68B
Roche's Enspryng (satralizumab-mwge) Receives the US FDA's Approval for Neuromyelitis Optica Spectrum Disorder
BMS Signs an Exclusive Worldwide License Agreement with Dragonfly Therapeutics for DF6002
Abeona Signs a License and Inventory Purchase Agreements with Taysha for ABO-202 to Treat CLN1 Disease (Infantile Batten disease)
Henlius' HLX02 Receives the NMPA's Approval as the First Trastuzumab Biosimilar in China
Gilead Expands its Oncology Collaboration with Tango for ~$6.3B
AstraZeneca Collaborates with mAbxience to Produce COVID-19 Vaccine in Latin America
PTC Reports the EMA's Acceptance of MAA for Evrysdi (risdiplam) to Treat SMA
AstraZeneca's Imfinzi (durvalumab) Receives the US FDA's Priority Review for Less Frequent Fixed-Dose Use in NSCLC and Bladder Cancer
G1 Therapeutics Reports the US FDA Acceptance and Priority Review of NDA for Trilaciclib to Treat SCLC
Lilly and Innovent Report the Global Expansion of their Alliance for Tyvyt (sintilimab)
Regeneron Collaborates with Roche to Improve the Global Supply of REGN-COV2 Against COVID-19
Novo Nordisk Collaborates with Evotec to Develop Therapies Targeting Chronic Kidney Disease
Sanofi's Dupixent (dupilumab) Receives the Health Canada Approval for Severe Chronic Rhinosinusitis with Nasal Polyposis
Johnson & Johnson to Acquire Momenta Pharmaceuticals for $6.5B
The US FDA Rejects Gilead's Filgotinib Due to Toxicity Issues
Roche's Tecentriq + Bevacizumab Receive Health Canada's Approval as 1L Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
Fitbit Reports Results of its COVID-19 Study for Early Detection of Diseases
Qiagen Launches QIAseq SARS-CoV-2 Primer Panel for Tracking COVID-19 Mutations and Strains
Sorrento Files IND for STI-1499 (COVI-GUARD) in Patients Hospitalized with COVID-19
Precision BioSciences Receives the US FDA's Fast Track Designation for PBCAR0191 to Treat Advanced B-cell Precursor Acute Lymphoblastic Leukemia
BioSymetrics Signs an Agreement with Janssen and Sema4 to Utilize AI for the Prediction of COVID-19
Evotec and Centogene Expand their Collaboration to Target Gaucher Disease
Novartis' Kesimpta (ofatumumab) Receives the US FDA's Approval as the First Self-Administered Therapy for Relapsing Multiple Sclerosis
"Jazz Pharmaceuticals' Xywav (calcium, magnesium, potassium, and sodium oxybates) Receives the US FDA's Approval for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy"
MC2 Therapeutics Wynzora Cream Receives the US FDA's Approval to Treat Plaque Psoriasis in Adults
Osmotica's Upneeq Receives the US FDA's Approval to Treat Blepharoptosis (Droopy Eyelid) in Adults
Pfizer and BioNTech Plan for Regulatory Review of its COVID-19 Vaccine in October 2020
AstraZeneca's Imfinzi (durvalumab) Receives MHLW's Approval for Extensive-Stage Small Cell Lung Cancer
Acacia Pharma's Byfavo (remimazolam) Receives the US FDA's Approval for the Induction and Maintenance of Procedural Sedation
The US FDA Approves Kyprolis (carfilzomib) + Darzalex (daratumumab) + Dexamethasone in Two Dosing Regimens for R/R Multiple Myeloma
Junshi and Impact to Establish Joint Venture for Senaparib (IMP4297) in China
BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia
AstraZeneca Collaborates with RenalytixAI to Develop Precision Medicine for Chronic Diseases
Vertex's Kaftrio + Ivacaftor Receive the EC's Approval to Treat Cystic Fibrosis in People Aged 12 Years and Older
Chugai's Kadcyla (trastuzumab emtansine) Receives MHLW's Approval for Adjuvant Therapy of HER2-Positive Early Breast Cancer
Takeda to Divest its Consumer Health Unit to Blackstone for $2.3B in Japan
ReiThera Reports First Patient Dosing with its COVID-19 Vaccine Candidate in Italy
BMS to Acquire Forbius for its AVID200 to Expand its Footprints in Oncology and Fibrosis
Bayer and One Drop Collaborate to Develop Digital Therapies Across Multiple Therapeutic Areas
Novartis' Triple Regimen Fails to Meet the Primary Endpoint in P-III COMBI-i Study for Advanced Melanoma
Bionano Genomics Acquires Lineagen to Facilitate the Clinical Adoption of Saphyr for Digital Cytogenetics
Merck's Keytruda (pembrolizumab) Receives Two New PMDA's Approvals in Japan
AstraZeneca Initiates P-I Study of AZD7442 Against COVID-19
"BeiGene Signs a License and Supply Agreement with Bio-Thera for BAT1706 (biosimilar, bevacizumab) in China"
AbbVie Exercises its Option to License Morphosys' avß6 Integrin Inhibitor Program for Fibrotic Disease
AbbVie and Harvard University Collaborate to Develop Novel Therapies Against Emergent Viral Diseases
ACADIA Acquires CerSci Therapeutics for $52.5M
Takeda and Ovid Report Results of Soticlestat (TAK-935/OV935) in P-II ELEKTRA Study for Dravet Syndrome or Lennox-Gastaut Syndrome
Novartis Reports Results of Asciminib (ABL001) in P-III ASCEMBL Study for Chronic Myeloid Leukemia
Qiagen to Launch Digital Test for Detecting SARS-CoV-2 Antibodies in the US
Philips and B. Braun's Onvision Needle Tip Tracking Technology Receive the US FDA's 510 (k) Clearance for Regional Anesthesia
Takeda Collaborates with Engitix to Target Fibrotic Liver Diseases
"Lupin and Mylan Launch Nepexto (biosimilar, etanercept) in Germany"
GSK's Blenrep (belantamab mafodotin) Receives EC's Approval for R/R Multiple Myeloma
Celltrion Initiates P-I Study of CT-P59 Against COVID-19 in Korea
FDC Launches Two Variants of Favipiravir for COVID-19 in India
Abbott's BinaxNOW COVID-19 Ag Card Receives the US FDA's EUA to Detect SARS-CoV-2 Infection
BeiGene Signs an Exclusive License Agreement with Singlomics for Neutralizing COVID-19 Antibodies
Otsuka Inqovi (decitabine and cedazuridine) Received the US FDA's Approval to MDS and CMML
Amazon Enters into Fitness Space with the Launch of Halo Band and App
BioNTech and Fosun Pharma to Supply ~10M Doses of COVID-19 Vaccine to Hong Kong and Macao
Philips to Acquire Intact Vascular for $360M
Galecto's GB0139 Receives the US FDA's and EMA's Orphan Drug Designations for Idiopathic Pulmonary Fibrosis
Bayer Reports the NDA Submission to NMPA for Vericiguat to Treat Chronic Heart Failure in China
Taysha Gene Therapies' TSHA-101 Receives the US FDA's Orphan Drug Designation and Rare Pediatric Disease Designation for GM2 Gangliosidosis
Novartis Reports Results of LNP023 in P-II Study for Paroxysmal Nocturnal Hemoglobinuria
World's First App-Based Nicotine Addiction Treatment Receives the MHLW's Approval in Japan
AstraZeneca Reports Results of Farxiga (dapagliflozin) in P-III DAPA-CKD Trial for Patients With and Without Type-2 Diabetes
"Cadila Launches Cadalimab (biosimilar, adalimumab) in India"
Mylan and Biocon Launch Semglee (insulin glargine injection) as Vials and Pre-Filled Pen in the US
Ionis to Acquire Remaining Stake in Akcea Therapeutics for $18.5/share
Johnson & Johnson Collaborates with the Government of Canada to Supply its Ad26.COV2.S for COVID-19
AstraZeneca Expands the Development of AZD1222 into P-III Study in the US Across All Adult Age Groups
GSK and VIR Biotechnology Initiate P-II/III COMET-ICE Study of VIR-7831 Against COVID-19
AstraZeneca Expands Supply Agreement with Oxford Biomedica for AZD1222 to Combat COVID-19
Roche's Enspryng (satralizumab) Receives Health Canada Approval for Neuromyelitis Optica Spectrum Disorder
Roche's cobas HIV-1/HIV-2 Qualitative Test Receives the US FDA's Approval to Detect HIV Infection
Gilead Signs an Exclusive License Agreement with Jounce for Cancer Immunotherapies
AstraZeneca's Imfinzi (durvalumab) Receives EC's Approval as 1L Treatment for Extensive-Stage Small Cell Lung Cancer
Nestlé to Acquire Aimmune Therapeutics for $2.6B
Medtronic's MiniMed 770G Insulin Pump System with Smartphone Connectivity Receives the US FDA's Approval for Patients with Type 1 Diabetes
BMS' Onureg (azacitidine) Receives the US FDA's Approval as Continued Treatment for Acute Myeloid Leukemia
"Celltrion Plans to Initiate P-I Trial for its CT-P41 (biosimilar, denosumab) in September 2020"
Idorsia Transfers its Agreement with ReveraGen to Santhera for Vamorolone
"Formycon with its Partner BIOEQ Plans to Initiate P-III MAGELLAN-AMD Trial for its FYB203 (biosimilar, aflibercept)"
"Samsung Bioepis' Aybintio (SB8, biosimilar, bevacizumab) Receives the EC's Approval for Launch in EU"
"Cadila to Launch its Cadalimab (biosimilar, adalimumab) in India"
"Sandoz Canada Negotiated with Pan-Canadian Pharmaceutical Alliance (pCPA) to Launch Ziextenzo (biosimilar, pegfilgrastim) and Riximyo (biosimilar, rituximab) in Canada"
Boehringer Ingelheim Collaborates with BiomX to Discover Microbiome-Based Biomarkers for Inflammatory Bowel Disease
Sanofi And GSK Initiate P-I/II Study of COVID-19 Protein-Based Vaccine
Merck Signs a Second Oncology Collaboration with Highlight Therapeutics
Janssen Halts the Development of Pimodivir for Influenza
Baxter's Theranova Dialyzers Receives the US FDA's De Novo Authorization to Deliver HDx Therapy
Bicycle Reports First Patient Dosing in P-IIa Study of BT1718 for MT1-MMP-Positive Squamous NSCLC
Bio-Thera Initiates P-I Study of BAT2206 Proposed Biosimilar to Stelara (ustekinumab)
Eli Lilly's Trulicity (dulaglutide) Receives the US FDA's Approval for Additional Doses to Treat Type 2 Diabetes
Roche Receives the US FDA's EUA for cobas SARS-CoV-2 and Influenza A/B Test
"Innovent's Sulinno (biosimilar, adalimumab) Receives NMPA's Approval for Autoimmune Diseases"
Abbott Initiates LIFE-BTK Trial to Evaluate the Esprit BTK Drug-Eluting Resorbable Scaffold
Kite and HiFiBiO Therapeutics Collaborate to Develop Antibodies Targeting Acute Myeloid Leukemia
AbbVie to License I-Mab's Lemzoparlimab (TJC4) for ~$2B
Chi-Med Initiates P-III FRESCO-2 Study of Fruquintinib in Metastatic Colorectal Cancer
Kite Reports sBLA Submission to the US FDA for Yescarta (axicabtagene ciloleucel) in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas
Genentech' Gavreto (pralsetinib) Receives the US FDA's Approval Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
AstraZeneca to Present Results of Breztri Aerosphere in P-III ETHOS Study at ERS International Congress 2020
Grifols to Acquire Remaining Stake of Alkahest for ~$146M
Project ALS' Prosetin Receives the US FDA's Orphan Drug Designation for Amyotrophic Lateral Sclerosis
Boehringer Ingelheim and Pharmaxis Halt the Development of BI 1467335 for Diabetic Retinopathy
Mylan to Acquire Aspen's Thrombosis Business in the EU for ~ $758M
Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA TRAVERSE OLE Study for Asthma
Roche's cobas BKV Test Receives the US FDA's 510 (k) Clearance to Improve Treatment for Transplant Patients
Silence Therapeutics Highlights its R&amp;D Pipeline and Initiates Dose Escalation Studies for SLN360
Janssen's Imbruvica (ibrutinib) + Rituximab Receives the EC's Marketing Authorization for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Roche Expands its MS Portfolio with the Initiation of P-III Clinical Program of Fenebrutinib and Ocrevus (ocrelizumab)
Takeda Divests its Select Non-Core Assets in the EU and Canada to Cheplapharm for $562M
Theranica's Nerivio Wearable Device Receives CE Mark for Acute Treatment of Migraine in Europe
Merck Reports Results of Gefapixant (45mg) in Two P-III Studies for the Treatment of Refractory or Unexplained Chronic Cough
Regenxbio Reports First Patients Dosing in its P-II AAVIATE Study of RGX-314 for Wet AMD
Sanofi to Present New Data of its Neurology Portfolio at MSVirtual2020
Bayer Collaborates with Recursion to Fortify Digital Drug Discovery for Fibrotic Diseases
AstraZeneca Reports Results of Fasenra (benralizumab) in P-III OSTRO Study for Chronic Rhinosinusitis with Nasal Polyps
Pfizer and BioNTech to Supply 200M Doses of it COVID-19 Vaccine in the EU
Genentech to Present New Data of Enspryng (satralizumab-mwge) for Neuromyelitis Optica Spectrum Disorder at MSVirtual2020
Jazz Collaborates with Redx Pharma to Develop Two Targeted Cancer Therapies
Takeda Reports Results of Ninlaro (ixazomib) in a P-III Clinical Study for Newly Diagnosed Multiple Myeloma
"Henlius Reports NMPA's Acceptance of NDA for HLX04 (biosimilar, bevacizumab)"
Roche to Present New Data of Ocrevus (ocrelizumab) for Relapsing-Remitting Multiple Sclerosis at MSVirtual2020
GSK and Innoviva's Trelegy Ellipta (FF/UMEC/VI) Receive the US FDA's Approval for Asthma and COPD
Chugai and Takeda Collaborate to Evaluate the Combination Therapy for Multiple Tumor Types in Japan
Janssen Reports sBLA Submission to the US FDA for Darzalex Faspro (daratumumab and hyaluronidase-fihj) to Treat Patients with Light Chain (AL) Amyloidosis
Janssen's Tremfya (guselkumab) Receives the US FDA's Approval as the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis
Gilead to Acquire Immunomedics for ~$21B
AstraZeneca Resumes COVID-19 Vaccine Trials in the UK
Sanofi's Dupixent Receives the US FDA's Breakthrough Therapy Designation for Eosinophilic Esophagitis
Novartis Reports Results of Beovu (brolucizumab) in P-III KITE Study for Diabetic Macular Edema
Boehringer Ingelheim and Click Collaborate on Digital Therapy for Behaviour Modification in Schizophrenia
Merck Signs Up to $4.5B Oncology Deal with Seattle Genetics
Fitbit to Launch ECG App in the US and EU in October 2020
Eli Lilly and Incyte's Olumiant + Gilead's Veklury Reduce Time to Recovery in Hospitalized Patients with COVID-19
Janssen Collaborates with SpringWorks to Evaluate Nirogacestat + Teclistamab for Relapsed or Refractory Multiple Myeloma
Novartis' Beovu (brolucizumab) Receives EMA's Approval for its Safety Label Update to Treat Wet Age-Related Macular Degeneration
The US FDA Rejects Mallinckrodt's Terlipressin Due to Doubts in its Risk-Benefit Profile
Boehringer Ingelheim Reports Results of BI 425809 in P-II Study for Patients with Schizophrenia
"Merck's Brenzys (etanercept, biosimilar) Receives Health Canada Approval for Multiple Indications"
BMS Exercises its Option to Globally License Obsidian's CD40L Cell Therapy
Gilead's Magrolimab Receives the US FDA's Breakthrough Therapy Designation for Myelodysplastic Syndrome
Takeda to Divest TachoSil to Corza Health for ~$416M
Roche's CINtec PLUS Cytology Test Receives the US FDA's Approval to Aid Clinicians in Preventing Cervical Cancer
Eli Lilly Reports POC Data of LY-CoV555 in P-II BLAZE-1 Study for COVID-19 in Outpatient Setting
Baxter Signs an Exclusive Distribution Agreement With bioMérieux for Acute Kidney Injury Diagnostic Test in the US and EU
Novartis Reports Results of Dual regimen in P-III COMBI-AD Study for Patients with Stage III Melanoma
"Samsung Bioepis to Present P-III Exploratory Analyses Results of Aybintio (bevacizumab, biosimilar) at ESMO 2020"
Sorrento to Initiate P-I Study of STI-1499 in COVID-19 Positive Patients
Junshi and Wigen Collaborate to Develop and Commercialize Four Therapies Targeting Cancer Indications
Roche to Present its Oncology Portfolio at the ESMO Virtual Congress 2020
NS Phrama's Viltepso (viltolarsen) Receives the US FDA's Approval for Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping Therapy
Bayer's Lampit (nifurtimox) Receives the US FDA's Approval for Treatment of Chagas Disease in Children
Trevena's Olinvyk (oliceridine) Receives the US FDA's Approval for the Treatment of Central Nervous System
Novo Nordisk's Sogroya (somapacitan-beco) Receives the US FDA Approval for Adult Growth Hormone Deficiency
Cassiopea's Winlevi (Clascoterone Cream) Receives the US FDA's Approval for the Treatment of Acne Vulgaris
Recordati Rare Diseases' Cystadrops (Cysteamine Ophthalmic Solution) Receives the US FDA's Approval for the Treatment of Ocular Manifestations of Cystinosis
Innocoll's Xaracoll (bupivacaine HCl) Receives the US FDA's Approval for the Acute Postsurgical Pain Relief in Adults Following Open Inguinal Hernia Repair
GSK's Blenrep (belantamab mafodotin-blmf) Receives the US FDA's Approval as a Monotherapy Treatment for Multiple Myeloma
AstraZeneca Acquires Dogma Therapeutics' Oral PCSK9 Inhibitor Program
Eli Lilly Collaborates with Amgen to Boost the Global Supply of its COVID-19 Therapies
Roche Launches Elecsys Anti-SARS-CoV-2 S Test for COVID-19 Antibodies
AstraZeneca and MSD Report Five Year Data of Lynparza in P-III SOLO-1 Study for 1L Maintenance Treatment in Patients with BRCA-Mutated Ovarian Cancer
Roche Reports Results of Actemra in P-III EMPACTA Study in Patients with COVID-19 Associated Pneumonia
AstraZeneca Reports Updated Results of Imfinzi in P-III Studies for NSCLC and ES-SCLC
AstraZeneca Reports the Results of Tagrisso (osimertinib) in P-III ADAURA Study for the Adjuvant Treatment of Patients Early-Stage EGFR-Mutated Lung Cancer
Takeda Collaborates with Foundation Medicine for Lung Cancer CDx
Roche Acquires Inflazome for ~$450M
AstraZeneca and MSD's Lynparza (Olaparib) Receives the CHMP's Positive Opinion as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer
Bausch Health Acquires Option to Purchase Allegro's Ophthalmology Assets
Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020
Lilly's Olumiant (baricitinib) Receives CHMP's Positive Opinion for Moderate to Severe Atopic Dermatitis
Novartis' Kisqali (ribociclib) Receives Highest Score on the ESMO Magnitude of Clinical Benefit Scale
Genentech Collaborates with Scenic Biotech to Develop Novel Therapies Targeting Genetic Modifiers
Alexion's Ultomiris (ravulizumab) Receives the CHMP's Positive Opinion for its New Advanced Formulation
Illumina to Acquire GRAIL for ~$8B
BMS' Inrebic (fedratinib) Receives Health Canada's Approval for Patients with Myelofibrosis
UCB Reports the FDA's and EMA's Acceptance of BLA and MAA for Bimekizumab to Treat Moderate to Severe Plaque Psoriasis
Novartis to Initiate Pivotal Confirmatory Study of AVXS-101 Intrathecal Formulation in Older Patients with SMA
BMS and bluebird bio Report the US FDA's Acceptance of Idecabtagene Vicleucel's BLA for Priority Review to Treat Multiple Myeloma
Micreos Initiates P-I/IIa Study Evaluating XZ.700 as the World's First Endolysin Therapy for Atopic Dermatitis
Sanofi's Supemtek Receives CHMP's Positive Opinion for Approval to Prevent Influenza
Pfizer Reports the US FDA's Acceptance of Xalkori's (crizotinib) sNDA for Pediatric Patients with R/R Systemic ALCL
J&J Initiates Global P-III Clinical Study of its COVID-19 Vaccine
Novartis and Siemens Collaborate to Develop Blood Tests for Multiple Sclerosis
Genentech and AC Immune's Semorinemab Flounders in P-II TAURIEL Study for Early Alzheimer's Disease
Pear Therapeutics Reports the Availability of its Prescription Digital Therapeutics to Wellpath Community Care Centers
Verona Initiates P-III ENHANCE Studies Evaluating Nebulized Ensifentrine for the Maintenance Treatment of COPD
IDEAYA and Pfizer Expand CTC and Supply Agreement for Solid Tumors Harboring GNAQ or GNA11 Mutations
"Accord Launches Zercepac (biosimilar, trastuzumab) in the UK"
Novavax Initiates P-III Study of its COVID-19 Vaccine in the UK
Roche's Polivy (polatuzumab vedotin) Receives Health Canada's Approval For R/R Diffuse Large B Cell Lymphoma
Medtronic Evaluates Insertable Cardiac Monitor to Identify Patients at High Risk of Worsening Heart Failure
BMS Reports Results of Opdivo (nivolumab) in P-III CheckMate -274 Study for Patients with High-Risk Muscle-Invasive Urothelial Carcinoma
Philips Launches QuickClear Mechanical Thrombectomy System for Blood Clot Removal
Roche Reports Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA
Gilead's Jyseleca (filgotinib) Receives the MHLW's Approval for Rheumatoid Arthritis in Japan
Chugai's Tecentriq (atezolizumab) and Avastin (bevacizumab) Receive MHLW's Approval as 1L Treatment for Unresectable Hepatocellular Carcinoma
GSK's Nucala (mepolizumab) Receives the US FDA's Approval as the First Treatment for Hypereosinophilic Syndrome
Innovent Report Results of Dual Regimen in P-III ORIENT-32 Study as 1L Therapy for Advanced HCC
Pfizer Initiates Clinical Study of Eighth Candidate Emerges Under the Collaboration with Sosei Heptares
Sarepta Reports Two-Year Follow Up Results of SRP-9001 for Duchenne Muscular Dystrophy
AbbVie's Elezanumab (ABT-555) Receives the US FDA's Orphan Drug and Fast Track Designation for Spinal Cord Injury
Pfizer's Xeljanz (tofacitinib) Receives the US FDA's Approval for Active Polyarticular Course Juvenile Idiopathic Arthritis
CSL Behring's Haegarda (C1 Esterase Inhibitor) Receives the US FDA's Approval for Pediatric Patients with Hereditary Angioedema
Boston Scientific Launches ACURATE neo2 Aortic Valve System in Europe
Inovio Reports FDA's Partial Clinical Hold on P-II/III Trial of INO-4800 Against COVID-19
Regeneron's REGN-COV2 Demonstrate Reduction in Viral Load and Improve Symptoms in Non-Hospitalized Patients with COVID-19
BMS's Reblozyl (luspatercept) Receives Health Canada Approval for Beta Thalassemia
Abbott's FreeStyle Libre 3 System Receives CE Mark in Europe
Galapagos Reports First Patients Dosing with GLPG3970 (Toledo Compound) for Psoriasis
Junshi Reports Results of Dual Regimen in P-III Jupiter-02 Study as 1L Therapy for Nasopharyngeal Carcinoma
Medtronic to Acquire Avenu Medical
Sanofi Launches Tetraxim (DTaP-IPV) for Preschoolers in India
"Henlius Signs an Exclusive License Agreement with Accord for HLX02 (biosimilar, trastuzumab) in the US and Canada"
"Janssen Reports the NDA Submission to the US FDA for Uptravi (selexipag, IV) to Treat Pulmonary Arterial Hypertension"
Lotus Signs an Exclusive Commercialization Agreement with CKD for Biosimilar Darbepoetin Alfa
Alnylam Reports Results of Lumasiran in P-III ILLUMINATE-B Study for Primary Hyperoxaluria Type 1 in Children Under the Age of Six
Moderna's mRNA-1273 COVID-19 Vaccine Demonstrate Immune Responses in Older Adults
Sobi & Selecta Report Results of SEL-212 in P-II COMPARE Study for Chronic Refractory Gout
Alvotech and DKSH Extend their Collaboration to Commercialize Six Biosimilars in Asia
"Henlius Reports First Patient Dosing with HLX11 (biosimilar, pertuzumab) for HER2-Positive Metastatic Breast Cancer and Early Breast Cancer"
"Henlius Presents P-III Data of HLX04 (biosimilar, bevacizumab) at CSCO 2020"
"Henlius Present P-III Data of HLX02 (biosimilar, trastuzumab) at ESMO"
Neuclone Discloses Two Biosimilars Referencing Opdivo (nivolumab) and Keytruda (pembrolizumab)
AstraZeneca Resumes Clinical Study of its COVID-19 Vaccine in Japan
Amgen Report Five Year Data of Aimovig (erenumab-aooe) in Open-Label Treatment Period of P-II Study for Episodic Migraine
Novartis Reports Results of Zolgensma in P-III STR1VE-EU Study for SMA Type 1
AstraZeneca's Farxiga Receives the US FDA's Breakthrough Therapy Designation for Chronic Kidney Disease
STADA Expands its Specialty Footprint with the Acquisition of Lobsor Pharmaceuticals
BMS to Acquire MyoKardia for ~$13.1B
GSK and AstraZeneca Plan to Deploy NVIDIA's Supercomputer for Drug Development
Novartis Reports Results of Beovu (brolucizumab) in Two New Post-Hoc Analyses of P-III HAWK and HARRIER Studies for Wet AMD
Pfizer Signs an Agreement with SpringWorks to Evaluate Nirogacestat + PF-06863135 for R/R Multiple Myeloma
Amgen Report Results of Sotorasib in P-II CodeBreaK 100 Study for Advanced Non-Small Cell Lung Cancer
GSK's Zejula (niraparib) Receives Health Canada Approval for 1L Treatment of Women with Advanced Ovarian Cancer
Santhera Halts P-III SIDEROS Study Evaluating Puldysa in Patients with DMD
Qiagen to Launch Viral RNA Epidemiology Test for COVID-19 and Other RNA Viruses
PhaseBio Reports First Patients Dosing in its P-III REVERSE-IT Study of Bentracimab in Canada
Merck Signs an Out-Licensing Agreement with Novartis for M6495 (Anti-ADAMTS5 Nanobody) for Osteoarthritis
"BioNTech and Pfizer Initiates Rolling Submission to EMA for SARS-CoV-2 Vaccine Candidate, BNT162b2"
"Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11 (biosimilar, ranibizumab)"
GSK Signs an Agreement with Vir Biotechnology to Develop Solutions for Coronaviruses
Exact Sciences and Pfizer Announce Extension and Amendment of their Cologuard Promotion Agreement
Eli Lilly Seeks the US FDA's EUA for its COVID-19 Antibody Treatment
Polarean Reports the NDA Submission of Hyperpolarised 129Xenon Gas Drug-Device Diagnostic to the US FDA for Lung Imaging
BMS Report Results of Opdivo (nivolumab) + CT in P-III CheckMate-816 Trial for Resectable Non-Small Cell Lung Cancer
Eli Lilly Collaborates with Dexcom for Diabetes Management
BMS' Zeposia (ozanimod) Receives Health Canada Approval for Relapsing Remitting Multiple Sclerosis
BioMarin Receives the US FDA's Approval Allowing Maximum Dose of 60mg with Palynziq (pegvaliase-pqpz) for PKU
Lilly and Incyte's Olumiant (baricitinib) Reports Additional Data Demonstrating Reduction in COVID-19 Recovery Time
Neurocrine Presents New Data Analyses of Ongentys (opicapone) for Parkinson Disease at ANA 2020 Virtual Meeting
Genentech Collaborates with Imbio to Develop Imaging Diagnostics for Lung Diseases
J&amp;J to Supply EU with up to 400M Doses of its COVID-19 Vaccine
Amgen Report Mixed Results of Omecamtiv Mecarbil in P-lll GALACTIC-HF Study for Heart Failure
Regeneron Seeks the US FDA's EUA for REGN-COV2 Antibody Combination to Treat COVID-19
Takeda Signs ~$1B Pact with Arrowhead for ARO-AAT Targeting Alpha-1 Antitrypsin-Associated Liver Disease
Pfizer's Ibrance (palbociclib) Fails to Meet its Primary Endpoint in P-lll PENELOPE-B Study for Early Breast Cancer
AstraZeneca Advances its AZD7442 in Two P-III Clinical Studies for COVID-19
True Digital Surgery and Aesculap Launch Aesculap Aeos Robotic Digital Microscope in US
"Innovent and Lilly's Halpryza (biosimilar, rituximab) Receive NMPA's Approval in China"
Novartis's Iptacopan (LNP023) Receives EMA's Prime Designation for C3 Glomerulopathy
Janssen Reports Results of Tremfya (guselkumab) in Interim Analysis of P-II GALAXI 1 Study for Moderately to Severely Active Crohn's Disease
Janssen Reports Five-Year Data of Stelara (ustekinumab) in P-lll LTE Study for Severe Crohn's Disease
Takeda Reports Results of Entyvio (vedolizumab) in Interim Analysis from VISIBLE OLE Study for Moderately to Severely Active Ulcerative Colitis
Lilly Reports Results of Mirikizumab in P-ll SERENITY Study for Crohn's Disease
Abbott's AdviseDx SARS-CoV-2 IgM Test Receives the US FDA's EUA for COVID-19
Gilead and Galapagos Report Results of Filgotinib in P-llb/lll SELECTION Study for Ulcerative Colitis
Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA VOYAGE Study in Children with Asthma
Roche to Launch Elecsys SARS-CoV-2 Antigen Test for Suspected COVID-19 Patients
J&amp;J Pauses Dosing in COVID-19 Vaccine Studies Due to Unexplained Illness
Linnaeus Reports First Patients Dosing with LNS8801 + Keytruda (pembrolizumab) in P-I/II Study for Advanced Cancer
Celltrion Launch P-III Post-Exposure Prophylaxis Clinical Trial of CT-P59 for COVID-19
Moderna Initiates Rolling Submission to Health Canada for mRNA-1273 Against COVID-19
Prestige's PBP1510 Receives EMA's Positive Opinion on Orphan Designation for Pancreatic Cancer
Boehringer Ingelheim Presents Results of Gilotrif (afatinib) for NSCLC at IASLC NACLC 2020
Roche Signs a License Agreement with Dyno to Develop AVV Gene Therapy for ~$1.8B
"Regeneron's Inmazeb (atoltivimab, maftivimab, and odesivimab) Receives the US FDA's Approval as the First Treatment for Ebola"
Takeda Collaborates with Accenture and AWS to Transform into a Cloud-Based Company
Bayer Report Results of Aliqopa (copanlisib) + Rituximab in P-III CHRONOS-3 Study for Relapsed Indolent Non-Hodgkin's Lymphoma
RadioMedix and Curium Detectnet (copper Cu 64 dotatate injection) Receives US FDA's Approval for Positive Neuroendocrine Tumors (NETs)
Athena Bioscience's Qdolo (tramadol hydrochloride) Receives US FDA's NDA Approval for Oral Solution
Sorrento to Initiate P-II Study of STI-5656 (abivertinib maleate) for COVID-19 in Brazil
Eton Pharmaceutical's Alkindi Sprinkle (hydrocortisone) Receives US FDA's Approval as Replacement Therapy in Pediatric Patients
Eli Lilly Pauses Enrollment in ACTIV-3 Clinical Trial Due to Safety Concerns
Eli Lily to Acquire Disarm Therapeutics for ~$1.36B
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Relapsed or Refractory Classical Hodgkin Lymphoma
Chugai Reports NDA Submission of Risdiplam to the MHLW as the First Oral Drug for SMA in Japan
Sanofi and Translate Bio to Advance MRT5500 into Clinical Study Against COVID-19
Galapagos &amp; Servier's GLPG1972/S201086 Fails to Meet its Primary Endpoint in P-II ROCCELLA Study for Knee Osteoarthritis
Novartis's Luxturna (voretigene neparvovec) Receives Health Canada Approval as the First Gene Replacement Therapy for Inherited Retinal Disease
Novartis' Leqvio (inclisiran) Receives CHMP's Positive Opinion for Approval to Treat Hypercholesterolemia
AbbVie and Roche's Venclexta (venetoclax) Receive the US FDA's Approval for Acute Myeloid Leukemia
"Henlius Signs a License Agreement with Essex to Co-develop HLX04 (biosimilar, bevacizumab) for Ophthalmic Diseases"
AstraZeneca's Trixeo Aerosphere Receives CHMP's Recommendation for Approval to Treat COPD
Janssen's Tremfya (guselkumab) Receives CHMP's Positive Opinion for Approval to Treat Active Psoriatic Arthritis (PsA)
Sanofi's Sarclisa (isatuximab) Receives NICE Recommendation for Patients with Multiple Myeloma
Roche Collaborates with Genesis Therapeutics for AI-Driven Drug Discovery
ImmunoGen Signs an Agreement with Huadong to Develop &amp; Commercialize Mirvetuximab Soravtansine in Greater China
AbbVie Submits Regulatory Applications to the US FDA and EMA for Rinvoq (upadacitinib) to Treat Atopic Dermatitis
Endo to Acquire BioSpecifics for ~ $540M
AstraZeneca's Tagrisso (osimertinib) Receives the US FDA's Priority Review for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer
Bayer and 111 Collaborate to Explore the Vast Blue Ocean of Online Healthcare in China
Samsung Biologics Collaborates with Dinona to Develop DNP-019 for COVID-19
Lilly's Taltz (ixekizumab) Receives Health Canada Approval for Non-Radiographic Axial Spondyloarthritis
Roche and Prothena to Advance Prasinezumab in P-IIb Study for Patients with Early Parkinson's Disease
"NeuClone Reports Positive Results of NeuLara (biosimilar, ustekinumab) in P-l Study for Autoimmune Diseases"
StageBio Acquires TPL Path Labs to Expand its Footprints Globally
"Jazz Reports Results of Xywav (calcium, magnesium, potassium, and sodium oxybates) in P-III Study for Cataplexy or EDS in Patients with Narcolepsy"
AWS and Onica Collaborate with Teva to Support its Digihaler Portfolio
Novo Nordisk Signs a License Agreement with Chugai for Antibody Engineering Technologies
Novartis's Branaplam (LMI070) Receives the US FDA's Orphan Drug Designation for Huntington's Disease
ViiV Healthcare Present Results of Long-Acting Cabotegravir and Rilpivirine at IDWeeK 2020
Roche Collaborates with Atea Pharmaceuticals to Develop AT-527 for COVID-19
GSK Presents Results of Maternal &amp; Older Adults RSV Vaccines at IDWeek 2020
Dicerna Presents New Interim Data of PHYOX 3 OLE Study Evaluating Nedosiran for Primary Hyperoxaluria at ASN Week 2020
Gilead's Veklury (remdesivir) Receives the US FDA's Approval as the First Treatment for COVID-19
UCB's Vimpat (lacosamide) Receives CHMP's Positive Opinion for Primary Generalized Tonic-Clonic Seizures
Daiichi Sankyo Initiates P-I Study of DS-1055 for Relapsed/Refractory Advanced or Metastatic Solid Tumors
Sanifit Presents Results of SNF472 for the Treatment of Vascular Calcification at ASN Kidney Week 2020
Akebia Presents Results of Vadadustat in P-lll INNO2VATE Program for Anemia Due to CKD at ASN Kidney Week
AstraZeneca Resumes P-III Study of AZD1222 Against COVID-19 in the US
Eisai and Cogstate Expand their Agreement to Develop and Commercialize Digital Cognitive Assessment Technologies
Boehringer Ingelheim and Eli Lilly Report Results of Jardiance in Adults with HFrEF Regardless of Chronic Kidney Disease Status
AstraZeneca Presents Results of Farxiga (dapagliflozin) in P-lll DAPA-CKD Study for Chronic Kidney Disease at ASN Kidney Week 2020
Foundation Medicine's FoundationOne CDx Receives the US FDA's Approval as a CDx for Vitrakvi (larotrectinib)
Bayer Acquires Asklepios for ~$4B
Jazz Pharmaceuticals Acquires SpringWorks' FAAH Inhibitor Program for Post-Traumatic Stress Disorder
"Samsung Bioepis Reports Results of Renflexis (biosimilar, infliximab) from Two Studies in IBD Patients"
Sanofi and Regeneron Report Results of Dupixent (dupilumab) in Part A of P-lll Study for Eosinophilic Esophagitis (EoE)
Novartis Presents Results of Iptacopan (LNP023) in P-ll Study for C3 Glomerulopathy at ASN Annual Meeting 2020
CStone Signs an Out-Licensing Agreement with EQRx for Sugemalimab and CS1003
Exact Sciences to Acquire Thrive Earlier Detection for ~$2.15B
Sanofi Presents Results of Olipudase Alfa in Two Clinical Studies at ASHG 2020
Novartis Signs an Option and License Agreement with Molecular Partners to Develop Two DARPin Therapies for COVID-19
Thermo Fisher Expands its Direct-to-Patient Service Offerings
AstraZeneca's Forxiga (dapagliflozin) Receive NMPA's Approval for Label Update to Include Data of P-III DECLARE-TIMI 58 Study
Dermavant Presents Results of Tapinarof in Pivotal P-III PSOARING Program at the 29th EADV Virtual Congress
BMS Signs a Five-Year Agreement with Insitro to Develop Therapies for ALS and Frontotemporal Dementia
Lilly Reports Results of Bamlanivimab (LY-CoV555) in P-II BLAZE-1 Study in New England Journal of Medicine
Novartis Acquires Vedere Bio for $280M
CStone Signs a License Agreement with LegoChem for LCB71 to Treat Multiple Cancer Indications
Boehringer Ingelheim Initiates P-II Study of BI 764198 for Patients with Severe Respiratory Illness from COVID-19
Roche's Tecentriq in Combination with Avastin Receives China NMPA's Approval for the Treatment of Unresectable Hepatocellular Carcinoma
AstraZenca Reports Results of Fasenra (benralizumab) in P-lllb PONENTE Trial for Asthma
Sanofi Entered into an Agreement with Merck to Conduct a P-II Study of THOR-707 in Sequenced Administration with MSD's KEYTRUDA (pembrolizumab) in Patients with Various Cancers
AbbVie Reports Results of SKYRIZI (risankizumab) in P-III LIMMitless Study in Patients with Moderate to Severe Plaque Psoriasis
GSK's Zejula (niraparib) Receives EC's Approval as a Treatment in Advanced Ovarian Cancer
AstraZenca Expands Supply Agreement with Cheplapharm for Atacand (candesartan cilexetil) and Atacand Plus (candesartan cilexetil + hydrochlorothiazide) to Cheplapharm
UCB Reports Results of Bimekizumab in P-III BE SURE Study for Moderate-to-Severe Psoriasis
Regeneron Pauses Dosing of Garetosmab (REGN2477) in P-II LUMINA-1 Study for Fibrodysplasia Ossificans Progressiva
Medtronic Expands ENT Portfolio with the Acquisition of Ai Biomed and the Approval of NIM Vital Nerve Monitoring System
Sun Pharma Reports Five Year Results of Ilumya (tildrakizumab-asmn) in P-III Studies for Moderate-to-Severe Plaque Psoriasis
Novartis Reports Results of Aimovig (erenumab) in P-lV Study for Episodic and Chronic Migraine
Sanofi to Acquire Kiadis for ~$358M
Janssen Reports sNDA Submission of Paliperidone Palmitate 6-Month (PP6M) to the US FDA for Schizophrenia
Tetra Therapeutics Reports Positive Results of BPN14770 in P-II Study for Fragile X Syndrome
AstraZeneca and Fusion Collaborate to Develop and Commercialize Radiopharmaceuticals and Combination Therapies for Cancer
"Celltrion Presents Results of CT-P17 (biosimilar, adalimumab) in P-III Study for RA at ACR 2020"
Roche's Tecentriq (atezolizumab) + Avastin (bevacizumab) Receive the EC's Approval for Unresectable Hepatocellular Carcinoma
Novartis Reports Results of Kisqali (ribociclib) in P-III MONALEESA-7 Study in Women with HR+/HER2- Advanced Breast Cancer
BMS' Deucravacitinib (BMS-986165) Demonstrate Superiority Over Amgen' Otezla (apremilast) in P-III POETYK PSO-1 Study for Plaque Psoriasis
SomaLogic Collaborates with the US FDA to Advance Biosimilar Development
CEPI to Invest ~$328M in Clover's COVID-19 Vaccine Candidate
Boston Scientific's Ranger DCB Receives the US FDA's Approval for Peripheral Artery Disease in the SFA and PPA
Biomarin Reports the US FDA's Acceptance of Vosoritide's NDA to Treat Children with Achondroplasia
Jounce Stops Enrollment in P-II EMERGE Study Evaluating Vopratelimab for Lung Cancer
Abbott to Launch its Cardiac Mapping Platform in Europe and Australia
Medicure Signs Agreement with Reliance Life Sciences for Marketing Rights of a Cardiovascular Biosimilar
"Henlius Present Results of HLX03 (biosimilar, adalimumab) in P-lll Study for Plaque Psoriasis at EADV 2020"
BioInvent Presents New Clinical and Preclinical Data of BI-1206 at ASH Annual Meeting
Innovent and Lilly Report Results of Tyvyt (sintilimab) in Seven Clinical Studies to be Presented at the ESMO ASIA Congress 2020
Novartis Reports Results of Cosentyx (secukinumab) in P-IIIb ULTIMATE Study for Psoriatic Arthritis
Novavax Collaborates with Commonwealth of Australia to Supply 40M doses of NVX-CoV2373 for COVID-19
Coloplast Acquires Nine Continents Medical
Merck to Acquire VelosBio for $2.75B
AstraZeneca's Forxiga (dapagliflozin) Receives EC's Approval for Heart Failure
Merck KGaA Collaborates with Iktos to Deploy AI in New Drug Design
AstraZeneca and MSD's Lynparza (olaparib) Receive EU's Approval as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer
"Formycon Reports BLA Resubmission Strategy for FYB201 (biosimilar, ranibizumab)"
Novo Nordisk to Acquire Emisphere Technologies for $1.8B
AstraZeneca's Brilinta (ticagrelor) Receives the US FDA's Approval to Reduce the Risk of Stroke in Patients with an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
Merck and Transcenta Collaborate to Implement Continuous Manufacturing for Protein Therapeutics
The US FDA's Advisory Panel Slams Biogen's Aducanumab for Alzheimer's Disease
Eisai Reports Results of Lenvima (lenvatinib) + Everolimus in P-II 218 Study for Advanced Renal Cell Carcinoma
Alvotech and Cipla Collaborate to Ensure Access to Biosimilars in South Africa
Celltrion Reports Results of CT-P59 in P-I Study for COVID-19
Novartis' Ilaris (canakinumab) Fails to Meet its Primary Endpoints in P-lll Study for COVID-19 Pneumonia and CRS
AstraZeneca's Calquence (acalabrutinib) Receives EU's Approval for Chronic Lymphocytic Leukaemia
Pfizer and BioNTech's BNT162b2 Demonstrates 90% Efficacy in Preventing COVID-19
Lilly's Bamlanivimab (LY-CoV555) Receives the US FDA's EUA for the Treatment of Recently Diagnosed COVID-19
Bayer Reports Regulatory Submission of Finerenone (BAY 94-8862) to the US and EU for CKD and T2D
AstraZeneca and Amgen Report Results of Tezepelumab in P-III NAVIGATOR for Asthma
Novavax Receives the US FDA's Fast Track Designation for NVX-CoV2373 to Treat COVID-19
"Henlius Reports First Patients Dosing in P-I Study of HLX14 (denosumab, biosimilar)"
NightWare Receives the US FDA's Approval for the First Medical Device to Stop NightMAres Related to PTSD
Abbott Launches IonicRF Generator for Patients with Chronic Pain in the US
Samsung Bioepis Initiates P-I Study of SB16 Proposed Biosimilar to Prolia (denosumab)
"Prestige Signs an Exclusive Agreement with Teva to Commercialize Tuznue (biosimilar, trastuzumab) in Israel"
CureVac Publishes Results of CVnCoV in Interim P-l Study for COVID-19
J&J Resumes all Clinical Trial of its COVID-19 Vaccine in the EU
Moderna Report Results of mRNA-4157 + Keytruda in Interim P-l Study for HNSCC and MSS-CRC
Pfizer Reports Results of Abrocitinib in Fifth P-lll JADE REGIMEN Across Different Dosing Regimens
Pfizer and BioNTech to Supply EU with up to 200M Doses of BNT162B2 Against COVID-19
Qiagen Collaborate with TScan to Develop T Cell-Based COVID-19 Test
AstraZenca's Calquence (acalabrutinib) Fails to Meet its Primary Endpoint in P-II Studies for COVID-19
Medtronic Launches InPen Integrated with CGM Data for People with Diabetes on MDI
UCB Acquires Handl Therapeutics to Augment its Gene Therapy Portfolio
Health2Sync Divulges Benefits of Integrating Fitbit Wearable Devices into Diabetes Care in Taiwan
GSK and Medicago Initiate P-II/III Study of its Plant-Derived COVID-19 Vaccine
Qiagen Launches Portable Digital SARS-CoV-2 Antigen Test in the US
BD Acquires the Medical Business Assets of CUBEX
Microsoft Collaborates with Twist and Illumina to Advance Data Storage in DNA
J&amp;J and US Government Amends their Agreement for the Next Phase of COVID-19 Vaccine Development
Eisai's Fycompa (perampanel) Receives EC's Approval for Expanded Indication in Pediatric Patients with POS and PGTCS
Roche's Xofluza (baloxavir marboxil) Receives CHMP's Recommendation for Approval to Treat Influenza
Eli Lilly Signs a License Agreement with Seed Therapeutics for Protein Degradation-Based Therapies
"Henlius Report the NMPA's Acceptance of HLX15 (biosimilar, Daratumumab) to Treat Multiple Myeloma"
Bharat Biotech Initiates P-III Study for Covaxin Against COVID-19
Moderna's mRNA-1273 Demonstrates 94.5% Efficacy in Preventing Symptomatic COVID-19
Zymeworks and ALX Oncology Collaborate to Evaluate Zanidatamab + ALX148 for Advanced HER2-Expressing Breast Cancer
Roche Signs a License Agreement with Lead Pharma to Develop Oral Therapies for Immune-Mediated Diseases
Johnson &amp; Johnson Initiates Second Global P-III Study of its COVID-19 Vaccine
QBiotics' Stelfonta (tigilanol tiglate) Receives the US FDA's Approval as the First Treatment for Non-Metastatic MCT in Dogs
Bayer's Finerenone Demonstrates Positive Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes
ViiV Healthcare's Cabotegravir Receives US FDA's Breakthrough Therapy Designation for HIV Prevention
Sanofi's Avalglucosidase alfa Receives US FDA's Priority Review as Enzyme Replacement Therapy for Pompe Disease
"Pfizer Launches US Pilot Programme for Delivery and Distribution of COVID-19 Vaccine, BNT162b2"
BioMarin Pharmaceutical Signs an Agreement with Deep Genomics on Advancing Programs Identified Using Artificial Intelligence
"Samsung Bioepis and Biogen Announces FDA Filing Acceptance of Lucentis' Biosimilar, SB11 for Retinal Vascular Disorders"
Sanofi's Supemtek (quadrivalent recombinant influenza vaccine) Receives the EC's Approval to Prevent Influenza
Pfizer and BioNTech's BNT162b2 Demonstrates 95% Efficacy in Preventing COVID-19
Pear Therapeutics Launches Somryst Insomnia App Via an End-to-End Virtual Care Experience
ViiV's PROgress Study Demonstrates Inclusion of PROs into Clinical Practice Can Improve HIV Care
Bayer to Fund Five New Startup Companies as Part of G4A Digital Health Partnerships Program
Lucira's All-In-One Test Kit Receives the US FDA's EUA as the First COVID-19 Test for Self-Testing at Home
Nevakar's Ephedrine Sulfate Injection Receives the US FDA's Approval as Ready-To-Use Vials
Kala Pharmaceuticals' Eysuvis (loteprednol etabonate ophthalmic suspension) Receives US FDA's Approval for Dry Eye Disease
Chiesi's Bronchitol (mannitol) Inhalation Powder Receives the US FDA's Approval for Cystic Fibrosis
Alvotech Reports the US FDA and EMA's Acceptance of AVT02 Proposed Biosimilar to Humira (adalimumab)
Novartis Signs a License Agreement with Mesoblast to Develop and Commercialize Remestemcel-L for ARDS
Eli Lilly and Incyte Receive FDA's EUA for Baricitinib + Remdesivir to Treat Hospitalized Patients with COVID-19
Lilly Signs Agreement with Ypsomed to Advance an Automated Insulin Delivery System for People with Diabetes
Pfizer And LianBio Collaborate to Expand the Development of Novel Therapeutics in Greater China
AstraZenca's Imfinzi (durvalumab) Receives the US FDA's Approval for Less-Frequent Fixed-Dose Use
Regeneron's Casirivimab and Imdevimab Receive the US FDA's EUA as the First Combination Therapy for COVID-19
Lilly's Bamlanivimab (LY-CoV555) Receives Health Canada's Interim Authorization as a Treatment for COVID-19
"Innovent Reports Results of Tyvyt + Byvasda (biosimilar, bevacizumab) in P-lll ORIENT-32 Study as 1L Treatment for HCC"
Eiger's Zokinvy (lonafarnib) Receives the US FDA's Approval for Treatment of Progeria and Processing-Deficient PL
Eli Lilly Signs an Exclusive Agreement with Precision BioSciences on Genome Editing Research
AstraZeneca's AZD1222 Meets its Primary Endpoint in Preventing COVID-19
Merck to Acquire OncoImmune for $425M
Schrödinger Signs a $2.7B Agreement with BMS to Develop and Commercialize Therapies in Multiple Disease Areas
Baxter's Homechoice Claria APD System Receives the US FDA's 510 (k) Clearance for Kidney Failure
Roche's Xofluza (baloxavir marboxil) Receives the US FDA's Approval for Post-Exposure Prevention of Influenza
Targovax Reports Results of ONCOS-102 in P-l/ll Study as 1L and 2L Treatment for Malignant Pleural Mesothelioma
Selvita to Acquire Fidelta from Galapagos for ~$37M
BMS' Opdivo (nivolumab) Receives EC's Approval as 2L Treatment for Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma
Alnylam's Oxlumo (lumasiran) Receives the US FDA's Approval for Treatment of Primary Hyperoxaluria Type 1 in Pediatric and Adult Patients
Alvotech and Alvotech & CCHT Sign an Exclusive Commercialization Agreement with Yangtze River for Eight Biosimilars in China
Russia's Sputnik V Demonstrates 91.4% Efficacy Against COVID-19
Evotec Collaborates with Rappta Therapeutics to Focus on Oncology Target
Bausch Health Initiates Second P-III Study for NOV03 (perfluorohexyloctane) to Treat DED Associated With MGD
Janssen's Tremfya (guselkumab) Receives EC's Approval as a First in Class Treatment for Active Psoriatic Arthritis
Bio-Thera Reports MAA Submission to EMA for BAT1706 a Proposed Biosimilar to Avastin
Urovant's Vibegron Fails to Meet its Primary Endpoint in P-IIa Study for IBS Pain
BioNTech and Fosun Pharma Initiate P-ll Study of BNT162b2 Against COVID-19 in China
CorticoMetrics's THINQ Receives the US FDA's 510(k) Clearance for MRI Brain Volumetric Reporting
Y-mAbs' Danyelza (naxitamab-gqgk) Receives the US FDA's Approval for Neuroblastoma
Merck KGaA Reports EMA's Validation of MAA for Tepotinib to Treat Advanced NSCLC with METex14 Skipping Alterations
Egle Identifies First Novel Regulatory T-cell Targets Under its Collaboration with Takeda
Merck Collaborates with Siemens for the Digitalization of Production
CoSara Receives CDSCO's Approval for its Saragene COVID-19 2-Gene Multiplex Test
PostEra Collaborates with NeuroLucent to Identify Therapies for Alzheimer's Disease
BASE10 Collaborates with DNA Link to Support Authorization of COVID-19 IgG Antibody Test at the Point of Care
Glenmark to Divest Select Anti-Allergy Brands to Dr. Reddy's in Russia and Other CIS Countries
Moderna Amends its Agreement with UK Government for an Additional 2M Doses of COVID-19 Vaccine
Shionogi Receives MHLW's Approval for Xofluza's sNDA to Treat Post-Exposure Prophylaxis of Influenza Virus Infection
Shionogi and Nagasaki University Collaborate with the Kitasato Institute for Antimalarial Drugs
AbbVie and Eisai's Humira (adalimumab) Receives MHLW's Approval for Pyoderma Gangrenosum
AstraZeneca's Forxiga (dapagliflozin) Receives MHLW's Approval for Chronic Heart Failure
Moderna to Seek the FDA and EMA's EUA for mRNA-1273 and Shows 100% Efficacy in P-III COVE-Study
Sanofi's Dupixent (dupilumab) Receives EC's Approval for Children with Severe Atopic Dermatitis
Member of COVID R&amp;D Alliance Report the First Patient Enrollment in COMMUNITY Study
Kaia Health Allied with Chiesi Group to Commercialize COPD App in Europe
AstraZeneca Initiates P-IIb Study of ION449 (AZD8233) to Lower LDL-cholesterol
Eisai Sign a Research Agreement with Wren Therapeutics to Discover Potential Treatment for Synucleinopathies
Genentech and Novartis's Xolair (omalizumab) Receives the FDA's Approval for Adults with Nasal Polyps
BioNTech and Pfizer Report CMA Submission of BNT162b2 to EMA for COVID-19
Boston Scientific to Divest BTG's Specialty Pharma Business for ~$800M
Regeneron Collaborates with Penn to Explore Intranasal Delivery of COVID-19 Ab Cocktail via Gene Therapy Platform
AstraZeneca to Divest European Rights of Crestor (rosuvastatin) to Grünenthal for ~$350M
"The US FDA Approves Pfizer's Oncology Supportive Care Biosimilar Nyvepria (biosimilar, pegfilgrastim)"
Roche's Gavreto (pralsetinib) Receives the US FDA's Approval for Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers
The US FDA Draft New Guidelines for Biosimilarity and Interchangeability
Samsung Biologics and AstraZeneca to Dissolve Rituximab Alliance
Genentech Files Complaint Against Centus Over Proposed Bevacizumab Biosimilar
"Formycon and Bioeq Report First Patients Dosing in P-III Study of FYB202 (biosimilar, ustekinumab)"
"Xbrane Reports Patient Enrollment Completion in P-lll XPLORE Study of Xlucane (biosimilar, ranibizumab)"
Pfizer &amp; BioNTech Receives MHRA's EUA for BNT162b2 Against COVID-19
Samsung Bioepis Presents Results of SB11 Proposed Biosimilar to Lucentis in P-III Study at the AAO 2020 Virtual
Roche's Elecsys Anti-SARS-CoV-2 S Receives the US FDA's EUA to Detect Ab Against SARS-CoV-2 Spike Protein
Samsung Bioepis and Biogen Report the FDA's Acceptance of BLA for SB11 Proposed Biosimilar to Lucentis
"Henlius Presents Results of HLX04 (biosimilar, bevacizumab) in P-III Study at ESMO Asia 2020"
AbbVie Collaborates with Frontier Medicines to Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets
"Innovent's Sulinno (biosimilar, adalimumab) Receive NMPA's Approval for Polyarticular Juvenile Idiopathic Arthritis"
AstraZeneca to Unveil its Robust Pipeline of Breast Cancer at SABCS
Janssen Acquires Rights to Hemera's HMR59 for Late-Stage Age-Related Macular Degeneration
Merck KGaA Collaborates with Artios Pharma for DNA Damage Cancer Therapies
Janssen Reports BLA Submission of Amivantamab to the US FDA for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
Richter Acquires Janssen's Evra Transdermal Contraceptive Patch Assets for $263.5M
Jazz Pharma and PharmaMar's Zepzelca Fail to Meet its Primary Endpoint in P-III ATLANTIS Study for SCLC
reMYND Commences P-l Study of RES19-T for Alzheimer's Disease
Abbott's FreeStyle Libre 2 Receives Health Canada's Approval for Adults and Children with Diabetes
Exactech Acquires Muvr and it's Digital Health Tech for Orthopedic Practices
Janssen Reports Long-Term Benefits of Imbruvica (ibrutinib) as 1L Treatment for High-Risk Chronic Lymphocytic Leukemia
Kite Reports Results of Yescarta in P-II ZUMA-5 Study for Adult Patients with R/R Indolent Non-Hodgkin lymphoma
Roche Reports Long-Term Benefits of Venclexta/Venclyxto Based Combination for R/R Chronic Lymphocytic Leukemia
AstraZeneca Reports Long-Term Efficacy and Tolerability of Calquence (acalabrutinib) in P-ll ACE-LY-004 Study for MCL
Roche Presents Results of Hemlibra Reinforcing the Long-Term Benefits for Hemophilia A at ASH 2020
Roche Reports of Polivy + Bendamustine and MabThera / Rituxan in P-lb/ll GO29365 Study for R/R Diffuse Large B-Cell Lymphoma
AbbVie Reports Results of Imbruvica (ibrutinib) in Two P-III Studies as 1L Treatment for Chronic Lymphocytic Leukemia
Nektar Therapeutics Presents Preclinical Data of NKTR-255 in P-Ib/II Study at ASH 2020
Bayer Signs an Exclusive Worldwide License Agreement with Atara for Mesothelin-Targeted CAR T-cell Therapies to Treat Solid Tumors
Qiagen Launches QuantiFERON SARS-CoV-2 RUO Solution for COVID-19
Astellas Collaborates with KaliVir to Develop and Commercialize VET2-L2
RetinAI Collaborates with Novartis to Provide AI Solutions in Ophthalmology
Novartis' Asciminib (ABL001) Demonstrate Superiority Over Pfizer's Bosulif in Chronic Myeloid Leukemia Trial
AstraZeneca Reports Results of AZD1222 in Interim Analysis of P-lll Program for COVID-19
Medtronic Launches Carpediem as the First Pediatric and Neonatal Acute Dialysis Machine in the US
Amgen's Sotorasib Receives the US FDA's Breakthrough Therapy Designation for Advanced or Metastatic NSCLC with KRAS G12C Mutation
Roche Highlights its Bispecific Antibody Portfolio Across a Range of Blood Cancers at ASH 2020
Elsevier Acquires Shadow Health
Boehringer Ingelheim to Acquires Labor Dr. Merk &amp; Kollegen for Boosting its Next Generation Cancer Immunology Program
Lilly Reports Results of Tirzepatide in P-lll SURPASS-1 Monotherapy Trial for Type-2 Diabetes
Roche Collaborate with Moderna to include SARS-CoV-2 Ab Test in COVID-19 Vaccine Trials
Novartis Reports Results of Kisqali in P-III MONALEESA-7 Trial to Treat HR+/HER2- Metastatic Breast Cancer
Google Launches Health Research App Focusing on Respiratory Illnesses
Pfizer and BioNTech ‘s BNT162b2 Receive Health Canada Authorization to Combat COVID-19
Boehringer Ingelheim to Acquires NBE-Therapeutics ~ $1.5B
Gilead to Acquire MYR for ~$1.4B
Biogen Reports NDA Submission of Aducanumab (BIIB037) to the MHLW for Alzheimer's Disease
Roche Presents Results of Tecentriq (atezolizumab) in P-III IMvigor010 Study for MIUC at ESMO 2020
Roche Launches Elecsys SARS-CoV-2 Antigen Test to Support High-Volume COVID-19 Testing
Chugai In-Licenses Roche's Antibody Cocktail for COVID-19 in Japan
AstraZeneca to Acquire Alexion for $39B
Pfizer and BioNTech's BNT162b2 Receives the US FDA's EUA to Prevent COVID-19
Alvotech and Fuji Pharma Extends Agreement for the Commercialization of Four Biosimilars in Japan
AstraZeneca's Trixeo Aerosphere Receives EU's Approval for the Maintenance Treatment of COPD
Novartis' Ruxolitinib Fails to Meet its Primary Endpoint in P-lll RUXCOVID Study for COVID-19
Daiichi Sankyo and AZ's Trastuzumab Deruxtecan Receives CHMP's Recommendation for Approval to Treat HER2 Positive Metastatic Breast Cancer
Genentech's Ocrevus Shorter 2-Hour Infusion Receives the US FDA's Approval for Relapsing & Primary Progressive Multiple Sclerosis
Genentech Signs a Worldwide License Agreement with Relay Therapeutics to Develop and Commercialize RLY-1971
Samsung Bioepis Initiates P-Ill Study of SB16 Proposed Biosimilar to Prolia (denosumab)
Roche Launches Cobas PIK3CA Mutation Test for Patients with Advanced or Metastatic Breast Cancer
CureVac Commences P-llb/lll Trial of CVnCoV for COVID-19
EMA's CHMP Recommends Four-Week Dosing Option for AstraZeneca's Imfinzi to Treat Unresectable NSCLC
Lilly to Acquire Prevail Therapeutics for ~$1.04B
Sedor's Sesquient Receives the US FDA's Approval for Status Epilepticus
Rhythm's Imcivree (setmelanotide) Receives the US FDA's Approval for Chronic Weight Management in Patients with Obesity
Gilead Amends Agreement with Galapagos for Development and Commercialization of Jyseleca (filgotinib)
Athenex's Klisyri (tirbanibulin) Receives the US FDA's Approval for Actinic Keratosis on the Face or Scalp
Takeda Reports the US FDA's Acceptance of NDA for TAK-721 (budesonide oral suspension) to Treat Eosinophilic Esophagitis
Bone Health's OsteoBoost Vibration Belt Receives the US FDA's Breakthrough Device Designation for Osteoporosis
Ellume's COVID-19 Home Test Receives the US FDA's EUA as First Over-the-Counter Diagnostic Test
Abbott's COVID-19 IgG Quantitative Antibody Blood Test Receives CE Mark
Novartis's Entresto Receives the US FDA's Advisory Committee Recommendation to Treat Patients with HFpEF
Novo Nordisk to Initiate a P-lll Study of Semaglutide to Treat Alzheimer Disease
Novartis's Zolgensma Receives Health Canada Approval as the One-Time Gene Therapy for Pediatric Patients with SMA
Amgen Reports NDA Submission of Sotorasib to the US FDA for Advanced/Metastatic NSCLC With KRAS G12C Mutation
Eli Lilly Signs an Exclusive Agreement with Precision BioSciences on Genome Editing Research
Kite's Tecartus (KTE-X19) Receives EC's Conditional Marketing Authorization for R/R Mantle Cell Lymphoma
Novartis to Acquire Cadent Therapeutics for ~$770M
Moderna's mRNA-1273 Receives the US FDA's Advisory Committee Vote Supporting EUA Against COVID-19
GSK Signs an Exclusive License Agreement with Surface Oncology to Develop and Commercialize SRF813
GSK's Benlysta (belimumab) Receives the US FDA's Approval as the First Therapy for Active Lupus Nephritis (LN)
"Sandoz to Launch Hyrimoz (biosimilar, adalimumab) in Canada"
"Amgen's Riabni (biosimilar, rituximab) Receives the US FDA's Approval for Multiple Diseases"
NOWDiagnostics Receives CE Mark for its ADEXUSDx COVID-19 Antibody Fingerstick Test
GSK Signs a License Agreement with Sosei Heptares Targeting Immune Disorders of the Digestive System
Merck Signs a ~$1B Pact with Janux to Develop Cancer Therapies Using T Cell Engager Technology
Philips to Acquire BioTelemetry for ~$2.8B
ViiV Healthcare's First Long-Acting Injectable Receive EC's Approval for the Treatment of HIV
Ultragenyx Signs a License Agreement with Mereo for Setrusumab in Osteogenesis Imperfecta
Moderna's mRNA-1273 Receives the US FDA's EUA Against COVID-19
AstraZeneca's Tagrisso (osimertinib) Receives the US FDA's Approval for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer
Roche Reports Results of Faricimab in Two Global P-III Studies for Diabetic Macular Edema
Servier to Acquire Agios' Oncology Business for ~$2B
"Biogen's Plegridy (peginterferon beta-1a, IM) Receives EC's Approval for Relapsing-Remitting MS"
Pfizer and BioNTech's Comirnaty (BNT162b2) Receives EC's Conditional Marketing Authorization for COVID-19
AstraZeneca's Tezepelumab Fails to Meet its Primary Endpoint in P-III SOURCE Study for Asthma
Janssen's Darzalex (daratumumab) Receives Health Canada Approval for the Treatment of Multiple Myeloma
Voyager Therapeutics Provides Update on NBIB-1817 (VY-AADC) Program to Treat Parkinson Disease
Janssen Initiates Rolling Submission of BLA to US FDA of Autoleucel (cilta-cel) to Treat Multiple Myeloma
Ocular Therapeutix Reports sNDA Submission of Dextenza (dexamethasone ophthalmic insert) to the US FDA for Ocular Itching
AMO Pharma Initiates P-II REACH-CDM study of AMO-02 (tideglusib) to treat Congenital Myotonic Dystrophy
Roche's Phesgo (Perjeta + Herceptin) Receives EC's Approval for the Treatment of HER2-Positive Breast Cancer
Innovent's Sulinno (Adalimumab biosimilar) Receives China's NMPA Approval for Pediatric Plaque Psoriasis and Non-infectious Uveitis
Innovent's Byvasda (Bevacizumab Biosimilar) Receive NMPA's Approval for Adult Recurrent Glioblastoma
Aurobindo Pharma Sign Agreement with COVAXX to Develop and Commercialize COVID-19 Vaccine UB-612 for India and UNICEF
Amyrt's AP103 Receives the US FDA's Orphan Drug designation for Dystrophic Epidermolysis Bullosa (DEB)
Casi and Juventas Cell Therapy's CNCT19 (CD19 CAR-T) Receives China NMPA's BT Designation for Relapsed/refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Algernon's Last Patient Out in NP-120 (Ifenprodil) P-IIb/III Study for COVID-19
Janssen Report MAA Submission of Amivantamab to EMA for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Zai Lab Signs an Exclusive License Agreement with Cullinan Oncology for the Development and Commercialization of CLN-081 in Greater China
Myovant Signs Agreement with Pfizer to Develop and Commercialize Relugolix in Oncology and Women's Health
Biocon has Launched Tacrolimus Capsules in the US
Pfizer Report the US FDA's Acceptance and Priority Review of sNDA for Lorbrena (lorlatinib) to treat (ALK)-Positive (NSCLC)
Alligator Bioscience Submits CTA for the P-II OPTIMIZE-1 Study of Mitazalimab
Chi-Med Initiates Rolling Submission of NDA to the US FDA of Surufatinib to Treat Advanced Neuroendocrine Tumors
"Novo Nordisk Reports Submission of Label Extension Application to the EMA for Semaglutide (once weekly, 2.0 mg) for T2D"
Skyhawk Collaborates with Vertex to Discover and Develop Novel Small Molecules Modulating RNA Splicing for Serious Diseases
AstraZeneca's AZD1222 Receives MHRA's Emergency Supply Authorization in the UK
Regeneron's Antibody Cocktail Demonstrate Promising Results in Hospitalized Patients on Low-Flow Oxygen
Zydus Cadila Seeks Approval to Commence P-III Clinical Study of ZyCoV-D
Sinopharm's COVID-19 Vaccine Demonstrates 79% Efficacy in P-III Study
Vertex Reports Health Canada's Acceptance of Trikafta's NDA for Priority Review to Treat Cystic Fibrosis
The US FDA Grants EUA for Quanterix's Simoa Semi-Quantitative SARS-CoV-2 IgG Antibody Test
Sorrento Reports Submission of MAA to COFEPRIS for COVI-STIX Rapid Detection Test
Health Canada Accelerates the Review for AstraZeneca's COVID-19 Vaccine
Incyte Collaborates with Cellenkos for CK0804 to Treat Myelofibrosis
RedHill Reports Results of Yeliva (opaganib) in P-II Study for COVID-19
AstraZeneca's COVISHIELD Receives EUA in India for COVID-19
Antengene Reports NDA Submission for ATG-010 (selinexor) to Treat RRMM and RR DLBCL in South Korea
Tiziana Completes Clinical Trial of Nasally Administered Foralumab for COVID-19 in Brazil
Oura Ring Monitors Body Temperature and Identify Early COVID-19 Symptoms
Provention Bio Reports Submission of BLA and Priority Review to the US FDA for Teplizumab to Prevent T1D
Hologic to Acquire Somatex for ~$64 M
Pfizer and OPKO Reports the US FDA's Acceptance of BLA for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
Genentech's Tiragolumab + Tecentriq Receive the US FDA's Breakthrough Therapy Designation for PD-L1-High Non-Small Cell Lung Cancer
aTyr Reports Results of ATYR1923 in P-ll Study for COVID-19 Patients with Severe Respiratory Complications
Y-Biologics Signs a License Agreement with 3D Medicines for YBL-013 in the Territory of Greater China
Biogen Signs a License Agreement with ViGeneron for Ophthalmic Gene Therapy Development
Stryker Acquires OrthoSensor and its Knee Surgery Sensor Technology
Evotec Receives Milestones in its Neurodegeneration Collaboration with BMS
Regenxbio Reports the Initiation of First Pivotal Program for RGX-314 to Treat Wet AMD
AbbVie Reports Results of Skyrizi (Risankizumab) in P-III Studies for Active Psoriatic Arthritis
AstraZeneca's Farxiga (dapagliflozin) Receives the US FDA's Priority Review for Chronic Kidney Disease
Nirmidas Receives the US FDA's EUA for its COVID-19 Rapid Antibody Fingerstick Test
Pfizer Collaborates with Dewpoint to Develop Therapies for Rare Form of Muscular Dystrophy
Genentech Signs ~$1B Pact with Ribometrix to Develop RNA-Targeted Small Molecule Therapies
Astellas Reports the US FDA's Acceptance of Priority Review for its NDO Therapy
"Merck KGaA Acquires AmpTec to Strengthen its mRNA Capabilities for Vaccines, Treatments and Diagnostics"
Pfizer Signs a License and Supply Agreement with ImaginAb for CD8 ImmunoPET Technology
Hologic to Acquire Biotheranostics for ~$230M
Bayer Collaborates with CureVac for CVnCoV Against COVID-19
Alnylam Reports Results of Vutrisiran in P-III HELIOS-A Study for Patients with hATTR Amyloidosis with Polyneuropathy
Pfizer Reports the First Patients Dosing of PF-06939926 in P-III CIFFREO Study for DMD
PerkinElmer to Acquire Oxford Immunotec for ~$591M
Sarepta Reports Mixed Results of SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) in Part 1 of Study 102 for DMD
Almirall and Tyris Collaborate to Develop Next Generation Gene Therapies
AbbVie Reports Results of Skyrizi (risankizumab) in P-III Induction Studies for Crohn's Disease
Roche's Xofluza Receives the EC's Approval for the Treatment of Influenza
BioMarin Reports Results of Valoctocogene Roxaparvovec in P-III GENEr8-1 Study for Hemophilia A
Sanofi to Acquire Kymab for ~$1.45B
Chi-Med and Inmagene Collaborate to Develop Therapies for Immunological Diseases
BMS Collaborates with ArsenalBio to Advance Next-Generation T cell Therapies for Solid Tumors
Biogen and Apple Collaborate to Launch Virtual Study on Cognitive Decline
Novartis In-Licenses BieGene's Tislelizumab to Expand its Oncology Portfolio
Bluebird bio to Spin Off its Oncology Business into Independent Company
AstraZeneca Collaborates with Adaptive on Mapping Immune Response in Cancer
Roche Reports Updated OS Data of Tecentriq + Avastin in P-III IMbrave150 Study for Unresectable HCC
GSK and VIR Biotechnology to Evaluate VIR-7832 in the Early Treatment of COVID-19
Gilead Collaborates with VIR to Evaluate Combination Therapy for Chronic Hepatitis B Virus
"Lundback's Vyepti (eptinezumab, IV) Receives Health Canada's Approval for Preventive Treatment of Migraine"
Bayer Reports the US FDA's Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D
UCB Launches Nile AI as a Digital Health Company to Transform the Course of Epilepsy
Teladoc Health and Dexcom Offers CGM-Powered Insight for T2D
The US Government to Purchase Additional Doses of Regeneron's Casirivimab and Imdevimab to Combat COVID-19
Kamada to Commercialize Three Biosimilar Products in Israel
Amgen Collaborates with Evoq to Develop Novel Therapies for Autoimmune Disorders
"ViiV Healthcare's Tivicay (dolutegravir, dispersible tablets) Receives the EMA's Approval for Children with HIV"
Celltrion Report Results of CT-P59 in P-II/III Study for COVID-19
Sanofi Signs a License Agreement with Biond for BND-22
BeiGene's Tislelizumab (BGB-A317) + CT Receive NMPA's Approval as 1L Therapy for Advanced Squamous NSCLC
Takeda and KSQ Collaborate to Develop and Commercialize Novel Immuno-Oncology Therapies
Pfizer's Xalkori (crizotinib) Receives the US FDA's Approval for ALK-Positive Anaplastic Large Cell Lymphoma In Children And Young Adults
Abbott to Launch NeuroSphere myPath App to Record Pain Relief in Chronic Pain Patients
"Henlius' HLX15 (biosimilar, daratumumab) Receives IND Approval for Multiple Myeloma in China"
Philips Collaborates with Merck KGaA to Advance Personalized Fertility Treatment
Novartis' Ligelizumab (QGE031) Receives the US FDA's Breakthrough Designation for Patients with Chronic Spontaneous Urticaria
GSK Presents Results of Dostarlimab in P-I GARNET Study for dMMR Solid Cancers at ASCO GI
Daiichi Sankyo and AstraZeneca's Enhertu Receive the US FDA's Approval for Previously Treated HER2-Positive Advanced Gastric Cancer
AstraZeneca's Imfinzi (durvalumab) New Dosing Option Receives Approval for NSCLC in the EU &amp; UK
Genmab's Darzalex Faspro (daratumumab and hyaluronidase-fihj) Receives the US FDA's Approval for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
Cardiff Oncology Report Results of Onvansertib in P- Ib/II Study for KRAS-Mutated Metastatic Colorectal Cancer
Nanobiotix Presents Results of NBTXR3 (PEP503) in P-Ib/II Study for Rectal Cancer at ASCO-GI 2021
Boehringer Ingelheim Collaborates with Cure Genetics to Develop Next-Generation Liver-Targeted Gene Therapy
Tessa's CD30 CAR-T Therapy Receives EMA's PRIME Designation for Relapsed or Refractory Classical Hodgkin Lymphoma
Janssen Signs a Research Agreement with TenNor to Develop Treatments for Nontuberculous Mycobacteria Diseases
Grifols to Evaluate New Immunoglobulin Therapy Against COVID-19 in Spain
"Innovent Out Licenses Byvasda's (biosimilar, bevacizumab) Development and Commercialization Rights to PT Etana in Indonesia"
Philips to Acquire Capsule Technologies for ~$635M
Biocryst's Orladeyo (berotralstat) Receives the US FDA's Approval to Prevent Attacks of Hereditary Angioedema (HAE)
Myovant's Orgovyx (relugolix) Receives the US FDA's Approval as the First Oral GnRH Receptor Antagonist for Advanced Prostate Cancer
Lilly and Merus Collaborate to Discover Novel T-Cell Re-Directing Bispecific Antibodies
Thermo Fisher to Acquire Mesa Biotech for $450M
Omeros Reports the US FDA's Acceptance and Priority Review of BLA for Narsoplimab (OMS721) to Treat HSCT-TMA
Daiichi Sankyo and AstraZeneca's Enhertu (trastuzumab deruxtecan) Receives EU's Approval for the HER2 Positive Metastatic Breast Cancer
Sorrento Presents Preliminary Results of STI-2020 Against COVID-19
Biohaven's Troriluzole Fails to Meet its Co-Primary Endpoints in P-II/III Study for Alzheimer's Disease
MacroGenics' Margenza (margetuximab-cmkb) Receives the US FDA's Patients with Pretreated Metastatic HER2-Positive Breast Cancer
Ridgeback's Ebanga (mAb114) Receives the US FDA's Approval for the Treatment of Ebola
Urovant's Gemtesa (vibegron) Receives the US FDA's Approval for Overactive Bladder
Merck KGaA and GSK's Bintrafusp Alfa Fails to Meet its Co-Primary Endpoints in Lung Cancer Study
Vanda's Hetlioz (tasimelteon) Receives the US FDA's Approval for Nighttime Sleep Disturbances in Smith-Magenis Syndrome
Bayer and Merck's Verquvo (vericiguat) Receives the US FDA's Approval to Treat Chronic Heart Failure
Haemonetics to Acquire Cardiva Medical for ~$510M
Qiagen's PCR Tests Demonstrate Effectiveness in Detecting Mutations in SARS-CoV-2 Virus
Roche Reports the US FDA's Acceptance of sNDA and Granted Priority Review for Esbriet (pirfenidone) to Treat UILD
Novo Nordisk Report Submission of label Expansion Application to US FDA's for Ozempic (semaglutide) for T2D
The US FDA Approves Gallium 68 PSMA-11 as the First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer
Boston Scientific to Acquire Preventice for ~$1.2B
Servier and MiNA Therapeutics Collaborate to Develop saRNA Therapies for Neurological Diseases
Eli Lilly Reports Results of Bamlanivimab (LY-CoV555) in P-III BLAZE-2 Study for Preventing COVID-19 at Nursing Homes
ViiV's Cabenuva (cabotegravir and rilpivirine) Receives the US FDA's Approval as the First and Only Complete Long-Acting Regimen for HIV treatment
MTPA and Aquestive Sign a License and Supply Agreement for Exservan (riluzole) to Treat ALS in the US
Takeda's Alunbrig (brigatinib) Receives MHLW's Approval as a 1L and 2L Treatment for ALK+ Advanced or Recurrent NSCLC
Exelixis Cabometyx (cabozantinib) + Opdivo (nivolumab) Receives US FDA's Approval as a 1L Treatment for Patients with Advanced Renal Cell Carcinoma
P&G Signs a License Agreement with Rhinostics to Launch its Novel Nasal Swab into the Market for Rapid COVID-19 Testing and Address Supply Shortages
Aurinia Lupkynis (voclosporin) Receives US FDA's Approval to Treat Adult Patients with Active Lupus Nephritis
Pfizer and BioNTech Signs an Agreement with Covax for Advance Purchase of Vaccine to Help Combat COVID-19
Incyte Reports Acceptance and Priority Review of BLA for Retifanlimab to Treat Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
Ervaxx and Cardiff University Collaborate to Develop Novel T-cell and T-cell Receptor-based Immunotherapeutics Targeting Dark Antigens
Merck's Keytruda (pembrolizumab) Receives EC's Approval as 1L Treatment for Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer
Eli Lilly and AbCellera Report Results of Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV16) in P-II/III BLAZE-1 Study for Preventing COVID-19
Shionogi Concludes a License Agreement with BioAge for BGE-175 to Control the Aggravation of COVID-19
Regeneron Reports Results of REGEN-COV Antibody Cocktail Used as Passive Vaccine to Prevent COVID-19
AbbVie's Rinvoq (upadacitinib) Receives the EC's Approval for Psoriatic Arthritis and Ankylosing Spondylitis
Abbott's Panbio Rapid Antigen Test Receives CE Mark for Mass COVID-19 Screening
Eli Lilly Collaborates with GSK and VIR to Evaluate Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
"Innovent's Byvasda (biosimilar, bevacizumab) Receives NMPA's Approval for the Treatment of Adult Recurrent Glioblastoma"
AMCP Partnership Forum Develops Strategies to Support the Use and Development of Biosimilar in the US
AstraZeneca Selects AI-Generated CKD Target Under its Collaboration with BenevolentAI
Pfizer's Xeljanz (tofacitinib) Fails to Meet its Co-Primary Endpoint in ORAL Surveillance Safety Study
Regeneron's REGEN-COV Antibody Cocktail Confirms its Effectiveness Against UK and South Africa SARS-CoV-2 Variants
ImaginAb Signs a Multi-Year Non-Exclusive License Agreement with Neuvogen for CD8 ImmunoPET Technology
BioInvent Report Results of BI-1206 + Rituximab in P- I/IIa Study for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
"Bio-Thera Collaborates with Biomm to Commercialize BAT1706 (biosimilar, bevacizumab) in Brazil"
"Celltrion Receives the CHMP's Positive Opinion for CT-P17 (biosimilar, adalimumab)"
"Henlius Receives the NMPA's Approval for HLX03 (biosimilar, adalimumab) to Treat Autoimmune Disease"
Merck Signs an Exclusive Worldwide License Agreement with Artiva to Develop CAR-NK Cell Therapies
Amgen Report Results of Sotorasib in P-II Study for KRAS G12C-Mutated Advanced NSCLC
Bio-Thera Solutions Reports the US FDA's Acceptance of BLA for BAT1706 (Proposed Biosimilar to Avastin)
Lilly Signs a License Agreement with Asahi Kasei Pharma for AK1780 to Treat Chronic Pain
Janssen Reports Results of Amivantamab in P-I CHRYSALIS Study for Metastatic or Unresectable NSCLC and EGFR Exon 20 Insertion Mutations
Roche Collaborate with Cambridge Quantum Computing to Develop Quantum Algorithm for Drug Discovery and Development
Merck's Report Results of Keytruda (pembrolizumab) in Combination With Ipilimumab vs Keytruda Monotherapy in P-III KEYNOTE-598 for Metastatic Non-Small Cell Lung Cancer Patients
Novo Nordisk Receives the CHMP's Positive Opinion for Sogroya (somapacitan)
Amgen's Sotorasib Receives NMPA's Breakthrough Therapy Designation in China for the Treatment of Advanced NSCLC With KRAS G12C Mutation
Johnson & Johnson Report Results from P-III ENSEMBLE Trial for COVID-19 Vaccine
Gan &amp; Lee Receives the US FDA's Fast Track Designation for GLR2007 for the Treatment of Patients with Glioblastoma
Incyte Receive Positive CHMP's Opinion for Pemigatinib
Horizon Therapeutics to Acquire Viela Bio for ~ $3.05B
Gilead Signs an Option and License Agreement with Gritstone for HIV Vaccine
Janssen Reports CHMP's Acceptance for Accelerated Assessment of Cilta-cel's MAA to Treat Patients with Heavily Pretreated Multiple Myeloma
Medtronic Receives the US FDA's Approval for DiamondTemp Ablation System to Treat Atrial Fibrillation
Clover and Dynavax Plan to Initiate P-II/III Trial for Adjuvanted COVID-19 Vaccine Candidate
"Celltrion Receives Health Canada's Approval for Remsima SC (biosimilar, infliximab) for Rheumatoid Arthritis"
BMS' Deucravacitinib Demonstrate Superiority Over Otezla (apremilast) in P-III POETYK PSO-2 Study for Plaque Psoriasis
Genentech Signs an Exclusive License Agreement with X-Chem to Discover Oncology Targets
Innovent's Tyvyt (sintilimab) + Pemetrexed and Platinum CT Receives NMPA's Approval as 1L Therapy with Non-squamous Non-Small Cell Lung Cancer
GSK Collaborate with CureVac to Develop Next Generation mRNA COVID-19 Vaccines
Russia's Sputnik V Demonstrates 92% Efficacy Against COVID-19
Covaxx Initiates P-II Trial of UB-612 Against COVID-19 in Taiwan
Jazz to Acquire GW Pharmaceuticals for $7.2B
EMA's CHMP Recommends the Approval of Two Bevacizumab Biosimilars
"Innovent Reports sNDA Acceptance of Tyvyt (sintilimab) + Byvasda (biosimilar, bevacizumab) as 1L Therapy for Hepatocellular Carcinoma"
Merck KGaA's Tepmetko (tepotinib) Receives the US FDA's Approval for Patients with Metastatic NSCLC with METex14 Skipping Alterations
Pfizer Signs a License and Research Agreement with Imcyse to Develop Imotopes for Rheumatoid Arthritis
"Henlius to Initiate P-III Study of HLX04-O (biosimilar, bevacizumab) in Australia"
Thermo Fisher Collaborates with JW Therapeutics for CAR-T Therapies in China
Daiichi Sankyo Initiates P-II Study of Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC
Astellas' Xospata (gilteritinib) Receives NMPA's Conditional Approval for R/R AML with a FLT3 Mutation
AstraZeneca's Forxiga (dapagliflozin) Receives NMPA's Approval for Chronic Heart Failure
Biocon Biologics Signs an Agreement with CHAI to Expand Access to its Oncology Biosimilars in 30 Countries
23andMe Going Public Via Virgin Group SPAC Merger
Johnson &amp; Johnson Reports EUA Submission to US FDA's for its Single Shot COVID-19 Vaccine Candidate
Enzene Receives Marketing Authorization for Teriparatide (biosimilar) in India
Reistone Report Results for SHR0302 in P-II Study to Treat Ulcerative Colitis
BMS' Breyanzi (lisocabtagene maraleucel) Receives the US FDA's Approval for Adults With R/R Large-B-Cell Lymphoma
Daiichi Sankyo Signs an Outsourcing Agreement with AstraZeneca for COVID-19 Vaccine in Japan
Roche's Elecsys GDF-15 Assay Receives the US FDA's Breakthrough Device Designation as a CDX in Cancer Treatment
CureVac Collaborate with UK Government to Develop Vaccines Against SARS-CoV-2 variants
AstraZeneca's Imfinzi Fails to Meet its Primary Endpoints in P-III KESTREL Study
Celltrion's Regdanvimab (CT-P59) Receives Korean MFDS Conditional Marketing Authorization for COVID-19
ViiV Healthcare's Rukobia (fostemsavir) Receives Marketing Authorization for the Treatment of Adults with Multidrug-Resistant HIV
Hologic Collaborate with Google Cloud to Advance Screening in Cervical Cancer
Signifier's eXciteOSA Receives US FDA's Approval for the Treatment of Mild Obstructive Sleep Apnea and Snoring
BMS' Inrebic (fedratinib) Receives EC's Approval for Patients with Newly Diagnosed and Previously Treated Myelofibrosis
Medidata Launches Sensor Cloud to Connect Device and Wearables in Clinical Trials
BMS Report Results of Opdivo (nivolumab) + Cabometyx (cabozantinib) in P-III CheckMate -9ER Trial for 1L Treatment of Advanced Renal Cell Carcinoma
Lee's Pharma Socazolimab Receives NMPA's Breakthrough Therapy Designation for Treatment of Recurrent or Metastatic Cervical Cancer
Regeneron and Sanofi's Libtayo (cemiplimab-rwlc) Receives US FDA's Approval for Patients with Advanced Basal Cell Carcinoma
Eli Lilly and AbCellera's Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Receive the US FDA's EUA for COVID-19
Lannett Expand its Partnership with HEC to Include Biosimilar Fast-Acting Insulin
Vico's VO659 Receives EC's Orphan Drug Designation for Spinocerebellar Ataxia
Lonza to Divest Specialty Ingredients Business to Bain Capital and Cinven for $4.7B
Kaia Health Offers a Complete Musculoskeletal Care Solution with Kaia Gateway and Premium Partners
Galapagos and Gilead Discontinue the P-III Trials of Ziritaxestat (GLPG1690) for Idiopathic Pulmonary Fibrosis
AbbVie Signs a License Agreement with Caribou Biosciences for CAR-T Cell Therapies
Sanofi Collaborates with i2O Therapeutics to Evaluate Oral i2O Therapeutics
AstraZeneca Signs Letter of Intent with IDT Biologika to Boost COVID-19 Vaccine Manufacturing Capability in the EU
Evotec Collaborates with Related Sciences for Drug Discovery and Development
BMS Collaborates with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer
Novartis to Acquire GSK's Cephalosporin Antibiotics Business
Regeneron's Evkeeza (evinacumab-dgnb) Receives the US FDA's Approval for Patients with Homozygous Familial Hypercholesterolemia
Roche Reports Results of Faricimab in Four P-III Studies for Diabetic Macular Edema and Age-Related Macular Degeneration
Takeda Collaborates with Ensoma to Accelerate Next-Generation In Vivo Gene Therapies
Visby's POC COVID-19 Test Receives the US FDA's EUA for Use in CLIA Waived Settings
G1 Therapeutics' Cosela (trilaciclib) Receives US FDA's Approval as the First Myeloprotection Therapy for Extensive-Stage Small Cell Lung Cancer
Takeda Report Results of TAK-620 (maribavir) in P-III SOLCTICE Trial for the Treatment of Post-Transplant Patients with Cytomegalovirus Infection
Pfizer's Panzyga Receives the US FDA's Approval of sBLA for Chronic Inflammatory Demyelinating Polyneuropathy
Merck Report Result of Keytruda (pembrolizumab) + Lenvima (lenvatinib) as 1L Treatment for Advanced Renal Cell Carcinoma
"Biocon Biologics and Viatris Receive EC's Approval for Kixelle (biosimilar, insulin aspart) for Diabetes Mellitus"
Roche's Receives the US FDA's Clearance for Urine Sample Type for BK Virus Quantitative Test
Exelixis Report Results of Cabometyx (cabozantinib) in P-II PAPMET Study for Patients with Metastatic Papillary Renal Cell Carcinoma
"Celltrion Receives EC's Approval for Yuflyma (biosimilar, adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases"
Targovax Receives US FDA's Fast Track Designation for ONCOS-102 for Malignant Pleural Mesothelioma
AstraZeneca and Serum Institute of India's COVID-19 Vaccine Receive WHO's EUA to Prevent COVID-19
Aker BioMarine Collaborate with Université de Sherbrooke Department of Medicine for Alzheimer's Disease
Onward Signs a Worldwide Exclusive License and Co-Development Agreement with Biomunex for Immuno-Oncology
Guardant Health Launches Guardant Reveal Liquid Biopsy Test for Early-Stage Colorectal Cancer
BMS and Acceleron's Reblozyl (Luspatercept) Receives Health Canada Approval for Adult Patients With Myelodysplastic Syndromes
Novartis Report Results of Kesimpta (ofatumumab) Sensoready Autoinjector Pen for Multiple Sclerosis
GSK Initiates P-III study for RSV Candidate Vaccine Programme for Older Adults
Novartis's Entresto Receives US FDA's Approval for Chronic Heart Failure
Boehringer Ingelheim Animal Health Establishes Pawru for its PetPro Portfolio
"Coherus Reports the US FDA's Acceptance of BLA for CHS-1420 (biosimilar, adalimumab)"
Lilly Reports Results of Tirzepatide in P-lll SURPASS-3 and 5 Trials for Type-2 Diabetes
Novartis Collaborates with Bill &amp; Melinda Gates Foundation to Discover and Develop Gene Therapy for Sickle Cell Disease
GSK Expand its 2020 Collaboration with Vir to Advance New Therapies for Influenza and Other Respiratory Viruses
Myovant and Pfizer Publish the Results of Relugolix Combination Regimen in P-III LIBERTY Studies in NEJM
BeiGene Reports the US FDA's Acceptance of sNDA for Brukinsa (zanubrutinib) in Waldenström's Macroglobulinemia
"ViiV's Vocabria (cabotegravir, tablet formulation) Receives the US FDA's Approval for the Treatment of HIV-1 infection"
Lilly Collaborates with Rigel to Develop RIPK1 Inhibitors for Immunological and Neurodegenerative Diseases
"Fresenius Kabi Launches Idacio (biosimilar, adalimumab) for Multiple Chronic Inflammatory Conditions in Canada"
Dermavant Report Results of Tapinarof Cream in P-III PSOARING 3 Study with Durable and Remittive Benefits for Plaque Psoriasis
The US FDA Approves Patient Specific Talus Spacer to Treat AVN of Ankle Joint as a Humanitarian Use Device
Astellas and Seagen Reports Submission of Two BLA to the US FDA for Padcev (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
RedHill Signs a Manufacturing Agreement with Cosmo for Movantik and RHB-204
Roche Concludes the License Agreement with Chugai for AT-527 to Treat COVID-19 in Japan
Immunocore's Tebentafusp Receives the US FDA's Breakthrough Therapy Designation for Unresectable or Metastatic Uveal Melanoma
Astellas Reports Results of Fezolinetant in Two P-III Studies for the Nonhormonal Treatment of VMS in Postmenopausal Women
Incyte Reports the US FDA's Acceptance of NDA for Priority Review of Ruxolitinib Cream to Treat Atopic Dermatitis
AstraZeneca to Withdraw Imfinzi Indication in Advanced Bladder Cancer in the US
Sanofi and GSK Initiate P-II Study of their Adjuvanted Recombinant Protein-Based COVID-19 Vaccine
Regeneron and Sanofi's Libtayo (cemiplimab-rwlc) Receive the US FDA's Approval as 1L Treatment for Advanced NSCLC
AbbVie Report Results of Rinvoq (upadacitinib) in Second P-III Induction Study for Ulcerative Colitis
Incyte Reports the US FDA's Acceptance of sNDA for Priority Review of Jakafi (ruxolitinib) to Treat Chronic Graft Versus Host Disease
BMS Expands its Collaboration with Compugen to Evaluate the Combination of COM701 + Opdivo
Amgen Reports sNDA Submission of Otezla (apremilast) to The US FDA's for Adults with Mild to Moderate Plaque Psoriasis
MatriSys Report Results of MSB-0221 in P-I study for the Topical Treatment of Atopic Dermatitis
Graviton Signs an Exclusive Worldwide License Agreement with Beijing Tide for TDI01
Sanofi's Dupixent (dupilumab) Receives Health Canada Approval as the First Biologic to Treat Atopic Dermatitis in Children
Merck KGaA Signs an Exclusive Worldwide License Agreement with Day One for Pimasertib and MSC2015103B
Pfizer Reports the US FDA's Acceptance and Priority Review of BLA for Ticovac (Tick-Borne Encephalitis Vaccine)
Takeda Reports First Patients Dosing in P-I/II Study of Novavax's COVID-19 Vaccine Candidate in Japan
Bio-Techne Collaborates with Luminary to Utilize TcBuster in the Development of CAR-T cell Therapies
UCB Collaborates with Microsoft to Accelerate Drug Discovery and Development
Sanofi Collaborates with Sirion to Develop Gene Therapy Treatment with Improved AAV Capsids
Roche Report Results of Evrysdi (risdiplam) in FIREFISH Study for Infants with Type 1 SMA
AbbVie's Humira (adalimumab) Receives the US FDA's Approval to Treat Pediatric Patients with Ulcerative Colitis
Qiagen Expand its Collaboration with Inovio to Develop Liquid Biopsy Based CDx for VGX-3100 to Treat Advanced Cervical Dysplasia
Intra-Cellular Reports the Expansion of Pipeline with the Addition of ITI-1284
Merck to Acquire Pandion for ~$1.85B
Otsuka and Click Initiate Digital Study in Adults with Major Depressive Disorder
GSK Report Results of Otilimab in P-II OSCAR Study to Treat Hospitalized Patients with COVID-19
Lilly to Integrate its Digital Insulin Pen with Welldoc's BlueStar App
Daiichi Sankyo Collaborates with LYSA-LYSARC-CALYM for Valemetostat in Patients with R/R B-Cell Lymphoma
Regeneron Reports IDMC Clearance of Efficacy for REGEN-COV (Casirivimab + Imdevimab) in P-III COVID-19 Outpatient Outcomes Trial
BridgeBio and Origin's Nulibry (fosdenopterin) Receives the US FDA's Approval as the First Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A
Roivant to Acquire Silicon Therapeutics for ~$450M
AstraZeneca and Amgen Report Results of Tezepelumab in P-III NAVIGATOR Trial for Severe Asthma
Johnson &amp; Johnson Receives the US FDA's EUA for COVID-19 Vaccine
Regeneron's Ab Cocktail (casirivimab + imdevimab) Receives the CHMP's Positive Opinion to Treat COVID-19
BMS' Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive CHMP's Positive Opinion as 1L Treatment for Advanced Renal Cell Carcinoma
Merck KGaA Sign an Exclusive Worldwide License Agreement with Debiopharm for Xevinapant
Merck Reports the US FDA's Acceptance of NDA for Review of Gefapixant to Treat Refractory or Unexplained Chronic Cough
Samsung Bioepis Initiates P-I Study of SB17 Proposed Biosimilar to Stelara (ustekinumab)
Hologic to Acquire Diagenode for ~$159M
YL Biologics Reports the NDA Submission of YLB217 (biosimilar product of long-acting erythropoiesis stimulating agent Nesp)
AstraZeneca Collaborates with Junshi to Commercialize Toripalimab in China
Veru to Advance VERU-111 in P-III Study for COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Fujifilm Kyowa Kirin and Mylan EPD Launch Adalimumab Biosimilar in Japan
"Sandoz Launches Hyrimoz (biosimilar, adalimumab) in Canada"
AbbVie Signs a Purchase Right Agreement to Acquire Mitokinin
"Viatris Launches Hulio (biosimilar, adalimumab) in Canada"
"Biocon Biologics and Viatris Receive CHMP's Positive Opinion for Abevmy (biosimilar, bevacizumab)"
"Tanvex Reports Results of TX05 (biosimilar, trastuzumab) in P-III Study for HER2-Positive Early Breast Cancer"
"Celltrion Initiates P-III Study of CT-P42 (biosimilar, aflibercept)"
G1 Therapeutics and Boehringer Ingelheim Launch Cosela (trilaciclib) in the US
Fusion to Acquire Ipsen's IPN-1087 to Expand its Pipeline of Radiopharmaceuticals
BeiGene's Brukinsa (zanubrutinib) Receives Health Canada's Approval for Waldenström's Macroglobulinemia
Amgen Reports Results of Blincyto (blinatumomab) in P-III Study for Relapsed Acute Lymphoblastic Leukemia in Pediatric Patients
Boston Scientific Signs an Agreement with BPEA to Acquire Lumenis' Surgical Business
Takeda Signs an Exclusive License Agreement with Ovid for Soticlestat to Treat Dravet Syndrome and Lennox-Gastaut Syndrome
Pfizer's Lorbrena (lorlatinib) Receives FDA's Approval for Expanding its Indication to Treat ALK-Positive Metastatic Lung Cancer
Regeneron and Sanofi Report the US FDA's Acceptance of sBLA for Review of Dupixent to Treat Moderate-to-Severe Asthma in Children
Roche Collaborates with Tempest to Evaluate TPST-1120 in a Combination Study as 1L Treatment for Hepatocellular Carcinoma
Vir and GSK Provide Update on ACTIV-3 Trial of VIR-7831 in Hospitalized Adults with COVID-19
Amgen to Acquire Five Prime for ~$1.9B
Lilly Reports Results of Tirzepatide in P-lll SURPASS-2 Trial for Type-2 Diabetes
Agilent to Acquire Resolution Bioscience for $695M
Roche's Actemra/RoActemra (tocilizumab) Receives the US FDA's Approval as the First Biologic for Systemic Sclerosis-Associated Interstitial Lung Disease
Takeda Reports NDA Submission to Import and Distribute Moderna's mRNA-1273 in Japan
Eli Lilly and Incyte Report Results of Olumiant (baricitinib) in P-III BRAVE-AA2 Study for Severe Alopecia Areata
ViiV Healthcare Present Results of Long- Acting Cabotegravir and Rilpivirine in P-IIIb ATLAS-2M Study for HIV at CROI 2021
Lee's Pharma to Initiate P-III Trial of Socazolimab as 1L Treatment of Extensive-stage Small-Cell Lung Cancer
Roche to Withdraw Tecentriq Indication in Metastatic Bladder Cancer in the US
Gilead Presents Four-Year Data of Biktarvy for HIV-1 in Treatment-Naïve Adults at CROI 2021
Kite's Yescarta Receives the US FDA's Approval for R/R Follicular Lymphoma
Atea Presents Results of AT-527 in P-I Study for COVID 19 at CROI
"Alteogen Reports Completion of P-I Study of ALT-L9 (biosimilar, aflibercept) in Korea"
Lilly Collaborates with Biolojic to Discover and Develop Antibody Therapies for Diabetes
TrinamiX Signs a Joint Development Agreement with VIAVI Solutions to Bring Near-Infrared Spectroscopy into Smartphones
Abbott Launches NeuroSphere Virtual Clinic for Remote Neurostim Programming in the US
Axsome's AXS-05 Receives US FDA's Breakthrough Therapy Designation for the Treatment of Alzheimer's Disease Agitation
Roche's Ventana ALK (D5F3) CDx Assay Receives the US FDA's Approval for the Treatment of ALK-Positive NSCLC
Junshi's Toripalimab Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Nasopharyngeal Carcinoma
Novartis' Iptacopan (LNP023) Receives the US FDA's Breakthrough Therapy Designation for PNH and Rare Pediatric Disease Designation for C3G
Exelixis Signs an Exclusive License Agreement with WuXi Biologics to Expand its Growing Oncology Biologics Pipeline
RemeGen's Disitamab Vedotin (RC48) Receives the US FDA's Breakthrough Therapy Designation for Urothelial Cancer
Zymeworks' Zanidatamab Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Biliary Tract Cancer
IO Biotech's IO102 + IO103 Receive the US FDA's Breakthrough Therapy Designation for Unresectable/ Metastatic Melanoma
PolyPid's D-PLEX100 Receives the US FDA's Breakthrough Therapy Designation for the Prevention of Surgical Site Infections in Colorectal Surgery
ImmunoGen's IMGN632 Receives the US FDA's Breakthrough Therapy Designation for Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
Takeda to Acquire Maverick for ~$525M
Novartis' Canakinumab Fails to Meet its Primary Endpoint in P-III CANOPY-2 Study
ViiV Healthcare Presents Results of GSK3640254 (GSK'254) in P-IIa study for the Treatment of HIV at CROI
Avelas' AVB-620 (pegloprastide) Receives the US FDA's Breakthrough Therapy Designation for Use During Breast Cancer Surgery
F2G Receives the US FDA's Breakthrough Therapy Designation for Olorofim
Telix Receives the US FDA's Breakthrough Therapy Designation for TLX250-CDx (89Zr-girentuximab)
Sorrento Collaborates with Mount Sinai to Develop Ab Combination for Neutralizing SARS-CoV-2 and other Emerging Variants of COVID-19
Resverlogix Receives the US FDA Breakthrough Therapy Designation for Apabetalone
Concert's CTP-543 Receives the US FDA's Breakthrough Therapy Designation to Treat Alopecia Areata
SMA Foundation Collaborates with PTC to Discover and Develop Regenerative Medicine
Insmed's Brensocatib Receives the US FDA's Breakthrough Therapy Designation to Treat Non-Cystic Fibrosis Bronchiectasis
Gilead Present Results of Lenacapavir in P-II/III CAPELLA Trial for the Treatment of HIV at CROI
MyoKardia's Mavacamten Receives the US FDA's Breakthrough Therapy Designation for Symptomatic Patients with Obstructive Hypertrophic Cardiomyopathy
Debiopharm's Debio 1143 Receives the US FDA's Breakthrough Therapy Designation for Front-Line Treatment of Head and Neck Cancer
Kiniksa's Vixarelimab Receives the US FDA's Breakthrough Therapy Designation to Treat Pruritus Associated with Prurigo Nodularis
Turning Point's Repotrectinib Receives the US FDA's Breakthrough Therapy Designation for the Treatment of ROS1-Positive Metastatic Non-Small Cell Lung Cancer
Inventiva's Lanifibranor Receives the US FDA's Breakthrough Designation for the Treatment of NASH
Elli Lilly Reports Results of Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) in P-III BLAZE-1 Study for the Prevention of COVID-19
Grifols Acquires Remaining 56% of GigaGen for ~$80M
Empatica's Aura System Receives European CE Mark for Detecting Early Symptoms of COVID-19 Using Wearables
Cyprium's CUTX-101 Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Menkes Disease
Roche's Actemra/RoActemra (tocilizumab) + Veklury Fail to Meet its Primary Endpoints in P-III REMDACTA Study for Patients with Severe COVID-19 Pneumonia
Aprea's APR-246 Receives the US FDA's Breakthrough Therapy Designation for Myelodysplastic Syndromes with a TP53 Mutation
ContraFect's Exebacase Receives the US FDA's Breakthrough Therapy Designation for MRSA Bacteremia including Right-Sided Endocarditis
BeyondSpring's Plinabulin Receives the US FDA's and NMPA's Breakthrough Therapy Designations for Chemotherapy-Induced Neutropenia Indication
Lannett Receives the US FDA's Feedback for Development of Biosimilar Insulin Glargine
Vertex's VX-880 Receives the US FDA's Fast Track Designation for T1D
Acceleron's Sotatercept Receives the US FDA's Breakthrough Therapy Designation for Pulmonary Arterial Hypertension
Vir and GSK Report Results of VIR-7831 in P-III COMET-ICE Trial for COVID-19
Astellas Reports NDA Submission of Enfortumab Vedotin to the MHLW for Locally Advanced or Metastatic Urothelial Cancer in Japan
Abbott Launches Pandemic Defense Coalition to Detect Future Threats
Sanofi and Translate Bio Initiate P-I/II Study of MRT5500 Against COVID-19
Takeda Reports NDA Submission of Lanadelumab to the MHLW as a Preventive Treatment for Hereditary Angioedema Attack in Japan
PhaseBio Signs a Supply Agreement with BioVectra to Support the Development and Commercialization of Bentracimab
Eli Lilly Report Result of Donanemab in P-II TRAILBLAZER-ALZ Study for Alzheimer's Disease
Regeneron and Sanofi Report Results of Libtayo (cemiplimab) in P-III Trial for Cervical Cancer
Roche to Acquire GenMark Diagnostics for $1.8B
BMS Collaborates with Aveo to Evaluate Opdivo (nivolumab) + Fotivda (tivozanib) in P-III Study for Relapsed Renal Cell Carcinoma
Cardinal Health to Divest its Cordis Business to Hellman &amp; Friedman for $1B
BioXcel's BXCL501 Receives the US FDA's Breakthrough Therapy Designation for Acute Treatment of Agitation Associated with Dementia
Takeda Signs a License Agreement with Genevant to Develop Novel Nucleic Acid Therapeutics for Liver Fibrosis
Gilead Collaborates with Merck to Jointly Develop and Commercialize Lenacapavir + Islatravir for HIV
Novartis and Molecular Partners Report Inclusion of Ensovibep (MP0420) in NIH-Sponsored ACTIV-3 Trial for the Treatment of COVID 19
Roche Launches Cobas SARS-CoV-2 Variant Test to Detect Emerging Coronavirus Mutations
Genentech Reports Two-Year Data of Evrysdi (risdiplam) for People with Type 2 or Type 3 SMA
Merck Reports the US FDA's Acceptance of NDA for Priority Review of Belzutifan (MK-6482) to Treat Patients with Von Hippel-Lindau Disease Associated RCC
TG Therapeutics' Ukoniq (umbralisib) Receives the US FDA's Approval for R/R Marginal Zone Lymphoma and Follicular Lymphoma
Oncopeptides' Pepaxto (melphalan flufenamide) Receives the US FDA's Approval for Triple Class Refractory Multiple Myeloma
GSK and Medicago Initiate P-III Trial for Adjuvanted COVID-19 Vaccine Candidate
Lilly Reports Results of Mirikizumab in P-III LUCENT-1 Induction Study for Ulcerative Colitis
Sanofi Out Licenses Two Sickle Cell Disease Programs to GBT for $353M
FibroGen Initiates P-III LELANTOS-2 Study of Pamrevlumab for Duchenne Muscular Dystrophy
Johnson &amp; Johnson Report Long-Term Data of Tremfya (guselkumab) in P-III DISCOVER-2 Study for Active Psoriatic Arthritis
NCCN Collaborates with Pfizer for New Biosimilars Research Projects in Oncology
Merck Collaborates with Amathus Therapeutics to Develop Treatments for Neurodegenerative Diseases
WuXi Biologics to Acquire Pfizer's Biologics Manufacturing Facilities in China
Merck Signs a Five-Year Agreement with M2GEN to Advance Cancer Therapies
FSD Pharma Signs a License Agreement with Innovet to Develop Veterinary Drugs for Gastro-Intestinal Diseases in Dogs and Cats
Merck's Keytruda (pembrolizumab) Receives the EC's Approval in Adults &amp; Pediatric patients with R/R cHL
Durect's Posimir (bupivacaine solution) Receives the US FDA's Approval for the Treatment of Post-Surgical Pain
Sarepta's Amondys 45 (casimersen) Receives the US FDA's Approval for DMD in Patients Amenable to Skipping Exon 4
GSK Initiates P-III Study of GSK3511294 (GSK'294) for the Treatment of Severe Asthma
B. Braun's Acetaminophen Injection Receives the US FDA Approval in Multiple Doses
Gilead Expands its Collaboration with Novo Nordisk to Evaluate Triple Combination Regimen for Compensated Cirrhosis (F4) due to NASH
Boston Signs Out-License and Option Agreement with GSK to Advance Two Programs for Oncology and CNS Disorders
Pfizer Signs a WW License Agreement with Pyxis to Develop and Commercialize Two ADC Candidates
Sarepta Therapeutics Report Results of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E
Kiniksa's Arcalyst (rilonacept) Receives the US FDA's Approval for the Treatment of Pericarditis
Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases
BMS Reports the US FDA's Acceptance of NDA for Mavacamten to Treat Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Merck Presents Results of Keytruda (pembrolizumab) + Lenvima (lenvatinib) in P-III KEYNOTE-775/Study 309 trial for the Treatment of Advanced Endometrial Cancer at SGO
Janssen's Ponvory (ponesimod) Receives the US FDA's Approval for the Treatment of Relapsing Multiple Sclerosis
BridgeBio Presents Results of Encaleret in P-IIb Study for the Treatment of ADH1 at ENDO 2021
BioMarin Report Results of Vosoritide in P-III OLE Study for the Treatment of Children with Achondroplasia at ENDO 2021
AstraZeneca's AZD1222 Meets its Primary Endpoint in Preventing COVID-19
Takeda Collaborates with Evotec on RNA Targeting Drug Development
Roche Reports Results of Tecentriq in P-III IMpower010 Study for Patients with Early Lung Cancer
Roche Pauses Dosing of Tominersen in P-III GENERATION HD1 for Manifest Huntington's Disease
Insulet Presents Results of Omnipod 5 Automated Insulin Delivery System for T1D at ENDO 2021
Novo Nordisk Receives the US FDA's Refusal to File Letter for Semaglutide to Treat T2D
Regeneron Reports Results of REGEN-COV Antibody Cocktail in P-III Trial to Prevent COVID-19
Roche Launches New Configurations for Cobas Pro to Increase Testing Efficiency
Zealand's Zegalogue (dasiglucagon) Receives the US FDA's Approval for the Treatment of Severe Hypoglycemia
Incyte's Pemazyre (pemigatinib) Receives MHLW's Approval for Unresectable Biliary Tract Cancer with a FGFR2 Fusion Gene
Fresenius Medical Care Collaborates with DaVita to Expand the Use of NxStage Home Hemodialysis Machines
Novo Nordisk Presents Results of Semaglutide in P-IIIa STEP 4 Trial to Treat Obesity at ENDO 2021
Bayer's Vitrakvi Receives MHLW's Approval for the Treatment of NTRK Fusion-Positive Advanced or Recurrent Solid Tumors
AstraZeneca Reports Results of AZD1222 in Primary Analysis of P-III Trial for the Prevention of COVID-19
Chugai's Polivy Receives MHLW's Approval for Relapsed or Refractory Diffuse Large B-cell Lymphoma
J&amp;J Visions' Acuvue Theravision with Ketotifen Receives MHLW's Approval for Vision Correction and Allergic Eye Itch
"EirGenix Report Results of EG12014 (biosimilar, trastuzumab) in P-III Trial for HER2-Positive Breast Cancer"
ProQR Reports Results of QR-421 in P-I/II Stellar Trial for Usher Syndrome
Pfizer and Myovant Report Results of Relugolix Combination Therapy in P-III LIBERTY Withdrawal Study in Women with Uterine Fibroids
BMS Report Results of Relatlimab + Opdivo (nivolumab) in P-II/III RELATIVITY-047 Study in Patients with Previously Untreated Metastatic or Unresectable Melanoma
Takeda Reports EMA's Acceptance of TAK-003 for the Prevention of Dengue
Astellas and Seagen Report EMA's Acceptance of MAA for Enfortumab Vedotin to Treat Locally Advanced or Metastatic Urothelial Cancer
Immunai Acquire Dropprint Genomics to Expand its Target Discovery Capabilities
Tetra Bio-Pharma Initiates Additional Studies of ARDS-003 in Neuroinflammation and Antiviral Diseases
Pfizer and BioNTech Initiate COVID-19 Vaccine Trial in Children Under 12
BMS and bluebird bio's Abecma (idecabtagene vicleucel) Receive the US FDA's Approval as the First Anti-BCMA CAR T Cell Therapy for R/R Multiple Myeloma
GSK's Benlysta (belimumab) Receives CHMP's Opinion Recommending its Approval for Active Lupus Nephritis
Helius Medical's PoNS Receives the US FDA's Approval to Improve Gait in Multiple Sclerosis Patients
GSK and VIR Report EUA Submission to the US FDA for VIR-7831 to Treat COVID-19
Qiagen's NeuMoDx Multiplex Test Receives the US FDA's EUA and Expands its COVID-19 Portfolio
Roche's Tecentriq Receives CHMP's Positive Opinion for 1L Treatment for Metastatic Non-Small Cell Lung Cancer
"Samsung Bioepis Expand its Footprints with the Launch of Hadlima (biosimilar, adalimumab) in Australia and Canada"
Roche and PTC's Evrysdi (risdiplam) Receive the EC's Approval as First and Only at Home Treatment For Spinal Muscular Atrophy
Medtronic's Harmony Transcatheter Pulmonary Valve Receives the US FDA's Approval for Patients with Congenital Heart Disease
Eli Lilly along with VIR and GSK Report Results of Bamlanivimab + VIR-7831 in P-II BLAZE-4 Study for Low-Risk Adults with COVID
Cipla Expands its Partnership with Alvotech to Commercialize Biosimilars in Australia and New Zealand
Cerecor Signs a Worldwide License Agreement with Kyowa Kirin for CERC-00
Novartis' Kesimpta (ofatumumab) Receives the EC's Approval for Adult Patients with Relapsing Multiple Sclerosis
Novartis In-Licenses Fibroblast Activation Protein (FAP) to Expand its Oncology Radioligand Pipeline
Merck to Acquire Alydia Health for ~$240M on Behalf of its Planned Spinoff of Organon
AbbVie Reports the US FDA's Acceptance of NDA for Atogepant as a Preventive Treatment for Migraine
Ipsen's Cabometyx + Opdivo Receive EC's Approval as a 1L Treatment for Patients with Advanced Renal Cell Carcinoma
Amgen to Acquire Rodeo Therapeutics for ~$721M
Waters Launches Peptide Multi-Attribute Method for BioAccord System to Develop and Commercialize Biosimilars
Roche Launches Elecsys Epstein-Barr Virus (EBV) Immunoassay Panel to Identify EBV Infection Staging
"Samsung Bioepis and Yuhan Collaborate for the Commercialization of Adalloce (biosimilar, adalimumab) in Korea"
mAbxience Collaborates with ABEC to Expand Biosimilar and CDMO Manufacturing Capacity
"Henlius Reports First Patient Dosing in P-II/III Study of HLX10 + HLX04 (biosimilar, bevacizumab) for 1L mCRC"
"Henlius' HLX04-O (biosimilar, bevacizumab) Receives the US FDA's IND Approval for wAMD"
"Formycon and Bioeq Confirms BLA Submission Strategy and Timeline for FYB201 (biosimilar, ranibizumab)"
BridgeBio Collaborates with Helsinn to Co- Develop and Commercialize Infigratinib in Oncology
BioXcel Report Results of BXCL501 in P-Ib/II RELEASE Study for the Treatment of Opioid Withdrawal Symptoms
Amryt Reports NDA Submission for Oleogel-S10 (filsuvez) to Treat Cutaneous Manifestations of Junctional and Dystrophic Epidermolysis Bullosa
ADQ to Acquire Amoun Pharmaceutical from Bausch Health for ~$740M
Sanofi's Sarclisa (isatuximab-irfc) + Carfilzomib and Dexamethasone Receives the US FDA's Approval for the Treatment of R/R Multiple Myeloma
"Alnylam Report Results of Lumasiran in P-III ILLUMINATE-A Study for Primary Hyperoxaluria Type 1, Published in NEJM"
BeyondSpring Submits NDA to the US FDA and China NMPA for Plinabulin to Prevent CT-Induced Neutropenia
Kite Reports Submission of sBLA to the US FDA for Tecartus in Adult Patients with R/R Acute Lymphoblastic Leukemia
Janssen and SpringWorks Reports Dosing of First Patient in P-Ib trial for Nirogacestat + Teclistamab to Treat Relapsed or Refractory Multiple Myeloma
Revance Presents Results of DaxibotulinumtoxinA for Injection in P-III ASPEN-1 Trial for the Treatment of Cervical Dystonia at AAN2021
"Acceleron Presents Results of Sotatercept in P-II PULSAR Trial for the Treatment of Pulmonary Arterial Hypertension, Published in NEJM"
Pfizer and BioNTech Report Results of BNT162b2 to Prevent COVID-19
Merck KGaA Exercises Third Option in its Immuno-Oncology Collaboration with F- star
Gilead Expands its Collaboration with AbCellera to Develop Antibodies Against Multiple Indications
Taiho Oncology's Futibatinib (TAS-120) Receives the US FDA's Breakthrough Therapy Designation for Advanced Cholangiocarcinoma
Lilly's Taltz (ixekizumab) Receives Health Canada's Approval for Pediatric Patients with Moderate to Severe Plaque Psoriasis
"mAbxience's MB02 (biosimilar, bevacizumab) Receives EC's Approval for the Treatment of Cancer"
uniQure Reports Completion of Enrollment in First Cohort of P- I/II Trial for AMT-130 to Treat Huntington's Disease
Sorrento to Acquire ACEA Therapeutics for ~$488M
Welldoc Expands their Partnership with Dexcom to Offer Type 2 Diabetes Management Solution
Ultragenyx Collaborates with n-Lorem Foundation to Advance Personalized Medicines Treatment for Patients with Ultra-Rare Diseases
Exelixis Reports the US FDA's Acceptance of IND for XB002 in Patients with Advanced Solid Tumors
Horizon Presents Results of Uplizna (inebilizumab-cdon) in N-MOmentum Trial for NMOSD at AAN 2021
Passage Bio's PBKR03 Receives EC's Orphan Drug Designation for Krabbe Disease
The US FDA Extends Review Period of Olumiant's sNDA to Treat Moderate to Severe Atopic Dermatitis
Pear Sign a Multiple Agreements to Expands its Prescription Digital Therapeutic Platform
Progenity Signs an Agreement with Ionis Pharmaceuticals to Evaluate Oral Biotherapeutics Delivery System with Antisense Oligonucleotides
AstraZeneca Collaborates with MGH to Accelerate Digital Health Solutions
J&amp;J Vision Collaborates with Menicon to Offer Contact Lenses for Managing the Progression of Myopia in Children
Novartis Collaborates with Artios Pharma to Discover Next Generation DDR Cancer Therapies
BMS and PsiOxus Therapeutics Expand their 2016 Immuno-Oncology Collaboration
"Biogen's Tysabri (natalizumab, SC) Receives EC's Marketing Authorization to Treat Relapsing-Remitting Multiple Sclerosis"
AbbVie Submits Regulatory Applications to the US FDA and EMA for Skyrizi (risankizumab) to Treat Psoriatic Arthritis
Merck KGaA Selects PRA's Remote Patient Monitoring Platform for Human Growth Hormone Treatment System
Daiichi Sankyo Reports First patient Dosing in P- I/II Trial of DS-1594 to Treat Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER Study for Hospitalized Patients with COVID-19
Top 20 BioPharma Companies based on 2020 Total Revenue
"Biogen Signs a License and Commercialization Agreement with Bio-Thera for BAT1806 (biosimilar, tocilizumab) to Treat Moderate to Severe Rheumatoid Arthritis"
Hologic to Acquire Mobidiag for ~ $795M
Merck Report Results of Keytruda (pembrolizumab) in P-III KEYNOTE-564 Trial as Adjuvant Treatment for Renal Cell Carcinoma
BMS Reports Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC
PlantForm Signs Research and Development Agreement with Bio-Manguinhos/Fiocruz to Develop Biosimilar Pembrolizumab
Evotec and Exscientia Initiate Human Clinical Trials of their Novel Immuno-Oncology Drug
Sanofi to Acquire Tidal Therapeutics for ~$470M
Roche Report Results of Ab Cocktail (Casirivimab + Imdevimab) in P-III REGN-COV 2069 Trial for Symptomatic COVID 19 Infection
AstraZeneca's Farxiga (dapagliflozin) Fails to Meet its Primary Endpoint in P-III DARE-19 Trial for COVID 19
Daiichi Sankyo Initiates P-II Trial of Pexidartinib for Tenosynovial Giant Cell Tumor in Japan
Bayer Reports Results of Aliqopa (copanlisib) + Rituximab in P-III CHRONOS-3 Study for Relapsed Indolent Non-Hodgkin's Lymphoma
BMS Presents Results of Opdivo (nivolumab) + CT in P-III CheckMate-816 Trial for Resectable NSCLC at AACR2021
Microsoft to Acquire Nuance for ~$19.7B
Novartis's Xolair (omalizumab) Prefilled Syringe for Self-Injection Receives the US FDA's Approval Across All Indications
Sage and Biogen Report Results of SAGE-324 in P-II KINETIC Study for Essential Tremor
DiaSorin to Acquire Luminex for ~$1.8B
Sanofi Collaborates with C4XD for an Oral Therapy to Treat Inflammatory Diseases
Avantor to Acquire Ritter and its Affiliates for ~$1.06B
J&amp;J Pauses Dosing of COVID-19 Vaccine Due to Blood Clotting
Roche and Biocorp Launch Mallya Smart Insulin Pen for Patients with Diabetes in France
AstraZeneca's Tagrisso (osimertinib) Receives the NMPA's Approval for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer
Spark Therapeutics Signs an Option Agreement with Senti Bio to Develop Precision Gene Therapies
Innovent and Lilly Present Results of Tyvyt (sintilimab) in P-III ORIENT-3 Trial as 2L Treatment for Advanced or Metastatic Squamous NSCLC at AACR 2021
Merck KGaA Expand its Collaboration with NKMax to Evaluate the Combination of SNK01 + Erbitux (cetuximab) for Metastatic NSCLC
Eli Lilly Signs an Exclusive License Agreement with SciNeuro to Develop and Commercialize Alpha-synuclein Targeted Therapies in China
Genentech Presents Results of Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA at AAN2021
Medtronic Launches World's First Extended Insulin Infusion Set to Reduce Burden for People with Diabetes in Europe
BMS' Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive EC's Approval for 1L Treatment of Advanced Renal Cell Carcinoma
Melinta's Kimyrsa (oritavancin) Receives the US FDA's Approval for the Treatment of Acute Bacterial Skin and Skin Structure Infections
The US FDA Approves New Indication and Formulation for Astellas' Myrbetriq
AVEO Oncology's Fotivda (tivozanib) Receives the US FDA's Approval for the Treatment of R/R Advanced Renal Cell Carcinoma
Boehringer Ingelheim and MD Anderson Expand their Collaboration to Accelerate Targeted Therapies for Lung Cancer
Corium's Azstarys (serdexmethylphenidate and dexmethylphenidate) Receives the US FDA's Approval for ADHD in Patients Aged 6 Years and Older
Althera's Roszet (rosuvastatin and ezetimibe) Receives the US FDA's Approval for Treatment of Elevated Low-Density Lipoprotein Cholesterol
"Prestige Biopharma and Pharmapark Sign an Exclusive License and Supply Agreement to Commercialize HD204 (biosimilar, bevacizumab) in Russia"
Genentech Presents New Data of Ocrevus (ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis at AAN2021
Omada Health Launches the First Virtual Cardiometabolic Clinic for Patients with Diabetes and Hypertension
GSK Discontinues the P-II Trials of Feladilimab for Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
Roche's Evrysdi (risdiplam) Receives Health Canada's Approval for Spinal Muscular Atrophy in Adults and Children
ThermoFisher to Acquire PPD for ~$17.4B
"Zogenix Presents Results of Fintepla's (fenfluramine) Study Highlighting the Impact of Treatment on Dravet Syndrome Patients, Caregivers, and Families at AAN 2021"
Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER Study for Hospitalized Patients with COVID-19
Sanofi's Sarclisa (isatuximab) Receives EC's Approval for Adults with Relapsed and Refractory Multiple Myeloma
Evotec Signs a License Agreement with Kazia Therapeutics for Clinical Development of EVT801
Janssen Presents Results of Nipocalimab (M281) in P-II Vivacity-MG Study for Adults with Generalized Myasthenia Gravis at AAN2021
Novartis Reports Results of Kesimpta (ofatumumab) in P- III ASCLEPIOS Trials for Newly Diagnosed Patients with RMS
Incyte and MorphoSys Report First Patient Dosing in P-III inMIND Study for Relapsed or Refractory Follicular or Marginal Zone Lymphoma
Astellas and Seagen Report the US FDA's Acceptance of Two sBLA for Padcev (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
Alnylam Presents Results of Vutrisiran in P-III HELIOS-A Study for Patients with hATTR Amyloidosis with Polyneuropathy at AAN 2021
Biogen and Eisai Report Results of Lecanemab (BAN2401) in P-IIb Study 201 for Patients with Early Alzheimer Disease
"Janssen's Darzalex (daratumumab, SC) Combination Regimen Receives Health Canada's Approval for Patients with Newly Diagnosed Light Chain Amyloidosis"
Lilly and Incyte Report Results of Baricitinib in P-III BRAVE-AA1 Study for Severe Alopecia Areata
Vertex Amend its Collaboration with CRISPR Therapeutics for Development and Commercialization of CTX001 in SCD and Beta Thalassemia
Jazz Presents Results of Xywav (Oral Solution) in P-III Withdrawal Study for Adult Patients with Idiopathic Hypersomnia at AAN2021
SparingVision Acquires GAMUT Therapeutics to Expands its Novel Ocular Disease Pipeline
Janssen Collaborates with PhysIQ for Wearable Biosensors and Digital Biomarkers Initiatives
GW Pharmaceuticals' Epidyolex (cannabidiol) Receives EC's Approval for the Treatment of Seizures Associated with Tuberous Sclerosis Complex
LEXEO Therapeutics Receives the US FDA's Fast Track Designation for LX1001 to Treat APOE4 Associated Alzheimer Disease
Medtronic Receives the US FDA's Approval for Pipeline Flex Embolization Device with Shield Technology
Novo Nordisk to Initiate P-IIIa Study for Oral Semaglutide to Treat Obesity
TG Therapeutics Initiates Patient Enrolment in P-III ULTRA-V Trial for Triple Combination Regimen to Treat R/R Chronic Lymphocytic Leukemia
AgeneBio Reports Completion of Patient Enrollment in P-IIB HOPE4MCI Trial for AGB101 to Treat Amnestic Mild Cognitive Impairment due to Alzheimer Disease
Johnson &amp; Johnson Publishes Results of COVID-19 Single Shot Vaccine in NEJM
Claritas Collaborates with CMAX to Initiate P-I Study of R-107 for Pulmonary Arterial Hypertension
PharmaShots' Key Highlights of First Quarter 2021
Vertex Signs a License Agreement with Obsidian Therapeutics to Discover Regulated Gene Editing Therapies
Roche Receives the US FDA's Approval for First CDx to Identify Endometrial Cancer Patients Eligible for Immunotherapy
GSK's Jemperli (dostarlimab-gxly) Receives the US FDA's Approval for dMMR Endometrial Cancer
AbbVie's Humira (adalimumab) Receives Health Canada's Approval for Pediatric Patients with Active Ulcerative Colitis
Gilead Reports NDA Submission of Filgotinib to PMDA for Ulcerative Colitis in Japan
BMS' Opdivo + Yervoy and Onureg Receive EC's CHMP Positive Opinion for MPM and AML
BMS Presents Results of Deucravacitinib in Two P- III Trials for Moderate to Severe Plaque Psoriasis at AAD2021
GSK's Jemperli (dostarlimab) Receives the EC's Approval for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer
Dermavant Presents Results of Tapinarof in Two P-III Trials for the Treatment of Psoriasis at AAD2021
Sanofi and AstraZeneca Report Results of Nirsevimab in P-III MELODY Study for the Protection of Healthy Infants Against Respiratory Syncytial Virus Disease
AstraZeneca and MSD's Selumetinib Receive EU's CHMP Positive Opinion as the First Therapy for Pediatric Patients with Neurofibromatosis Type 1 Plexiform Neurofibromas
AstraZeneca's Tagrisso (osimertinib) Receives EU's CHMP Positive Opinion for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer
"Biocon Biologics and Viatris Receive European Commission Approval for Abevmy (biosimilar, bevacizumab)"
Medtronic Collaborates with Surgical Theater to Provide Augmented Reality Platform to Neurosurgery
I-Mab Reports Results of Olamkicept (TJ301) in P-II Study for Ulcerative Colitis
Pieris Out-licenses PRS-342 to Boston Pharmaceuticals for ~$363M
Daiichi Sankyo Expands its Collaboration with Esperion to Additional Territories
Glenmark's Ryaltris Nasal Spray Receives EC's Approval as 1L Treatment for Allergic Rhinitis
The US FDA Grants Priority Review to Takeda's Mobocertinib (TAK-788) for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer
Abbott Launches AI-Powered Coronary Imaging Platform in Europe
Y-mAbs Reports MAA Submission to EMA for Omburtamab to Treat Pediatric Patients with CNS/Leptomeningeal Metastasis from Neuroblastoma
InveniAI Collaborates with Shionogi on AI-Based Drug Discovery
LogicBio Signs an Option Agreement with Canbridge to Develop Gene Editing Therapies
Voluntis Collaborates with Eisai to Develop Digital Therapeutics for Oncology Patients
Pfizer Acquires Amplyx to Expand its Infectious Disease Portfolio
Organicell Reports the Expansion of its Trial for Zofin to Treat COVID-19 Patients in India
BioMarin Collaborates with Allen Institute to Develop Gene Therapies for Rare Brain Diseases
BeiGene Reports Results of Brukinsa (zanubrutinib) in P-III Head-to-Head APSEN Trial for R/R Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Alcon to Acquire Exclusive US Commercialization Rights to Novartis' Simbrinza
Angion and Vifor Pharma Report Completion of Patient Enrollment in P-II AKI-002-15 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury
Alphamab and Pfizer Initiate P-II Trial Evaluating KN046 + Inlyta (axitinib) as a 1L Treatment of Non-Small Cell Lung Cancer
Innovent Reports First Patient Dosing in P-II Trial of IBI302 for Neovascular Age-Related Macular Degeneration
Celltrion Reports Results of Regdanvimab (CT-P59) in Pre-Clinical Study Against the South African Variant (B.1.351)
Repertoire Collaborates with Yale University to Identify Novel Antigen and T- Cell Receptor for Multiple Sclerosis
Janssen Reports MAA Submission to EMA for Cilta-cel to Treat Relapsed/ Refractory Multiple Myeloma
BMS Reports the US FDA's Acceptance of Opdivo's sBLA for Priority Review to Treat Muscle Invasive Urothelial Carcinoma
AstraZeneca's Farxiga (dapagliflozin) Receives the US FDA's Approval for Chronic Kidney Disease
Samsung Bioepis Presents Results of SB11 (proposed biosimilar ranibizumab) at ARVO 2021
Novartis Presents Results of Beovu (brolucizumab -dbll) in P-III KESTREL and KITE Studies for Diabetic Macular Edema at ARVO2021
British Columbia Adds Humira Adalimumab to Biosimilar Switching Program
Valeo Pharma Launches Redesca and Redesca HP (LMHW biosimilar) in Canada
Xcenda's FormularyDecisions Launches Resource Hub for Biosimilars
Sobi and Hellenic Institute Report Results of Anakinra in P-III SAVE-MORE Study for Hospitalized Patients with COVID-19 Pneumonia
Guardant Health Reports Results of Blood-Only Liquid Biopsy Test Predicting Risk of Colorectal Cancer Recurrence
Eli Lilly and Incyte Present New Data of Olumiant (baricitinib) in P-III BREEZE-AD5 Trial Moderate to Severe Atopic Dermatitis at AAD2021
Province Expands the Use of Biosimilars to Improve the Sustainability of Public Drug Plans
"Boehringer Ingelheim Reports Results of Cyltezo (biosimilar, adalimumab) in P-III VOLTAIRE-X Study for Moderate-to-Severe Chronic Plaque Psoriasis"
New Brunswick Government Introduces Biosimilars Switch Policy to Improve Patient Access to Safe and Effective Medicine
Roivant Going Public Via MAAC SPAC Merger for ~$7.3B
Labcorp to Acquire Myriad's Vectra Testing Business for $150M
Sandoz Initiates Patient Enrolment of Proposed Biosimilar Aflibercept in P-III MYLIGHT Study for Neovascular Age-Related Macular Degeneration
Novavax Reports the Pediatric Expansion for P-III Clinical Trial of NVX-CoV2373 Against COVID-19
BMS Presents Clinical and RWE Data of Mavacamten for Obstructive Hypertrophic Cardiomyopathy at ACC 2021
Vaxart Reports News Data of VXA-CoV2-1 (Oral COVID-19 Vaccine) in P-I Trial Against Other Coronaviruses
Athenex to Acquire Kuur Therapeutics for ~$185M
Roche's Tecentriq Receives EC's Approval as 1L Treatment for Metastatic Non-Small Cell Lung Cancer
"Amgen Launches Amgevita (biosimilar, adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases in Canada"
AbCellera to Initiate Clinical Trial of LY-CoV1404 Against Viral Variants of COVID 19
ProQR Therapeutics Signs an Exclusive Worldwide License Agreement with Yarrow to Develop Therapies for Non-Ophthalmic Target
Exelixis Acquires GamaMabs' Oncology Antibody Program to Expand its Biotherapeutics Portfolio
GSK's Benlysta (belimumab) Receives EC's Approval for the Treatment of Active Lupus Nephritis
Phenomix Collaborates with Mayo Clinic for AI-Powered Obesity Phenotype Blood Test
Medtronic Launches CareGuidePro App for Managing Spinal Cord Stimulation
Sanofi Signs a Three-Year Collaboration with Stanford Medicine to Accelerate Immunology Research
Roche's Ab Cocktail (Casirivimab and Imdevimab) Receives EUA to Treat COVID-19 in India
Amgen Reports the US FDA's Acceptance of sNDA for Review of Otezla (apremilast) to Treat Mild-To-Moderate Plaque Psoriasis
Merck and Eisai Receive the US FDA‘s Priority Review for Keytruda (pembrolizumab) + Lenvima (lenvatinib) to Treat Advanced Renal Cell Carcinoma and Endometrial Carcinoma
AbCellera Signs a Multi-Target Collaboration with Angios to Develop Bispecific Antibodies for the Treatment of Diabetic Retinopathy
BeiGene and Asieris Enter into Clinical Collaboration for APL-1202 + Tislelizumab to Treat Muscle Invasive Bladder Cancer
BMS Signs a Research Collaboration with DarwinHealth to Discover Novel Cancer Target Initiative
Merck and Fusion Pharmaceuticals Enter into a Clinical Collaboration for FPI-1434 + Keytruda (pembrolizumab) to Treat Solid Tumors Expressing IGF-1R
AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV Non-Small Cell Lung Cancer
GSK and Vir Report Initiation of EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19
BD to Spin Off its Diabetes Care Business into New Public Company
Eli Lilly Signs an International Agreements with Four Diabetes Technology Companies for Connected Insulin Pen Solutions
Walmart Health Signs an Agreement to Acquire MeMD for its Telehealth Services
Pfizer and BioNTech Initiate Rolling Submission of BLA for the US FDA's Approval of their COVID-19 Vaccine
Aurinia Publishes the Results of Lupkynis (voclosporin) in P-III AURORA 1 Study for Patients with Active Lupus Nephritis in The Lancet
Bayer Reports Results of Finerenone in P- III FIGARO-DKD CV Outcomes Study for Chronic Kidney Disease and Type 2 Diabetes
Pfizer and BioNTech Receive the US FDA's EMA for COVID-19 Vaccine in Adolescents
AstraZeneca and Amgen Submit BLA to US FDA for Tezepelumab to Treat Severe Asthma
Allergan Aesthetics to Acquire Soliton and its Resonic Device for ~$550M
Biogen Collaborates with Capsigen to Discover Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
Lilly Signs a ~$1.25B Research Collaboration with MiNA Therapeutics to Develop saRNA Therapies
Autobahn Acquires Global Rights to Astellas' ASP3652 to Bolster its Brain Targeting Chemistry Platform
Cellectis Collaborates with Sanofi for Alemtuzumab to be Utilized in CART-Cell Trials
Incyte and MorphoSys Report First Patient Dosing in P-III frontMIND Study of Tafasitamab + Lenalidomide as a 1L Treatment for DLBCL
Nanobiotix Collaborates with Lianbio to Develop and Commercialize NBTXR3 in China and other Asian Countries
Medtronic Launches SonarMed Airway Monitoring System to Detect Airway Obstruction During Ventilation in Pediatric Patients
ADC Therapeutics' Zynlonta (loncastuximab tesirine-lpyl) Receives the US FDA's Approval for the Treatment of R/R Diffuse Large B-Cell Lymphoma
InflaRx Reports Results of Vilobelimab in P- II IXPLORE Study in Patients with Anti-Neutrophil Cytoplasmic Autoantibody Associated Vasculitis
Mayne Pharma' Nextstellis Receives the US FDA's Approval for the Prevention of Pregnancy
Biogen Exercises its Option to Acquire TMS-007 for Acute Ischemic Stroke
Supernus' Qelbree (SPN-812) Receives the US FDA's Approval for the Treatment of ADHD
Regeneron and Sanofi Present Positive Results of Libtayo (cemiplimab) from P-III Trial for Cervical Cancer at ESMO2021
Antengene Receives IND Approval for P-III SIENDO Trial of XPOVIO (Selinexor) to Treat Advanced or Recurrent Endometrial Cancer in China
AstraZeneca and Amgen Present Results of Tezepelumab in P-III NAVIGATOR Study for Severe Asthma at ATS2021
Fulcrum Therapeutics' Losmapimod Receives the US FDA's Fast Track Designation to Treat Facioscapulohumeral Muscular Dystrophy
Dr Reddy's Acquires an Exclusive License for Pregene's PRG1801 in India
Hikma' Kloxxado (naloxone hydrochloride) Receives the US FDA's Approval for the Treatment of Opioid Overdose
Biogen and Envisagenics Enter into a Collaboration for the Advancement of RNA Splicing Research to Treat Central Nervous System Diseases
Novo Nordisk Reports Results of Semaglutide from P-IIIa STEP 1 Trial in Patients with Obesity
Heron Therapeutics' ZYNRELEF (HTX-011) Receives the US FDA's Approval for the Management of Postoperative Pain
Reistone Reports First Patient Dosing in P-III RSJ10333 Trial of SHR0302 for the Treatment of Atopic Dermatitis
Goldfinch Bio Initiates P-I Clinical Trial of GFB-024 for the Treatment of Severe Insulin Resistant Diabetic Nephropathy
AzurRx BioPharma Reports Positive Interim P-II Data of MS1819 + PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
Biogen's BIIB112 (cotoretigene toliparvovec) Fails to Meet its Primary Endpoint in P-II/III XIRIUS Study for XLRP
BMS Presents Results of Mavacamten in P-III Study for Obstructive Hypertrophic Cardiomyopathy at ACC 2021
Sanofi and GSK Report Results of its COVID-19 Vaccine in a P-II Study Across All Adult Age Groups
PerkinElmer to Acquire Immunodiagnostic Systems Holdings for ~$155M
Apellis' Empaveli (pegcetacoplan) Receives the US FDA's Approval for Paroxysmal Nocturnal Hemoglobinuria
Charles River to Acquire Vigene Biosciences for $292.5M
Abbott Receives CE Mark for Next-Generation Navitor TAVI System to Treat Aortic Stenosis
Regeneron and Sanofi Present Results of Dupixent (dupilumab) in P-III VOYAGE Study for Asthma at ATS 2021
Eli Lilly and Innovent Report the US FDA's Acceptance of Sintilimab + Chemotherapy's BLA for 1L Treatment for Non-Squamous NSCLC
Roche Receives the US FDA's EUA for cobas SARS-CoV-2 Test to Suspect COVID-19
Medicago and GSK Report Results of Plant-Derived Vaccine in a P-II Study for COVID-19
BlueRock Collaborates with Fujifilm and Opsis to Discover and Develop Cell Therapies for Eye Diseases
BMS Signs an Exclusive Global License with Agenus for its Anti-TIGIT Bispecific Antibody Program
Sarepta's SRP-9001 Demonstrates Robust Expression and Safety Results in ENDEAVOR Study for DMD
Glaukos Expands its Partnership with Santen for Preserflo MicroShunt
Janssen Signs an Option and License Agreement with Mestag to Discover Novel Fibroblast Targets for Inflammatory Disease
BMS Extends its 2019 Collaboration with Exscientia for AI Driven Drug Discovery
BioXcel Reports the US FDA's Acceptance of BXCL501's NDA for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II
Genentech Reports Results of Tecentriq in P-III IMpower010 Study for 1L Treatment of NSCLC
Takeda Presents Results of Mobocertinib in P-I/II Study for Patients with EGFR Exon20 Insertion+ mNSCLC
Janssen Reports Updated Data of Amivantamab + Lazertinib in P-I CHRYSALIS Study for EGFR-Mutated NSCLC
Allogene Reports Results of ALLO-501 and ALLO-501A in P-I Studies for Relapsed/Refractory Non-Hodgkin Lymphoma
Janssen to Present Results of Imbruvica (ibrutinib)-based Combination Regimen as 1L Treatment for Chronic Lymphocytic Leukemia at ASCO
Lilly Reports Results of Tirzepatide in SURPASS-4 Study for Patients with Type 2 Diabetes
Moderna's COVID-19 Vaccine Receives Approval for Emergency Use in Japan
AstraZeneca's Vaxzevria (AZD1222) Receives Approval for Emergency Use in Japan to Treat COVID-19
Takeda Reports the US FDA's Acceptance and Priority Review of Maribavir's NDA for Post-Transplant CMV Infection
Astellas and Seagen Report Updated Results of Padcev in Two Studies for Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy
Aurinia to Present Results of Lupkynis (voclosporin) in AURORA 2 Continuation Study for Lupus Nephritis at EULAR 2021
BeiGene Reports Results of Tislelizumab + CT in P-III RATIONALE 309 Study as 1L Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
BMS Receive the CHMP's Positive Opinion Recommending Approval of Opdivo (nivolumab) + Yervoy (ipilimumab) for dMMR or MSI-H mCRC After Prior Chemotherapy
Janssen's Rybrevant (amivantamab-vmjw) Receives the US FDA's Approval as the First Targeted Treatment for Patients with NSCLC with EGFR Exon 20 Insertion Mutations
Regeneron Receives CHMP's Positive Opinion Recommending the Approval of Libtayo (cemiplimab) for NSCLC and BCC
Takeda Reports Long-Term Safety and Efficacy Results of its Dengue Vaccine Candidate
Lilly Presents Results of Mirikizumab in P-II SERENITY Study for Crohn's Disease at DDW 2021
Pfizer Initiates Study to Evaluate its Pneumococcal Vaccine with Booster dose of its COVID-19 Vaccine
Boehringer Ingelheim to Develop Dicerna's GalXC RNAi Candidate for NASH
"Janssen's Stelara Fails to Show Superiority over AbbVie's Humira in P-IIIb SEAVUE Study for Crohn's Disease, Presented at DDW 2021"
AbbVie Presents New Late-Breaking Data Analyses of Skyrizi (risankizumab) for Crohn's Disease at DDW 2021
Bayer Seeks Approval of Larotrectinib for Advanced Solid Tumors in China
Boehringer Ingelheim's BI 425809 Receives the US FDA's Breakthrough Therapy Designation for Cognitive Impairment Associated with Schizophrenia
Merck Signs a Clinical Trial Collaboration with Xilio for Anti-CTLA-4 Monoclonal Antibody Program
BMS and Xencor Collaborate to Use Xtend XmAb Technology in SARS-CoV-2 Neutralizing mAb Combination for COVID-19
QIAGEN Collaborates with Mirati to Develop KRASG12C CDx for Non-Small Cell Lung Cancer
"BioFactura Initiates P-I Study of BFI-751 (biosimilar, ustekinumab) in Australia and New Zealand"
AbbVie's Venclyxto Receives the EC's Approval for Patients with Newly Diagnosed Acute Myeloid Leukemia who are Ineligible for Intensive Chemotherapy
Moderna's mRNA-1273 Meets its Primary Endpoint in P-II/III TeenCOVE Study to Prevent COVID 19 in Adolescents
TG Therapeutics Reports the US FDA's Acceptance of BLA for Ublituximab + Ukoniq (umbralisib) to Treat Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
GSK and Vir Receive the US FDA's EUA for Sotrovimab (VIR-7831) to Treat COVID-19 in Adults and Pediatric Patients
Pfizer and Myovant's Myfembree Receive the US FDA's Approval for Heavy Menstrual Bleeding Associated with Uterine Fibroids
Sanofi and GSK Initiate P-III Clinical Study of their COVID-19 Vaccine
Novartis and Molecular Partners Initiate P-II/III EMPATHY Study to Evaluate Ensovibep (MP0420) for the Treatment of COVID-19
Senti Bio Collaborates with BlueRock to Develop Gene Circuit Engineered Cell Therapies for Regenerative Medicine
Eli Lilly to Initiate P-I Study of LY3819469 for Cardiometabolic Diseases
ONO and BMS' Opdivo + Yervoy Receive Approval for 1L Treatment for Unresectable Advanced or Recurrent Malignant Pleural Mesothelioma
BMS' Zeposia (ozanimod) Receives the US FDA's Approval for Ulcerative Colitis
AstraZeneca's Tagrisso (osimertinib) Receives EU's Approval for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer
uniQure Provides Positive Recommendation to Advance P- I/II Study of AMT-130 for Huntington Disease
The US FDA's EMDAC Supports Provention Bio's Teplizumab in Delaying Diabetes
Seelos' SLS-005 (Trehalose) Receives EC's Orphan Drug Designation to Treat Amyotrophic Lateral Sclerosis
Amgen's Lumakras (sotorasib) Receives the US FDA's Approval as the First KRAS Blocking Cancer Therapy
Pfizer and BioNTech Receive EC's Conditional Marketing Approval for the COVID-19 Vaccine in Adolescents
Novartis Reports One Year Results of Beovu (brolucizumabin) in P- III MERLIN Study to Treat Wet Age-Related Macular Degeneration
BridgeBio and Helsinn's Truseltiq (infigratinib) Receive the US FDA's Approval for Cholangiocarcinoma
Novo Nordisk Resubmits Label Expansion Application to the US FDA for Semaglutide (2.0mg)
Ipsen Reports the US FDA's Acceptance of NDA for Palovarotene to Treat Fibrodysplasia Ossificans Progressiva
BMS' Abecma (idecabtagene vicleucel) Receives the Health Canada's Approval as the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma
Sanofi Stops the P-II/III STAGED-PKD Study of Venglustat for Autosomal Dominant Polycystic Kidney Disease
AB Science Holds the Clinical Studies of Masitinib Globally
Biohaven's Nurtec ODT (rimegepant) Receives the US FDA's Approval for Treatment of Migraine
Amgen and Kyowa Kirin Collaborate to Develop and Commercialize KHK4083 for Atopic Dermatitis
Santhera and ReveraGen Report Results of Vamorolone in P-IIb VISION-DMD Study for Duchenne Muscular Dystrophy
Novartis' Cosentyx (secukinumab) Receives the US FDA's Approval for the Treatment of Moderate to Severe Plaque Psoriasis
Janssen's Teclistamab Receives the US FDA's Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma
Alnylam Reports Completion of Patient Enrollment in P-III APOLLO-B Study for Patisiran to Treat Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy
AstraZeneca Presents Results of Anifrolumab in New Post-Hoc Analysis of P-III TULIP Study for Systemic Lupus Erythematosus at EULAR 2021
Novartis Presents Two-Year Data of Cosentyx in P-III JUNIPERA Study for JPsA and ERA at EULAR 2021
AbbVie Presents Results of Long-Term Efficacy and Safety Analyses for Rinvoq (upadacitinib) in P-III SELECT-COMPARE Study for Rheumatoid Arthritis at EULAR 2021
MorphoSys to Acquire Constellation Pharmaceuticals for ~$1.7B
Prime Therapeutics Launches MedDrive for Greater Biosimilar Drug Adoption
BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive EC's Approval for 1L Treatment for Unresectable Malignant Pleural Mesothelioma
Xbrane to Initiate New Biosimilar Development Program Annually
Novartis Presents Results of Kymriah in P-II ELARA Study for Relapsed or Refractory Follicular Lymphoma at ASCO 2021
Quebec Reports the Intention on Implementing Shift Towards Biosimilars
Sandoz Canada Congratulates the Quebec Government on Implementing a Shift Towards Biosimilars
"Sandoz Launches Inclunox and Inclunox HP (biosimilar, enoxaparin sodium solution) in Canada"
"Zydus Cadila Launches Ujvira (biosimilar, trastuzumab emtansine) for Early and Advanced HER2 Positive Breast Cancer"
"Celltrion Presents One Year Results of Yuflyma (biosimilar, adalimumab) in P-III CT-P17 3.1 Trial for Rheumatoid Arthritis at EULAR 2021"
Meiji Reports Results of P-I Study of DMB-3115 (proposed ustekinumab biosimilar) and Initiate P-III Study for Plaque Psoriasis
Lupin Reports the US FDA Acceptance of BLA for Pegfilgrastim Biosimilar
"Biogen and Bio-Thera Report Results of BAT1806 (biosimilar, tocilizumab) in P-III Study for Moderate to Severe Rheumatoid Arthritis"
"The US Supreme Court Denies Sandoz's Petition for Erelzi (biosimilar, etanercept)"
Viatris Expects its First Interchangeable Designation for Insulin Products
Alvotech Seeks to End the AbbVie's Wrong Monopoly on Humira and Develops New Biosimilar for Chronic Pain
Innovent and Lilly's Tyvyt (sintilimab injection) + Gemcitabine and Platinum CT Receive NMPA's Approval as 1L Therapy for Squamous Non-Small Cell Lung Cancer
Merck Presents Results of Keytruda (pembrolizumab) in P-III KEYNOTE-564 as Adjuvant Therapy for Renal Cell Carcinoma at ASC0 2021
United Therapeutics Reports the First Patient Enrollment in P-III TETON Study of Tyvaso for Idiopathic Pulmonary Fibrosis
BMS Presents Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC at ASCO 2021
Dermavant Submits NDA to the US FDA for Tapinarof Cream to Treat Plaque Psoriasis
Tonix Pharmaceuticals Presents Results of TNX-102 SL in P-III RELIEF study for the Management of Fibromyalgia at ASCP 2021
Novartis Presents Results of Iptacopan in P-II Study for IgA Nephropathy at ERA-EDTA Congress
ProMetic' Ryplazim (plasminogen) Receives the US FDA's Approval as First Treatment for Patients with Plasminogen Deficiency
"Novo Nordisk's Wegovy (semaglutide, 2.4mg) Receives the US FDA's Approval for Weight Management in Adults with Obesity"
AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III Head-to-Head ELEVATE-RR Trial for Chronic Lymphocytic Leukemia
AstraZeneca Reports Updated Results of Imfinzi (durvalumab) in P-III PACIFIC Trial for Non-Small Cell Lung Cancer
SpringWorks and Seagen Enter into a Clinical Collaboration to Evaluate Nirogacestat + SEA-BCMA for R/R Multiple Myeloma
Biogen and Eisai's Aduhelm (aducanumab-avwa) Receive the US FDA's Accelerated Approval for Alzheimer Disease
MSD Animal Health Acquires LICA's Assets to Enhance its Dairy Farm Management Solutions
Janssen Discontinues its 2018 License Agreement with Argenx for Cusatuzumab
Roche's SARS-CoV-2 Antigen Test Receives CE mark For Self Testing of COVID-19 at Home
BeiGene Reports NMPA's Acceptance of sBLA for Tislelizumab to Treat MSI-H or dMMR Solid Tumors
AbbVie's Rinvoq (upadacitinib) Receives the Health Canada's Approval for the Treatment of Psoriatic Arthritis
Bayer to Advance its Investigational Cell and Gene Therapy for Parkinson's Disease
Progentec Signs a Research Collaboration with GSK to Evaluate Proteomics and Digital Health Tools for SLE
Pfizer's Prevnar 20 (Pneumococcal 20-Valent Conjugate Vaccine) Receives the US FDA's Approval for the Prevention of Invasive Disease and Pneumonia
Cardiff Oncology Reports First Patient Dosing in P-II Trial for Onvansertib + Irinotecan and 5-FU as a 2L Treatment for Metastatic Pancreatic Ductal Adenocarcinoma
"Bio-Thera Reports the Initiation of P-III Clinical Trial for BAT2506 (biosimilar, golimumab)"
AbbVie Collaborates with Caraway to Develop TMEM175 for Parkinson's Disease and Other Related Disorders
Merck Signs ~$1.2B Supply Agreement with US Government for Molnupiravir to Treat COVID-19
Inovio Expands its Partnership with Advaccine to Initiate P-III Efficacy Trial for INO-4800 to Treat COVID-19
Hummingbird Collaborates with Novogene to Expand Precision Therapy Testing for NRG1-Fusion Driven Cancers in China
Vertex's Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Receives the US FDA's Approval in Children Aged 6 to 11 with Certain Mutations in Cystic Fibrosis
BeiGene Signs an Exclusive Worldwide Collaboration with Shoreline to Develop and Commercialize Genetically Modified NK Cell Therapies
Takeda Expands its License Agreement with Codexis to Discover Novel Gene Therapies for Fourth Rare Genetic Disorders
Gilead's Epclusa (Sofosbuvir/Velpatasvir) Receives the US FDA's Approval for Children with Chronic Hepatitis C Infection
BeyondSpring Presents Results of Plinabulin in P-III PROTECTIVE-1 Study for Prevention of Chemotherapy-Induced Neutropenia at ASCO 2021
Verona Pharma Signs $219M Agreement with Nuance Pharma to Develop and Commercialize Ensifentrine in Greater China
Roche Reports New Interim Data of JEWELFISH &amp; RAINBOWFISH Studies for Evrysdi (risdiplam) to Treat Spinal Muscular Atrophy
AbbVie Reports Results of Four-Year Follow-Up Analysis in P-III CLL14 Trial for Venclyxto/Venclexta to Treat Chronic Lymphocytic Leukemia
Vertex and CRISPR Therapeutics Present New Data of CTX001 from 22 Patients with TDT and SCD at EMA 2021
Sanofi Presents Results of Sutimlimab in P-III CADENZA Trial to Treat Hemolysis Patients with Cold Agglutinin Disease at EHA 2021
"Celltrion Presents Real-World Data of Truxima (biosimilar, rituximab) for Diffuse Large B-Cell Lymphoma at EHA 2021"
Janssen Presents Results of Darzalex (daratumumab) in P-III MAIA Study for Transplant Ineligible Patients with Multiple Myeloma at EHA 2021
AbbVie Presents Results of Imbruvica (ibrutinib) + Venclexta/Venclyxto in P-III GLOW Study as 1L Treatment for CLL or SLL at EHA 2021
Kite Presents Results of Yescarta (axicabtagene ciloleucel) in P-II ZUMA-5 Trial for R/R Follicular Lymphoma at EHA 2021
GSK Signs an Agreement with iTeos to Develop and Commercialize EOS-448 for Patients with Cancer
Biogen's BIIB111 Fails to Meet its Primary Endpoint in P-III STAR Study for Choroideremia
Novavax's COVID-19 Vaccine Demonstrates 90.4% Efficacy in P-III PREVENT-19 Study
AstraZeneca's COVID-19 Vaccine Demonstrates 92% Efficacy Against Delta (Indian) Variant
BeiGene's Tislelizumab in Combination with Asieris' APL-1202 Receive the US FDA's IND Approval for MIBC
AstraZeneca's AZD7442 Fails to Meet its Primary Endpoint in P-III STORM CHASER Study for the Prevention of Symptomatic COVID-19
Sage and Biogen Report Results of Zuranolone in P-III WATERFALL Study for Major Depressive Disorder
Innovent Reports First Patient Dosing in P-II Clinical Trial for the Treatment of Obesity in China
Linnaeus Therapeutics Reports the Expansion of Clinical Collaboration with Merck to Evaluate LNS8801 + Keytruda for the Treatment of Patients with Advanced Cancer
Gilead and Jounce's JTX-1811 Receives US FDA's IND Clearance for Cancer Immunotherapies
Regeneron Reports Results of REGEN-COV (casirivimab and imdevimab) in P-III RECOVERY Trial for COVID-19 Patients
Organicell Reports Results of Expanded Access Trial for Zofin to Treat Mild to Moderate COVID-19
Lundbeck Presents Results of Vyepti (eptinezumab-jjmr) in RELIEF Study for Preventive Treatment of Migraine at JAMA
Pfizer Presents Results of Tofacitinib in STOP-COVID Study for Patients Hospitalized with COVID-19 Pneumonia at NEJM
MannKind and United Therapeutics Reports the US FDA's Acceptance of NDA for Priority Review of Tyvaso DPI to Treat PAH and PH-ILD
CureVac Report Results of CVnCoV in Second Interim Analysis of P-llb/lll HERALD Trial to Treat COVID-19
Blueprint Medicines' Ayvakit (avapritinib) Receives FDA's Approval to Treat Patients with Advanced Systemic Mastocytosis
Atea Pharma Secures $50M Milestone Payment with Roche in the Development of AT-527 for COVID-19
Biogen's Gosuranemab (BIIB092) Fails to Meet its Primary Endpoint in P-II TANGO Study for Alzheimer Disease
Lantheus' Pylarify (piflufolastat F 18) Injection Receives the US FDA's Approval for the Treatment of Prostate Cancer
Biogen Reports First Patient Dosing in P-III TOPAZ-1 Study of BIIB059 to Treat Systemic Lupus Erythematosus
Kite Enter into a Partnership with Shoreline Biosciences to Develop Novel Allogeneic Cell Therapies
BeiGene Reports First Patient Dosing in P-III AdvanTIG-302 Trial of Ociperlimab (BGB-A1217) + Tislelizumab (BGB-A317) to Treat Non-Small Cell Lung Cancer
CytoReason Collaborates with Sanofi to Initiate its Project Utilizing AI Technology for Asthma
BioNTech Reports First Patient Dosing in P-II Clinical Trial of BNT111 to Treat Advanced Melanoma
Lineage Signs an Exclusive Option Agreement with Amasa Therapeutics to Supply and Use of Clinical-Grade Hystem
Sanofi's Aubagio (teriflunomide) Receives EC's Approval as First Oral MS Therapy for 1L Treatment with Relapsing-Remitting Multiple Sclerosis in Children and Adolescents
BMS' Onureg (azacytidine) Receives EC's Approval for as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia
Novartis Presents New Data of Zolgensma in P-III Studies in Symptomatic Children with SMA at EAN2021
Eisai Collaborates with BMS for the Co-Development and Co-Commercialization of MORAb-202
BeiGene's Brukinsa (zanubrutinib) Receives the NMPA's Approval for Relapsed or Refractory Waldenström's Macroglobulinemia
FibroGen Collaborates with HiFiBiO to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease
Bayer Reports sNDA Submission to US FDA and MAA to EMA for Copanlisib + Rituximab to Treat B-iNHL and Relapsed MZL
Arrowhead Signs a License Agreement with Horizon to Develop siRNA Therapeutic Targeting XDH for Uncontrolled Gout
"Innovent Publishes the Results of Sintilimab + IBI305 (bevacizumab, biosimilar) in P-II/III ORIENT-32 Study as 1L Treatment for HCC in The Lancet Oncology"
AstraZeneca and MSD's Koselugo (selumetinib) Receive the EU's Approval for Neurofibromatosis Type 1 and Plexiform Neurofibromas
ViiV Healthcare Signs a License Agreement with Halozyme for ENHANZE Drug Delivery Technology to Develop Ultra Long-Acting Medicines for HIV
GSK and Vir Report Results of Sotrovimab in P-III COMET-ICE Trial for High-Risk Adult Patients with Mild-To-Moderate COVID-19
MacroGenics Signs a License Agreement with Zai Lab to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
LEO Pharma' Adtralza (tralokinumab) Receives EC's Approval for Moderate-To-Severe Atopic Dermatitis
Novartis Reports New Data of Kesimpta (ofatumumab) in ALITHIOS Study for Multiple Sclerosis
uniQure Reports 52-Week Clinical Data of Etranacogene Dezaparvovec in P-III HOPE-B Trial for Hemophilia B
uniQure to Acquire Corlieve Therapeutics for $55M
Pear Therapeutics to Become Public Via THMA SPAC Merger for ~$1.6B
Sorrento Enters a Multi-Year Research and Development Agreement with US NAMRU-3 Against COVID-19
Roche Report the US FDA's Acceptance of BLA for Port Delivery System with Ranibizumab to Treat Neovascular Age-Related Macular Degeneration
Eisai and Biogen Receive FDA's Breakthrough Therapy Designation for Lecanemab (BAN2401) to Treat Alzheimer's Disease
Bayer's Verquvo (vericiguat) Receives MHLW's Approval for Chronic Heart Failure
Chugai's Evrysdi (risdiplam) Receives MHLW's Approval for the Treatment of Spinal Muscular Atrophy
Janssen Reports Submission of NDA to the US FDA for Xarelto (rivaroxaban) to Prevent and Treat Blood Clots in Children
Tecan to Acquire Paramit for ~$1B
AbbVie Acquire TeneoOne and its TNB-383B for the Treatment of Relapsed or Refractory Multiple Myeloma
Lilly's Donanemab Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Alzheimer's Disease
AbbVie Receive the CHMP's Positive Opinion Recommending Approval of Rinvoq (upadacitinib) for Atopic Dermatitis
Roche's Actemra/RoActemra (tocilizumab) Receives the US FDA's EUA for Hospitalized Patients with COVID-19
Regeneron and Sanofi's Libtayo (cemiplimab) Receive the EC's Approval as 1L Treatment for Advanced NSCLC
Regeneron and Sanofi's Libtayo (cemiplimab) Receive the EC's Approval as 1L Treatment for Advanced Basal Cell Carcinoma
AstraZeneca Reports First Patient Vaccinating in P-II/III D7220C00001 Trial for AZD2816 to Prevent COVID-19
Mirati's Adagrasib (MRTX849) Receives the US FDA's Breakthrough Therapy Designation for Advanced Non-Small Cell Lung Cancer
Lilly Presents the Results of Tirzepatide in SURPASS-1 Trial for Type-2 Diabetes at ADA2021
Roche's Enspryng Receives EC's Approval as First Home Subcutaneous Treatment for NMOSD
AstraZeneca's Forxiga (dapagliflozin) Receives CHMP's Recommendation for Approval to Treat Chronic Kidney Disease in EU
"Samsung Bioepis and Biogen Receive the CHMP's Positive Opinion Recommending Approval of Byooviz (biosimilar, ranibizumab) for Retinal Vascular Disorders"
Gilead Reports Submission of NDA to the US FDA for Lenacapavir to Treat HIV-1 in People with Limited Therapy Options
"Innovent's Tyvyt (sintilimab) + Byvasda (biosimilar, bevacizumab) Receive the NMPA's Approval as 1L Therapy for Hepatocellular Carcinoma"
"Teva Signs an Exclusive Commercialization Agreement with Bioeq for FYB201 (biosimilar, ranibizumab)"
AstraZeneca's Vaxzevria (AZD1222) Delivers Strong Immune Responses in COV001 and COV002 Trials Against COVID-19
Medtronic Presents Real-World Data of InPen Smart Insulin Pen for Controlling Blood Sugar Levels at ADA2021
Sanofi Reports Results of Soliqua (insulin glargine and lixisenatide) in SoliMix Study for the Treatment of Type 2 Diabetes
Medtronic Launches its First App-Based Research Study to Manage Atrial Fibrillation Disease Burden
BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive EC's Approval for dMMR or MSI-H mCRC After Prior Chemotherapy
AbbVie Report Results of Rinvoq (upadacitinib) in P-III Maintenance Study for the Treatment of Ulcerative Colitis
"Amneal Reports the US FDA's Acceptance of BLA for Alymsys (biosimilar, bevacizumab)"
Theramex Collaborates with Enzene for the Registration and Commercialization of Biosimilar Denosumab
"Celltrion Launches Remsima SC (biosimilar, infliximab) for Rheumatoid Arthritis in Canada"
Arbutus and Antios Enter into a Clinical Collaboration to Evaluate AB-729 + ATI-2173 for Chronic Hepatitis B Virus Infection
Alvotech Reaches PCD in its Switching Study for AVT02 (Proposed Biosimilar to Humira)
Vivoryon and Simcere Sign a License Agreement for N3pE Amyloid-Targeting Medicines to Treat Alzheimer's Disease in Greater China
Celltrion to Acquire Controlling Stake of Iksuda Therapeutics
"Formycon and Bioeq Report MAA Submission to EMA for FYB201 (biosimilar, ranibizumab)"
Apellis and Beam Sign a Five-Year Research Collaboration to Discover Novel Therapies for Complement-Driven Diseases
"STADA and Xbrane's Xlucane (biosimilar, ranibizumab) Meet its Primary Endpoint in P-III Xplore Study"
LEXEO Therapeutics' LX2006 Receives the US FDA's Rare Pediatric Disease Designation and Orphan Drug Designation to Treat Friedreich Ataxia
Abbott's XIENCE Stent Receives the US FDA's Approval for Shortest Blood Thinner Course in Patients with High Bleeding Risk
Jazz's Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Receives the US FDA's Approval for Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Orchard Collaborates with Pharming to Develop and Commercialize OTL-105 for Hereditary Angioedema
Nestle and Seres Collaborate to Jointly Commercialize SER-109 for Recurrent Clostridioides difficile Infection
The US FDA Approves FoundationOne CDx for Alunbrig (brigatinib) in Patients with ALK+ NSCLC
Almirall and Kaken Enter into a License Agreement for the Development and Commercialization of Efinaconazole in Europe
Zydus Seeks EUA for ZyCoV-D Against COVID-19 in India
Denovo In-Licenses Lundbeck's Idalopirdine for Alzheimer's Disease and Other Indications
Hutchmed Reports the US FDA's Acceptance of Surufatinib's NDA for Advanced Neuroendocrine Tumors
GSK and Alector Sign $2.2B Collaboration to Develop Therapies for Neurodegenerative Diseases
"Gan Lee Presents P-I Results of Proposed Biosimilar Insulins Aspart, Lispro and Glargine at ADA 2021"
Roche to Present New data of Hemlibra (emicizumab) in P-IIIb STASEY Study for Hemophilia A at ISTH 2021
Ocugen and Bharat Biotech Present Results of Covaxin in P-III Study Against COVID-19
Merck Amends Collaboration with NGM to Advance Novel Therapies for Retinal and CVM Diseases
Lupin's Solosec (secnidazole) Receives the US FDA's Approval for the Treatment of Trichomoniasis
Spero Therapeutics Enters into a License Agreement with Pfizer for SPR206 to Treat MDR Gram Negative Infections
Immunic's IMU-838 Receives the US FDA's IND Approval to Initiate P-III ENSURE &amp; P-II CALLIPER Studies for RRMS &amp; PMS
Abbisko Signs an Exclusive License Agreement with Sperogenix to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China
Hutchmed Initiates P-I Trial of HMPL 295 for the Treatment of Advanced Solid Tumors in China
Roche Enter into a Collaboration with Mimetas to Develop Human Disease Models for Drug Development
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Expanded Indication in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma
Sanofi Signs ~$1B Agreement with Eureka &amp; MSK for their Multiple Myeloma Candidate
Alvotech Initiates AVT04-GL-301 Study of AVT04 Proposed Biosimilar to Stelara (ustekinumab) for the Treatment of Plaque Psoriasis
Sorrento's Resiniferatoxin Receives the US FDA's Clearance to Initiate P-II Trial for the Treatment of Knee Pain in Patients with Osteoarthritis
Merck Collaborates with OncoSec to Evaluate TAVO (tavokinogene telseplasmid) + Keytruda (pembrolizumab) in P-III KEYNOTE-C87 Trial for Late-Stage Metastatic Melanoma
Y-mAbs Reports BLA Submission to the NMPA for Danyelza (naxitamab-gqgk) to Treat Relapsed/Refractory High-Risk Neuroblastoma
Mallinckrodt Reports Results of StrataGraft in P-III STRATA2016 Study for Thermal Burns
"Teva Enters Into a Commercialization Agreement with Bioeq for FYB201 (biosimilar, ranibizumab)"
Chugai Files an Application with MHLW for an Additional Indication of Tecentriq as an Adjuvant Treatment for NSCLC in Japan
Roche Enters into a Clinical Collaboration with Treos Bio for PolyPEPI1018 + atezolizumab in P-I/II Trial to Treat Late Stage Microsatellite Stable Metastatic Colorectal Cancer
BeiGene Signs a Supply Agreement with PureTech for LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors
BeiGene Reports NMPA's Acceptance of sBLA for Tislelizumab to Treat Esophageal Squamous Cell Carcinoma in China
AstraZeneca and Amgen Report the US FDA's Acceptance of BLA and Priority Review of Tezepelumab for the Treatment of Asthma
AstraZeneca Signs an Exclusive License Agreement with F-star Therapeutics for Novel STING Inhibitors
BeiGene's Kyprolis (carfilzomib) Receives NMPA's Conditional Approval for the Treatment of Relapsed or Refractory Multiple Myeloma
Lilly Signs a Three-Year Collaboration with Verge Genomics to Discover and Develop Novel Therapies for ALS
Janssen Collaborates with Vor to Develop Engineered Hematopoietic Stem Cell Transplants with Bi-Specific Antibody Therapy to Treat AML
Jazz's Vyxeos (daunorubicin and cytarabine liposome) for Injection Receives Health Canada Approval for the Treatment of High-risk Acute Myeloid Leukemia
Lysogene Receives the US FDA's Fast Track Designation for LYS-GM101 Gene Therapy to Treat GM1 Gangliosidosis
Bayer's Kerendia (finerenone) Receives the US FDA's Approval for the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes
Takeda Presents Results of Takhzyro (lanadelumab) in P-III HELP Study Open-Label Extension to Treat Hereditary Angioedema Attacks at EAACI 2021
Astellas and Seagen's Padcev (enfortumab vedotin-ejfv) Receive the US FDA's Full Approval and Expands Indication for Patients with Locally Advanced or Metastatic Urothelial Cancer
Innovent Reports First Patient Dosing in P-I CIBI323A101 Study of IBI323 to Treat Advanced Malignant Tumors
Galapagos Reports New Post-Hoc Analyses from P-III SELECTION Program of Filgotinib to Treat Ulcerative Colitis
Janssen Presents Three-Year Data of Stelara (ustekinumab) in P-lll UNIFI LTE Study for the Treatment of Moderately to Severely Active Ulcerative Colitis at ECCO
Scynexis' Brexafemme (ibrexafungerp tablets) Receives the US FDA's Approval as the First Oral Non-Azole Treatment for Vaginal Yeast Infections
Chimerix's Tembexa (brincidofovir) Receives the US FDA's Approval for the Treatment of Smallpox
Novo Nordisk to Acquire Prothena's ATTR Amyloidosis Program for ~$1.2B
Biogen Signs a License Agreement with Innocare for Orelabrutinib to Treat Multiple Sclerosis
Menagen Signs a Commercialization Agreement with CKD for Biosimilar Darbepotein Alfa
Janssen's Darzalex Faspro (daratumumab and hyaluronidase-fihj) + Pomalidomide and Dexamethasone Receive the US FDA's Approval to Treat Patients with Multiple Myeloma
Hutchmed Reports First Commercial Sale of Orpathys (savolitinib) in China
Astellas and Affinivax Present Results of ASP3772 in P-II Study for Streptococcus Pneumoniae
Hepion Reports Results of CRV431 in P-IIa AMBITION Trial for the Treatment of NASH
Hologic Receives CE Mark to Use Saliva Samples with Aptima SARS-CoV-2 Test in EU
Ionis Signs an Exclusive WW License Agreement with Bicycle to Develop Targeted Oligonucleotide Therapeutics Using TfR1 Bicycle Technology
Astellas Signs a License Agreement with ExCellThera for In Vitro Use of UM171 in Pluripotent Stem Cells
Strongbridge Reports Results of Post Hoc Analyses from a One Year HYPHOP Study of Keveyis (dichlorphenamide) to Treat Primary Periodic Paralysis
Caribou Reports the First Patient Dosing in P-I ANTLER Study of CB-010 to Treat Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Eli Lilly to Acquire Protomer Technologies for ~$1B
Galapagos Reports Results of GLPG3667 in P-Ib Study for the Treatment of Psoriasis
Incyte and Novartis Publish Results of Jakafi (ruxolitinib) in P-III REACH3 Study to Treat Chronic Graft-Versus-Host Disease in NEJM
Johnson &amp; Johnson Publishes Interim Results of Single-Shot COVID-19 Vaccine in P-I/IIa Sub-Study for COVID 19 in NEJM
Heat Biologics Signs a Research License Agreement with ProBioGen for Transposase System and Suspension HEK293 Cell Line
Skyhawk Collaborate with Aragen to Develop Novel Small Molecule Therapeutics to Correct RNA Expression
Eton's Rezipres (ephedrine hydrochloride injection) Receives the US FDA's Approval for the Treatment of Hypotension
Sarfez's Soaanz Receives the US FDA's Approval for the Treatment of Heart Failure and Renal Disease
Ipsen Signs an Exclusive WW License Agreement with IRLAB for Mesdopetam to Treat Parkinson Disease
Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study for Generalized Myasthenia Gravis
Vir Reports First Patient Dosing in P-II MARCH Trial for VIR-2218 + VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection
Bio-Thera Reports First Patient Dosing in P-III Study for BAT2206 Proposed Biosimilar of Stelara (ustekinumab)
AcelRx Signs a License Agreement with Aguettant to Commercialize Dzuveo in EU and for Two Pre-Filled Syringe Products in US
Eli Lilly Signs an Agreement with Banner Alzheimer's Institute to Evaluate Donanemab in P-III TRAILBLAZER-ALZ 3 Trial for Alzheimer's Disease
GSK Reports Results of Daprodustat in P-III ASCEND Program for the Treatment of Anemia due to Chronic Kidney Disease
Merck's Vaxneuvance (pneumococcal 15-valent conjugate vaccine) Receives the US FDA's Approval for the Prevention of Invasive Pneumococcal Disease Caused by 15 Serotypes
Sanofi's Fexinidazole Receives the US FDA's Approval as the First Oral Treatment for Sleeping Sickness
AstraZeneca's Imfinzi (durvalumab) Receives NMPA's Approval as a 1L Treatment of Extensive-Stage Small Cell Lung Cancer
Gilead Reports New Data of Lenacapavir in P-II/III CAPELLA Trial for the Treatment of HIV
Genentech Reports New Data of Hemlibra (emicizumab-kxwh) in P-IIIb STASEY Study to Treat Hemophilia A
AstraZeneca Signs an Exclusive WW License Agreement with Aridis for Suvratoxumab to Prevent Pneumonia
Regeneron's Ronapreve Antibody Cocktail (casirivimab and imdevimab) Receives MHLW's Approval for the Treatment of Mild to Moderate COVID-19
Samsung Bioepis Initiates P-III Clinical Trial of SB17 Proposed Biosimilar to Stelara (ustekinumab)
Kadmon's Rezurock (belumosudil) Receives the US FDA's Approval for the Treatment of Chronic Graft Versus Host Disease
"BioNTech Signs a Purchase Agreement to Acquire Kite's Cell Therapy, R&amp;D Platform and Manufacturing Facility in Gaithersburg, MD"
"Myovant's Ryeqo (relugolix, estradiol, and norethindrone acetate) Receives EC's Approval for the Treatment of Women with Uterine Fibroids"
Merck Presents Results from P-IIa Clinical Trial of Islatravir (MK-8591) for the Prevention of HIV at IAS 2021
Relmada In-Licenses Psilocybin Program from Arbormentis
Albireo's Bylvay (odevixibat) Receives the US FDA's Approval for the Treatment of Progressive Familial Intrahepatic Cholestasis
Scilex Reports Completion of Patient Enrollment in P-III C.L.E.A.R. Program for Semdexa (SP-102) to Treat Sciatica Pain Management
Genentech's Venclexta (venetoclax) + Azacitidine Receives Breakthrough Therapy Designation for the Treatment of Myelodysplastic Syndromes
Calliditas Signs a License Agreement with STADA to Commercialize Specialty Therapy for the Treatment of IgA Nephropathy in EU
Lexeo Acquires Stelios to Expands its Gene Therapy Pipeline for Rare Cardiovascular Diseases
Bayer and Merck's Verquvo (vericiguat) Receives the EC's Approval for the Treatment of Chronic Heart Failure
IM Reports Results of IMT-002 in P-Ib MAD Trial for the Treatment of Type 1 Diabetes
Mabpharm's Biobetter (CMAB008) for Infliximab Receives NMPA's Approval in China
Bluebird Bio's Skysona (elivaldogene autotemcel) Receives EC's Approval for the Treatment of Cerebral Adrenoleukodystrophy
Merck and Eisai's Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive the US FDA's Approval for the Treatment of Advanced Endometrial Carcinoma
"Bioeq Collaborates with Teva to Commercialize FYB201 (biosimilar, ranibizumab)"
Synaffix Signs a License Agreement with ProfoundBio for ADC Technologies
NGM Reports Completion of Patient Enrollment in P-II CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Celltrion Collaborates with Inhalon to Develop Regdanvimab (CT-P59) for the Treatment of COVID-19 at Home
"Meiji and Dong-A ST Sign an Exclusive License Agreement with Intas to Commercialize DMB-3115, Proposed Biosimilar to Ustekinumab"
ImaginAb Signs a Multi-Year Non-Exclusive License Agreement with Boehringer Ingelheim for CD8 ImmunoPET Technology
AstraZeneca's Bydureon BCise (exenatide extended-release) Receives the US FDA's Approval for the Treatment of Type2 Diabetes
Alexion's Ultomiris (ravulizumab) Receives CHMP's Positive Opinion Recommending its Approval for Children and Adolescents with PNH
AstraZeneca's Vaxzevria Demonstrates Effectiveness After One Dose Against Beta/Gamma and Delta Variants of SARS-CoV-2 Virus
AbbVie Presents Results of AGN-190584 in P-III GEMINI 1 Study for Presbyopia at 2021 ASCRS
The US FDA Declines to Approve Incyte's Retifanlimab to Treat Patients with Squamous Cell Carcinoma of the Anal Canal
Denali Reports Results of DNL310 in P-I/II Study in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)
PerkinElmer to Acquire BioLegend for $5.25B
BeiGene's Brukinsa (Zanubrutinib) Receives Health Canada's Approval for Mantle Cell Lymphoma
Prothena Presents Preclinical Data of its Alzheimer's Candidates at AAIC 2021
GSK's Shingrix Receives the US FDA's Approval to Prevent Shingles in Immunocompromised Adults
Adagio Collaborates with Biocon to Provide COVID-19 Ab Treatment to Patients in India and Other Emerging Markets
BioNTech Plans to Initiate the Clinical Study of Malaria and Tuberculosis Vaccines in 2022
"AstraZeneca and Regeneron Collaborate to Research, Develop and Commercialize Therapies for Obesity"
Amgen to Acquire Teneobio for ~$2.5B
PeptiDream and Takeda Expand its Research and License Agreement to Develop Peptide Drug Conjugates Targeting CNS Diseases
AbbVie and Calico Expand its Existing Collaboration to Focus on Aging and Age-Related Diseases
Sanofi's Avalglucosidase alfa Receives CHMP's Positive Opinion for Patients with Pompe Disease
BridgeBio Enters into Clinical Collaboration with BMS to Evaluate BBP-398 + Opdivo for Advanced Solid Tumors with KRAS Mutations
Arena and Aristea Collaborate to Develop RIST4721 for Treatment of Complicated Immune-Mediated Inflammatory Diseases
BD Acquires Tepha to Boost its Surgical Mesh Portfolio
Roche Reports the US FDA's Acceptance of BLA for Faricimab to Treat Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III LIBERTY CUPID Clinical Program for Chronic Spontaneous Urticaria
"Viatris and Biocon's Semglee (biosimilar, insulin glargine) Receive the US FDA's Approval as the First Interchangeable Biosimilar for Diabetes"
Janssen Amends its Agreement with Protagonist to Develop and Commercialize IL-23 Antagonists
Takeda's TAK-994 Receives Breakthrough Therapy Designation for the Treatment of Narcolepsy Type 1
"Henlius Reports First Patient Dosing in P-I Study of HLX04-O (biosimilar, bevacizumab) for Wet Age-Related Macular Degeneration"
Lilly Collaborates with Kumquat to Develop Novel Small Molecules that Enhance Tumor-Specific Immune Responses
GSK's Nucala (mepolizumab) Receives the US FDA's Approval for the Treatment of Chronic Rhinosinusitis with Nasal Polyps
Junshi Reports NMPA's Acceptance of sNDA for Toripalimab + CT as 1L Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Alnylam Signs a License Agreement with PeptiDream to Develop and Commercialize Peptide-siRNA Conjugates for Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues
BeiGene Reports Results of Brukinsa (zanubrutinib) in P-III SEQUOIA Trial for the Treatment of Chronic Lymphocytic Leukemia
Roche Publishes the Results of Evrysdi (risdiplam) in FIREFISH Study to Treat of Type 1 SMA at NEJM
Astellas Signs a License Agreement with Minovia for Novel Mitochondrial Cell Therapy Programs
Takeda and Frazier Collaborate to Launch HilleVax (biopharma company) for the Development of Norovirus Vaccine
AstraZeneca's Saphnelo (anifrolumab-fnia) Receives the US FDA's Approval for the Treatment of Moderate to Severe Systemic Lupus Erythematosus
Janssen's Uptravi (selexipag) Receives the US FDA's Approval for IV Use in Adults with Pulmonary Arterial Hypertension
Ipsen Signs an Exclusive Collaboration with Exicure to Develop SNA-Based Therapeutics for Rare Neurodegenerative Disorders
Regeneron Reports the EUA Expansion for REGEN-COV (casirivimab and imdevimab) to Treat COVID 19
"BioFactura Initiates P-I Study of BFI-751 (biosimilar, ustekinumab)"
Abzena and BioXpress Collaborate to Develop and Manufacture Biosimilars for Third Party Customers
Abbott Launches Jot Dx Insertable Cardiac Monitor to Detect Abnormal Heart Rhythms in US
Sanofi to Acquire Translate Bio for ~$3.2B
Roche Reports the US FDA's Acceptance of BLA and Priority Review of Tecentriq (atezolizumab) as an Adjuvant Treatment for NSCLC
Novartis Lifts Partial Clinical Trial Hold on OAV-101 Clinical Program to Treat SMA
UCB's Bimekizumab Receives NICE Recommendation for the Fast-Track Appraisal to Treat Severe Plaque Psoriasis
Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER Study for Patients with COVID-19 Receiving Invasive Mechanical Ventilation
Marinus Signs an Agreement with Orion for the Commercialization of Ganaxolone in EU
Bayer Reports Results of Eliapixant (BAY1817080) in P-IIb Study for the Treatment of Refractory Chronic Cough
Tachyon Collaborates with AbCellera to Develop Novel Antibody Therapies Targeting TGF-ß Superfamily Member for Cancer
"Celltrion to Supply Herzuma (biosimilar, trastuzumab) and Truxima (biosimilar, rituximab) in Brazil"
Outlook Reports Results of ONS-5010 / Lytenava (bevacizumab-vikg) in P-III NORSE TWO Trial for the Treatment of Wet AMD
BeyondSpring Reports Results of Plinabulin + Docetaxel in P-III DUBLIN-3 Trial for 2L and 3L Treatment of NSCLC with EGFR Wild Type
F-star Collaborates with MSD to Evaluate FS120 + Keytruda for the Treatment of Cancer
Schrödinger Signs a R&amp;D Collaboration with Zai Lab for Oncology Program Targeting DNA Damage Response
Regeneron Publishes the Results of REGEN-COV (casirivimab and imdevimab) in P-III Trial to Prevent COVID-19 at NEJM
Pfizer Reports Results of Ritlecitinib in P-IIb/III Trial for the Treatment of Alopecia Areata
Regeneron and Sanofi Stop P-III EMPOWER-Lung 3 Trial Early Due to Improvement in OS for 1L Treatment of NSCLC
Merck's Keytruda (pembrolizumab) Receives the US FDA's Priority Review for the Adjuvant Treatment of Stage II Resected High-Risk Melanoma
Bayer to Acquire Vividion for ~$2B
AstraZeneca Signs an Exclusive License Agreement with Sierra for AZD5153 to Treat Myelofibrosis
Takeda Publishes the Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks in the Journal Allergy
"Polpharma &amp; Bioeq Report BLA Submission to the US FDA for FYB201 (biosimilar, ranibizumab)"
Kite Signs a License Agreement with Appia to Develop Allogeneic Cell Therapies for the Treatment of Cancer
Medtronic to Acquire Intersect ENT for ~$1.1B
Sanofi's Nexviazyme (avalglucosidase alfa-ngpt) Receives the US FDA's Approval for the Treatment of Late-Onset Pompe Disease
Genentech Reports Results of Polivy (polatuzumab vedotin-piiq) + R-CHP in P-III POLARIX Trial for the Treatment of Diffuse Large B-Cell Lymphoma
Eli Lilly and Innovent Report Results of Sintilimab + CT in P-III ORIENT-11 Study as 1L Treatment of NSCLC
AstraZeneca's Forxiga (dapagliflozin) Receives EC's Approval for the Treatment of Chronic Kidney Disease in Patients with and without T2D
UCB Presents Two-Year Data of Bimekizumab in BE BRIGHT Trial for the Treatment of Moderate to Severe Plaque Psoriasis at AAD 2021
Calliditas Receives the US FDA's Fast Track Designation for Setanaxib to Treat Primary Biliary Cholangitis
AbbVie Terminates its License Agreement with Molecular Partners for Abicipar Pegol
Harmony Acquires ConSynance's Asset for the Treatment of Narcolepsy and other Rare Neurological Diseases
AbbVie Receives $20M Milestone in its DUB Targets Collaboration with Mission to Treat Alzheimer and Parkinson Diseases
Seagen Signs an Exclusive WW License Agreement with RemeGen to Develop and Commercialize Disitamab Vedotin
Alnylam Reports Completion of Patient Enrollment in P-III HELIOS-B Study for Vutrisiran to Treat ATTR Amyloidosis with Cardiomyopathy
Merck Reports the US FDA's Acceptance of sBLA and Priority Review for Keytruda (pembrolizumab) as an Adjuvant Treatment for RCC
Takeda to Advance FIN-524 Development Program in Ulcerative Colitis
Dermavant Reports the US FDA's Acceptance of NDA for Tapinarof Cream to Treat Plaque Psoriasis
GW's Epidyolex (cannabidiol) Receives MHRA's Approval for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in UK
Merck Reports the US FDA's Acceptance of Keytruda's sBLA for Review to Treat MSI-H/dMMR Advanced Endometrial Carcinoma
Boston's EXALT Model B Single-Use Bronchoscope Receives the US FDA's Clearance for Bronchoscopy Procedures
The US FDA's Rejects FibroGen's Roxadustat for the Treatment of Anemia Due to CKD
Sorrento to License Dyadic's DYAI-100 and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
Merck's Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive the US FDA's Approval as 1L Treatment of Advanced Renal Cell Carcinoma
C4T's CFT7455 Receives the US FDA's Orphan Drug designation for the Treatment of Multiple Myeloma
Innovent's IBI306 Meets its Primary Endpoint in P-III CREDIT-2 Study for Heterozygous Familial Hypercholesterolemia
I-Mab Reports Interim Data of Plonmarlimab (TJM2) in P-II/III Study to Treat COVID-19
GC Publishes the Results of GC5107 in P-III Trial for the Treatment of Primary Immunodeficiency in Frontiers in Immunology
Jazz' Xywav Receives the US FDA's Approval for the Treatment of Idiopathic Hypersomnia
Aprea Reports the FDA's Hold on Clinical Trials for the Treatment Lymphoid Malignancy
Wise and NYU Langone Health Publish the Results of Personal Zen App for Multiple Sclerosis in Frontiers in Neurology
Ipsen Reports the Withdrawal of NDA for Palovarotene to Treat Fibrodysplasia Ossificans Progressiva
Celltrion's Regdanvimab (CT-P59) Receives the ANVISA's EUA for the Treatment of COVID-19 in Brazil
Junshi and Coherus's Toripalimab Receive the US FDA's Breakthrough Therapy Designation as 1L Treatment of Nasopharyngeal Carcinoma
Merck's Welireg (belzutifan) Receives the US FDA's Approval for the Treatment of Von Hippel-Lindau Disease Associated Tumors
The US FDA Rejects Sesen Bio's Vicineum (oportuzumab monatox-qqrs) for the Treatment of BCG-Unresponsive NMIBC
Lilly Reports Results of Lebrikizumab in P-III ADvocate 1 and 2 Studies for the Treatment of Moderate to Severe Atopic Dermatitis
Pfizer's Ticovac Receives the US FDA's Approval for the Prevention of Tick-Borne Encephalitis
Merck Reports the Initiation of Rolling Submission to Health Canada for Molnupiravir to Treat COVID-19
The US FDA Lifts the Clinical Hold of Rocket's RP-A501 Clinical Trial to Treat Danon Disease
Eli Lilly's Lyumjev (insulin lispro-aabc injection) Receives the US FDA's Expanded Label Approval for the Treatment of Type 1 and Type 2 Diabetes
Incyte Signs a License Agreement with InnoCare to Develop and Commercialize Tafasitamab in Greater China
Exelixis Expands its Collaboration with Invenra to Develop Novel Biologics in Oncology
Abbott's Amplatzer Amulet Device Receives the US FDA's Approval for the Treatment of Atrial Fibrillation
Novartis' Cosentyx (secukinumab) Receives the NMPA's Approval for the Treatment of Pediatric Psoriasis in China
BMS Reports EMA's Validation of MAA for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + CT to Treat Esophageal Squamous Cell Carcinoma
Sol-Gel Technologies' Twyneo (tretinoin/benzoyl peroxide) Cream Receives the US FDA's Approval for the Treatment of Acne Vulgaris
GSK's Jemperli (dostarlimab-gxly) Receives the US FDA's Accelerated Approval for the Treatment of dMMR Recurrent or Advanced Solid Tumors
Agios Reports the US FDA's Acceptance of NDA and Priority Review for Mitapivat to Treat Pyruvate Kinase Deficiency
Verily Acquires SignalPath to Expand its Clinical Research Capabilities
BeiGene and EUSA Receive the NMPA's Approval of Qarziba (dinutuximab beta) for High-Risk Neuroblastoma
Novartis Reports Results of Beovu (brolucizumab) in P-III KITE &amp; KINGFISHER Trials for the Treatment of Diabetic Macular Edema
BMS Exercises its Option to Develop Exscientia's AI-Designed Drug Candidate
AbbVie Publishes 12-week Results of Atogepant in P-III ADVANCE Trial for the Preventive of Migraine in NEJM
Boehringer Ingelheim and Eli Lilly's Jardiance (empagliflozin) Receive the US FDA's Approval for the Treatment of Heart Failure with Reduced Ejection Fraction
Coherus and Junshi Report Interim Results of Toripalimab + CT in P-III CHOICE-01 Trial as 1L Treatment for Non-Small Cell Lung Cancer
Merck Signs a Supply Agreement with Werewolf for WTX-124 INDUKINE Program to Treat Solid Tumors
Orion Signs a License and Research Agreement with Alligator to Develop Bispecific Antibody for the Treatment of Cancer
Merck Enters in Third Clinical Trial Collaboration with Adagene to Advance ADG106 + Keytruda (pembrolizumab) for Solid Tumors and Hematological Malignancies
BMS' Abecma (Idecabtagene Vicleucel) Receives EC's Conditional Approval for Relapsed and Refractory Multiple Myeloma
Gilead Reports EMA's Validation of MAA for Lenacapavir to Treat HIV-1 in People with Limited Therapy Options
Astellas and FibroGen's Evrenzo (roxadustat) Receive EC's Approval for Symptomatic Anemia Associated with Chronic Kidney Disease
Janssen Presents Results of Rybrevant (amivantamab-vmjw) in P-I CHRYSALIS Study for Advanced NSCLC with METex14 Mutations at WCLC
AstraZeneca's AZD7442 Meets its Primary Endpoint in P-III PROVENT Study for the Prevention of COVID-19
Roche's Ventana MMR RxDx Panel Test Receives the US FDA's Approval as First CDx to Detect dMMR Solid Tumor
BMS' Opdivo(nivolumab) Receives the US FDA's Approval for the Adjuvant Treatment of High-Risk Urothelial Carcinoma
BeiGene Reports NMPA's Acceptance of sBLA for Tislelizumab (BGB-A317) to Treat Nasopharyngeal Cancer in China
Pfizer's Xeljanz (tofacitinib citrate) Receives EC's Approval for the Treatment of Active Polyarticular JIA &amp; Juvenile PsA
Zydus' ZyCoV-D Receives the DCGI's EUA for the Treatment of COVID-19
Alexion to Discontinue its P-III CHAMPION-ALS Trial of Ultomiris (ravulizumab) for Amyotrophic Lateral Sclerosis
Pfizer to Acquire Trillium for ~$2.26B
Pfizer and BioNTech's Comirnaty Receive the US FDA's Approval to Prevent COVID-19 in Individuals Aged 16 Years and Older
Takeda Signs a License Agreement with Genevant to Develop and Commercialize Novel Nonviral Gene Therapies for Liver Diseases
Theravance Reports Results of Izencitinib in P-IIb Dose-Finding Induction Study for the Treatment of Ulcerative Colitis
Merck KGaA and GSK Discontinue P-II INTR@PID BTC 055 Study of Bintrafusp Alfa as 1L Treatment of Biliary Tract Cancer
Novartis' Kymriah (tisagenlecleucel) Fails to Meet its Primary Endpoint in P-III BELINDA Study as 2L Treatment in Aggressive B-Cell Non-Hodgkin Lymphoma
UCB's Bimzelx (bimekizumab) Receives EC's Approval for the Treatment of Moderate to Severe Plaque Psoriasis
Roche Signs a License Agreement with Shape to Advance AAV-based RNA Editing Technology for Neuroscience and Rare Disease
AbbVie's Rinvoq (upadacitinib) Receives EC's Approval for the Treatment of Moderate to Severe Atopic Dermatitis
Vertex Expands its 2018 Agreement with Arbor to Develop Novel Ex Vivo Engineered Cell Therapies
Takeda and Ono's Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive MHLW's Approval for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma
Argenx Reports EMA's Validation of MAA for Efgartigimod to Treat Generalized Myasthenia Gravis
Cara and Vifor's Korsuva (difelikefalin) Receive the US FDA's Approval for the Treatment of Moderate-to-Severe Pruritus Due to CKD in Patients with Hemodialysis
Lilly Signs a License Agreement with Lycia to Develop Novel LYTAC Degraders
Thermo Fisher's Oncomine Dx Target Test Receives the US FDA's Approval as a CDx for the Treatment of IDH1-Mutated Cholangiocarcinoma
Merck Reports Results of Vaxneuvance (pneumococcal 15-valent conjugate vaccine) in P-III PNEU-PED Study for the Prevention of Invasive Pneumococcal Disease
AstraZeneca's Forxiga (dapagliflozin) Receives MHLW's Approval for the Treatment of Chronic Kidney Disease in Patients with and without T2D
Pfizer and BioNTech Initiate Rolling Submission of sBLA for the US FDA's Approval of Comirnaty's Booster Dose in Individuals Aged 16 Years and Older
AstraZeneca's ALXN1840 Meets its Primary Endpoint in P-III FoCus Trial for the Treatment of Wilson Disease
NovaRock Signs an Exclusive License Agreement with Flame to Co-Develop and Commercialize NBL-015
MorphoSys and Incyte's Minjuvi (tafasitamab) + Lenalidomide Receive EC's Approval for the Treatment of R/R DLBCL
BeyondSpring Signs an Exclusive Agreement with Jiangsu Hengrui to Co- Develop &amp; Commercialize Plinabulin in Greater China
Innovent Collaborates with Bolt to Develop Three Oncology Boltbody ISAC Programs
Amgen Presents Results of Repatha (evolocumab) in P-III HUYGENS Study for the Treatment of Acute Coronary Syndrome at ESC 2021
Ascendis' Skytrofa (lonapegsomatropin-tcgd) Receives the US FDA's Approval for Pediatric Growth Hormone Deficiency
BeiGene Signs a Clinical Trial Agreement with ImmixBio to Evaluate IMX-110 + Tislelizumab in Solid Tumors
MicroTransponder Receives the US FDA's Approval for Vivistim System as the First Vagus Nerve Stimulation Implant for Stroke Rehabilitation
"Bio-Thera and Hikma Sign an Exclusive Commercialization and License Agreement for BAT2206 (biosimilar, ustekinumab) in the US"
Sanofi and Regeneron's Dupixent Meets All Endpoints in P-III Study in Children with Atopic Dermatitis
SpringWorks Collaborates with Dana-Farber to Evaluate Nirogacestat in Multiple Myeloma
Pfizer Reports Results of Abrocitinib in P-III JADE DARE Study to Treat Atopic Dermatitis
Abbott Reports Head-to-Head Data for Amplatzer Amulet Against Boston Scientific's Watchman Device to Treat Atrial Fibrillation #ESC2021
GSK and SK Bioscience Initiate P-III Study of GBP510 Against AZ/Oxford's COVID-19 Vaccine
Bone Therapeutics's JTA-004 Fails to Meet its All Endpoints in P-III Study for Knee Osteoarthritis
Baxter in Talks to Acquire Hill-Rom for ~$10B
Janssen Reports Post-Hoc Analysis of P-III GRIPHON and P-IIIb TRITON Studies of Uptravi (selexipag) for the Treatment of Pulmonary Arterial Hypertension #ESC2021
Boehringer Ingelheim and Eli Lilly Present Results of Jardiance (empagliflozin) in P-III EMPEROR-Preserved Trial for the Treatment of HFpEF at ESC 2021
"Centus Reports Results of FKB238 (bevacizumab, biosimilar) in P-III AVANA Trial for the Treatment of Advanced/Recurrent nonsq.NSCLC"
Cipla Collaborates with Kemwell to Form Joint Venture to Develop and Commercialize Biosimilars
"Formycon and Bioeq Report Submission of BLA to the US FDA for FYB201 (biosimilar, ranibizumab)"
"Samsung Bioepis' Byooviz (biosimilar, ranibizumab) Receives EC's Approval for the Treatment of Ophthalmic in EU"
Novartis Signs an Agreement with NHS to Commercialize Leqvio (inclisiran) for the Treatment of Cardiovascular Disease
AC Immune Report Results of Semorinemab in P-II Lauriet Study for the Treatment of Alzheimer's Disease
Bayer Initiates P-III OASIS Program of Elinzanetant for the Treatment of Vasomotor Symptoms During Menopause
Johnson &amp; Johnson Discontinues the P-IIb Imbokodo Trial of HIV Vaccine Regimen for HIV Infection
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Label Update to Treat Advanced Urothelial Carcinoma
Merck and Ridgeback Initiate P-III MOVe-AHEAD Study of Molnupiravir for the Prevention of COVID-19 Infection
"Celltrion's Herzuma (biosimilar, trastuzumab) Overtook the Original Treatments for Cancer"
Enzene Receives Marketing Authorization for Romiplostim (biosimilar) in India
Nora Signs an Exclusive Agreement Biopharmaceutical Partner to Launch a Biosimilar in Canada
AstraZeneca Signs a Multiyear Agreement with Thermo Fisher to Co-Develop NGS-based CDx for Targeted Therapies
CVS Dropped Sanofi's Diabetes Drugs Lantus for Biosimilars
Takeda's Pevonedistat Fails to Meet Primary Endpoints in P-III PANTHER Trial as 1L Treatment for Patients with Rare Bone Marrow Cancer
BMS Exercised Its Option to License Evotec's EVT8683 for the Treatment of Neurodegenerative Disease
BeiGene's Brukinsa (zanubrutinib) Receives the US FDA's Approval for the Treatment of Waldenström's Macroglobulinemia
Astellas Pauses Dosing of AT132 in ASPIRO Clinical Trial for the Treatment of X-linked Myotubular Myopathy
Janssen's Invega Hafyera (paliperidone palmitate) Receives the US FDA's Approval for the Treatment of Schizophrenia
"Sandoz Reports Results of Omnitrope (biosimilar, somatropin) in PATRO Children Study for the Treatment of Turner Syndrome"
Baxter to Acquire Hillrom for ~$10.5B
Abbott to Acquire Walk Vascular to Bolster its Peripheral Vascular Offerings
Alexion's Ultomiris (ravulizumab) Receives EC's Approval for Expanded Use to Treat Paroxysmal Nocturnal Haemoglobinuria
Pfizer Initiates P-III RENOIR Trial of RSVpreF Vaccine for the Treatment of Respiratory Syncytial Virus
Novartis Cosentyx (secukinumab) Receives NICE Recommendation for Patients with Plaque Psoriasis
Forte's FB-401 Fails to Meet Primary Endpoints in P-II Clinical Trial For the Treatment of Atopic Dermatitis
Novartis to Discontinue CIRRUS-1 Study of CFZ533 (iscalimab) in Kidney Transplant Patients
Dr. Reddy's Collaborates with Citius to Sell Rights of its Anti-Cancer Agent (E7777)
BioMarin Reports FDA's Hold on P-I/II Phearless Trial of BMN 307 in Adults with PKU
AstraZeneca and Amgen's Tezepelumab Demonstrates 86% Reduction in Exacerbations in Patients with Asthma and Nasal Polyps
Bayer Reports Results of Eliapixant in P-IIb PAGANINI Study for Patients with Refractory Chronic Cough
Moderna's Spikevax Receives TGA's Provisional Approval to Treat COVID-19 in Patients Aged 12-17 Years
JW's Relmacabtagene Autoleucel Receives the NMPA's Approval for the Treatment of R/R Large B-Cell Lymphoma in China
NeuExcell Signs a Research Agreement with Spark to Develop a Novel Gene Therapy for Huntington's Disease
Advent and GIC to Acquire Sobi for ~$8B
Impel NeuroPharma's Trudhesa (dihydroergotamine mesylate) Nasal Spray Receives the US FDA's Approval for the Treatment of Migraine
Sorrento Initiates Enrollment in P-II MSC-COV-202BR Study for the Treatment of Acute Respiratory Distress due to COVID-19 in Brazil
"Hetero's Tocira (biosimilar, tocilizumab) Receives the DCGI's EUA for the Treatment of COVID-19 in Hospitalized Adults"
Genentech Signs a License Agreement with Adaptimmune to Develop and Commercialize Cancer-Targeted Allogeneic T-cell Therapies
Sanofi to Acquire Kadmon for ~$1.9B
Google Collaborates with Mayo Clinic to Develop AI Algorithm for the Treatment of Neurological Diseases
AM-Pharma Enters into an Exclusive License Agreement with Kyowa Kirin to Commercialize Ilofotase Alfa in Japan
United Therapeutics Presents Results of Tyvaso DPI in BREEZE Clinical Study for the Treatment of Pulmonary Arterial Hypertension at ERS 2021
AstraZeneca Presents Results of Fasenra in P-IIIb PONENTE Study for the Treatment of Asthma at ERS 2021
"Sandoz Enters into a Commercialization and License Agreement with Bio-Thera to Commercialize BAT1706, a Proposed Biosimilar Avastin (bevacizumab)"
AstraZeneca and Hutchmed Initiate P-III SANOVO Trial for Orpathys (savolitinib) + Tagrisso (osimertinib) as a 1L Therapy for Non-small Cell Lung Cancer in China
Sanofi Provides Update on P-III PEGASUS Trial of Rilzabrutinib for the Treatment of Pemphigus
AstraZeneca Reports Results of PT027 (albuterol and budesonide) in P-III MANDALA and DENALI Trials for the Treatment of Asthma
Cardiff Oncology Reports Results of Onvansertib in P-Ib/II Trial for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer
ICU Medical Commits to Acquire Smith for ~$2.35B
Eli Lilly Signs a License and Research Agreement with ProQR to Develop &amp; Commercialize RNA Therapeutic for the Treatment of Liver and Nervous System Disorders
Roche to Acquire TIB Molbiol for Bolstering its Molecular Diagnostics Portfolio
Dermavant Reports the First Patient Dosing in P-III ADORING Program of Tapinarof for the Treatment of Atopic Dermatitis
Boehringer Ingelheim and Eli Lilly's Jardiance (empagliflozin) Receive the US FDA's Breakthrough Therapy Designation for the Treatment of Heart Failure with Preserved Ejection Fraction
"Samsung Bioepis Reports Results of Post-Hoc Analysis from P-III Study of Byooviz (biosimilar, ranibizumab) for the Treatment of nAMD"
Boehringer Ingelheim Signs a Research Agreement with Twist to Discover Therapeutic Antibodies Against Multiple Targets
BeiGene and Novartis Report the US FDA's Acceptance of BLA for Tislelizumab to Treat Esophageal Squamous Cell Carcinoma
AstraZeneca Presents Results of Imfinzi (durvalumab) + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV NSCLC at WCLC 2021
ZOLL to Acquire Itamar for ~$538M
Hutchmed's Amdizalisib (HMPL-689) Receives Breakthrough Therapy Designation for the Treatment of R/R Follicular Lymphoma in China
AbbVie Collaborates with Regenxbio to Develop and Commercialize RGX-314 for the Treatment of Retinal Diseases
BMS Reports Three-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -743 Trial for 1L Treatment of Unresectable Malignant Pleural Mesothelioma
Nuformix Signs an Exclusive WW License Agreement with Oxilio to Develop NXP001 for Oncology Disease
AzurRx Signs a Reverse Triangular Merger Agreement to Acquire First Wave Bio for ~$229M
Coherus and Junshi Present Interim Results of Toripalimab in P-III CHOICE-01 Trial as 1L Treatment for Non-Small Cell Lung Cancer at WCLC 2021
Everest Signs a License Agreement with Providence to Advance mRNA Vaccines
ONO and BMS Report Submission of sBLA for Opdivo (nivolumab) + Yervoy (ipilimumab) as 1L Treatment of Unresectable Advanced or Recurrent ESCC in Japan
Amgen's Lumakras (sotorasib) Receives Health Canada's Approval for KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ginkgo Going Public with ~1.63B in Proceed Via Soaring Eagle SPAC Merger
RedHill's Opaganib (ABC294640) Fails to Meet its Primary Endpoints in P-II/III Study for the Treatment of Severe COVID-19
Roche Collaborates with Temedica to Launch Brisa App for the Treatment of Multiple Sclerosis
AbCellera Acquires TetraGenetics to Enhance its Capabilities for Developing Antibodies
MSD Enters into a Clinical Collaboration with IO to Evaluate IO102-IO103 + Keytruda as 1L Treatment of Metastatic Melanoma
BeiGene's Brukinsa (zanubrutinib) Receives the US FDA's Accelerated Approval for the Treatment of R/R Marginal Zone Lymphoma
Takeda's Exkivity (mobocertinib) Receives the US FDA's Approval as the First Oral Therapy for EGFR Exon20 Insertion+ NSCLC
Biogen to Initiate P-IIIb ASCEND Study Evaluating Higher Doses of Spinraza (nusinersen) for the Treatment of Spinal Muscular Atrophy
Merck Enters into a Clinical Collaboration with Hookipa to Evaluate Keytruda (pembrolizumab) + HB-200 as 1L Treatment of Advanced Head and Neck Cancers
BioCryst's Orladeyo (berotralstat) Receives NICE Recommendation as First Oral Therapy to Prevent HAE Attacks in the UK
Amgen Presents Results of Lumakras (sotorasib) + Vectibix (panitumumab) in P-Ib/II CodeBreaK 101 study for KRAS G12C-Mutated Colorectal Cancer at ESMO21 2021
BMS Reports Five-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -214 for the Treatment of Advanced or Metastatic Renal Cell Carcinoma
Boehringer Ingelheim Enters into a Clinical Collaboration with Amgen to Evaluate BI 1701963 + Lumakras (sotorasib) for Locally Advanced or Metastatic NSCLC
Clarus Signs an Exclusive WW License Agreement with McGill University to Develop and Commercialize its Technology for Rare Conditions Due to Coenzyme-Q10 Deficiencies
Biogen Reports Mixed Results of Vixotrigine (BIIB074) in P-II CONVEY Study for the Treatment of Small Fiber Neuropathy
AbbVie Submits Regulatory Applications to the US FDA and EMA for Rinvoq (upadacitinib) to Treat Active Ulcerative Colitis
Coherus and Junshi Present Interim Results of Toripalimab in P-III JUPITER-06 Trial as 1L Treatment for Advanced Esophageal Squamous Cell Carcinoma at ESMO 2021
Coave Signs an Exclusive License Agreement with Théa to Co-Development and Commercialize CTx-PDE6b for PDE6b Associated Retinitis Pigmentosa in EU
Everest Enter into an Exclusive License Agreement with Sinovent and SinoMab to Develop and Commercialize XNW1011 for Renal Diseases
Mirati Presents Results of Adagrasib (MRTX849) in P-I/II KRYSTAL–1 Study for the Treatment of KRAS G12C-Mutated Colorectal Cancer at ESMO 2021
Regeneron and Sanofi Present Results of Libtayo (cemiplimab) in P-III EMPOWER-Lung 3 Study as 1L Treatment of Advanced NSCLC at ESMO 2021
Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-826 Trial as 1L Treatment for Cervical Cancer
Exelixis' Cabometyx (cabozantinib) Receives the US FDA's Approval for the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Cancer
AstraZeneca Presents the Updated Results of Imfinzi (durvalumab) in P-III CASPIAN Trial for the Treatment of Extensive-Stage Small Cell Lung Cancer at ESMO 2021
"Samsung Bioepis and Biogen's Byooviz (biosimilar, ranibizumab) Receives the US FDA's Approval for the Treatment of Retinal Vascular Disorders"
Abbott's Portico with Flexnav Tavr System Receives the US FDA's Approval for the Treatment of Aortic Valve Disease
Bayer Signs a License and Research Agreement with Gubra to Develop Novel Peptide Therapeutics for Cardiorenal Diseases
Novartis to Acquire Arctos to Boost its Optogenetics Portfolio to Treat Eye Diseases
Amgen Collaborates with Verastem to Evaluate VS-6766 + Lumakras (Sotorasib) in P-I/II Trial for KRAS G12C-Mutant Non-Small Cell Lung Cancer
Boston Scientific to Acquire Devoro for ~$336M
Incyte's Opzelura (ruxolitinib) Receives the US FDA's Approval for the Treatment of Atopic Dermatitis
Boehringer Ingelheim Acquires Abexxa to Expands its Immuno-oncology Research
Seagen and Genmab's Tivdak (tisotumab vedotin-tftv) Receive the US FDA's Accelerated Approval for the Treatment of Recurrent or Metastatic Cervical Cancer
Exelixis Presents Results of Cabometyx (cabozantinib) in P-III COSMIC-311 Trial for the Treatment of Radioactive Iodine-Refractory DTC at ESMO 2021
Takeda Enters into an Exclusive License Agreement with Mirum to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
Vigeo Reports Completion of VT1021 in P-I/II Study for the Treatment of Recurrent Glioblastoma and Pancreatic Cancer
AbCellera Enters into a License Agreement with Everest to Discover Antibody Therapies
Innovent Reports NMPA's Acceptance of sNDA for Sintilimab as 1L Treatment for Esophageal Squamous Cell Carcinoma
Abbott's Epic Plus Tissue Valves Receives the US FDA's Approval for the Treatment of Mitral or Aortic Valve Replacement
Incyte's Jakafi (ruxolitinib) Receives the US FDA's Approval for the Treatment of Chronic Graft-Versus-Host Disease
Gilead Reports Results of Veklury (remdesivir) in P-III Trial for the Treatment of COVID-19
Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 &amp; N4-Hydroxycytidine to Treat Viral Infections
Roche Presents Results of Evrysdi (risdiplam) in RAINBOWFISH Study for the Treatment of Neuromuscular Disorder at WMS 2021
AstraZeneca Collaborates with VaxEquity to Develop and Commercialize Self-Amplifying RNA Therapeutics
Innovent Reports the First Patient Dosing in P-II CIBI112A201 Trial of IBI112 for the Treatment of Plaque Psoriasis
Pfizer and BioNTech's COVID-19 Vaccine Booster Receive the US FDA's EUA for the Treatment of COVID-19
GE Healthcare to Acquire BK Medical for ~ $1.45B
Everest's SPR206 Receives the NMPA's IND Approval for the Treatment of MDR Gram-Negative Bacterial Infections
Amgen's Repatha (evolocumab) Receives the US FDA's Approval for the Treatment of Heterozygous Familial Hypercholesterolemia
Innovent and AnHeart Report Interim Results of Taletrectinib (AB-106) in P-II TRUST Trial for the Treatment of ROS1-Positive NSCLC at CSCO 2021
JW Reports One-Year Follow-Up Results of Relmacabtagene Autoleucel in P-II RELIANCE Study for the Treatment of R/R LBCL at CSCO 2021
Boehringer Ingelheim Receives Positive Opinion for the Use of Ingelvac CircoFLEX + Ingelvac PRRSFLEX for Pig Health Management in the EU
Astellas and Seagen's Padcev (enfortumab vedotin) Receive MHLW's Approval for the Treatment of Radically Unresectable Urothelial Carcinoma
Takeda's Alofisel (darvadstrocel) Receives MHLW's Approval for the Treatment of Complex Perianal Fistulas with Non-active or Mildly Active Luminal CD
Incyte Enters into an Exclusive WW License Agreement with Syndax to Develop and Commercialize Axatilimab for cGVHD and Other Fibrotic Diseases
Bio-Thera Signs a License Agreement with Intract for Soteria and Phloral Technologies to Develop Oral Antibody Therapies
Innovent Signs a License Agreement with Union to Develop &amp; Commercialize Orismilast for Inflammatory Dermatology Conditions in China
AstraZeneca's Saphnelo (anifrolumab) Receives MHLW's Approval for the Treatment of Systemic Lupus Erythematosus
Eisai Initiates Rolling Submission of BLA to the US FDA for Lecanemab to Treat Alzheimer's Disease
ViiV Healthcare Signs an Exclusive License Agreement with Shionogi to Develop S-365598 for HIV
Boehringer Ingelheim Signs an Agreement with Invetx to Develop and Commercialize Novel Veterinary Therapies
The US FDA Approves New Indication for Lilly's Erbitux (cetuximab) + Braftovi (encorafenib) to Treat Metastatic Colorectal Cancer with a BRAF V600E Mutation
AbbVie's Qulipta (atogepant) Receives the US FDA's Approval for the Treatment of Migraine
AstraZeneca to Acquire Caelum for ~500M
ViiV Healthcare Presents Three-Year Results of Dovato (dolutegravir/lamivudine) in P-III TANGO Study for the Treatment of HIV at IDWeek 2021
Novartis Reports Results of ligelizumab (QGE031) in P-IIb Study for the Treatment of Chronic Spontaneous Urticaria
Medtronic's Radial Artery Catheter Device Receives CE Mark Approval for the Treatment of Neurovascular Diseases
Regeneron Publishes the Results of REGEN-COV (casirivimab and imdevimab) in P-III Trial for COVID-19 in NEJM
Janssen Initiates P-III EVERGREEN Study of RSV Vaccine for the Treatment of Lower Respiratory Tract Disease Due to Respiratory Syncytial Virus
TransMedics' OCS Liver System Receives the US FDA's Approval for Liver Transplantation
Takeda Signs an Exclusive License Agreement with JCR to Commercialize JR-141 for the Treatment of Hunter Syndrome
Eli Lilly Reports Results of Tirzepatide in P-III SURPASS-3 MRI Sub-Study for the Treatment of Type 2 Diabetes
Merck to Acquire Acceleron for ~$11.5B
Otsuka Enters into a WW License Agreement with Sunovion and Sumitomo Dainippon to Develop and Commercialize Neuropsychiatric Candidates
Novartis Presented Results of Remibrutinib (LOU064) in P-IIb Study for the Treatment of Chronic Spontaneous Urticaria at EADV
Dermavant Presented Long-Term Results of Tapinarof in P-III PSOARING 3 Study for the Treatment of Plaque Psoriasis at EADV
Sanofi Presents Results of Amlitelimab (KY1005) in P-IIa Study for the Treatment of Moderate-To-Severe Atopic Dermatitis at EADV 2021
Merck and Ridgeback Report Interim Results of Molnupiravir in P-III MOVe-OUT Trial for the Treatment of COVID-19
BMS Reports EMA's Validation of MAA for Relatlimab and Nivolumab as 1L Treatment for Unresectable or Metastatic Melanoma
Kite's Tecartus Receives the US FDA's Approval as the First and Only Car T for Adults with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Merck KGaA and GSK Terminate their ~$4.2B Collaboration Due to Clinical Failures
Takeda Enters into a License Agreement with Selecta to Develop Gene Therapies for the Treatment of Lysosomal Storage Disorders
"Polpharma Biologics Reports the US FDA?s Acceptance of BQ201's (biosimilar, ranibizumab) BLA for Review to Treat Wet Age-Related Macular Degeneration"
AstraZeneca Seeks the US FDA?s EUA for AZD7442 to Treat COVID-19
"Coherus Report Results of CHS-201 (biosimilar, ranibizumab) in COLUMBUS-AMD Clinical Trial for the Treatment of nAMD"
Xenon?s XEN1101 Meets its Primary Efficacy Endpoint in P-IIb X-TOLE Clinical Trial for the Treatment of Focal Epilepsy
Guardant Health Initiates ORACLE Study of Guardant Reveal Blood Test for the Treatment of Early-Stage Cancers
Johnson &amp; Johnson Reports EUA Submission to the US FDA for Supporting the Booster of its Single Shot COVID-19 Vaccine Candidate
Inotiv to Acquire Plato BioPharma for ~$15.0M
Sage and Biogen Present Results of Zuranolone in LANDSCAPE and NEST Clinical Development Programs for the Treatment of MDD and PPD at ECNP 2021
Novartis?s Adakveo (crizanlizumab) Receives NICE Recommendation as a New Therapy for Sickle Cell Disease
Kaleido Reports Results of KB295 in Clinical and Preclinical Studies for the Treatment of Mild-to-Moderate Ulcerative Colitis
Boston to Acquire Baylis for ~$1.75B
"Biocad Presents Results of BCD-021 (biosimilar, bevacizumab) in P-III Study for the Treatment of Non-Squamous Non-Small Cell Lung Cancer at ESMO 2021"
"Fresenius Kabi Reports Results of MSB11456 (biosimilar, tocilizumab) in Two Clinical Trials for the Treatment of Rheumatoid Arthritis"
"Tanvex Presents Results of TX05 (biosimilar, trastuzumab) in P-III Study for the Treatment of HER2-Positive Early Stage Breast Cancer at ESMO 2021"
Alvotech?s AVT02 (a proposed biosimilar to Humira) Receives CHMP?s Positive Opinion for the Treatment of Autoimmune Diseases
"Samsung Bioepis Presents Five-year Follow-up Results of Ontruzant (biosimilar, trastuzumab) in Early or Locally Advanced HER2 Positive Breast Cancer at ESMO 2021"
Pfizer Signs an Option and License Agreement with Voyager to Develop and Commercialize Gene Therapies for Neurologic and Cardiovascular Diseases
Sanofi Reports Interim Results of Fluzone High-Dose Quadrivalent Vaccine + COVID-19 mRNA Booster Dose in First Descriptive Study for COVID-19
PharmaTher Initiates P-II KET-LID Study of Ketamine for Levodopa-Induced Dyskinesia in Patients with Parkinson?s Disease
Denali Presented Results of DNL343 and SAR443820 in P-I Clinical Studies for the Treatment of Amyotrophic Lateral Sclerosis at NEALS 2021
BMS? Deucravacitinib Fails to Meet its Primary and Secondary Endpoints in P-II LATTICE-UC Study for the Treatment of Moderate to Severe Ulcerative Colitis
Amgen Signs a R&amp;D Collaboration with Neumora to Advance Novel Precision Therapies for Neuropsychiatric and Neurodegenerative Diseases
"Apobiologix?s Bambevi (biosimilar, bevacizumab) Receives Health Canada Approval for Multiple Cancer Indications"
"Alvotech Reports Results of AVT02 (biosimilar, adalimumab) in AVT02-GL-302 Study to Treat Chronic Diseases"
AbbVie?s Rinvoq (upadacitinib) Met Primary and Secondary Endpoints in P-III SELECT-AXIS 2 Clinical Trial for Non-Radiographic Axial Spondyloarthritis
Schr?dinger Signs a Two-Year Research Collaboration with MD Anderson to Advance its WEE1 Program
Sanofi Signs a Non-Exclusive Clinical Collaboration Agreement with Mirati to Evaluate Adagrasib + SAR442720 (RMC-4630) in P-I/II Study for KRAS G12C-Mutated Lung Cancer
Allogene Reports the US FDA?s Clinical Hold on ALPHA2 Study of ALLO-501A to Treat Large B Cell Lymphoma
Takeda Receives the US FDA Advisory Committee?s Recommendation for TAK-620 (maribavir) to Treat CMV Infection in Post-Transplant Recipients
AbbVie?s Rinvoq (upadacitinib) Receives the Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis
Janssen Report Submission of sBLA to the US FDA for the Approval of Stelara (ustekinumab) to Treat Juvenile Psoriatic Arthritis
Genentech?s Gantenerumab Receives the US FDA?s Breakthrough Therapy Designation for the Treatment of Alzheimer?s Disease
Turning Point Presents Results of Repotrectinib in P-I/II TRIDENT-1 Study for the Treatment of Solid Tumors at AACR-NCI-EORTC 2021
Regenxbio Presents Results of RGX-314 in P-II ALTITUDE Trial for the Treatment of Diabetic Retinopathy at ASRS Annual Meeting
Merck and Ridgeback Report EUA Submission to the US FDA for Molnupiravir to Treat COVID-19
Supernus to Acquire Adamas for ~$450M
AstraZeneca?s AZD7442 Meet its Primary Endpoints in P-III TACKLE Trial for the Treatment of COVID-19
Pacira to Acquire Flexion for ~427M
Sarepta Presents the New Analyses and Functional Data of SRP-9001 in Multiple Studies for the Treatment of DMD at SRP-9001 Micro-dystrophin Day
AbCellera Enters into a Collaboration and License Agreement with Salipro to Boost Therapeutic Antibodies
Sutro Signs an Option Agreement with BioNova to Develop and Commercialize STRO-001 for Hematologic Cancers in Greater China
The US FDA Lifts the Clinical Hold of Protagonist?s Rusfertide Clinical Development Program
Takeda Signs an Exclusive License Agreement with Poseida for Novel Non-Viral In Vivo Gene Therapies
Spark Signs an Exclusive Global Licensing Agreement with CombiGene for CG01 to Treat Focal Epilepsy
Ultimovacs Reports Results of 24-month Follow-up Study of UV1 + Pembrolizumab for 1L Treatment of Metastatic Malignant Melanoma
Sanofi Presents Results of Tolebrutinib in a P-IIb LTS for Relapsing Forms of Multiple Sclerosis at ECTRIMS 2021
Eli Lilly?s Verzenio (abemaciclib) Receives the US FDA?s Approval for People with HR+ HER2- High Risk Early Breast Cancer
Sanofi's Sarclisa Combination Regimen Receives Health Canada?s Approval for Multiple Myeloma
PharmaTher?s Ketamine Receives the US FDA?s Orphan Drug Designation for Complex Regional Pain Syndrome
Turning Point and EQRx Collaborate to Evaluate Elzovantinib + Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced NSCLC
Merck?s Keytruda (pembrolizumab) Receives the US FDA?s Approval for Second Indication in Cervical Cancer
Novartis Reports the US FDA and EMA Filing Acceptance of Beovu for Patients with Diabetic Macular Edema
Regeneron Reports the US FDA?s Acceptance of Priority Review for REGEN-COV for the Treatment and Prophylaxis of COVID-19
Asieris Receives NMPA?s IND Approval to Evaluate APL-1202 + Tislelizumab as Neoadjuvant Therapy for MIBC Patients
Lilly Presents Updated Data of Verzenio (abemaciclib) in P-III monarchE Trial Presented at ESMO and Published in the Annals of Oncology
AstraZeneca Reports Results of Imfinzi + Tremelimumab in P-III HIMALAYA Study for 1L Treatment of Unresectable Liver Cancer
Hologic to Acquire Bolder Surgical for $160M
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA?s Acceptance of IND for P-I Study of XL114 in Non-Hodgkin?s Lymphoma
Gan &amp; Lee Completes P-III Studies of GL-GLA for Patients with T1D &amp; T2D
Bristol Myers Squibb?s Zeposia (ozanimod) Receives CHMP?s Positive Opinion for Adult Patients with Moderately to Severely Active Ulcerative Colitis
Genentech?s Tecentriq Receives the US FDA?s Approval as Adjuvant Treatment for Early Non-Small Cell Lung Cancer
AbbVie? Skyrizi (risankizumab) Receives CHMP?s Positive Opinion for the Treatment of Adults with Active Psoriatic Arthritis in the EU
"Boehringer Ingelheim?s Cyltezo (biosimilar, adalimumab) Receives the US FDA?s sBLA Approval as the 1st Interchangeable Biosimilar for Multiple Chronic Inflammatory Diseases"
"Bio-Thera Expands its Partnership with Pharmapark to Commercialize BAT2206 (biosimilar, ustekinumab in Russia and other CIS Countries"
Innovent Reports Results of Sintilimab in P-III ORIENT-31 Study for EGFR-Mutated Non squamous Non-Small Cell Lung Cancer
Ipsen Signs an Exclusive WW Collaboration with Accent to Develop and Commercialize METTL3 Program
Takeda Amend its Collaboration with Wave Life Sciences to Advance CNS Programs
Lipocine Enters into an Exclusive License Agreement with Antares to Commercialize Tlando in the US
Gilead?s Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Low-Dose Tablet Receives the US FDA?s Approval for Expanded Indication to Treat HIV-1
Takeda Signs an Agreement with Calithera to Acquire Sapanisertib and Mivavotinib
Lilly Published Results of Tirzepatide in SURPASS-4 Study for the Treatment of Type 2 Diabetes in The Lancet
Sanofi?s Dupixent (dupilumab) Receives NICE Recommendation for the Treatment of Severe Asthma
Sana Entered into an Agreement with Beam for Non-Exclusive Commercial Rights of its CRISPR Cas12b Nuclease System for Cell Therapy Programs
Antios Enters into a Clinical Collaboration Agreement with Assembly Biosciences to Evaluate ATI-2173 and Vebicorvir for Chronic Hepatitis B Virus Infection
Boehringer Ingelheim Exercised its Option to License Oxford Biomedica?s Lentiviral Vector Technology to Commercialize BI 3720931 for CF
Atea Reports Results of AT-527 in P-II MOONSONG Trial for the Treatment of COVID-19
Dicerna Reports Results of Nedosiran in PHYOX4 Study for the Treatment of Primary Hyperoxaluria Type 3
SpringWorks Enters into an Exclusive WW License Agreement with Academic Institutions to Advance Portfolio of Mutation-Selective EGFR Inhibitors
Janssen Enters into a License and Collaboration Agreement with F-star to Develop and Commercialize Multiple Bispecific Antibody Therapeutics
Sumitomo Dainippon Pharma Signs a Definitive Agreement with BehaVR to Develop and Commercialize PDTs and Wellness Product for CNS Disorders
Regeneron and Sanofi?s Dupixent (dupilumab) Receive the US FDA?s Approval as an Add-On Maintenance Treatment to Treat Moderate-To-Severe Asthma
Pfizer and BioNTech Report Results of COVID-19 Vaccine Booster in P-III Trial for the Treatment of COVID-19
Pfizer?s Prevnar 20 (Pneumococcal 20-Valent Conjugate Vaccine) Receives the CDC?s Advisory Committee Recommendation for Invasive Disease and Pneumonia
Antengene Enters into a Research Collaboration &amp; License Option Agreement with LegoChem Biosciences for Antibody-Drug Conjugate Candidates
Mirum?s Livmarli (maralixibat) Receives US FDA?s Approval as the First Approved Therapy for Cholestatic Pruritus in Patients with Alagille Syndrome
Selecta Enters into an Exclusive License Agreement with Genovis to Advance IgG Protease in Gene Therapy and Autoimmune Disease
Incyte Enters into a Supply Agreement with Specialised Therapeutics to Launch Tafasitamab and Pemigatinib in Australia and Other Countries
Scynexis Reports Results of Ibrexafungerp in P-III VANISH-303 Trial for Treatment of Vaginal Yeast Infection
Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III PRIME2 Trial for the Treatment of Prurigo Nodularis
LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis
Marinomed Biotech Signs a License Agreement with Luoxin to Commercialize Budesolv (budesonide nasal spray) in Greater China
Agenus Reports the Withdrawal of BLA for Balstilimab to Treat Cervical Cancer
Genentech?s Susvimo Receives the US FDA?s Approval for the Treatment of Wet Age-Related Macular Degeneration
Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III Trial for the Treatment of Eosinophilic Esophagitis
Merck Reports Results of Doravirine/Islatravir as Fixed Dose Combination in P-III Trials for the Treatment of HIV-1 Infection
Merck and Ridgeback Report the Initiation of EMA Rolling Review of Molnupiravir for the Treatment of COVID-19
Novartis Reports Results of Canakinumab in P-III CANOPY-1 Study for the Treatment of Lung Cancer
Daiichi Sankyo and AstraZeneca Entered into a Second Clinical Trial Collaboration with Merck for Datopotamab Deruxtecan (Dato-DXd) + Keytruda (pembrolizumab)
MSD Entered into a Clinical Trial Collaboration with Evaxion to Evaluate EVX-01 + Keytruda (pembrolizumab) for Metastatic Melanoma
AstraZeneca Reports Results of Imfinzi in P-III TOPAZ-1 Trial as 1L Treatment for Advanced Biliary Tract Cancer
Moderna Reports Results of COVID-19 Vaccine in P-II/III KidCOVE Study for the Treatment of COVID-19
Glenmark launches Remogliflozin + Vildagliptin + Metformin as Fixed Dose Combination for the Treatment of Type 2 Diabetes in India
Guardant Health Presents Results of LUNAR-2 Blood Test for the Treatment of Early-Stage Colorectal Cancer at ACG 2021
Pfizer and BioNTech?s COVID-19 Vaccine Receive the US FDA?s Advisory Committee Vote Supporting EUA Against COVID-19
Selecta Collaborates with Ginkgo to Develop Therapeutic Enzymes for the Treatment of Orphan and Rare Diseases
Vertex Collaborates with Mammoth Biosciences to Develop In Vivo Gene-Editing Therapies for Genetic Diseases
Vifor and Angion?s ANG-3777 Fail to Meet its Primary and Secondary Endpoint for Patients with High-Risk Kidney Transplant
